"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Welcome to the DaVita HealthCare Partners Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] And now I'll turn the call over to your host, Mr. Jim Gustafson. Thank you. You may begin.",32,"Welcome to the DaVita HealthCare Partners Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] And now I'll turn the call over to your host, Mr. Jim Gustafson. Thank you. You may begin."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thank you, Vince, and welcome, everyone, to our fourth quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Jim Hilger, our inter",218,"Thank you, Vince, and welcome, everyone, to our fourth quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Jim Hilger, our interim CFO and Chief Accounting Officer; BJ Cotey, our CFO for Healthcare Partners; and Leanne Zumwalt, Group Vice President.
I'd like to start by noting that during this, we may make forward-looking statements within the meaning of the Federal Securities Laws. All of these statements are subject to known and unknown risks and certainties that could cause the actual results to differ materially from those described in these statements. For further details concerning these risks and uncertainties, please refer to our SEC filings included our most recent annual report and subsequent quarterly reports. Our forward-looking statements are based upon information currently available to us, and we do not intend and disclaim any duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website. 
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","All right. Thank you, Jim, and welcome to all. This will be a pretty high density call, and I'll be covering more topics than normal because of some of the nuances contained therein. As usual, I will first talk about our clinical outcomes because that is",2546,"All right. Thank you, Jim, and welcome to all. This will be a pretty high density call, and I'll be covering more topics than normal because of some of the nuances contained therein. As usual, I will first talk about our clinical outcomes because that is what comes first. Second, for each major business unit, I'll talk about the operating performance for the quarter and year-end, provide some thoughts on '16. Third, we'll then step back on each business briefly and on the enterprise overall to try to set the table for our Capital Markets Day coming up on May 18, in New York City. And then lastly, I'll talk about enterprise capital allocation.
So let's launch right in since there's quite a bit to cover. On the clinical outcome front, excellent news once again. Kidney care, 97% of our patients with a Kt/V of 1.2 or greater, 73% of patients with fistula placed for access. And with recently final results announced for the CMS the program for another year period, once again we outperformed the rest of the community with only 1.4% of our facilities facing a penalty compared to 7.1% for the rest of the industry. Of course, no quality rating system is perfect, but in rating tests after rating tests, we come out as clinically differentiated. 
On the HCP front, equally promising results. With respect to HEDIS clinical metrics, the District of Nevada this time, we try to move it around for you geographically. And in terms of subject matter, we once again the Medicare fee-for-service benchmark on all metrics, then have 4 or 5 star across all MA patients on all non-HEDIS metrics. So in both cases, both main sides of the house, our outcomes compared very favorably to national averages. This is good for patients. This is good for the taxpayer.
Now let's move on to the quarter and the year. We'll hit HCP first; international, second; kidney care, third.
HCP operating performance for the quarter, $25 million. That excluded the estimated writedown. This was within our guidance range. On a normalized basis, this was actually about $37 million, if you normalize for a prior period adjustments, et cetera, which actually is about exactly the same amount of profit in Q4 of 2014 normalized.
For the full year, [indiscernible] approved, as you know, from $215 million to $240 million, which is also within our guidance although at the low end. In order to achieve that, the legacy markets were up a bit, the new markets were up a bit. And the combination of those bits was more than enough to make a for the medical cost inflation and some very substantial investments and capability building/G&A, and BJ Cotey, our new HCP CFO, will discuss those investments and capabilities in G&A in more detail in just a few minutes.
But I will certainly move right on our 2016 guidance for HCP. It is $175 million to $225 million. There are 3 primary drivers of that range. Driver number  one, $58 million in reimbursement cuts. This is primarily the result of the new acuity coding RAF model being implementation to final trunk of the way, 100% implemented as of that time. As previously discussed, the HCP was more comprehensive in its coding capture. Complete diagnosis of patient condition is a good thing, but also left the entity far more vulnerable to any coding reimbursement compression. So $58 million from that source, most of it the model and the model's now 100%. And second the driver of that range is our investment in additional capabilities. 
There's 2 components to this $60 million year-over-year increase. Component A is really remedial, with their prior business leadership essentially stopped investing in the company. It was working to maximize profitability for the sale, either knowingly or unknowingly. And as a side note, I just want to remind you that we knew that. That is why we only paid a 6x multiple in a world where there are allegedly comparable assets were going for 9x to 10x than in now much greater than 10x in the market. 
And the second component of that big G&A capability investment is offensive. Meaning investments that we think that are going to create significant competitive advantage for us over time. 
The third primary driver is the positive one, which offsets a big chunk of those 2 negative ones: Solid operating performance. Good old solid operating performance. So if you look at the math, you have a $58 million hit from the -- essentially the completion of the RAF model. You have a $60 million hit from the increased investment in G&A, half remedial, half offensive. That would equal $118 million hit. You then have a $78 million operating performance improvement, which offsets all but $40 million of the 2 negative trends. And that yields the change from the $240 million in 2015 OI [ph] to the midpoint of the guidance $200 million for 2016. We can, of course, take questions on all of that, but those are the 3 primary drivers. 
2017 does look better than 2016. The model will be behind us, and we continue to make steady progress on our capabilities and our contracting. If we put the P&L aside for a moment and look at cash flow and take other scenario, the midpoint of our guidance. In other words, the $200 million for HCP and simultaneously take the midpoint of our guidance for the total enterprise, that $200 million would equal 11% of total enterprise operating income.
However, HCP operating cash flow is projected to be over $400 million, about 25% of total enterprise operating cash flow. This happens because of what we've talked about in the past. The low working capital intensity, low CapEx requirements and $100 million per year hard dollar cash tax benefit.
If we step back for a moment and look back at 3 difficult years, the total reimbursement cuts from the implementation of the new RAF model for us, $165 million. What we had anticipated was a much smaller number than that. In fact, less than half. So about $100 million of incremental P&L harm that we had not expected is due to that single variable, $100 million. Now the fact that it came from that does not make it any less painful than as it came from anything else, but the important message is it did not come from operating problems or operating issues.
Looking forward, instead of backward, we have 6 primary markets: California, Nevada, Florida, New Mexico, Colorado and Washington and more particular, the Seattle area. In those primary markets, we have 6 leading independent medical groups. It is in those places, plus our joint venture, Tandigm in Philadelphia, of course, but that is a horse of a different color. That is where we'll be placing was of our emphasis in the near and perhaps intermediate term. Prices are very high rate that for variable properties. Our bandwidth is pretty stretched given how much we've grown and given how much opportunity we have in those 6 markets, plus with Tandigm.
And then third, we need to prove to you that we can get the right returns and margins in a number of those places before we do too many other significant things. Because of all that, it is unlikely we will do in the other big Everett-like deal, unless it is through a capital-like transaction or is for a very attractive multiple. 
Other good news to take into account and looking forward instead of backward, a list of few of them, each of a different type. First, our legacy markets in 2015 once again outgrew the markets in terms of MA growth. The markets grew 6%. We grew 9%.
Number two, we've dramatically improved patient service metrics since the time of the transaction.
Number three, we've had a number of significant IT advances that it improved our support for our frontline physicians. We have a long journey there, and BJ will talk about that a little more, but we've got some nice early momentum and victories and better supporting our frontline physicians.
Number four, we've had a number of forecasting and prior project period adjustment issues. You now that painful truth as we do. Our finance leadership team is literally 90% new.
And fifth and finally in this case, if you look at our top 22 executives, we have 5 great veterans with immense amounts of valuable ACP experience and 17 new executives that we think are the right people to help take us into that next chapter going forward.
So that's in on HCP for now. Although BJ will come back and talk about some of those capability and G&A investments a little bit later.
Let's move onto international. We underperformed in 2015. $55 million in losses compared to original $40 million of guidance. Why? Well, we had a $5 million AR reserve, which almost entirely came from 1 country where there were 2 fiscal intermediaries that became unsolved. We actually hope to get a bunch of that money back. We also are $10 million behind plan or were $10 million behind plan in 2 countries, where we built new centers and patient growth was behind plan.
In 2016 for international, our guidance is losses of approximately $40 million. This assumes no unusual AR reserves. We are experiencing payment delays with the Saudi government, and that's a watch out but we have done nothing on that front now. We still expect to receive all of the funds. And the good news is the Ministry of Health in Saudi is explicitly very happy with our service and very impressed by the patient feedback they have received. They're words, not ours.
In 2017, we anticipate improvement over '16 on an OI basis. And in 2018, in international dialysis on our current country portfolio, we expect to achieve breakeven. We are, in fact, already in 2015, or we did already in 2015, generate positive aggregate EBITDA at the clinic level in 8 out of our 10 countries as we continue to grow and cover our G&A. In another reference point, that gives you a sense of the per country scale. In 2014, we had an average of $10 million revenue per country. 2015, an increase of 50% or up to $15 [ph] million. 2016, if we hit our plan, we'll be $27 million in revenue per country. So you can see that at reasonable margins, we are making strong progress in covering the fixed amount of a global G&A.
Finally, most of our growth internationally has been through acquisitions. Virtually, every 1 of those acquisitions has been completed for with others. And so these are market-valuable assets that real competition wanted to have. And our competitors continue to invest in growing internationally as well because of the returns they see. Stepping back for a moment with respect to international, we are still very bullish on the long-term opportunity of the kidney care and other healthcare services.
Now onto the kidney care operating performance. Once again, strong quarter, strong year. Operating income, 4 49. And then for the year 1.658. First number was for the quarter. Of course, once again excluding some non-recurring stuff. Jim Hilger will provide more details on the numbers. I'll go right into the guidance. 
We anticipate in 2016 another solid year, 1.625 to 1.725. Of course, there's always risks we'll fall short and there's always hope that we will exceed this guidance for our normal customs does include the international economics and it also includes the unfortunate fact of flat Medicare reimbursement for the third straight year.
The uncertainty in our 2016 performance, as in many recent years, it centers on revenue and revenue per treatment. We anticipate our performance in the first half of the year with respect to RPT to be positive, but we have a lot less visibility into the second half of the year, hence, the broadest of the range. 
And regarding the strategic initiatives, there could be some earnings volatility there. One reason is ESCOs, as you know we have launched, and so we incur those costs particularly those extra startup costs now, and we get the shared savings payment later if we perform and the data is correct. Now the second variable are some RX, the lead RX renewals. All this, of course, is incorporated into our guidance.
Stepping back now with respect to kidney care and looking out 3, 4, 5 years, is one big downside and 3 attractive upsides. The big downside is what will happen to private pay? It is unfortunate that we have a large cost shift in our dialysis industry in America with private patients paying a lot more to subsidize the 80% to 90% of our patients that are Medicare and Medicaid. And when you put that on top of payer consolidation, distributed risk pools, exchanges and other things going on, it will not be prudent to not be nervous about what will happen with private pay.
On the other hand, we do have 3 upsides. One is in the ESA market. For the long term, as many of you know, we spend about $800 million per year on ESAs. We are intensely looking for the light long-term partner or partners in the of the consummate some type of long-term partnership well before the expiration of our current contract at the end of 2018.
Second, integrated kidney care. We are very competent at this. Regardless of who has the risks, we think we will be one of the subcontractors of choice.
And third, finally, the flat Medicare reimbursement is scheduled to go away at the end of 2018. In 2019, we hope to be back to our normal market basket. All in all, our strategic position in U.S. kidney care is strong.
Now let's step back to the enterprise overall. The guidance OI of $1.8 billion to $1.95 billion. OCF, $1.55 billion to $1.75 billion. But on unequally important topic, how are we thinking about capital allocation at the enterprise level? Well, first, with kidney care, we stayed the course. And since there aren't a lot of large properties available out there, that means they will not use all the cash they generate. 
HCP, they will focus on existing markets, unless something that is capital light or very attractive multiple comes along. International, we will continue to invest to grow. Putting all 3 of those together, what does our capital allocation look like if you pick something arbitrary like the next 3-year period? We will generate, in a reasonable scenario, with, of course, downside risks and upside, but in the reasonable scenario, we will generate operating cash flow of approximately $5.5 billion in the next 3 years. If you count normal use, meaning our current operating plans, business plans, et cetera, which of course could change, we will use about $3.5 billion for those purposes. This leaves about $2 billion on the side for us to contemplate what to do with, with, of course, your counsel as well as we compare other growth opportunities to debt repayment opportunities to share repurchase opportunities. 
Now BJ Cotey, our new CFO of Healthcare Partners, will walk through a few more details."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. I'll take 2 minutes to provide more detail into the investments we're making into the future. As Kent stated before, we are continuing to make both remedial and offensive investments into the business. The best way to look at these items is",232,"Thanks, Kent. I'll take 2 minutes to provide more detail into the investments we're making into the future. As Kent stated before, we are continuing to make both remedial and offensive investments into the business. The best way to look at these items is to put 2015 and 2016 together. When you do that, we have a total of approximately $80 million in incremental investments over 2014. To provide more context into these investments, I'll put them into 3 primary buckets. 
First, we have information technology. Second, legal and compliance. And third, the next-generation capability and change management.
In the bucket of IT, we plan to spend $40 million more in '16 than we did in 2014. This includes the following areas: First, security; second, application to support population health; third, community portal to enhance munication between patients and providers and enterprise data warehouse, our accounting system conversion and a national IT infrastructure to enable our creation of one company. 
Next, in the legal and compliance bucket, we will invest an additional $10 million to $15 million over 2014. In our final bucket, we're investing approximately $18 million into research and development related to next-generation care management capabilities, a team we call catalysts, with applications to our current markets as well as others.
Now Jim Hilger, our CFO, will walk you through a few more details on the numbers in the quarter."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thanks, BJ. First, I'd like to point out a couple of non-GAAP items in the quarter. In the fourth quarter, we recorded an estimated accrual of $23 million for potential damages and liabilities in our DaVita RX pharmacy business. We have excluded these num",661,"Thanks, BJ. First, I'd like to point out a couple of non-GAAP items in the quarter. In the fourth quarter, we recorded an estimated accrual of $23 million for potential damages and liabilities in our DaVita RX pharmacy business. We have excluded these numbers from our reported non-GAAP into for Mark continuing operations. 
A few words about this estimated accrual. The reserves relate to the period from 2010 through 2015. As a part of our normal process, last spring, we initiated an internal complaint review of DaVita RX, during which we identified potential billing and operational issues. We notified the government in September of 2015 that we were conducting this review of DaVita RX and began providing regular updates of our review. Upon completion of our review, we filed a self disclosure with the OIG in February -- on February 5, 2016, and we have been working to address and update the practices were identified in the self-disclosure. 
In addition, as disclosed earlier today, on February 5, 2016, DaVita Rx received a civil investigative demand from the U.S. Attorney's office. The information requested has some overlap with the items we self disclosed. And we do not know that the U.S. Attorney new we are already in the process of developing a self-disclosure with the OIG.
At HCP, we took an estimated $206 million impairment charge of non-cash goodwill and an intangible asset of certain healthcare partner operating units. These impairments were driven primarily by the underperformance of the business reporting units in recent quarters as well as changes in other market conditions including government reimbursement cuts and are expected ability to mitigate those cuts.
The final amount of these impairment charges will depend upon the final outcome of this valuation work, which we expect to be completed in the first quarter of 2016. This noncash charge will not impact go forward performance or our cash taxes.
Onto the overall enterprise. Our debt expense was $103 million in the fourth quarter, which is a good run rate for a debt expense in future quarters. Our income attributable to noncontrolling interests was $40 million.
Next, our effective tax rate. For income attributable to DaVita HealthCare Partners in the fourth quarter was 36% and for the year was 38.2%. And we expect the full year tax rate for 2016 to be in the range of 40% to 41%.
We have also repurchased $151 million of our common stock in the fourth quarter, and we also repurchased an additional $249 million in the month of January. As a result of these transactions, we now have approximately $259 million remaining under our current board authorization.
As you think about modeling the first quarter, here are a few things that you should keep in mind: In our dialysis business, Q1 2015 contains -- or '16 contains 1 fewer day than this past quarter. So you should expect lower revenues and higher fixed costs per treatment. Second, our payroll tax caps reset at the beginning of the year, which leads to higher cost of $1 to $1.50 per treatment. At HCP, OI fluctuates from quarter-to-quarter due to the seasonal needs of patients and, Q1 and tends to be a bit lighter than the full year average.
Now turning to cash flow. We continue to generate strong cash flows as operating cash flow was $437 million in the fourth quarter and $1.861 billion for all of 2015, excluding the Vainer settlement. The strong cash flows in 2015 are borrowing a bit from 2016 operating cash flow, mostly due to the timing of cash tax payments and other working capital items. But despite that, we still expect 2016 operating cash flow to be $1.55 billion to $1.75 billion, showing that we continue to generate strong cash flows. As always, this guidance range captures a majority of probabilistic outcomes, but we could be above or below this range. 
And with that, operator, let's go ahead and open it up for Q&A."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question comes from Mr. Matthew Borsch with Goldman Sachs.",13,"[Operator Instructions] Our first question comes from Mr. Matthew Borsch with Goldman Sachs."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Could you maybe just address the areas of operating performance improvement that you're expecting in HCP business? Maybe just -- I don't know if there's any kind of granularity that you're prepared to give at this point, whether it's by geography or funct",63,"Could you maybe just address the areas of operating performance improvement that you're expecting in HCP business? Maybe just -- I don't know if there's any kind of granularity that you're prepared to give at this point, whether it's by geography or function. I'm just curious the types of things that you think are going to be better this year versus last."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Mathew, this is Kent. It's -- thanks for getting on the call. It's pretty just broad-based, so there's nothing really that jumps out. There's no dramatic disparity in growth or margin enhancement either through MOR improvement or G&A savings or revenue en",49,"Mathew, this is Kent. It's -- thanks for getting on the call. It's pretty just broad-based, so there's nothing really that jumps out. There's no dramatic disparity in growth or margin enhancement either through MOR improvement or G&A savings or revenue enhancements. So it's pretty mixed across the portfolio."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","And let me ask on a different front, still related to HCP. As you look at things that are potentially for sale and you mentioned prices are high, is that still principally because of the major hospital systems that are bidding up? Is it, I mean, more of t",62,"And let me ask on a different front, still related to HCP. As you look at things that are potentially for sale and you mentioned prices are high, is that still principally because of the major hospital systems that are bidding up? Is it, I mean, more of the same hospital, how much is hospital how much is managed care versus another?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly, health system's a bit sometimes breathtaking amounts for these medical groups. But we have been surprised with some of the other players, including some of the health insurance entities and the offers that they've put on the table as well.",41,"Certainly, health system's a bit sometimes breathtaking amounts for these medical groups. But we have been surprised with some of the other players, including some of the health insurance entities and the offers that they've put on the table as well."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Kevin Ellich with Piper Jaffray.",11,"Our next question comes from Mr. Kevin Ellich with Piper Jaffray."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Kent, I guess, just kind of big picture. Thinking about the guidance, which historically, you've had a track record of being conservative. But if you look over the last few years, we haven't seen much growth in operating income. I guess, clearly, there's",64,"Kent, I guess, just kind of big picture. Thinking about the guidance, which historically, you've had a track record of being conservative. But if you look over the last few years, we haven't seen much growth in operating income. I guess, clearly, there's been some issues with HealthCare Partners, but I guess, broadly speaking, what will it take before -- to get growth reaccelerating?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","A very fair question, Kevin, and one that we're pretty intense about on the inside. On the kidney care front with a 5 Medicare reimbursement, that's just a real problem that we've got to get addressed and then hopefully through new partner or the same par",147,"A very fair question, Kevin, and one that we're pretty intense about on the inside. On the kidney care front with a 5 Medicare reimbursement, that's just a real problem that we've got to get addressed and then hopefully through new partner or the same partner and a new partnership with DSAs or getting some integrated care runway we can start to break out of the current trend. On the HCP side, of course, some of the declines have taken away their kidney care gains. And so if we just stop adding it back to reasonable steady growth in HCP, that together with the normal growth in kidney care, could start to generate some much more interesting numbers. And then lastly, international is unfortunately just a couple of years away from being able to really help. Although onceit starts helping, it could be a long-term big deal."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Got it. Okay. And then going back to your comments on kidney care and potential balance side and creating factors for potential upside. In the ESA component, you said that contract expires in 2018. Should we expect to see something happen over the next ye",47,"Got it. Okay. And then going back to your comments on kidney care and potential balance side and creating factors for potential upside. In the ESA component, you said that contract expires in 2018. Should we expect to see something happen over the next year or 2?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","We would like to develop the right kind of long-term win-win partnership sooner rather than later. We have the contract we have with Amgen. And so if they don't want to do anything new with us, we certainly can't force them to. Having said that, there are",160,"We would like to develop the right kind of long-term win-win partnership sooner rather than later. We have the contract we have with Amgen. And so if they don't want to do anything new with us, we certainly can't force them to. Having said that, there are other people that we can create agreements with that just wouldn't kick in until the day after the Amgen agreement expired. So our point is pretty simple. That we think we can be a great partner for someone for the next 5 to 10 years in that area, and we're eager to find that party and start working towards that long-term future. Necessarily, even if we got a very serious with someone tomorrow, the deals are pretty complicated and nothing would be signed for sometime. But that's one of the reasons why we want to start working on them now because it takes a while to put them together. Is that responsive?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","It is. And can you remind us, I think in the contract, you had ability for 10% of your ESA supply to come from someone else. Are you guys testing other options out right now? And if so, how's that going?",41,"It is. And can you remind us, I think in the contract, you had ability for 10% of your ESA supply to come from someone else. Are you guys testing other options out right now? And if so, how's that going?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Leanne, you want to talk about that?",7,"Leanne, you want to talk about that?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly. We do plan to do some highlights over the next year.",12,"Certainly. We do plan to do some highlights over the next year."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. Will you go with 1 source? Or will you try different options, Leanne?",14,"Okay. Will you go with 1 source? Or will you try different options, Leanne?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly, we'll try multiple options.",5,"Certainly, we'll try multiple options."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. Great. And then, I guess, going to hammer -- going to the share repurchase. You guys were very active in January. I think you said you have 259 million remaining. Should we expect to see continued share repurchase activity maybe get -- are you guys",73,"Okay. Great. And then, I guess, going to hammer -- going to the share repurchase. You guys were very active in January. I think you said you have 259 million remaining. Should we expect to see continued share repurchase activity maybe get -- are you guys going to go back to the board to reup the authorization? And even though you don't provide EPS guidance, is that part of your outlook for 2016?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I'll go ahead and take that one. We're going to apply the same sort of measured calculus we've always applied looking at the alternative deployments, looking at the different scenarios going forward, looking at interest rates, looking at the stock price.",162,"I'll go ahead and take that one. We're going to apply the same sort of measured calculus we've always applied looking at the alternative deployments, looking at the different scenarios going forward, looking at interest rates, looking at the stock price. As a CEO, I'm feeling a little sheepish about the fact that we bought back quite a bit when the stock was a fair amount higher than it is today, and we would have done more value for -- crated more value for our long-term shareholders by waiting a little bit as opposed to buying when we were above historical average EBITDA multiple. So we bring our normal sort of intellectual calculus to it. But certainly, we demonstrated over the last year and certainly many of you were actively engaged in encouraging us to certainly we demonstrated as we have in different types of the history the willingness to go into the market and take some shares out of play."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Kevin Fischbeck of Bank of America Merrill Lynch.",14,"Our next question comes from Mr. Kevin Fischbeck of Bank of America Merrill Lynch."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","This is actually in Joanna Gajuk filling in for Kevin today. So on HCP guidance and the breakdown on different elements that are impacting the output income. Specifically, I recall the company mentioned on the last call medicated headwinds of $20 [ph] mil",63,"This is actually in Joanna Gajuk filling in for Kevin today. So on HCP guidance and the breakdown on different elements that are impacting the output income. Specifically, I recall the company mentioned on the last call medicated headwinds of $20 [ph] million? So should we assume that you no longer include that headwind? Or is that all that you didn't disclose it?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","What happened we thought it would be Medicaid at 20. It turns that Medicaid is 8. And so when we talk about 58, 50 was that RAF model Medicare, 8 was Medicaid.",32,"What happened we thought it would be Medicaid at 20. It turns that Medicaid is 8. And so when we talk about 58, 50 was that RAF model Medicare, 8 was Medicaid."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. That makes sense. So then I know you mentioned those headwinds, you expect to be offered by a broad ,] I guess, base operating improvement. But are you willing to talk about the legacy markets performance 2015? I don't know whether the specific numb",66,"Okay. That makes sense. So then I know you mentioned those headwinds, you expect to be offered by a broad ,] I guess, base operating improvement. But are you willing to talk about the legacy markets performance 2015? I don't know whether the specific numbers are up or down or the magnitude of improvement? And then what do you think this would be 2016 versus '15?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. In 2015, our legacy markets contributed to the profit growth, the OI growth -- excuse me, the OI growth as did our new markets. So both were contributors to our ability to offset the bad stuff that happened in normal medical costs inflation and our",75,"Right. In 2015, our legacy markets contributed to the profit growth, the OI growth -- excuse me, the OI growth as did our new markets. So both were contributors to our ability to offset the bad stuff that happened in normal medical costs inflation and our big investments. In 2016, we anticipate the same that independent of the rate cuts that both legacy markets and new markets will do better than they did in '15."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And then just a follow-up on your comment around dialysis business around the pricing that you expect pricing to be positive in first half, but less visibility for the second half of the year. So can you shed a little more light why you think that?",47,"Great. And then just a follow-up on your comment around dialysis business around the pricing that you expect pricing to be positive in first half, but less visibility for the second half of the year. So can you shed a little more light why you think that?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's not because of any particular normal negotiation between us and the payer. It's just because of all the noise in the air with everything going on with exchanges, regulatory ambiguity and those areas, what some of the new payers are going to do in ter",73,"It's not because of any particular normal negotiation between us and the payer. It's just because of all the noise in the air with everything going on with exchanges, regulatory ambiguity and those areas, what some of the new payers are going to do in terms of getting in and out of exchanges. So it's just so much going on that we're uneasy, increasingly uneasy and we thought we should share that."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","So there's nothing specific across [indiscernible] you mentioned something about the specific contract? Or I guess, maybe there was rather [indiscernible] on the SAP side so maybe that was irrelevant. I guess, that's all from me now. Thank you.",40,"So there's nothing specific across [indiscernible] you mentioned something about the specific contract? Or I guess, maybe there was rather [indiscernible] on the SAP side so maybe that was irrelevant. I guess, that's all from me now. Thank you."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Okay thank you. I think you might be referring to the DaVita Rx renewals I referred to. Now that is an independent point separate from what's going on in mainstream kidney care.",32,"Okay thank you. I think you might be referring to the DaVita Rx renewals I referred to. Now that is an independent point separate from what's going on in mainstream kidney care."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Ms. Margaret Kaser with William Blair.",11,"Our next question comes from Ms. Margaret Kaser with William Blair."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","First of all, thanks for all the details in terms of where you guys are investing in HCP. So maybe a question on that. What impact should we expect these investments to have? I assume its better outcomes that are going to lead to these higher patient adds",76,"First of all, thanks for all the details in terms of where you guys are investing in HCP. So maybe a question on that. What impact should we expect these investments to have? I assume its better outcomes that are going to lead to these higher patient adds. But even more specifically, over what timeframe should be see the fruits of these investments? Is it as early as '17? Or is it more '18, '19, '20?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Well, Margaret, we knew this question was going to come and dreaded it because it's going to be the answer you hate. It's not going to happen right away. For example, in technology space, it will take a year, 1 to 2 years to get a lot of that stuff done a",167,"Well, Margaret, we knew this question was going to come and dreaded it because it's going to be the answer you hate. It's not going to happen right away. For example, in technology space, it will take a year, 1 to 2 years to get a lot of that stuff done and then the benefit has -- does not immediately rebuff the P&L. In terms of our NexGen care management and change management group, that's got some near-term upside. When you're managing $4 billion of medical costs, spending that extra, whatever it is, $20 million, with some new talent, with some new analytics and with some new approaches, you can get a pretty good pay back on that pretty quickly. But the whole team is so new and the processes we're putting in place are so new that we would just say to great expectations and then fail. We're very bullish on the impact they are going to have but it's just not going to be overnight."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. So maybe to take that even further, and I'm sure you'll appreciate this question as well. But you talked about profitability in HCP maybe improving in '17. And part of that is that the reimbursement cuts from the RAF model go away. And so that shoul",101,"Okay. So maybe to take that even further, and I'm sure you'll appreciate this question as well. But you talked about profitability in HCP maybe improving in '17. And part of that is that the reimbursement cuts from the RAF model go away. And so that should be, if I'm thinking of it right, about a $60 million tailwind. But then are you going to increase investments further in '17 to offset that? And then also the final bucket in terms of the OI performance. Should that improve in '17 as center [ph] and efforts are to have a larger impact?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Well, you do know us well. The elimination of the RAF model that's been hanging our heads. That's certainly the elimination of a headwind. It doesn't lead to a tailwind. It just leads to the absence of wind, which for us right now would feel pretty good a",104,"Well, you do know us well. The elimination of the RAF model that's been hanging our heads. That's certainly the elimination of a headwind. It doesn't lead to a tailwind. It just leads to the absence of wind, which for us right now would feel pretty good assuming that benchmark rate increases would be, roughly speaking, equivalent what goes on with medical costs inflation. And so we do want 2017 OI to be nicely higher than 2016 OI because of the elimination of those headwinds and a lot of the other stuff hopefully kicking in. But did I miss a part of your question?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes. So the operating performance in Centur and what kind of impact with they have in '17 and '18?",19,"Yes. So the operating performance in Centur and what kind of impact with they have in '17 and '18?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Oh, thank you. On Everett, we would also expect '17 to be better than '16. '16 has some integration expenses. '16 has some adding talent to take on risk pools, so we have that expense. We have some additional amortization from the deal that we have some s",179,"Oh, thank you. On Everett, we would also expect '17 to be better than '16. '16 has some integration expenses. '16 has some adding talent to take on risk pools, so we have that expense. We have some additional amortization from the deal that we have some special additional expenses that exists for the first year or 2 of the deal and then go away. And so we are counting on -- we're expecting a nice operating income trajectory at Everett Clinic in '17 versus '16 and '18 versus '17 and '19 versus '18. We have high hopes for the significant growth of the business there. And then on Centura. That is a tougher one. We certainly expect it to do better in '17 than '16, really depends on if we get a quality risk on track, what the effective date is and then how quickly we can make a difference. So that one could stretch out a little bit based on the timing of all that. We're making nice progress, but right now there's nothing locked and loaded."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. Great. And then just one more for me. You guys were nice enough to provide the kind of the nouveau clinics that very waiting for regulatory approval last quarter. How are those looking this quarter? And should we expect that they're still to be able",59,"Okay. Great. And then just one more for me. You guys were nice enough to provide the kind of the nouveau clinics that very waiting for regulatory approval last quarter. How are those looking this quarter? And should we expect that they're still to be able as clinics that we'll see open in the first half of the year?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","The de novo backlog is still about the same as what it was last quarter. But what we're seeing is a much better improvement in opening new clinics. So that's where we'll see improvement in the first half of the year.",41,"The de novo backlog is still about the same as what it was last quarter. But what we're seeing is a much better improvement in opening new clinics. So that's where we'll see improvement in the first half of the year."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","And first, speaking is Patrick Mackinnon, Chief Financial Officer of kidney care.",12,"And first, speaking is Patrick Mackinnon, Chief Financial Officer of kidney care."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Garry Lieberman with Wells Fargo.",11,"Our next question comes from Mr. Garry Lieberman with Wells Fargo."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Sticking to HCP for a second. Is it possible to get some color on Albuquerque maybe just how it's -- how the recovery has gone? And where it is versus where it was, say, a year or 2 years ago?",40,"Sticking to HCP for a second. Is it possible to get some color on Albuquerque maybe just how it's -- how the recovery has gone? And where it is versus where it was, say, a year or 2 years ago?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Garry, this is Kent. I'll handle that. The difference between a year or 2 ago is night and day. There's just huge orders of magnitude better, so that's the high-level answer. The operations have been stabilized. We're in very constructive risk full conver",131,"Garry, this is Kent. I'll handle that. The difference between a year or 2 ago is night and day. There's just huge orders of magnitude better, so that's the high-level answer. The operations have been stabilized. We're in very constructive risk full conversations with one of the major payers. We're in healthy collaboration discussions with 2 of the significant health systems. The leadership has been stabilized bigger the management team has been improved. So there hasn't been any -- I mean, the numbers are certainly way better than 2 years ago, but I'm not trying to represent this as we're on some stunningly steep trajectory of profit improvement. But all the fundamentals are better, and I will -- we'll see what we can get done in the next couple of years."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then how much of your time are you spending on HCP versus the kidney care business?",18,"Okay. And then how much of your time are you spending on HCP versus the kidney care business?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I spend significantly more time on HCP than on domestic kidney care.",12,"I spend significantly more time on HCP than on domestic kidney care."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe just talking about the self disclosure and the CID, both happening on the same day. Is that just coincidence? Or is there something else that we could read into from that?",35,"Okay. And then maybe just talking about the self disclosure and the CID, both happening on the same day. Is that just coincidence? Or is there something else that we could read into from that?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","That's just totally coincidence.",5,"That's just totally coincidence."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And is there any additional color you could give us around it?",13,"Okay. And is there any additional color you could give us around it?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I don't think so, Garry. We just don't know much yet. We -- the good news is that through our own internal normal compliance processes, we uncovered some issues. And we did the right thing in investigated them. We did the right thing in reporting to the g",147,"I don't think so, Garry. We just don't know much yet. We -- the good news is that through our own internal normal compliance processes, we uncovered some issues. And we did the right thing in investigated them. We did the right thing in reporting to the government. We did the right thing in doing some refunds. All of these were small dollar issues and transactions that were a tiny, tiny percentage of overall transactions. And we kept the OIG up-to-date along the way as to the work we were doing but not completed. And we set off our formal self-disclosure document. And it just so happened that very same day that we got the CID from the Department of Justice, and we have no idea if the Department of Justice had any idea that we were already 9 months down the track with the OIG."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And I think you said your analysis went back to 2010, and it looks like their inquiry was passed 2006. Is there anything to read into that?",28,"Okay. And I think you said your analysis went back to 2010, and it looks like their inquiry was passed 2006. Is there anything to read into that?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No. I guess, I would suggest again that there -- the 2 things aren't all linked because clearly, they were coming up with their own set of issues and their own set of dates. But beyond that, we don't year. As you know, in many instances once they decide t",65,"No. I guess, I would suggest again that there -- the 2 things aren't all linked because clearly, they were coming up with their own set of issues and their own set of dates. But beyond that, we don't year. As you know, in many instances once they decide to take a look, they opened that first document is very, very broad because why not?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on your comments regarding negotiating any SA contract, it sounds like you're talking about it more than I that I think you had in the past on new contract. Is there any tangible you can share with us? Or any hope that it could yet done in",53,"Okay. And then on your comments regarding negotiating any SA contract, it sounds like you're talking about it more than I that I think you had in the past on new contract. Is there any tangible you can share with us? Or any hope that it could yet done in the near term?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No idea. This is -- what we are eager -- I'll be redundant, but we are eager to have a long-term partner and a long-term plan, and we just think there's a lot of opportunity. By getting their, we'll take either our current partner and decide they want to",107,"No idea. This is -- what we are eager -- I'll be redundant, but we are eager to have a long-term partner and a long-term plan, and we just think there's a lot of opportunity. By getting their, we'll take either our current partner and decide they want to create the next generation together or us doing it with someone else. In which case, the implementation, of course, will have to wait. But the reason we're talking about it more as people are getting more serious because it's just not that far away anymore, and $800 million a year and growing is a lot to play with."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","And then maybe just last point on that. Is there anything do you can share with us or you're aware of the one short-term biosimilar that has been expected to come to market but has not yet?",37,"And then maybe just last point on that. Is there anything do you can share with us or you're aware of the one short-term biosimilar that has been expected to come to market but has not yet?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I don't -- I personally don't think it makes much sense for us to start talking with individual biosimilar's and what exactly is going on. And so, Leanne, I don't know if there's anything you'd like to get out on the table. Anything I do will just be repe",53,"I don't -- I personally don't think it makes much sense for us to start talking with individual biosimilar's and what exactly is going on. And so, Leanne, I don't know if there's anything you'd like to get out on the table. Anything I do will just be repeating publicly known information."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No, Kent. I think you answered that correctly.",8,"No, Kent. I think you answered that correctly."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Chris Rigg with Susquehanna.",10,"Our next question comes from Mr. Chris Rigg with Susquehanna."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","We're going to get the advance notice for 2017 MA rates next week. And obviously, I don't want to -- it's hard for you guys to predict what's going to be in there. But one thing that's been kicked around is potentially adjusting the risk model to better c",86,"We're going to get the advance notice for 2017 MA rates next week. And obviously, I don't want to -- it's hard for you guys to predict what's going to be in there. But one thing that's been kicked around is potentially adjusting the risk model to better code for duals. Do you have any thoughts on that, particularly with this budget neutral? And if not, could you at least give us a sense for within the HCP pool of enrollment? How many are duals?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. Like you observed, we don't have any idea what they're going to do. And we do believe that currently, in Medicare Advantage, the sickest people we get under reimbursed for and the healthiest people, they over reimbursed for. And for people like us wh",112,"Yes. Like you observed, we don't have any idea what they're going to do. And we do believe that currently, in Medicare Advantage, the sickest people we get under reimbursed for and the healthiest people, they over reimbursed for. And for people like us who are not insurance companies and we want to keep the patients we have, we do keep them. We can't really determine which new ones come to us. The current reality works to our disadvantage. And then with respect to duals in particular, while we have a bunch, it's impossible to say whether we would benefit materially or not until you know whatever the heck they would do."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Got you. And then changing gears here. Just with regard to the seamless care organization rollout or pilot last fall. Can you give us a sense for some initial feedback from patients? Or just anything with regard to that will be helpful.",42,"Got you. And then changing gears here. Just with regard to the seamless care organization rollout or pilot last fall. Can you give us a sense for some initial feedback from patients? Or just anything with regard to that will be helpful."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is regarding ESCOs?",4,"This is regarding ESCOs?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes.",1,"Yes."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's just too soon. But we can't tell you though. We've been in a globally capitated pilot with CMS for 7, 8 years now, and it's pretty significant. There's 800 patients there or so, and then we have another 800, 900 globally capitated patients within our",129,"It's just too soon. But we can't tell you though. We've been in a globally capitated pilot with CMS for 7, 8 years now, and it's pretty significant. There's 800 patients there or so, and then we have another 800, 900 globally capitated patients within our HealthCare Partners universe. And in general, and in particular on the kidney care side, where they snap plan, special needs plans are focused us on these kidney care patients, it's spectacular. The patients get extra services. The doctors have extra support. The referring doctors get better information. The nurses get to provide coordinated care. The patient and family get support at home. So I can tell you in our mature other work where we're globally capitated, it's a spectacular beautiful transparent victory."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Witt Mayo with Robert W. Baird.",12,"Our next question comes from Mr. Witt Mayo with Robert W. Baird."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Kent, you've discussed in the past your desire to reengage in productive conversation with your health plan partners to ensure that your incentives are aligned with their incentives and they treat you as a good partner with MA rate cuts. Are there just an",57,"Kent, you've discussed in the past your desire to reengage in productive conversation with your health plan partners to ensure that your incentives are aligned with their incentives and they treat you as a good partner with MA rate cuts. Are there just any developments along the recontracting front that will be of any interest to us?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes is the short answer. Every -- I'm not going to get the mix right, but if you ask on Capital Markets Day, we'll have it and James Rechtin is not here right now. But I'll say a healthy percentage of our renewals and up with a new agreement where our int",134,"Yes is the short answer. Every -- I'm not going to get the mix right, but if you ask on Capital Markets Day, we'll have it and James Rechtin is not here right now. But I'll say a healthy percentage of our renewals and up with a new agreement where our interests are much more aligned. And that's been true every year, the big shift from what existed before. And the same statement is true with respect to health systems and hospitals where a very solid percentage of our new contracts there create a lot more alignment than the old ones, which were so [ph] 0 sum. So I would say it's steady progress, nothing dramatic, but it's really healthy in reducing downside risks, and over the long term will create some shared upside."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And just on Reno ventures. I don't think I've heard an update. Maybe I should know this and just divestitures of PC and any sense for the contribution this year?",31,"Great. And just on Reno ventures. I don't think I've heard an update. Maybe I should know this and just divestitures of PC and any sense for the contribution this year?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is Javier Rodriguez of Kidney Care. There is no update. We're still anticipating in Q2 close.",17,"This is Javier Rodriguez of Kidney Care. There is no update. We're still anticipating in Q2 close."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And maybe one last one is just any way to get the size of DaVita Rx now either by patients or revenue?",23,"Great. And maybe one last one is just any way to get the size of DaVita Rx now either by patients or revenue?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Boy, I don't remember what our historical policy has been. It is certainly grown. It is making some money. It is not losing money anymore. I'm going to have to turn to Jim Gustafson so I don't violate any policy. Go ahead, Jim.",43,"Boy, I don't remember what our historical policy has been. It is certainly grown. It is making some money. It is not losing money anymore. I'm going to have to turn to Jim Gustafson so I don't violate any policy. Go ahead, Jim."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. We disclosed -- we're serving in various capacities the 155,000 patients, and that includes both internal and external.",19,"Yes. We disclosed -- we're serving in various capacities the 155,000 patients, and that includes both internal and external."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Ryan Newman with Promise Capital.",11,"Our next question comes from Mr. Ryan Newman with Promise Capital."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","You spoke a lot about this of this in international markets and how other players were attracted to those as well. So I know you've expanded a little bit in Colombia and Portugal, China and Germany. Can you just talk about a bit how were the most softness",49,"You spoke a lot about this of this in international markets and how other players were attracted to those as well. So I know you've expanded a little bit in Colombia and Portugal, China and Germany. Can you just talk about a bit how were the most softness occurred?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Where the most of what has occurred?",7,"Where the most of what has occurred?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Where softness conditions existed internationally.",5,"Where softness conditions existed internationally."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Softness conditions?",2,"Softness conditions?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes.",1,"Yes."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","So soft as in. . .",6,"So soft as in. . ."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","The worst performance.",3,"The worst performance."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Poor performance? Okay. Thank you. Sorry for my...",8,"Poor performance? Okay. Thank you. Sorry for my..."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","I miss worded the question. I apologize.",7,"I miss worded the question. I apologize."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I'd say the softest performance from a profit point of view -- I mean, my mind is raising as to how much I should disclose. We've had some private problems in Colombia. That probably sticks out as one of the softest. In Saudi, we've been growing a little",181,"I'd say the softest performance from a profit point of view -- I mean, my mind is raising as to how much I should disclose. We've had some private problems in Colombia. That probably sticks out as one of the softest. In Saudi, we've been growing a little bit behind plan, but the microeconomics appear to be solid. And I think beyond that I have to get into so many nuances. In China, we still put in the R&D category where we are very steadily consistently interesting to look for the winning formula, and we don't have it yet, but we're not discouraged. We've got some stuff that's working there. We have some stuff that's not working, and that's kind of the hit rate we expected. India, we know is a long-haul kind of thing, an immense market but we're not going to start doing anything big there quickly because the microeconomics are just too tiny. So there's a little bit of flavor across 3 or 4, and I'm probably giving Jim Gustafson a heart attack by providing all this."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","At this time, we no have -- we no longer have further questions on queue. [Operator Instructions]",17,"At this time, we no have -- we no longer have further questions on queue. [Operator Instructions]"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Well, we -- the capital markets are May 18th, correct, Jim?",11,"Well, we -- the capital markets are May 18th, correct, Jim?"
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","In New York, we're going to nail down the location. There's a lot to talk about. We look forward to going into more detail. We're going to have a longer general session than we normally do, so that we hopefully give you a very comprehensive and analytical",102,"In New York, we're going to nail down the location. There's a lot to talk about. We look forward to going into more detail. We're going to have a longer general session than we normally do, so that we hopefully give you a very comprehensive and analytically thoughtful, not only reiteration of our strategy, but our progress and the right kind of leading indicators to stare at. So we're looking forward to a real high intensity extended exchange, and we'll do our best in between now and then to get through '16 and start growing again in '17. Thank you very much."
35644,324689788,932275,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Thank you so that concludes today's conference call. Thank you all for participating. You may now disconnect.",18,"Thank you so that concludes today's conference call. Thank you all for participating. You may now disconnect."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Welcome to the DaVita HealthCare Partners Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] And now I'll turn the call over to your host, Mr. Jim Gustafson. Thank you. You may begin.",32,"Welcome to the DaVita HealthCare Partners Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] And now I'll turn the call over to your host, Mr. Jim Gustafson. Thank you. You may begin."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thank you, Vince, and welcome, everyone, to our fourth quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Jim Hilger, our Inter",220,"Thank you, Vince, and welcome, everyone, to our fourth quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Jim Hilger, our Interim CFO and Chief Accounting Officer; Vijay Kotte, our CFO for Healthcare Partners; and Leanne Zumwalt, Group Vice President.
I'd like to start by noting that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and certainties that could cause the actual results to differ materially from those described in these statements. For further details concerning the risks and uncertainties, please refer to our SEC filings included in our most recent annual report and subsequent quarterly reports. Our forward-looking statements are based upon information currently available to us, and we do not intend and disclaim any duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website. 
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","All right. Thank you, Jim, and welcome to all. This will be a pretty high-density call, and I'll be covering more topics than normal because of some of the nuances contained therein. As usual, I will first talk about our clinical outcomes because that is",2545,"All right. Thank you, Jim, and welcome to all. This will be a pretty high-density call, and I'll be covering more topics than normal because of some of the nuances contained therein. As usual, I will first talk about our clinical outcomes because that is what comes first. Second, for each major business unit, I'll talk about the operating performance for the quarter and year-end, provide some thoughts on '16. Third, we'll then step back on each business briefly, and on the enterprise overall to try to set the table for our Capital Markets Day coming up on May 18, in New York City. And then lastly, I'll talk about enterprise capital allocation.
So let's launch right in since there's quite a bit to cover. On the clinical outcome front, excellent news, once again. Kidney care, 97% of our patients with a Kt/V of 1.2 or greater, 73% of patients with fistula placed for access. And then recently, final results announced for the CMS QUIP program for another year period, once again, we outperformed the rest of the community with only 1.4% of our facilities facing a penalty compared to 7.1% for the rest of the industry. Of course, no quality rating system is perfect, but in rating test after rating tests, we come out as clinically differentiated. 
On the HCP front, equally promising results. With respect to HEDIS clinical metrics, we'll just pick at this time. We try to move it around for you geographically. And in terms of subject matter, we, once again, exceeded the Medicare fee-for-service benchmark on all metrics, then had 4 or 5 star across all MA patients on all non-HEDIS metrics. So in both cases, both main sides of the house, our outcomes compare very favorably to national averages. This is good for patients. This is good for the taxpayer.
Now let's move on to the quarter and the year. We'll hit HCP first; international, second; kidney care, third.
HCP operating performance for the quarter, $25 million. That excluded the estimated write-down. This was within our guidance range. On a normalized basis, this was actually about $37 million, if you normalize for prior period adjustment, et cetera, which actually is about exactly the same amount of profit in Q4 of 2014 normalized.
For the full year, while improved, as you know, from $215 million to $240 million, which is also within our guidance, although at the low end. In order to achieve that, the legacy markets were up a bit. The new markets were up a bit. And the combination of those bits was more than enough to make up for the medical cost inflation and some very substantial investments and capability building/G&A. And Vijay Kotte, our new HCP CFO, will discuss those investments and capabilities in G&A in more detail in just a few minutes.
But I will certainly move right on to 2016 guidance for HCP. It is $175 million to $225 million. There are 3 primary drivers of that range. Driver number  one, $58 million in reimbursement cuts. This is primarily the result of the new acuity coding RAF model being implementation to final trunk of the way, 100% implemented as of that time. As previously discussed, the HCP was more comprehensive in its coding capture. Complete diagnosis of patient conditions is a good thing, but it also left the entity far more vulnerable to any coding reimbursement compression. So $58 million from that source, most of it, the model, and the model is now 100%. And second the driver of that range is our investment in additional capabilities. 
There's 2 components to this $60 million year-over-year increase. Component A is really remedial. Their prior business leadership essentially stopped investing in the company. It was working to maximize profitability for the sale, either knowingly or unknowingly. And as a side note, I just want to remind you that we knew that. That is why we only paid a 6x multiple in a world where there are allegedly comparable assets were going for 9x to 10x than in now much greater than 10x in the market. 
And the second component of that big G&A capability investment is offensive, meaning investments that we think that are going to create significant competitive advantage for us over time. 
The third primary driver is the positive one, which offsets a big chunk of those 2 negative ones: Solid operating performance, good old solid operating performance. So if you look at the math, you have a $58 million hit from the -- essentially the completion of the RAF model. You have a $60 million hit from the increased investment in G&A, half remedial, half offensive. That would equal $118 million hit. You then have a $78 million operating performance improvement, which offsets all but $40 million of the 2 negative trends. And that yields the change from the $240 million in 2015 OI to the midpoint of the guidance, $200 million for 2016. We can, of course, take questions on all of that, but those are the 3 primary drivers. 
2017 does look better than 2016. The model will be behind us, and we continue to make steady progress on our capabilities and our contracting. If we put the P&L aside for a moment and look at cash flow and take as a scenario the midpoint of our guidance, in other words, the $200 million for HCP, and simultaneously take the midpoint of our guidance for the total enterprise, that $200 million would equal 11% of total enterprise operating income.
However, HCP operating cash flow is projected to be over $400 million, about 25% of total enterprise operating cash flow. This happens because of what we've talked about in the past, low working capital intensity, low CapEx requirements and $100 million per year hard dollar cash tax benefit.
If we step back for a moment and look back at 3 difficult years, the total reimbursement cut from the implementation of the new RAF model for us, $165 million. What we had anticipated was a much smaller number than that. In fact, less than half. So about $100 million of incremental P&L harm that we had not expected is due to that single variable, $100 million. Now the fact that it came from that does not make it any less painful than if it came from anything else, but the important message is it did not come from operating problems or operating issues.
Looking forward, instead of backward, we have 6 primary markets: California, Nevada, Florida, New Mexico, Colorado and Washington, and more particular, the Seattle area. In those primary markets, we have 6 leading independent medical groups. It is in those places, plus our joint venture, Tandigm in Philadelphia, of course, but that is a horse of a different color, that is where we'll be placing most of our emphasis in the near and perhaps intermediate term. Prices are very high right now for variable properties. Our bandwidth is pretty stretched given how much we've grown and given how much opportunity we have in those 6 markets, plus with Tandigm.
And then third, we need to prove to you that we can get the right returns and margins in a number of those places before we do too many other significant things. Because of all that, it is unlikely we will do in the other big Everett-like deal, unless it is through a capital-light transaction or is for a very attractive multiple. 
Other good news to take into account, and looking forward instead of backward, a list of few of them, each of a different type. First, our legacy markets in 2015, once again, outgrew the markets in terms of MA growth. The markets grew 6%. We grew 9%.
Number two, we've dramatically improved patient service metrics since the time of the transaction.
Number three, we've had a number of significant IT advances that it improved our support for our frontline physicians. We have a long journey there, and BJ will talk about that a little more, but we've got some nice early momentum and victories in better supporting our frontline physicians.
Number four, we've had a number of forecasting and prior project period adjustment issues. You now that painful truth as we do. Our finance leadership team is literally 90% new.
And fifth, and finally, in this case, if you look at our top 22 executives, we have 5 great veterans with immense amounts of valuable ACP experience and 17 new executives that we think are the right people to help take us into that next chapter going forward.
So that's it on HCP for now, although BJ will come back and talk about some of those capability and G&A investments a little bit later.
Let's move onto international. We underperformed in 2015. $55 million in losses compared to original $40 million of guidance. Why? Well, we had a $5 million AR reserve, which almost entirely came from one country where there were 2 fiscal intermediaries that became insolvent. We actually hope to get a bunch of that money back. We also are $10 million behind plan or were $10 million behind plan in 2 countries where we built new centers and patient growth was behind plan.
In 2016, for international, our guidance is losses of approximately $40 million. This assumes no unusual AR reserves. We are experiencing payment delays with the Saudi government, so that's a watch-out, but we have done nothing on that front now. We still expect to receive all of the funds. And the good news is the Ministry of Health in Saudi is explicitly very happy with our service and very impressed by the patient feedback they have received. Their words, not ours.
In 2017, we anticipate improvement over '16 on an OI basis. And in 2018, in international dialysis, on our current country portfolio, we expect to achieve breakeven. We are, in fact, already in 2015, or we did already in 2015, generate positive aggregate EBITDA at the clinic level in 8 out of our 10 countries as we continue to grow and cover our G&A. In another reference point, that gives you a sense of the per-country scale. In 2014, we had an average of $10 million revenue per country. 2015, an increase of 50% or up to $15 million. 2016, if we hit our plan, we'll be $27 million in revenue per country. So you can see that at reasonable margins, we are making strong progress in covering the fixed amount of global G&A.
Finally, most of our growth internationally has been through acquisition. Virtually, every one of those acquisitions has been competed for with others. And so these are market-valuable assets that real competition wanted to have. And our competitors continue to invest in growing internationally as well because of the returns they see. Stepping back for a moment, with respect to international, we are still very bullish on the long-term opportunity of the kidney care and other healthcare services.
Now onto the kidney care operating performance. Once again, strong quarter, strong year. Operating income, $449 million. And then for the year, $1.658 billion. First number was for the quarter, of course, once again excluding some non-recurring stuff. Jim Hilger will provide more details on the numbers. I'll go right into guidance. 
We anticipate, in 2016, another solid year, $1.625 million to $1.725 billion. Of course, there's always risks we'll fall short and there's always hope that we will exceed. This guidance, for our normal customs, does include the international economics and it also includes the unfortunate fact of flat Medicare reimbursement for the third straight year.
The uncertainty in our 2016 performance, as in many recent years, it centers on revenue and revenue per treatment. We anticipate our performance in the first half of the year with respect to RPT to be positive, but we have a lot less visibility into the second half of the year, hence, the broadest of the range. 
And regarding the strategic initiatives, there could be some earnings volatility there. One reason is ESCOs, as you know we have launched, and so we incur those costs, particularly those extra startup costs now, and we get the shared savings payment later if we perform and the data is correct. Now the second variable are some RX, to be the RX renewals. All of this, of course, is incorporated into our guidance.
Stepping back now with respect to kidney care and looking out 3, 4, 5 years, is one big downside and 3 attractive upsides. The big downside is what will happen to private pay? It is unfortunate that we have a large cost shift in our dialysis industry in America with private patients paying a lot more to subsidize the 80% to 90% of our patients that are Medicare and Medicaid. And when you put that on top of payer consolidation, distributed risk pools, exchanges and other things going on, it would not be prudent to not be nervous about what will happen with private pay.
On the other hand, we do have 3 upsides. One is in the ESA market. For the long term, as many of you know, we spend about $800 million per year on ESAs. We are intensely looking for the right long-term partner or partners in the hope to consummate some type of long-term partnership well before the expiration of our current contract at the end of 2018.
Second, integrated kidney care. We are very competent at this. Regardless of who has the risks, we think we will be one of the subcontractors of choice.
And third, finally, the flat Medicare reimbursement is scheduled to go away at the end of 2018. In 2019, we hope to be back to our normal market basket. All in all, our strategic position in U.S. kidney care is strong.
Now let's step back to the enterprise overall. The guidance OI of $1.8 billion to $1.95 billion. OCF, $1.55 billion to $1.75 billion. But on an unequally important topic, how are we thinking about capital allocation at the enterprise level? Well, first, with kidney care, we stayed the course. And since there aren't a lot of large properties available out there, that means they will not use all the cash they generate. 
HCP, they will focus on existing markets, unless something that is capital-light or very attractive multiple comes along. 
International, we will continue to invest to grow. Putting all 3 of those together, what does our capital allocation look like if you pick something arbitrary like the next 3-year period? We will generate, in a reasonable scenario, with, of course, downside risks and upside, but in the reasonable scenario, we will generate operating cash flow of approximately $5.5 billion in the next 3 years. If you count normal use, meaning our current operating plans, business plans, et cetera, which, of course, could change, we will use about $3.5 billion for those purposes. This leaves about $2 billion on the side for us to contemplate what to do with, with, of course, your counsel as well as we compare other growth opportunities to debt repayment opportunities to share repurchase opportunities. 
Now Vijay Kotte, our new CFO of Healthcare Partners, will walk through a few more details."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. I'll take a few minutes to provide more detail into the investments we're making into the future. As Kent stated before, we are continuing to make both remedial and offensive investments into the business. The best way to look at these items",234,"Thanks, Kent. I'll take a few minutes to provide more detail into the investments we're making into the future. As Kent stated before, we are continuing to make both remedial and offensive investments into the business. The best way to look at these items is to put 2015 and 2016 together. When you do that, we have a total of approximately $80 million in incremental investments over 2014. To provide more context into these investments, I will put them into 3 primary buckets: First, we have information technology; second, legal and compliance; and third, the next-generation capability and change management.
In the bucket of IT, we plan to spend $40 million more in '16 than we did in 2014. This includes the following areas: First, security; second, application to support population health; third, community portal to enhance munication between patients and providers, an enterprise data warehouse, our accounting system conversion and a national IT infrastructure to enable our creation of one company.
Next, in the legal and compliance bucket, we will invest an additional $10 million to $15 million over 2014. 
In our final bucket, we're investing approximately $18 million into research and development related to next-generation care management capabilities, a team we call catalysts, with applications to our current markets as well as others.
Now Jim Hilger, our CFO, will walk you through a few more details on the numbers in the quarter."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thanks, BJ. First, I'd like to point out a couple of non-GAAP items in the quarter. In the fourth quarter, we recorded an estimated accrual of $23 million for potential damages and liabilities in our DaVita RX pharmacy business. We have excluded these num",655,"Thanks, BJ. First, I'd like to point out a couple of non-GAAP items in the quarter. In the fourth quarter, we recorded an estimated accrual of $23 million for potential damages and liabilities in our DaVita RX pharmacy business. We have excluded these numbers from our reported non-GAAP income from continuing operations. 
A few words about this estimated accrual. The reserves relate to the period from 2010 through 2015. As a part of our normal process, last spring, we initiated an internal compliance review of DaVita RX, during which, we identified potential billing and operational issues. We notified the government in September of 2015 that we were conducting this review of DaVita RX and began providing regular updates of our review. Upon completion of our review, we filed a self disclosure with the OIG on February 5, 2016, and we have been working to address and update the practices we identified in the self-disclosure. 
In addition, as disclosed earlier today, on February 5, 2016, DaVita Rx received a civil investigative demand from the U.S. Attorney's Office. The information requested has some overlap with the items we self-disclosed. And we do not know that the U.S. Attorney knew we are already in the process of developing a self-disclosure with the OIG.
At HCP, we took an estimated $206 million impairment charge of non-cash goodwill and an intangible asset of certain healthcare partner operating units. These impairments were driven primarily by the underperformance of the business reporting units in recent quarters as well as changes in other market conditions, including government reimbursement cuts and our expected ability to mitigate those cuts.
The final amount of these impairment charges will depend upon the final outcome of this valuation work, which we expect to be completed in the first quarter of 2016. This noncash charge will not impact go-forward performance or our cash taxes.
Onto the overall enterprise. Our debt expense was $103 million in the fourth quarter, which is a good run rate for a debt expense in future quarters. Our income attributable to noncontrolling interests was $40 million.
Next, our effective tax rate. For income attributable to DaVita HealthCare Partners in the fourth quarter was 36% and for the year was 38.2%. And we expect the full year tax rate for 2016 to be in the range of 40% to 41%.
We have also repurchased $151 million of our common stock in the fourth quarter, and we also repurchased an additional $249 million in the month of January. As a result of these transactions, we now have approximately $259 million remaining under our current board authorization.
As you think about modeling the first quarter, here are a few things that you should keep in mind: In our dialysis business, Q1 2015 contains -- or '16 contains 1 fewer day than this past quarter. So you should expect lower revenues and higher fixed costs per treatment. 
Second, our payroll tax caps reset at the beginning of the year, which leads to higher cost of $1 to $1.50 per treatment. At HCP, OI fluctuates from quarter-to-quarter due to the seasonal needs of patients, and Q1 and tends to be a bit lighter than the full year average.
Now turning to cash flow. We continue to generate strong cash flows as operating cash flow was $437 million in the fourth quarter and $1.861 billion for all of 2015, excluding the Vainer settlement. The strong cash flows in 2015 are borrowing a bit from 2016 operating cash flow, mostly due to the timing of cash tax payments and other working capital items. But despite that, we still expect 2016 operating cash flows to be $1.55 billion to $1.75 billion, showing that we continue to generate strong cash flows. As always, this guidance range captures a majority of probabilistic outcomes, but we could be above or below this range. 
And with that, operator, let's go ahead and open it up for Q&A."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question comes from Mr. Matthew Borsch with Goldman Sachs.",13,"[Operator Instructions] Our first question comes from Mr. Matthew Borsch with Goldman Sachs."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Could you maybe just address the areas of operating performance improvement that you're expecting in HCP business? Maybe just -- I don't know if there's any kind of granularity that you're prepared to give at this point, whether it's by geography or funct",63,"Could you maybe just address the areas of operating performance improvement that you're expecting in HCP business? Maybe just -- I don't know if there's any kind of granularity that you're prepared to give at this point, whether it's by geography or function. I'm just curious, the types of things that you think are going to be better this year versus last."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Mathew, this is Kent. It's -- thanks for getting on the call. It's pretty broad-based, so there's nothing, really, that jumps out. There's no dramatic disparity in unit growth or margin enhancement either through MOR improvement or G&A savings or revenue",49,"Mathew, this is Kent. It's -- thanks for getting on the call. It's pretty broad-based, so there's nothing, really, that jumps out. There's no dramatic disparity in unit growth or margin enhancement either through MOR improvement or G&A savings or revenue enhancements. So it's pretty mixed across the portfolio."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","And let me ask on a different front, still related to HCP. As you look at things that are potentially for sale, and you mentioned prices are high, is that still principally because of the major hospital systems that are bidding up? Is it, I mean, more of",62,"And let me ask on a different front, still related to HCP. As you look at things that are potentially for sale, and you mentioned prices are high, is that still principally because of the major hospital systems that are bidding up? Is it, I mean, more of the same hospital? How much is hospital? How much is managed care versus other?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. Certainly, health system is a bit sometimes breathtaking amounts for these medical groups, but we have been surprised by some of the other players, including some of the health insurance entities and the offers that they've put on the table as well",43,"Right. Certainly, health system is a bit sometimes breathtaking amounts for these medical groups, but we have been surprised by some of the other players, including some of the health insurance entities and the offers that they've put on the table as well."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Kevin Ellich with Piper Jaffray.",11,"Our next question comes from Mr. Kevin Ellich with Piper Jaffray."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Kent, I guess, just kind of big picture. Thinking about the guidance, which historically, you've had a track record of being conservative. But if you look over the last few years, we haven't seen much growth in operating income. I guess, clearly, there's",64,"Kent, I guess, just kind of big picture. Thinking about the guidance, which historically, you've had a track record of being conservative. But if you look over the last few years, we haven't seen much growth in operating income. I guess, clearly, there's been some issues with HealthCare Partners, but I guess, broadly speaking, what will it take before -- to get growth reaccelerating?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes, a very fair question, Kevin, and one that we are pretty intense about on the inside. On the kidney care front, with that 5 Medicare reimbursement, that's just a real problem that we've got to get addressed. And then hopefully, through a new partner o",153,"Yes, a very fair question, Kevin, and one that we are pretty intense about on the inside. On the kidney care front, with that 5 Medicare reimbursement, that's just a real problem that we've got to get addressed. And then hopefully, through a new partner or the same partner and a new partnership with the SAs, we're getting some integrated care runway that we can start to break out of the current trend. On the HCP side, of course, some of the declines have taken away their kidney care gains. And so if we just stop adding it back to reasonable steady growth in HCP, that, together with the normal growth in kidney care, could start to generate some much more interesting numbers. And then lastly, international is unfortunately just a couple of years away from being able to really help. Although once it starts helping, it could be a long-term big deal."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Got it. Okay. And then going back to your comments on kidney care and potential downside and 3 factors for a potential upside, in the ESA component, you said that contract expires in 2018. Should we expect to see something happen over the next year or 2?",47,"Got it. Okay. And then going back to your comments on kidney care and potential downside and 3 factors for a potential upside, in the ESA component, you said that contract expires in 2018. Should we expect to see something happen over the next year or 2?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","We would like to develop the right kind of long-term win-win partnership sooner rather than later. We have the contract we have with Amgen, and so if they don't want to do anything new with us, we certainly can't force them to. Having said that, there are",161,"We would like to develop the right kind of long-term win-win partnership sooner rather than later. We have the contract we have with Amgen, and so if they don't want to do anything new with us, we certainly can't force them to. Having said that, there are other people that we can create agreements with that just wouldn't kick in until the day after the Amgen agreement expired. So our point is pretty simple. That we think we can be a great partner for someone for the next 5 to 10 years in that area, and we're eager to find that party and start working towards that long-term future. Necessarily, even if we got a very serious with someone tomorrow, the deals are pretty complicated and nothing would be signed for some time. But that's one of the reasons why we want to start working on them now because it takes a while to put them together. Is that responsive?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","It is. And can you remind us, I think in the contract, you had the ability for 10% of your ESA supply to come from someone else. Are you guys testing other options out right now? And if so, how's that going?",42,"It is. And can you remind us, I think in the contract, you had the ability for 10% of your ESA supply to come from someone else. Are you guys testing other options out right now? And if so, how's that going?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Leanne, you want to talk about that?",7,"Leanne, you want to talk about that?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly. We do plan to do some highlights over the next year.",12,"Certainly. We do plan to do some highlights over the next year."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. Will you go with one source? Or will you try different options, Leanne?",14,"Okay. Will you go with one source? Or will you try different options, Leanne?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly, we'll try multiple options.",5,"Certainly, we'll try multiple options."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, great. And then, I guess, going to hammer -- going to the share repurchase, you guys were very active in January. I think you said you have $259 million remaining. Should we expect to see continued share repurchase activity maybe get a -- are you gu",78,"Okay, great. And then, I guess, going to hammer -- going to the share repurchase, you guys were very active in January. I think you said you have $259 million remaining. Should we expect to see continued share repurchase activity maybe get a -- are you guys going to go back to the board to get a -- to reup the authorization? And even though you don't provide EPS guidance, is that part of your outlook for 2016?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes, I'll go ahead and take that one. We're going to apply the same sort of measured calculus we've always applied that looking at the alternative deployments, looking at the different scenarios going forward, looking at interest rates, looking at the sto",164,"Yes, I'll go ahead and take that one. We're going to apply the same sort of measured calculus we've always applied that looking at the alternative deployments, looking at the different scenarios going forward, looking at interest rates, looking at the stock price, as a CEO, I'm feeling a little sheepish about the fact that we bought back quite a bit when the stock was a fair amount higher than it is today, and we would have done more value for -- created more value for our long-term shareholders by waiting a little bit as opposed to buying when we were at above historical average EBITDA multiple. So we bring our normal sort of intellectual calculus to it. But certainly, we demonstrated over the last year, and certainly, many of you were actively engaged in encouraging us to, certainly we've demonstrated, as we have in different types of the history, the willingness to go into the market and take some shares out of play."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Kevin Fischbeck of Bank of America Merrill Lynch.",14,"Our next question comes from Mr. Kevin Fischbeck of Bank of America Merrill Lynch."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","This is actually in Joanna Gajuk, filling in for Kevin today. So on HCP guidance and the breakdown on different elements that are impacting the output income, specifically, I recall the company mentioned on the last call Medicaid headwinds of $20 million?",66,"This is actually in Joanna Gajuk, filling in for Kevin today. So on HCP guidance and the breakdown on different elements that are impacting the output income, specifically, I recall the company mentioned on the last call Medicaid headwinds of $20 million? So should we assume that you'd no longer include that headwind? Or it's just all that if you don't -- you didn't disclose that?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. When it happened, we thought it would be Medicaid at $20 million. It turns out, Medicaid is $8 million. And so we talked about $58 million. $50 million was that RAF model at Medicare, $8 million was Medicaid.",39,"Yes. When it happened, we thought it would be Medicaid at $20 million. It turns out, Medicaid is $8 million. And so we talked about $58 million. $50 million was that RAF model at Medicare, $8 million was Medicaid."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, that makes sense. So then I know you mentioned that those headwinds, you expect to be offered by a broad, I guess, base operating in an improvement. But are you willing to talk about the legacy markets performance 2015? I don't know whether specific",67,"Okay, that makes sense. So then I know you mentioned that those headwinds, you expect to be offered by a broad, I guess, base operating in an improvement. But are you willing to talk about the legacy markets performance 2015? I don't know whether specific numbers are up or down or the magnitude of improvement? And then what do you think this would be 2016 versus '15?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. In 2015, our legacy markets contributed to the profit growth, the OI growth, as did our new markets. So both were contributors to our ability to offset the bad stuff that happened in normal medical cost inflation and our big investments. In 2016, w",69,"Right. In 2015, our legacy markets contributed to the profit growth, the OI growth, as did our new markets. So both were contributors to our ability to offset the bad stuff that happened in normal medical cost inflation and our big investments. In 2016, we anticipate the same, that independent of the rate cuts, that both legacy markets and new markets will do better than they did in '15."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And then just a follow-up on your comment around the dialysis business and the pricing that you expect the pricing to be positive in first half, but there's less visibility for the second half of the year. So can you shed a little more light why yo",50,"Great. And then just a follow-up on your comment around the dialysis business and the pricing that you expect the pricing to be positive in first half, but there's less visibility for the second half of the year. So can you shed a little more light why you think that?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's not because of any particular normal negotiation between us and the payer. It's just because of all the noise in the air with everything going on with exchanges, regulatory ambiguity in those areas, what some of the new payers are going to do in term",72,"It's not because of any particular normal negotiation between us and the payer. It's just because of all the noise in the air with everything going on with exchanges, regulatory ambiguity in those areas, what some of the new payers are going to do in terms of getting in and out of exchanges. So just so much going on that we're uneasy, increasingly uneasy, and we thought we should share that."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","So there's nothing specific across -- because I want to say, you mentioned something about the specific contract? Or I guess, maybe there was rather, on the HCP side, so maybe that's irrelevant. And I think that's all from me now.",42,"So there's nothing specific across -- because I want to say, you mentioned something about the specific contract? Or I guess, maybe there was rather, on the HCP side, so maybe that's irrelevant. And I think that's all from me now."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Okay, thank you. I think you might be referring to the DaVita Rx renewals I referred to.",17,"Okay, thank you. I think you might be referring to the DaVita Rx renewals I referred to."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Right.",1,"Right."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","That is an independent point separate from what's going on in mainstream kidney care.",15,"That is an independent point separate from what's going on in mainstream kidney care."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Ms. Margaret Kaser with William Blair.",11,"Our next question comes from Ms. Margaret Kaser with William Blair."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","First of all, thanks for all the details in terms of where you guys are investing in HCP. So maybe a question on that. What impact should we expect these investments to have? I might assume its better outcomes that are going to lead to these higher patien",78,"First of all, thanks for all the details in terms of where you guys are investing in HCP. So maybe a question on that. What impact should we expect these investments to have? I might assume its better outcomes that are going to lead to these higher patient adds. But even more specifically, over what time frame should be see the fruits of these investments? Is it as early as '17? Or is it more '18, '19, '20?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Well, Margaret, we knew this question was going to come and dreaded it because it's going to be the answer you hate. It's not going to happen right away. For example, in technology space, it'll take a year, 1 to 2 years, to get a lot of that stuff done, a",168,"Well, Margaret, we knew this question was going to come and dreaded it because it's going to be the answer you hate. It's not going to happen right away. For example, in technology space, it'll take a year, 1 to 2 years, to get a lot of that stuff done, and then the benefit has -- does not immediately leap off that P&L. In terms of our NexGen care management and change management group, that's got some near-term upside. When you're managing $4 billion of medical costs, the -- spending that extra, whatever it is, $20 million, with some new talent, with some new analytics and with some new approaches, you can get a pretty good payback on that pretty quickly. But the whole team is so new and the processes we're putting in place are so new that we would just hate to create expectations and then fail. We're very bullish on the impact they're going to have, but it just is not going to be overnight."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. So maybe to take that even further, and I'm sure you'll appreciate this question as well. But you talked about profitability in HCP maybe improving in '17, and part of that is that the reimbursement cuts from the RAF model go away. And so that shoul",99,"Okay. So maybe to take that even further, and I'm sure you'll appreciate this question as well. But you talked about profitability in HCP maybe improving in '17, and part of that is that the reimbursement cuts from the RAF model go away. And so that should be, if I'm thinking of it right, about a $60 million tailwind. But then are you going to increase investments further in '17 to offset that? And then also the final bucket in terms of the OI performance. Should that improve in '17 as Centura efforts start to have a larger impact?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. Well, you're -- you do know us well. The elimination of the RAF model that's been hanging our heads, that's certainly the elimination of a headwind. It doesn't lead to a tailwind. It just leads to the absence of wind, which, for us right now, would f",107,"Yes. Well, you're -- you do know us well. The elimination of the RAF model that's been hanging our heads, that's certainly the elimination of a headwind. It doesn't lead to a tailwind. It just leads to the absence of wind, which, for us right now, would feel pretty good assuming that benchmark rate increases would be, roughly speaking, equivalent what goes on with medical cost inflation. And so we do want 2017 OI to be nicely higher than 2016 OI because of the elimination of those headwinds and a lot of the other stuff hopefully kicking in. But did I miss a part of your question?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes. So the operating performance in Centura and effort, what kind of impact with they have in '17 and '18?",20,"Yes. So the operating performance in Centura and effort, what kind of impact with they have in '17 and '18?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Oh, thank you. On Everett, we would also expect '17 to be better than '16. '16 has some integration expenses. '16 has some adding talent to take on risk pools, so we have that expense. We have some additional amortization from the deal. And we have some s",180,"Oh, thank you. On Everett, we would also expect '17 to be better than '16. '16 has some integration expenses. '16 has some adding talent to take on risk pools, so we have that expense. We have some additional amortization from the deal. And we have some special additional expenses that exists for the first year or 2 of the deal and then go away. And so we are counting on -- we are expecting a nice operating income trajectory at Everett Clinic in '17 versus '16 and '18 versus '17 and '19 versus '18. We have high hopes for the significant growth of the business there. And then on Centura, that is a tougher one. We certainly expect it to do better in '17 than '16. It really depends on if we get a quality risk contract, what the effective date is and then how quickly we can make a difference. So that one could stretch out a little bit based on the timing of all that. We're making nice progress, but right now, there's nothing locked and loaded."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, great. And then just one more for me. You guys were nice enough to provide the kind of the nouveau clinics that were waiting for regulatory approval last quarter. How are those looking this quarter? And should we expect -- they're still to be able t",60,"Okay, great. And then just one more for me. You guys were nice enough to provide the kind of the nouveau clinics that were waiting for regulatory approval last quarter. How are those looking this quarter? And should we expect -- they're still to be able to see clinics that we'll see open in the first half of the year?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","The DeNovo backlog is still about the same as what it was last quarter. But what we're seeing is a much better improvement in opening new clinics. So that's where we'll see improvement in the first half of the year.",40,"The DeNovo backlog is still about the same as what it was last quarter. But what we're seeing is a much better improvement in opening new clinics. So that's where we'll see improvement in the first half of the year."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","And first, speaking is Patrick McKinnon, Chief Financial Officer of Kidney Care.",12,"And first, speaking is Patrick McKinnon, Chief Financial Officer of Kidney Care."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Garry Lieberman with Wells Fargo.",11,"Our next question comes from Mr. Garry Lieberman with Wells Fargo."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Sticking with HCP for a second. Is it possible to get some color on Albuquerque, maybe just how it's -- how the recovery has gone and where it is versus where it was, say, a year, 2 years ago?",39,"Sticking with HCP for a second. Is it possible to get some color on Albuquerque, maybe just how it's -- how the recovery has gone and where it is versus where it was, say, a year, 2 years ago?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is KT. I'll handle that. The difference between a year or 2 ago is night and day. It's just huge orders of magnitude better. So that's the high-level answer. The operations have been stabilized. We're in very constructive risk full conversations with",126,"This is KT. I'll handle that. The difference between a year or 2 ago is night and day. It's just huge orders of magnitude better. So that's the high-level answer. The operations have been stabilized. We're in very constructive risk full conversations with one of the major payers. We're in healthy collaboration discussions with 2 other significant health systems. The leadership has been stabilized. The management team has been improved. So there hasn't been any -- I mean, the numbers are certainly way better than 2 years ago, but I'm not wanting to represent this as we're on some stunningly steep trajectory of profit improvement. But all the fundamentals are better. And now we'll see what we can get done in the next couple of years."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then how much of your time are you spending on HCP versus on the kidney care business?",19,"Okay. And then how much of your time are you spending on HCP versus on the kidney care business?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I spend significantly more time on HCP than on domestic kidney care.",12,"I spend significantly more time on HCP than on domestic kidney care."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe just talking about the self disclosure and the CID, both happening on the same day. Is that just coincidence? Or is there something else that we could read into from that?",35,"Okay. And then maybe just talking about the self disclosure and the CID, both happening on the same day. Is that just coincidence? Or is there something else that we could read into from that?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's just totally coincidence.",5,"It's just totally coincidence."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And is there any additional color you could give us around it?",13,"Okay. And is there any additional color you could give us around it?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I don't think so, Garry. We just don't know much yet. We -- the good news is that through our own internal normal compliance processes, we uncovered some issues. And we did the right thing in investigated them. We did the right thing in reporting to the g",148,"I don't think so, Garry. We just don't know much yet. We -- the good news is that through our own internal normal compliance processes, we uncovered some issues. And we did the right thing in investigated them. We did the right thing in reporting to the government. We did the right thing in doing some refunds. All of these were small dollar issues and transactions that were a tiny, tiny percentage of overall transactions. And we kept the OIG up-to-date along the way as to the work we were doing but not completed, and then we send off our formal self-disclosure document. And it just so happened that very same day that we got the CID from the Department of Justice, and we have no idea if the Department of Justice had any idea that we were already 9 months down the track with the OIG."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And I think you said your analysis went back to 2010. And it looks like their inquiry was passed 2006. Is there anything to read into that?",28,"Okay. And I think you said your analysis went back to 2010. And it looks like their inquiry was passed 2006. Is there anything to read into that?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No. I guess, I would suggest again that there -- the 2 things aren't at all linked because clearly, they were coming up with their own set of issues and their own set of dates. But beyond that, we don't know it. As you know, in many instances, when they'r",72,"No. I guess, I would suggest again that there -- the 2 things aren't at all linked because clearly, they were coming up with their own set of issues and their own set of dates. But beyond that, we don't know it. As you know, in many instances, when they're -- once they've decide to take a look, they -- that often, that first document is very, very broad because why not?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on your comments regarding negotiating any SA contract, it sounds like you've talked -- you're talking about it more than I think you had in the past on new contract. Is there anything tangible you can share with us? Or any hope that it cou",54,"Okay. And then on your comments regarding negotiating any SA contract, it sounds like you've talked -- you're talking about it more than I think you had in the past on new contract. Is there anything tangible you can share with us? Or any hope that it could get done in the near term?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No idea. This is what -- we are eager -- I'll be redundant, but we are eager to have a long-term partner and a long-term plan, and we just think there's a lot of opportunity. But getting there, we'll take either our current partner, deciding they want to",106,"No idea. This is what -- we are eager -- I'll be redundant, but we are eager to have a long-term partner and a long-term plan, and we just think there's a lot of opportunity. But getting there, we'll take either our current partner, deciding they want to create the next generation together or us doing it with someone else. In which case, the implementation, of course, will have to wait. But the reason we're talking about it more is people are getting more serious because it's just not that far away anymore, and $800 million a year and growing is a lot to play with."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","And then I just want to maybe -- just last point on that. Is there anything do you can share with us or that you're aware of the one short-term biosimilar that has been expected to come to market but has not yet?",43,"And then I just want to maybe -- just last point on that. Is there anything do you can share with us or that you're aware of the one short-term biosimilar that has been expected to come to market but has not yet?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I don't -- I personally don't think it makes much sense for us to start talking about individual biosimilars and what exactly is going on. And so, Leanne, I don't know if there's anything you'd like to get out on the table. I -- anything I do will just be",55,"I don't -- I personally don't think it makes much sense for us to start talking about individual biosimilars and what exactly is going on. And so, Leanne, I don't know if there's anything you'd like to get out on the table. I -- anything I do will just be repeating publicly known information."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No, Kent. I think you answered that correctly.",8,"No, Kent. I think you answered that correctly."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Chris Rigg with Susquehanna.",10,"Our next question comes from Mr. Chris Rigg with Susquehanna."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","We're going to get the advance notice for 2017 MA rates next week. And obviously, I don't want to -- it's hard for you guys to predict what's going to be in there, but one thing that's been kicked around is potentially adjusting the risk model to better c",86,"We're going to get the advance notice for 2017 MA rates next week. And obviously, I don't want to -- it's hard for you guys to predict what's going to be in there, but one thing that's been kicked around is potentially adjusting the risk model to better code for duals. Do you have any thoughts on that, particularly if it's this budget-neutral? And if not, could you at least give us a sense for, within the HCP pool of enrollment, how many are duals?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. Like you observed, we don't have any idea what they're going to do. And we do believe that currently, in Medicare Advantage, the sickest people we get under reimbursed for and the healthiest people, they over reimbursed for. And for people like us wh",112,"Yes. Like you observed, we don't have any idea what they're going to do. And we do believe that currently, in Medicare Advantage, the sickest people we get under reimbursed for and the healthiest people, they over reimbursed for. And for people like us who are not insurance companies, and we want to keep the patients we have, we do keep them, we can't really determine which new ones come to us. The current reality works to our disadvantage. And then with respect to duals in particular, while we have a bunch, it's impossible to say whether we would benefit materially or not until you know whatever the heck they would do."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Got you. And then changing gears here. Just with regards to the seamless care organization rollout or pilot last fall, can you give us a sense for some initial feedback from patients? Or just anything with regard to that will be helpful.",42,"Got you. And then changing gears here. Just with regards to the seamless care organization rollout or pilot last fall, can you give us a sense for some initial feedback from patients? Or just anything with regard to that will be helpful."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is regarding ESCOs?",4,"This is regarding ESCOs?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes, yes.",2,"Yes, yes."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's just too soon, but I -- we can't tell you, though. We've been in a globally capitated pilot with CMS for 7, 8 years now, and it's pretty significant. There's 800 patients there or so, and then we have another 800, 900 globally capitated patients with",131,"It's just too soon, but I -- we can't tell you, though. We've been in a globally capitated pilot with CMS for 7, 8 years now, and it's pretty significant. There's 800 patients there or so, and then we have another 800, 900 globally capitated patients within our HealthCare Partners universe. And in general, and in particular on the kidney care side were they SNIP plan, special needs plan is focused just on these kidney care patients, it's spectacular. The patients get extra services. The doctors have extra support. The referring doctors get better information. The nurses get to provide coordinated care. The patient and family get support at home. So I can tell you in our mature other work where we're globally capitated, it's a spectacular beautiful transparent victory."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Whit Mayo with Robert W. Baird.",12,"Our next question comes from Mr. Whit Mayo with Robert W. Baird."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Kent, you've discussed in the past your desire to reengage in productive conversations with your health plan partners to ensure that your incentives are aligned with their incentives, and they treat you as a good partner with the MA rate cuts. And are the",59,"Kent, you've discussed in the past your desire to reengage in productive conversations with your health plan partners to ensure that your incentives are aligned with their incentives, and they treat you as a good partner with the MA rate cuts. And are there just any developments along the recontracting front that would be of any interest to us?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes is the short answer. Every -- I'm not going to get the mix right, but if you ask on Capital Markets Day, we'll have it, and Jim Rechtin is not here right now. But a -- I would say a healthy percentage of our renewals and up with a new agreement where",137,"Yes is the short answer. Every -- I'm not going to get the mix right, but if you ask on Capital Markets Day, we'll have it, and Jim Rechtin is not here right now. But a -- I would say a healthy percentage of our renewals and up with a new agreement where our interests are much more aligned. And that's been true every year. There's a big shift from what existed before. And the same statement is true with respect to health systems and hospitals where a very solid percentage of our new contracts there create a lot more alignment than the old ones, which were so 0 sum. So I would say it's steady progress, nothing dramatic, but it's really healthy in reducing downside risks, and over the long term will create some shared upside."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And just on Renal Ventures. I don't think I've heard an update. Just -- maybe I should know this, but just divestitures of TC and any sense for the contribution this year?",33,"Great. And just on Renal Ventures. I don't think I've heard an update. Just -- maybe I should know this, but just divestitures of TC and any sense for the contribution this year?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is Javier Rodriguez, CEO of Kidney Care. There is no update. We're still anticipating in Q2 close.",18,"This is Javier Rodriguez, CEO of Kidney Care. There is no update. We're still anticipating in Q2 close."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And maybe one last one is just any way to get the size of DaVita Rx now either by patients or revenue?",23,"Okay. And maybe one last one is just any way to get the size of DaVita Rx now either by patients or revenue?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Boy, I don't remember what our historical policy has been. It is certainly grown. It is making some money. It's not losing money anymore. And I'm going to have to turn to Jim Gustafson so I don't violate any policy. Go ahead, Jim.",43,"Boy, I don't remember what our historical policy has been. It is certainly grown. It is making some money. It's not losing money anymore. And I'm going to have to turn to Jim Gustafson so I don't violate any policy. Go ahead, Jim."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. We disclosed -- we're serving in various capacities 155,000 patients, and that includes both internal and external.",18,"Yes. We disclosed -- we're serving in various capacities 155,000 patients, and that includes both internal and external."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Ryan Newman with Promus Capital.",11,"Our next question comes from Mr. Ryan Newman with Promus Capital."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","You spoke a little bit about softness in some of the international markets and how other players were attracted to those as well. So I didn't you've expanded a little bit in Colombia, in Portugal and then China, Germany. Can you just talk about a bit how",52,"You spoke a little bit about softness in some of the international markets and how other players were attracted to those as well. So I didn't you've expanded a little bit in Colombia, in Portugal and then China, Germany. Can you just talk about a bit how where the most softness occurred?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Where the most of what has occurred?",7,"Where the most of what has occurred?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Where the softness conditions existed internationally.",6,"Where the softness conditions existed internationally."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Softness conditions?",2,"Softness conditions?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes.",1,"Yes."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","So soft as in...",5,"So soft as in..."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","The worst performance.",3,"The worst performance."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Poor performance? Okay. Thank you. Sorry for my...",8,"Poor performance? Okay. Thank you. Sorry for my..."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","I misworded the question. I apologize.",6,"I misworded the question. I apologize."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I'd say the softest performance from a profit point of view -- I mean, my mind is raising as to how much I should disclose.",26,"I'd say the softest performance from a profit point of view -- I mean, my mind is raising as to how much I should disclose."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Sure.",1,"Sure."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes, we've had some profit problems in Colombia. That probably sticks out as one of the softest. In Saudi, we've been growing a little bit behind plan, but the microeconomics appear to be solid. And I think beyond that, I'd have to get into so many nuance",155,"Yes, we've had some profit problems in Colombia. That probably sticks out as one of the softest. In Saudi, we've been growing a little bit behind plan, but the microeconomics appear to be solid. And I think beyond that, I'd have to get into so many nuances. In China, we still put in the R&D category where we're very steadily consistently interesting to look for the winning formula, and we don't have it yet but we're not discouraged. We've got some stuff that's working there. We have some stuff that's not working, and that's kind of the hit rate we expected. India, we know is a long-haul kind of thing, an immense market, but we're not going to start doing anything big there quickly because the microeconomics are just too tiny. So there's a little bit of flavor across 3 or 4, and I'm probably giving Jim Gustafson a heart attack by providing all this."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","At this time, we no longer have further questions on queue. [Operator Instructions]",13,"At this time, we no longer have further questions on queue. [Operator Instructions]"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Well, we -- the Capital Markets are May 18th, correct, Jim?",11,"Well, we -- the Capital Markets are May 18th, correct, Jim?"
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","In New York. We're going to nail down the location. There's a lot to talk about. We look forward to going into more detail. We're going to have a longer general session than we normally do, so that we hopefully give you a very comprehensive and analytical",101,"In New York. We're going to nail down the location. There's a lot to talk about. We look forward to going into more detail. We're going to have a longer general session than we normally do, so that we hopefully give you a very comprehensive and analytically thoughtful, not only reiteration of our strategy, but our progress and the right kind of leading indicators to stare at. So we're looking forward to a real high-intensity extended exchange, and we'll do our best in between now and then to get through '16 and start growing again in '17. Thank you very much."
35644,324689788,932483,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Thank you. So that concludes today's conference call. Thank you all for participating. You may now disconnect.",17,"Thank you. So that concludes today's conference call. Thank you all for participating. You may now disconnect."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Welcome to the DaVita HealthCare Partners Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] And now, I'll turn the call over to your host, Mr. Jim Gustafson. Thank you. You may begin.",32,"Welcome to the DaVita HealthCare Partners Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] 
And now, I'll turn the call over to your host, Mr. Jim Gustafson. Thank you. You may begin."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thank you, Vince, and welcome, everyone, to our fourth quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Jim Hilger, our Inter",220,"Thank you, Vince, and welcome, everyone, to our fourth quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Jim Hilger, our Interim CFO and Chief Accounting Officer; Vijay Kotte, our CFO for Healthcare Partners; and LeAnne Zumwalt, Group Vice President.
I'd like to start by noting that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in these statements. For further details concerning the risks and uncertainties, please refer to our SEC filings included in our most recent annual report and subsequent quarterly reports. Our forward-looking statements are based upon information currently available to us, and we do not intend and disclaim any duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website. 
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","All right. Thank you, Jim, and welcome to all. This will be a pretty high-density call, and I'll be covering more topics than normal because of some of the nuances contained therein. As usual, I will first talk about our clinical outcomes because that i",2547,"All right. Thank you, Jim, and welcome to all. This will be a pretty high-density call, and I'll be covering more topics than normal because of some of the nuances contained therein. 
As usual, I will first talk about our clinical outcomes because that is what comes first. Second, for each major business unit, I'll talk about the operating performance for the quarter and year and provide some thoughts on '16. Third, we'll then step back on each business briefly, and on the enterprise overall to try to set the table for our Capital Markets Day coming up on May 18, in New York City. And then lastly, I'll talk about enterprise capital allocation.
So let's launch right in since there's quite a bit to cover. On the clinical outcome front, excellent news, once again. Kidney Care, 97% of our patients with a Kt/V of 1.2 or greater, 73% of patients with fistulas placed for access; and very recently, final results announced for the CMS QUIP program for another year period, once again, we outperformed the rest of the community with only 1.4% of our facilities facing a penalty compared to 7.1% for the rest of the industry. Of course, no quality rating system is perfect, but in rating test after rating test, we come out as clinically differentiated. 
On the HCP front, equally promising results. With respect to HEDIS clinical metrics, we'll just pick Nevada this time. We try to move it around for you geographically. And in terms of subject matter, we once again exceeded the Medicare fee-for-service benchmark on all metrics, then had 4 or 5 star across all MA patients on all non-HEDIS metrics. So in both cases, both main sides of the house, our outcomes compare very favorably to national averages. This is good for patients. This is good for the taxpayer.
Now let's move on to the quarter and the year. We'll hit HCP first; international, second; kidney care, third. HCP operating performance for the quarter, $25 million. That excluded the estimated write-down. This was within our guidance range. On a normalized basis, this was actually about $37 million, if you normalize for prior-period adjustments, et cetera, which actually is about exactly the same amount of profit in Q4 of 2014 normalized.
For the full year, OI improved, as you know, from $215 million to $240 million, which is also within our guidance, although at the low end. In order to achieve that, the legacy markets were up a bit. The new markets were up a bit. And the combination of those bits was more than enough to make up for the medical cost inflation and some very substantial investments in capability building/G&A. And Vijay Kotte, our new HCP CFO, will discuss those investments and capabilities in G&A in more detail in just a few minutes.
But I will, as said, move right on to 2016 guidance for HCP. It is $175 million to $225 million. There are 3 primary drivers of that range. Driver number one, $58 million in reimbursement cuts. This is primarily the result of the new acuity coding RAF model being implemented the final trunk of the way, 100% implemented as of that time. As previously discussed, the HCP was more comprehensive in its coding capture. Complete diagnosis of patient conditions is a good thing, but it also left the entity far more vulnerable to any coding reimbursement compression. So $58 million from that source, most of it, the model, and the model is now 100%. 
And second big driver of that range is our investment in additional capabilities. There's 2 components to this $60 million year-over-year increase. Component A is really remedial. Their prior business leadership essentially stopped investing in the company. It was working to maximize profitability for the sale, either knowingly or unknowingly. And as a side note, I just want to remind you that we knew that. That is why we only paid a 6x multiple in a world where other allegedly comparable assets were going for 9x to 10x then and now, much greater than 10x in the market. 
And the second component of that big G&A capability investment is offensive, meaning investments that we think that are going to create significant competitive advantage for us over time. 
The third primary driver is the positive one, which offsets a big chunk of those 2 negative ones: Solid operating performance, good old solid operating performance. So if you look at the math, you have a $58 million hit from the -- essentially the completion of the RAF model. You have a $60 million hit from the increased investment in G&A, half remedial, half offensive. That would equal $118 million hit. You then have a $78 million operating performance improvement, which offsets all but $40 million of the 2 negative trends. And that yields the change from the $240 million in 2015 OI to the midpoint of the guidance, $200 million for 2016. We can, of course, take questions on all of that, but those are the 3 primary drivers. 
2017 does look better than 2016. The model will be behind us, and we continue to make steady progress on our capabilities and our contracting. If we put the P&L aside for a moment and look at cash flow and take as a scenario the midpoint of our guidance, in other words, the $200 million for HCP, and simultaneously take the midpoint of our guidance for the total enterprise, that $200 million would equal 11% of total enterprise operating income.
However, HCP operating cash flow is projected to be over $400 million, about 25% of total enterprise operating cash flow. This happens because of what we've talked about in the past, lower in capital intensity, low CapEx requirements and $100 million per year hard dollar cash tax benefit.
If we step back for a moment and look back at 3 difficult years, the total reimbursement cut from the implementation of the new RAF model for us, $165 million. What we had anticipated was a much smaller number than that. In fact, less than half. So about $100 million of incremental P&L harm that we had not expected is due to that single variable, $100 million. Now the fact that it came from that does not make it any less painful than if it came from anything else, but the important message is it did not come from operating problems or operating issues.
Looking forward, instead of backward, we have 6 primary markets: California, Nevada, Florida, New Mexico, Colorado and Washington, and more particularly, the Seattle area. In those primary markets, we have 6 leading independent medical groups. It is in those places, plus our joint venture, Tandigm in Philadelphia, of course, but that is a horse of a different color, that is where we'll be placing most of our emphasis in the near and perhaps intermediate term. Prices are very high right now for variable properties. Our bandwidth is pretty stretched given how much we've grown and given how much opportunity we have in those 6 markets, plus with Tandigm.
And then third, we need to prove to you that we can get the right returns and margins in a number of those places before we do too many other significant things. Because of all that, it is unlikely we will do any other big Everett-like deal, unless it is through a capital-light transaction or is for a very attractive multiple. 
Other good news to take into account, and looking forward instead of backward, a list of few of them, each of a different type. First, our legacy markets in 2015, once again, outgrew their markets in terms of MA growth. The markets grew 6%. We grew 9%.
Number two, we've dramatically improved patient service metrics since the time of the transaction.
Number three, we've had a number of significant IT advances that have improved our support for our frontline physicians. We have a long journey there, and Vijay will talk about that a little more, but we've got some nice early momentum and victories in better supporting our frontline physicians.
Number four, we've had a number of forecasting and prior period adjustment issues. You know that painful truth as we do. Our finance leadership team is literally 90% new.
And fifth, and finally, in this case, if you look at our top 22 executives, we have 5 great veterans with immense amounts of valuable ACP experience and 17 new executives that we think are the right people to help take us into that next chapter going forward.
So that's it on HCP for now, although Vijay will come back and talk about some of those capability and G&A investments a little bit later.
Let's move onto international. We underperformed in 2015. $55 million in losses compared to original $40 million of guidance. Why? Well, we had a $5 million AR reserve, which almost entirely came from 1 country where there were 2 fiscal intermediaries who became insolvent. We actually hope to get a bunch of that money back. We also are $10 million behind plan or were $10 million behind plan in 2 countries where we built new centers and patient growth was behind plan.
In 2016, for international, our guidance is losses of approximately $40 million. This assumes no unusual AR reserves. We are experiencing payment delays with the Saudi government, so that's a watch-out, but we have done nothing on that front now. We still expect to receive all of the funds. And the good news is the Ministry of Health in Saudi is explicitly very happy with our service and very impressed by the patient feedback they have received. Their words, not ours.
In 2017, we anticipate improvement over '16 on an OI basis. And in 2018, in international dialysis, in our current country portfolio, we expect to achieve breakeven. We are, in fact, already in 2015 -- or we did already in 2015, generate positive aggregate EBITDA at the clinic level in 8 out of our 10 countries as we continue to grow and cover our G&A. 
And another reference point that gives you a sense of the per-country scale. In 2014, we had an average of $10 million revenue per country. 2015, an increase of 50%, up to $15 million. 2016, if we hit our plan, we'll be $27 million in revenue per country. So you can see that, at reasonable margins, we are making strong progress in covering the fixed amount of global G&A.
Finally, most of our growth internationally has been through acquisition. Virtually, every 1 of those acquisitions has been competed for with others. And so these are market-valuable assets that real competition wanted to have. And our competitors continue to invest in growing internationally as well because of the returns they see. 
Stepping back for a moment, with respect to international, we are still very bullish on the long-term opportunity both in kidney care and other health care services.
Now onto the kidney care operating performance. Once again, strong quarter, strong year. Operating income, $449 million. And then for the year, $1.658 billion. First number was for the quarter, of course, once again excluding some nonrecurring stuff. Jim Hilger will provide more details on the numbers. 
I'll go right into guidance. We anticipate, in 2016, another solid year, $1.625 billion to $1.725 billion. Of course, there's always risk we'll fall short and there's always hope that we will exceed. This guidance, for our normal customs, does include the international economics and it also includes the unfortunate fact of flat Medicare reimbursement for the third straight year.
The uncertainty in our 2016 performance, as in many recent years, it centers on revenue and revenue per treatment. We anticipate our performance in the first half of the year with respect to RPT to be positive, but we have a lot less visibility into the second half of the year, hence, the broadness of the range. 
And regarding the strategic initiatives, there could be some earnings volatility there. One reason is ESCOs, as you know we have launched, and so we incur those costs, particularly those extra startup costs now, and we get the shared savings payment later if we perform and the data is correct. And the second variable are some Rx, to be the Rx renewals. All of this, of course, is incorporated into our guidance.
Stepping back now with respect to kidney care and looking out 3, 4 or 5 years, is one big downside and 3 attractive upsides. The big downside is what will happen to private pay? It is unfortunate that we have a large cost shift in our dialysis industry in America with private patients paying a lot more to subsidize the 80% to 90% of our patients that are Medicare and Medicaid. And when you put that on top of payer consolidation, distributed risk pools, exchanges and other things going on, it would not be prudent to not be nervous about what will happen with private pay.
On the other hand, we do have 3 upsides. One is in the ESA market. For the long term, as many of you know, we spend about $800 million per year on ESAs. We are intensely looking for the right long-term partner or partners in the hope to consummate some type of long-term partnership well before the expiration of our current contract at the end of 2018.
Second, integrated kidney care. We are very competent at this. Regardless of who has the risk, we think we will be one of the subcontractors of choice.
And third, finally, the flat Medicare reimbursement is scheduled to go away at the end of 2018. In 2019, we hope to be back to our normal market basket. All in all, our strategic position in U.S. kidney care is strong.
Now let's step back to the enterprise overall. The guidance OI of $1.8 billion to $1.95 billion. OCF, $1.55 billion to $1.75 billion. But on an equally important topic, how are we thinking about capital allocation at the enterprise level? Well, first, with kidney care, we stay the course. And since there aren't a lot of large properties available out there, that means they will not use all the cash they generate. 
HCP, they will focus on existing markets, unless something that is capital-light or at a very attractive multiple comes along. 
International, we will continue to invest to grow. Putting all 3 of those together, what does our capital allocation look like if you pick something arbitrary like the next 3-year period? We will generate, in a reasonable scenario, with, of course, downside risk and upside, but in the reasonable scenario, we will generate operating cash flow of approximately $5.5 billion in the next 3 years. If you count normal use, meaning our current operating plans, business plans, et cetera, which, of course, could change, we will use about $3.5 billion for those purposes. This leaves about $2 billion on the side for us to contemplate what to do with, with, of course, your counsel as well as we compare other growth opportunities to debt repayment opportunities, to share repurchase opportunities. 
Now Vijay Kotte, our new CFO of Healthcare Partners, will walk through a few more details."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. I'll take a few minutes to provide more detail into the investments we're making into the future. As Kent stated before, we are continuing to make both remedial and offensive investments into the business. The best way to look at these items",235,"Thanks, Kent. I'll take a few minutes to provide more detail into the investments we're making into the future. As Kent stated before, we are continuing to make both remedial and offensive investments into the business. The best way to look at these items is to put 2015 and 2016 together. When you do that, we have a total of approximately $80 million in incremental investments over 2014. 
To provide more context into these investments, I will put them into 3 primary buckets: First, we have information technology; second, legal and compliance; and third, the next-generation capability and change management.
In the bucket of IT, we plan to spend $40 million more in '16 than we did in 2014. This includes the following areas: First, security; second, applications to support population health; third, a community portal to enhance communication between patients and providers, an enterprise data warehouse, our accounting system conversion and a national IT infrastructure to enable our creation of one company.
Next, in the legal and compliance bucket, we will invest an additional $10 million to $15 million over 2014. 
In our final bucket, we're investing approximately $18 million into research and development related to next-generation care management capabilities, a team we call catalysts, with applications to our current markets as well as others.
Now Jim Hilger, our CFO, will walk you through a few more details on the numbers in the quarter."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. First, I'd like to point out a couple of non-GAAP items in the quarter. In the fourth quarter, we recorded an estimated accrual of $23 million for potential damages and liabilities in our DaVita Rx pharmacy business. We have excluded these",654,"Thanks, Vijay. First, I'd like to point out a couple of non-GAAP items in the quarter. In the fourth quarter, we recorded an estimated accrual of $23 million for potential damages and liabilities in our DaVita Rx pharmacy business. We have excluded these numbers from our reported non-GAAP income from continuing operations. 
A few words about this estimated accrual. The reserves relate to the period from 2010 through 2015. As a part of our normal process, last spring, we initiated an internal compliance review of DaVita Rx, during which, we identified potential billing and operational issues. We notified the government in September of 2015 that we were conducting this review of DaVita Rx and began providing regular updates of our review. Upon completion of our review, we filed a self-disclosure with the OIG on February 5, 2016, and we have been working to address and update the practices we identified in the self-disclosure. 
In addition, as disclosed earlier today, on February 5, 2016, DaVita Rx received a civil investigative demand from the U.S. Attorney's Office. The information requested has some overlap with the items we self-disclosed. And we do not know that the U.S. Attorney knew we are already in the process of developing a self-disclosure with the OIG.
At HCP, we took an estimated $206 million impairment charge of noncash goodwill and an intangible asset of certain health care partner operating units. These impairments were driven primarily by underperformance of the business reporting units in recent quarters, as well as changes in other market conditions, including government reimbursement cuts and our expected ability to mitigate those cuts.
The final amount of these impairment charges will depend upon the final outcome of this valuation work, which we expect to be completed in the first quarter of 2016. This noncash charge will not impact go-forward performance or our cash taxes.
Onto the overall enterprise. Our debt expense was $103 million in the fourth quarter, which is a good run rate for a debt expense in future quarters. Our income attributable to noncontrolling interests was $40 million.
Next, our effective tax rate for income attributable to DaVita HealthCare Partners in the fourth quarter was 36% and for the year was 38.2%. And we expect the full year tax rate for 2016 to be in the range of 40% to 41%.
We have also repurchased $151 million of our common stock in the fourth quarter, and we also repurchased an additional $249 million in the month of January. As a result of these transactions, we now have approximately $259 million remaining under our current board authorization.
As you think about modeling the first quarter, here are a few things that you should keep in mind. In our dialysis business, Q1 2015 contains -- or '16 contains 1 fewer day than this past quarter. So you should expect lower revenues and higher fixed costs per treatment. 
Second, our payroll tax cap is reset at the beginning of the year, which leads to higher costs of $1 to $1.50 per treatment. At HCP, OI fluctuates from quarter-to-quarter due to the seasonal needs of patients, and Q1 tends to be a bit lighter than the full year average.
Now turning to cash flow. We continue to generate strong cash flows as operating cash flow was $437 million in the fourth quarter and $1.861 billion for all of 2015, excluding the Vainer settlement. The strong cash flows in 2015 are borrowing a bit from 2016 operating cash flow, mostly due to the timing of cash tax payments and other working capital items. But despite that, we still expect 2016 operating cash flows to be $1.55 billion to $1.75 billion, showing that we continue to generate strong cash flows. As always, this guidance range captures a majority of probabilistic outcomes, but we could be above or below this range. 
And with that, operator, let's go ahead and open it up for Q&A."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question comes from Mr. Matthew Borsch with Goldman Sachs.",13,"[Operator Instructions] Our first question comes from Mr. Matthew Borsch with Goldman Sachs."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Could you maybe just address the areas of operating performance improvement that you're expecting in the HCP business? Maybe just -- I don't know if there's any kind of granularity that you're prepared to give at this point, whether it's by geography or f",64,"Could you maybe just address the areas of operating performance improvement that you're expecting in the HCP business? Maybe just -- I don't know if there's any kind of granularity that you're prepared to give at this point, whether it's by geography or function. I'm just curious the types of things that you think are going to be better this year versus last."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Matthew, this is Kent. It's -- thanks for getting on the call. It's pretty broad-based, so there's nothing, really, that jumps out. There's no dramatic disparity in unit growth or margin enhancement either through MOR improvement or G&A savings or revenue",49,"Matthew, this is Kent. It's -- thanks for getting on the call. It's pretty broad-based, so there's nothing, really, that jumps out. There's no dramatic disparity in unit growth or margin enhancement either through MOR improvement or G&A savings or revenue enhancements. So it's pretty mixed across the portfolio."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","And let me ask on a different front, still related to HCP. As you look at things that are potentially for sale, and you mentioned prices are high, is that still principally because of the major hospital systems that are bidding up? Is it, I mean, more the",61,"And let me ask on a different front, still related to HCP. As you look at things that are potentially for sale, and you mentioned prices are high, is that still principally because of the major hospital systems that are bidding up? Is it, I mean, more the same hospitals? How much is hospitals? How much is managed care versus other?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. Certainly, health system is a bit sometimes breathtaking amounts for these medical groups, but we have been surprised by some of the other players, including some of the health insurance entities and the offers that they've put on the table as well",43,"Right. Certainly, health system is a bit sometimes breathtaking amounts for these medical groups, but we have been surprised by some of the other players, including some of the health insurance entities and the offers that they've put on the table as well."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Kevin Ellich with Piper Jaffray.",11,"Our next question comes from Mr. Kevin Ellich with Piper Jaffray."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Kent, I guess, just kind of big picture. Thinking about the guidance, which historically, you've had a track record of being conservative. But if you look over the last few years, we haven't seen much growth in operating income. I guess, clearly, there's",64,"Kent, I guess, just kind of big picture. Thinking about the guidance, which historically, you've had a track record of being conservative. But if you look over the last few years, we haven't seen much growth in operating income. I guess, clearly, there's been some issues with HealthCare Partners, but I guess, broadly speaking, what will it take before -- to get growth reaccelerating?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","A very fair question, Kevin, and one that we are pretty intense about on the inside. On the kidney care front, with that flat Medicare reimbursement, that's just a real problem that we've got to get addressed. And then hopefully, through a new partner or",152,"A very fair question, Kevin, and one that we are pretty intense about on the inside. On the kidney care front, with that flat Medicare reimbursement, that's just a real problem that we've got to get addressed. And then hopefully, through a new partner or the same partner and a new partnership with the SAs, or getting some integrated care runway, we can start to break out of the current trend. On the HCP side, of course, some of the declines have taken away their kidney care gains. And so if we just stopped that and get back to reasonable steady growth on HCP, that, together with the normal growth in kidney care, could start to generate some much more interesting numbers. And then lastly, international is, unfortunately, just a couple of years away from being able to really help. Although once it starts helping, it could be a long-term big deal."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Got it. Okay. And then going back to your comments on kidney care and the potential downside and 3 factors for a potential upside, in the ESA component, you said that contract expires in 2018. Should we expect to see something happen in the next year or 2",48,"Got it. Okay. And then going back to your comments on kidney care and the potential downside and 3 factors for a potential upside, in the ESA component, you said that contract expires in 2018. Should we expect to see something happen in the next year or 2?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","We would like to develop the right kind of long-term win-win partnership sooner rather than later. We have the contract we have with Amgen, and so if they don't want to do anything new with us, we certainly can't force them to. Having said that, there are",160,"We would like to develop the right kind of long-term win-win partnership sooner rather than later. We have the contract we have with Amgen, and so if they don't want to do anything new with us, we certainly can't force them to. Having said that, there are other people that we can create agreements with that just wouldn't kick in until the day after the Amgen agreement expired. So our point is pretty simple. That we think we can be a great partner for someone for the next 5 to 10 years in that area, and we're eager to find that party and start working towards that long-term future. Necessarily, even if we got very serious with someone tomorrow, these deals are pretty complicated and nothing would be signed for some time. But that's one of the reasons why we want to start working on them now because it takes a while to put them together. Is that responsive?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","It is. And can you remind us, I think in the contract, you had the ability for 10% of your ESA supply to come from someone else. Are you guys testing other options out right now? And if so, how's that going?",42,"It is. And can you remind us, I think in the contract, you had the ability for 10% of your ESA supply to come from someone else. Are you guys testing other options out right now? And if so, how's that going?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","LeAnne, you want to talk about that?",7,"LeAnne, you want to talk about that?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly. We do plan to do some pilots over the next year.",12,"Certainly. We do plan to do some pilots over the next year."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. Will you go with 1 source? Or will you try different options, LeAnne?",14,"Okay. Will you go with 1 source? Or will you try different options, LeAnne?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly, we'll try multiple options.",5,"Certainly, we'll try multiple options."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, great. And then, I guess, going to hammer -- going to the share repurchase, you guys were very active in January. I think you said you have $259 million remaining. Should we expect to see continued share repurchase activity maybe get -- are you guys",77,"Okay, great. And then, I guess, going to hammer -- going to the share repurchase, you guys were very active in January. I think you said you have $259 million remaining. Should we expect to see continued share repurchase activity maybe get -- are you guys going to go back to the board to get a -- to re-up the authorization? And even though you don't provide EPS guidance, is that part of your outlook for 2016?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes, I'll go ahead and take that one. We're going to apply the same sort of measured calculus we've always applied, that looking at the alternative deployments, looking at the different scenarios going forward, looking at interest rates, looking at the st",164,"Yes, I'll go ahead and take that one. We're going to apply the same sort of measured calculus we've always applied, that looking at the alternative deployments, looking at the different scenarios going forward, looking at interest rates, looking at the stock price, as a CEO, I'm feeling a little sheepish about the fact that we bought back quite a bit when the stock was a fair amount higher than it is today, and we would have done more value for -- created more value for our long-term shareholders by waiting a little bit as opposed to buying when we were at above historical average EBITDA multiple. So we bring our normal sort of intellectual calculus to it. But certainly, we've demonstrated over the last year, and certainly, many of you were actively engaged in encouraging us to, certainly we've demonstrated, as we have at different types in our history, the willingness to go into the market and take some shares out of play."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Kevin Fischbeck of Bank of America Merrill Lynch.",14,"Our next question comes from Mr. Kevin Fischbeck of Bank of America Merrill Lynch."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","This is actually in Joanna Gajuk, filling in for Kevin today. So on HCP guidance and the breakdown on different elements that are impacting the output income, specifically, I recall the company mentioned on the last call Medicaid headwinds of $20 million?",66,"This is actually in Joanna Gajuk, filling in for Kevin today. So on HCP guidance and the breakdown on different elements that are impacting the output income, specifically, I recall the company mentioned on the last call Medicaid headwinds of $20 million? So should we assume that you'd no longer include that headwind? Or it's just all that if you don't -- you didn't disclose it?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","When it happened, we thought it would be Medicaid at $20 million. It turns out, Medicaid is $8 million. And so when we talked about $58 million, $50 million was that RAF model at Medicare, $8 million was Medicaid.",39,"When it happened, we thought it would be Medicaid at $20 million. It turns out, Medicaid is $8 million. And so when we talked about $58 million, $50 million was that RAF model at Medicare, $8 million was Medicaid."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, that makes sense. So then I know you mentioned that those headwinds, you expect to be offered by a broad, I guess, base operating improvement. But are you willing to talk about the legacy markets performance 2015? I don't know whether specific numbe",65,"Okay, that makes sense. So then I know you mentioned that those headwinds, you expect to be offered by a broad, I guess, base operating improvement. But are you willing to talk about the legacy markets performance 2015? I don't know whether specific numbers are up or down or the magnitude of improvement? And then what do you think this would be 2016 versus '15?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. In 2015, our legacy markets contributed to the profit growth, the OI growth, as did our new markets. So both were contributors to our ability to offset the bad stuff that happened in normal medical cost inflation and our big investments. In 2016, w",69,"Right. In 2015, our legacy markets contributed to the profit growth, the OI growth, as did our new markets. So both were contributors to our ability to offset the bad stuff that happened in normal medical cost inflation and our big investments. In 2016, we anticipate the same, that independent of the rate cuts, that both legacy markets and new markets will do better than they did in '15."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And then just a follow-up on your comment around the dialysis business and the pricing, that you expect the pricing to be positive in first half, but there's less visibility for the second half of the year. So can you shed a little more light why y",50,"Great. And then just a follow-up on your comment around the dialysis business and the pricing, that you expect the pricing to be positive in first half, but there's less visibility for the second half of the year. So can you shed a little more light why you think that?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's not because of any particular normal negotiation between us and the payer. It's just because of all the noise in the air with everything going on with exchanges, regulatory ambiguity and those areas, what some of the new payers are going to do in ter",73,"It's not because of any particular normal negotiation between us and the payer. It's just because of all the noise in the air with everything going on with exchanges, regulatory ambiguity and those areas, what some of the new payers are going to do in terms of getting in and out of exchanges. So it's just so much going on that we're uneasy, increasingly uneasy, and we thought we should share that."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","So there's nothing specific across -- because I want to say, you mentioned something about a specific contract? Or I guess, maybe there was rather, on the HCP side, so maybe that's irrelevant. And I think that's all from me now.",42,"So there's nothing specific across -- because I want to say, you mentioned something about a specific contract? Or I guess, maybe there was rather, on the HCP side, so maybe that's irrelevant. And I think that's all from me now."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Okay, thank you. I think you might be referring to the DaVita Rx renewals I referred to.",17,"Okay, thank you. I think you might be referring to the DaVita Rx renewals I referred to."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Right.",1,"Right."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","But that is an independent point separate from what's going on in mainstream kidney care.",16,"But that is an independent point separate from what's going on in mainstream kidney care."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Ms. Margaret Kaczor with William Blair.",11,"Our next question comes from Ms. Margaret Kaczor with William Blair."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","First of all, thanks for all the details in terms of where you guys are investing in HCP. So maybe a question on that. What impact should we expect these investments to have? I might assume it's better outcomes that are going to lead to these higher patie",78,"First of all, thanks for all the details in terms of where you guys are investing in HCP. So maybe a question on that. What impact should we expect these investments to have? I might assume it's better outcomes that are going to lead to these higher patient adds. But even more specifically, over what time frame should we see the fruits of these investments? Is it as early as '17? Or is it more '18, '19, '20?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. Well, Margaret, we knew this question was going to come and dreaded it because it's going to be the answer you hate. It's not going to happen right away. For example, in technology space, it'll take a year, 1 to 2 years to get a lot of that stuff d",169,"Right. Well, Margaret, we knew this question was going to come and dreaded it because it's going to be the answer you hate. It's not going to happen right away. For example, in technology space, it'll take a year, 1 to 2 years to get a lot of that stuff done, and then the benefit has -- does not immediately leap off the P&L. In terms of our NexGen care management and change management group, that's got some near-term upside. When you're managing $4 billion of medical cost, the -- spending that extra, whatever it is, $20 million, with some new talent, with some new analytics and with some new approaches, you can get a pretty good payback on that pretty quickly. But the whole team is so new and the processes we're putting in place are so new that we would just hate to create expectations and then fail. We're very bullish on the impact they're going to have, but it just is not going to be overnight."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. So maybe to take that even further, and I'm sure you'll appreciate this question as well. But you talked about profitability in HCP maybe improving in '17, and part of that is that the reimbursement cuts from the RAF model go away. And so that shoul",100,"Okay. So maybe to take that even further, and I'm sure you'll appreciate this question as well. But you talked about profitability in HCP maybe improving in '17, and part of that is that the reimbursement cuts from the RAF model go away. And so that should be, if I'm thinking of it right, about a $60 million tailwind. But then are you going to increase investments further in '17 to offset that? And then also, the final bucket in terms of the OI performance. Should that improve in '17 as Centura and Everett start to have a larger impact?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. Well, you're -- you do know us well. The elimination of the RAF model that's been hanging our heads, that's certainly the elimination of a headwind. It doesn't lead to a tailwind. It just leads to the absence of wind, which, for us right now, would f",108,"Yes. Well, you're -- you do know us well. The elimination of the RAF model that's been hanging our heads, that's certainly the elimination of a headwind. It doesn't lead to a tailwind. It just leads to the absence of wind, which, for us right now, would feel pretty good assuming that benchmark rate increases would be, roughly speaking, equivalent to what goes on with medical cost inflation. And so we do want 2017 OI to be nicely higher than 2016 OI because of the elimination of those headwinds and a lot of the other stuff hopefully kicking in. But did I miss a part of your question?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes. So the operating performance in Centura and Everett, what kind of impact will they have in '17 and '18?",20,"Yes. So the operating performance in Centura and Everett, what kind of impact will they have in '17 and '18?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Oh, thank you. On Everett, we would also expect '17 to be better than '16. '16 has some integration expenses. '16 has some adding talent to take on risk pools, so we have that expense. We have some additional amortization from the deal. And we have some s",180,"Oh, thank you. On Everett, we would also expect '17 to be better than '16. '16 has some integration expenses. '16 has some adding talent to take on risk pools, so we have that expense. We have some additional amortization from the deal. And we have some special additional expenses that exists for the first year or 2 of the deal and then go away. And so we are counting on -- we're expecting a nice operating income trajectory at The Everett Clinic in '17 versus '16 and '18 versus '17 and '19 versus '18. We have high hopes for the significant growth of the business there. And then on Centura, that is a tougher one. We certainly expect it to do better in '17 than '16. It really depends on if we get a quality risk contract, what the effective date is and then how quickly we can make a difference. So that one could stretch out a little bit based on the timing of all that. We're making nice progress, but right now, there's nothing locked and loaded."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, great. And then just one more for me. You guys were nice enough to provide kind of the nouveau clinics that were waiting for regulatory approval last quarter. How are those looking this quarter? And should we expect they're still being -- they're st",62,"Okay, great. And then just one more for me. You guys were nice enough to provide kind of the nouveau clinics that were waiting for regulatory approval last quarter. How are those looking this quarter? And should we expect they're still being -- they're still to be able as with clinics that we'll see open in the first half of the year?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","The DeNovo backlog is still about the same as what it was last quarter. But what we're seeing is a much better improvement in opening new clinics. So that's where we'll see improvement in the first half of the year.",40,"The DeNovo backlog is still about the same as what it was last quarter. But what we're seeing is a much better improvement in opening new clinics. So that's where we'll see improvement in the first half of the year."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","And that person speaking is Patrick McKinnon, Chief Financial Officer of Kidney Care.",13,"And that person speaking is Patrick McKinnon, Chief Financial Officer of Kidney Care."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Gary Lieberman with Wells Fargo.",11,"Our next question comes from Mr. Gary Lieberman with Wells Fargo."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Sticking with HCP for a second. Is it possible to get some color on Albuquerque, maybe just how it's -- how the recovery has gone and where it is today versus where it was, say, a year or 2 years ago?",41,"Sticking with HCP for a second. Is it possible to get some color on Albuquerque, maybe just how it's -- how the recovery has gone and where it is today versus where it was, say, a year or 2 years ago?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is KT. I'll handle that. The difference between a year or 2 ago is night and day. It's just huge orders of magnitude better. So that's the high-level answer. The operations have been stabilized. We're in very constructive risk pool conversations with",126,"This is KT. I'll handle that. The difference between a year or 2 ago is night and day. It's just huge orders of magnitude better. So that's the high-level answer. The operations have been stabilized. We're in very constructive risk pool conversations with 1 of the major payers. We're in healthy collaboration discussions with 2 other significant health systems. The leadership has been stabilized. The management team has been improved. So there hasn't been any -- I mean, the numbers are certainly way better than 2 years ago, but I'm not wanting to represent this as we're on some stunningly steep trajectory of profit improvement. But all the fundamentals are better. And now we'll see what we can get done in the next couple of years."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then how much of your time are you spending on HCP versus on the Kidney Care business?",19,"Okay. And then how much of your time are you spending on HCP versus on the Kidney Care business?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I spend significantly more time on HCP than on domestic Kidney Care.",12,"I spend significantly more time on HCP than on domestic Kidney Care."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe just talking about the self-disclosure and the CID, both happening on the same day. Is that just coincidence? Or is there something else that we could read into from that?",34,"Okay. And then maybe just talking about the self-disclosure and the CID, both happening on the same day. Is that just coincidence? Or is there something else that we could read into from that?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's just totally coincidence.",5,"It's just totally coincidence."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then is there any additional color you could give us around it?",14,"Okay. And then is there any additional color you could give us around it?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I don't think so, Gary. We just don't know much yet. We -- the good news is that through our own internal normal compliance processes, we uncovered some issues. And we did the right thing in investigating them. We did the right thing in reporting to the g",150,"I don't think so, Gary. We just don't know much yet. We -- the good news is that through our own internal normal compliance processes, we uncovered some issues. And we did the right thing in investigating them. We did the right thing in reporting to the government. We did the right thing in doing some refunds. All of these were small dollar issues and transactions that were a tiny, tiny percentage of overall transactions. And we kept the OIG up to date along the way as to the work we were doing but not completed, and then we sent off our formal self-disclosure document. And it just so happened that very same day that we got the CID from the Department of Justice, and we have no idea if the Department of Justice had any idea that we were already 9 months down the track with the OIG."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And I think you said your analysis went back to 2010. And it looks like their inquiry goes back to 2006. Is there anything to read into that?",29,"Okay. And I think you said your analysis went back to 2010. And it looks like their inquiry goes back to 2006. Is there anything to read into that?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No. I guess, it would suggest again that there -- the 2 things aren't at all linked because clearly, they were coming up with their own set of issues and their own set of dates. But beyond that, we don't know. As you know, in many instances, when they're",71,"No. I guess, it would suggest again that there -- the 2 things aren't at all linked because clearly, they were coming up with their own set of issues and their own set of dates. But beyond that, we don't know. As you know, in many instances, when they're -- once they've decide to take a look, they -- they often, that first document is very, very broad because why not?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on your comments regarding negotiating an ESA contract, it sounds like you've talked -- you're talking about it more than I think you had in the past on new contract. Is there anything tangible you can share with us? Or any hope that it cou",54,"Okay. And then on your comments regarding negotiating an ESA contract, it sounds like you've talked -- you're talking about it more than I think you had in the past on new contract. Is there anything tangible you can share with us? Or any hope that it could get done in the near term?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No idea. This is -- we are eager -- I'll be redundant, but we are eager to have a long-term partner and a long-term plan, and we just think there's a lot of opportunity. But getting there, we'll take either our current partner, deciding they want to creat",105,"No idea. This is -- we are eager -- I'll be redundant, but we are eager to have a long-term partner and a long-term plan, and we just think there's a lot of opportunity. But getting there, we'll take either our current partner, deciding they want to create the next generation together, or us doing it with someone else, in which case, the implementation, of course, would have to wait. But the reason we're talking about it more is people are getting more serious because it's just not that far away anymore, and $800 million a year and growing is a lot to play with."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","And then I guess, well, maybe just the last point on that. Is there anything that you can share with us or that you're aware of, of the one short-term biosimilar that has been expected to come to market but has not yet?",43,"And then I guess, well, maybe just the last point on that. Is there anything that you can share with us or that you're aware of, of the one short-term biosimilar that has been expected to come to market but has not yet?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I don't -- I personally don't think it makes much sense for us to start talking about individual biosimilars and what exactly is going on. And so, LeAnne, I don't know if there's anything you'd like to get out on the table. I -- anything I do would just b",55,"I don't -- I personally don't think it makes much sense for us to start talking about individual biosimilars and what exactly is going on. And so, LeAnne, I don't know if there's anything you'd like to get out on the table. I -- anything I do would just be repeating publicly known information."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No, Kent. I think you answered that correctly.",8,"No, Kent. I think you answered that correctly."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Chris Rigg with Susquehanna.",10,"Our next question comes from Mr. Chris Rigg with Susquehanna."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","We're going to get the advance notice for 2017 MA rates next week. And obviously, I don't want to -- it's hard for you guys to predict what's going to be in there, but one thing that's been kicked around is potentially adjusting the risk model to better c",86,"We're going to get the advance notice for 2017 MA rates next week. And obviously, I don't want to -- it's hard for you guys to predict what's going to be in there, but one thing that's been kicked around is potentially adjusting the risk model to better code for duals. Do you have any thoughts on that, particularly if there was budget-neutral? And if not, can you at least give us a sense for, within the HCP pool of enrollment, how many are duals?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. Like you observed, we don't have any idea what they're going to do. And we do believe that currently, in Medicare Advantage, the sickest people we get under-reimbursed for and the healthiest people, they over-reimburse for. And for people like us, wh",110,"Yes. Like you observed, we don't have any idea what they're going to do. And we do believe that currently, in Medicare Advantage, the sickest people we get under-reimbursed for and the healthiest people, they over-reimburse for. And for people like us, who are not insurance companies, and we want to keep the patients we have, we do keep them, we can't really determine which new ones come to us, the current reality works to our disadvantage. And then with respect to duals in particular, while we have a bunch, it's impossible to say whether we would benefit materially or not until you know whatever the heck they would do."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Got you. And then changing gears here. Just with regard to the seamless care organization rollout or pilots last fall, can you give us a sense for some initial feedback from patients? Or just anything with regard to that would be helpful.",42,"Got you. And then changing gears here. Just with regard to the seamless care organization rollout or pilots last fall, can you give us a sense for some initial feedback from patients? Or just anything with regard to that would be helpful."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is regarding ESCOs?",4,"This is regarding ESCOs?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes, yes.",2,"Yes, yes."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's just too soon, but I -- we can tell you, though, we've been in a globally capitated pilot with CMS for 7, 8 years now, and it's pretty significant. There's 800 patients there or so, and then we have another 800, 900 globally capitated patients within",131,"It's just too soon, but I -- we can tell you, though, we've been in a globally capitated pilot with CMS for 7, 8 years now, and it's pretty significant. There's 800 patients there or so, and then we have another 800, 900 globally capitated patients within our HealthCare Partners universe. And in general, and in particular on the kidney care side were they SNP plan, Special Needs Plan is focused just on these kidney care patients, it's spectacular. The patients get extra services. The doctors have extra support. The referring doctors get better information. The nurses get to provide coordinated care. The patient and family get support at home. So I can tell you in our mature other work where we're globally capitated, it's a spectacular beautiful transparent victory."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Whit Mayo with Robert W. Baird.",12,"Our next question comes from Mr. Whit Mayo with Robert W. Baird."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Kent, you've discussed in the past your desire to reengage in productive conversations with your health plan partners to ensure that your incentives are aligned with their incentives, and they treat you as a good partner with the MA rate cuts. And are the",59,"Kent, you've discussed in the past your desire to reengage in productive conversations with your health plan partners to ensure that your incentives are aligned with their incentives, and they treat you as a good partner with the MA rate cuts. And are there just any developments along the recontracting front that would be of any interest to us?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes is the short answer. Every -- I'm not going to get the mix right, but if you ask on Capital Markets Day, we'll have it, and Jim Rechtin is not here right now. But a -- I would say a healthy percentage of our renewals end up with a new agreement where",137,"Yes is the short answer. Every -- I'm not going to get the mix right, but if you ask on Capital Markets Day, we'll have it, and Jim Rechtin is not here right now. But a -- I would say a healthy percentage of our renewals end up with a new agreement where our interests are much more aligned. And that's been true every year with a big shift from what existed before. And the same statement is true with respect to health systems and hospitals, where a very solid percentage of our new contracts there create a lot more alignment than the old ones, which were so 0 sum. So I would say it's steady progress, nothing dramatic, but it's really healthy in reducing downside risk, and over the long term will create some shared upside."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And just on Renal Ventures. I don't think I've heard an update. Just -- maybe I should know this, but just divestitures, FTC and any sense for the contribution this year?",32,"Great. And just on Renal Ventures. I don't think I've heard an update. Just -- maybe I should know this, but just divestitures, FTC and any sense for the contribution this year?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is Javier Rodriguez, CEO of Kidney Care. There is no update. We're still anticipating a Q2 close.",18,"This is Javier Rodriguez, CEO of Kidney Care. There is no update. We're still anticipating a Q2 close."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And maybe one last one is just any way to get a sense of the size of DaVita Rx now either by patients or revenue?",26,"Okay. And maybe one last one is just any way to get a sense of the size of DaVita Rx now either by patients or revenue?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Boy, I don't remember what our historical policy has been. It is -- it has certainly grown. It is making some money. It's not losing money anymore. And I'm going to have to turn to Jim Gustafson so I don't violate any policy. Go ahead, Jim.",46,"Boy, I don't remember what our historical policy has been. It is -- it has certainly grown. It is making some money. It's not losing money anymore. And I'm going to have to turn to Jim Gustafson so I don't violate any policy. Go ahead, Jim."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. We disclosed -- we're serving in various capacities 165,000 patients, and that includes both internal and external.",18,"Yes. We disclosed -- we're serving in various capacities 165,000 patients, and that includes both internal and external."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Ryan Newman with Promus Capital.",11,"Our next question comes from Mr. Ryan Newman with Promus Capital."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","You spoke a little bit about softness in some of the international markets and how other players were attracted to those assets as well [ph]. So while I know you expanded a little bit in Colombia and Portugal and China, Germany. Can you just talk about a",54,"You spoke a little bit about softness in some of the international markets and how other players were attracted to those assets as well [ph]. So while I know you expanded a little bit in Colombia and Portugal and China, Germany. Can you just talk about a bit how where the most softness occurred?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Where the most of what has occurred?",7,"Where the most of what has occurred?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Where the softest conditions exist internationally.",6,"Where the softest conditions exist internationally."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Softness conditions?",2,"Softness conditions?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes.",1,"Yes."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","So soft as in...",5,"So soft as in..."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","The worst performance.",3,"The worst performance."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Poor performance? Okay. Thank you. Sorry for my...",8,"Poor performance? Okay. Thank you. Sorry for my..."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","No, I misworded the question. I apologize.",7,"No, I misworded the question. I apologize."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I'd say the softest performance from a profit point of view -- I mean, my mind is racing as to how much I should disclose.",26,"I'd say the softest performance from a profit point of view -- I mean, my mind is racing as to how much I should disclose."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Sure.",1,"Sure."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","We've had some profit problems in Colombia. That probably sticks out as one of the softest. In Saudi, we've been growing a little bit behind plan, but the microeconomics appear to be solid. And I think beyond that, I'd have to get into so many nuances. In",156,"We've had some profit problems in Colombia. That probably sticks out as one of the softest. In Saudi, we've been growing a little bit behind plan, but the microeconomics appear to be solid. And I think beyond that, I'd have to get into so many nuances. In China, we still put in the R&D category where we're very steadily consistently investing to look for the winning formula, and we don't have it yet, but we're not discouraged. We've got some stuff that's working there. We have some stuff that's not working, and that's kind of the hit rate we expected. India, we know is a long-haul kind of thing, an immense market, but we're not ever going to start doing anything big there quickly because the microeconomics are just too tiny. So there's a little bit of flavor across 3 or 4, and I'm probably giving Jim Gustafson a heart attack by providing all this."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","At this time, we no longer have further questions on queue. [Operator Instructions]",13,"At this time, we no longer have further questions on queue. [Operator Instructions]"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Well, we -- the Capital Markets are May 18th, correct, Jim?",11,"Well, we -- the Capital Markets are May 18th, correct, Jim?"
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","In New York. We're going to nail down the location. There's a lot to talk about. We look forward to going into more detail. We're going to have a longer general session than we normally do, so that we hopefully give you a very comprehensive and analytical",101,"In New York. We're going to nail down the location. There's a lot to talk about. We look forward to going into more detail. We're going to have a longer general session than we normally do, so that we hopefully give you a very comprehensive and analytically thoughtful, not only reiteration of our strategy, but our progress and the right kind of leading indicators to stare at. So we're looking forward to a real high-intensity extended exchange, and we'll do our best in between now and then to get through '16 and start growing again in '17. Thank you very much."
35644,324689788,932559,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Thank you. So that concludes today's conference call. Thank you all for participating. You may now disconnect.",17,"Thank you. So that concludes today's conference call. Thank you all for participating. You may now disconnect."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Welcome to the DaVita HealthCare Partners Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] And now, I'll turn the call over to your host, Mr. Jim Gustafson. Thank you. You may begin.",32,"Welcome to the DaVita HealthCare Partners Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] 
And now, I'll turn the call over to your host, Mr. Jim Gustafson. Thank you. You may begin."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thank you, Vince, and welcome, everyone, to our fourth quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Jim Hilger, our Inter",220,"Thank you, Vince, and welcome, everyone, to our fourth quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Jim Hilger, our Interim CFO and Chief Accounting Officer; Vijay Kotte, our CFO for Healthcare Partners; and LeAnne Zumwalt, Group Vice President.
I'd like to start by noting that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in these statements. For further details concerning the risks and uncertainties, please refer to our SEC filings included in our most recent annual report and subsequent quarterly reports. Our forward-looking statements are based upon information currently available to us, and we do not intend and disclaim any duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website. 
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","All right. Thank you, Jim, and welcome to all. This will be a pretty high-density call, and I'll be covering more topics than normal because of some of the nuances contained therein. As usual, I will first talk about our clinical outcomes because that i",2547,"All right. Thank you, Jim, and welcome to all. This will be a pretty high-density call, and I'll be covering more topics than normal because of some of the nuances contained therein. 
As usual, I will first talk about our clinical outcomes because that is what comes first. Second, for each major business unit, I'll talk about the operating performance for the quarter and year and provide some thoughts on '16. Third, we'll then step back on each business briefly, and on the enterprise overall to try to set the table for our Capital Markets Day coming up on May 18, in New York City. And then lastly, I'll talk about enterprise capital allocation.
So let's launch right in since there's quite a bit to cover. On the clinical outcome front, excellent news, once again. Kidney Care, 97% of our patients with a Kt/V of 1.2 or greater, 73% of patients with fistulas placed for access; and very recently, final results announced for the CMS QUIP program for another year period, once again, we outperformed the rest of the community with only 1.4% of our facilities facing a penalty compared to 7.1% for the rest of the industry. Of course, no quality rating system is perfect, but in rating test after rating test, we come out as clinically differentiated. 
On the HCP front, equally promising results. With respect to HEDIS clinical metrics, we'll just pick Nevada this time. We try to move it around for you geographically. And in terms of subject matter, we once again exceeded the Medicare fee-for-service benchmark on all metrics, then had 4 or 5 star across all MA patients on all non-HEDIS metrics. So in both cases, both main sides of the house, our outcomes compare very favorably to national averages. This is good for patients. This is good for the taxpayer.
Now let's move on to the quarter and the year. We'll hit HCP first; international, second; kidney care, third. HCP operating performance for the quarter, $25 million. That excluded the estimated write-down. This was within our guidance range. On a normalized basis, this was actually about $37 million, if you normalize for prior-period adjustments, et cetera, which actually is about exactly the same amount of profit in Q4 of 2014 normalized.
For the full year, OI improved, as you know, from $215 million to $240 million, which is also within our guidance, although at the low end. In order to achieve that, the legacy markets were up a bit. The new markets were up a bit. And the combination of those bits was more than enough to make up for the medical cost inflation and some very substantial investments in capability building/G&A. And Vijay Kotte, our new HCP CFO, will discuss those investments and capabilities in G&A in more detail in just a few minutes.
But I will, as said, move right on to 2016 guidance for HCP. It is $175 million to $225 million. There are 3 primary drivers of that range. Driver number one, $58 million in reimbursement cuts. This is primarily the result of the new acuity coding RAF model being implemented the final trunk of the way, 100% implemented as of that time. As previously discussed, the HCP was more comprehensive in its coding capture. Complete diagnosis of patient conditions is a good thing, but it also left the entity far more vulnerable to any coding reimbursement compression. So $58 million from that source, most of it, the model, and the model is now 100%. 
And second big driver of that range is our investment in additional capabilities. There's 2 components to this $60 million year-over-year increase. Component A is really remedial. Their prior business leadership essentially stopped investing in the company. It was working to maximize profitability for the sale, either knowingly or unknowingly. And as a side note, I just want to remind you that we knew that. That is why we only paid a 6x multiple in a world where other allegedly comparable assets were going for 9x to 10x then and now, much greater than 10x in the market. 
And the second component of that big G&A capability investment is offensive, meaning investments that we think that are going to create significant competitive advantage for us over time. 
The third primary driver is the positive one, which offsets a big chunk of those 2 negative ones: Solid operating performance, good old solid operating performance. So if you look at the math, you have a $58 million hit from the -- essentially the completion of the RAF model. You have a $60 million hit from the increased investment in G&A, half remedial, half offensive. That would equal $118 million hit. You then have a $78 million operating performance improvement, which offsets all but $40 million of the 2 negative trends. And that yields the change from the $240 million in 2015 OI to the midpoint of the guidance, $200 million for 2016. We can, of course, take questions on all of that, but those are the 3 primary drivers. 
2017 does look better than 2016. The model will be behind us, and we continue to make steady progress on our capabilities and our contracting. If we put the P&L aside for a moment and look at cash flow and take as a scenario the midpoint of our guidance, in other words, the $200 million for HCP, and simultaneously take the midpoint of our guidance for the total enterprise, that $200 million would equal 11% of total enterprise operating income.
However, HCP operating cash flow is projected to be over $400 million, about 25% of total enterprise operating cash flow. This happens because of what we've talked about in the past, lower in capital intensity, low CapEx requirements and $100 million per year hard dollar cash tax benefit.
If we step back for a moment and look back at 3 difficult years, the total reimbursement cut from the implementation of the new RAF model for us, $165 million. What we had anticipated was a much smaller number than that. In fact, less than half. So about $100 million of incremental P&L harm that we had not expected is due to that single variable, $100 million. Now the fact that it came from that does not make it any less painful than if it came from anything else, but the important message is it did not come from operating problems or operating issues.
Looking forward, instead of backward, we have 6 primary markets: California, Nevada, Florida, New Mexico, Colorado and Washington, and more particularly, the Seattle area. In those primary markets, we have 6 leading independent medical groups. It is in those places, plus our joint venture, Tandigm in Philadelphia, of course, but that is a horse of a different color, that is where we'll be placing most of our emphasis in the near and perhaps intermediate term. Prices are very high right now for variable properties. Our bandwidth is pretty stretched given how much we've grown and given how much opportunity we have in those 6 markets, plus with Tandigm.
And then third, we need to prove to you that we can get the right returns and margins in a number of those places before we do too many other significant things. Because of all that, it is unlikely we will do any other big Everett-like deal, unless it is through a capital-light transaction or is for a very attractive multiple. 
Other good news to take into account, and looking forward instead of backward, a list of few of them, each of a different type. First, our legacy markets in 2015, once again, outgrew their markets in terms of MA growth. The markets grew 6%. We grew 9%.
Number two, we've dramatically improved patient service metrics since the time of the transaction.
Number three, we've had a number of significant IT advances that have improved our support for our frontline physicians. We have a long journey there, and Vijay will talk about that a little more, but we've got some nice early momentum and victories in better supporting our frontline physicians.
Number four, we've had a number of forecasting and prior period adjustment issues. You know that painful truth as we do. Our finance leadership team is literally 90% new.
And fifth, and finally, in this case, if you look at our top 22 executives, we have 5 great veterans with immense amounts of valuable ACP experience and 17 new executives that we think are the right people to help take us into that next chapter going forward.
So that's it on HCP for now, although Vijay will come back and talk about some of those capability and G&A investments a little bit later.
Let's move onto international. We underperformed in 2015. $55 million in losses compared to original $40 million of guidance. Why? Well, we had a $5 million AR reserve, which almost entirely came from 1 country where there were 2 fiscal intermediaries who became insolvent. We actually hope to get a bunch of that money back. We also are $10 million behind plan or were $10 million behind plan in 2 countries where we built new centers and patient growth was behind plan.
In 2016, for international, our guidance is losses of approximately $40 million. This assumes no unusual AR reserves. We are experiencing payment delays with the Saudi government, so that's a watch-out, but we have done nothing on that front now. We still expect to receive all of the funds. And the good news is the Ministry of Health in Saudi is explicitly very happy with our service and very impressed by the patient feedback they have received. Their words, not ours.
In 2017, we anticipate improvement over '16 on an OI basis. And in 2018, in international dialysis, in our current country portfolio, we expect to achieve breakeven. We are, in fact, already in 2015 -- or we did already in 2015, generate positive aggregate EBITDA at the clinic level in 8 out of our 10 countries as we continue to grow and cover our G&A. 
And another reference point that gives you a sense of the per-country scale. In 2014, we had an average of $10 million revenue per country. 2015, an increase of 50%, up to $15 million. 2016, if we hit our plan, we'll be $27 million in revenue per country. So you can see that, at reasonable margins, we are making strong progress in covering the fixed amount of global G&A.
Finally, most of our growth internationally has been through acquisition. Virtually, every one of those acquisitions has been competed for with others. And so these are market-valuable assets that real competition wanted to have. And our competitors continue to invest in growing internationally as well because of the returns they see. 
Stepping back for a moment, with respect to international, we are still very bullish on the long-term opportunity both in kidney care and other health care services.
Now onto the kidney care operating performance. Once again, strong quarter, strong year. Operating income, $449 million. And then for the year, $1.658 billion. First number was for the quarter, of course, once again excluding some nonrecurring stuff. Jim Hilger will provide more details on the numbers. 
I'll go right into guidance. We anticipate, in 2016, another solid year, $1.625 billion to $1.725 billion. Of course, there's always risk we'll fall short and there's always hope that we will exceed. This guidance, for our normal customs, does include the international economics and it also includes the unfortunate fact of flat Medicare reimbursement for the third straight year.
The uncertainty in our 2016 performance, as in many recent years, it centers on revenue and revenue per treatment. We anticipate our performance in the first half of the year with respect to RPT to be positive, but we have a lot less visibility into the second half of the year, hence, the broadness of the range. 
And regarding the strategic initiatives, there could be some earnings volatility there. One reason is ESCOs, as you know we have launched, and so we incur those costs, particularly those extra startup costs now, and we get the shared savings payment later if we perform and the data is correct. And the second variable are some Rx, to be the Rx renewals. All of this, of course, is incorporated into our guidance.
Stepping back now with respect to kidney care and looking out 3, 4 or 5 years, is one big downside and 3 attractive upsides. The big downside is what will happen to private pay? It is unfortunate that we have a large cost shift in our dialysis industry in America with private patients paying a lot more to subsidize the 80% to 90% of our patients that are Medicare and Medicaid. And when you put that on top of payer consolidation, distributed risk pools, exchanges and other things going on, it would not be prudent to not be nervous about what will happen with private pay.
On the other hand, we do have 3 upsides. One is in the ESA market. For the long term, as many of you know, we spend about $800 million per year on ESAs. We are intensely looking for the right long-term partner or partners in the hope to consummate some type of long-term partnership well before the expiration of our current contract at the end of 2018.
Second, integrated kidney care. We are very competent at this. Regardless of who has the risk, we think we will be one of the subcontractors of choice.
And third, finally, the flat Medicare reimbursement is scheduled to go away at the end of 2018. In 2019, we hope to be back to our normal market basket. All in all, our strategic position in U.S. kidney care is strong.
Now let's step back to the enterprise overall. The guidance OI of $1.8 billion to $1.95 billion. OCF, $1.55 billion to $1.75 billion. But on an equally important topic, how are we thinking about capital allocation at the enterprise level? Well, first, with kidney care, we stay the course. And since there aren't a lot of large properties available out there, that means they will not use all the cash they generate. 
HCP, they will focus on existing markets, unless something that is capital-light or at a very attractive multiple comes along. 
International, we will continue to invest to grow. Putting all 3 of those together, what does our capital allocation look like if you pick something arbitrary like the next 3-year period? We will generate, in a reasonable scenario, with, of course, downside risk and upside, but in the reasonable scenario, we will generate operating cash flow of approximately $5.5 billion in the next 3 years. If you count normal use, meaning our current operating plans, business plans, et cetera, which, of course, could change, we will use about $3.5 billion for those purposes. This leaves about $2 billion on the side for us to contemplate what to do with, with, of course, your counsel as well as we compare other growth opportunities to debt repayment opportunities, to share repurchase opportunities. 
Now Vijay Kotte, our new CFO of Healthcare Partners, will walk through a few more details."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. I'll take a few minutes to provide more detail into the investments we're making into the future. As Kent stated before, we are continuing to make both remedial and offensive investments into the business. The best way to look at these items",235,"Thanks, Kent. I'll take a few minutes to provide more detail into the investments we're making into the future. As Kent stated before, we are continuing to make both remedial and offensive investments into the business. The best way to look at these items is to put 2015 and 2016 together. When you do that, we have a total of approximately $80 million in incremental investments over 2014. 
To provide more context into these investments, I will put them into 3 primary buckets: First, we have information technology; second, legal and compliance; and third, the next-generation capability and change management.
In the bucket of IT, we plan to spend $40 million more in '16 than we did in 2014. This includes the following areas: First, security; second, applications to support population health; third, a community portal to enhance communication between patients and providers, an enterprise data warehouse, our accounting system conversion and a national IT infrastructure to enable our creation of one company.
Next, in the legal and compliance bucket, we will invest an additional $10 million to $15 million over 2014. 
In our final bucket, we're investing approximately $18 million into research and development related to next-generation care management capabilities, a team we call catalysts, with applications to our current markets as well as others.
Now Jim Hilger, our CFO, will walk you through a few more details on the numbers in the quarter."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. First, I'd like to point out a couple of non-GAAP items in the quarter. In the fourth quarter, we recorded an estimated accrual of $23 million for potential damages and liabilities in our DaVita Rx pharmacy business. We have excluded these",654,"Thanks, Vijay. First, I'd like to point out a couple of non-GAAP items in the quarter. In the fourth quarter, we recorded an estimated accrual of $23 million for potential damages and liabilities in our DaVita Rx pharmacy business. We have excluded these numbers from our reported non-GAAP income from continuing operations. 
A few words about this estimated accrual. The reserves relate to the period from 2010 through 2015. As a part of our normal process, last spring, we initiated an internal compliance review of DaVita Rx, during which, we identified potential billing and operational issues. We notified the government in September of 2015 that we were conducting this review of DaVita Rx and began providing regular updates of our review. Upon completion of our review, we filed a self-disclosure with the OIG on February 5, 2016, and we have been working to address and update the practices we identified in the self-disclosure. 
In addition, as disclosed earlier today, on February 5, 2016, DaVita Rx received a civil investigative demand from the U.S. Attorney's Office. The information requested has some overlap with the items we self-disclosed. And we do not know that the U.S. Attorney knew we are already in the process of developing a self-disclosure with the OIG.
At HCP, we took an estimated $206 million impairment charge of noncash goodwill and an intangible asset of certain health care partner operating units. These impairments were driven primarily by underperformance of the business reporting units in recent quarters, as well as changes in other market conditions, including government reimbursement cuts and our expected ability to mitigate those cuts.
The final amount of these impairment charges will depend upon the final outcome of this valuation work, which we expect to be completed in the first quarter of 2016. This noncash charge will not impact go-forward performance or our cash taxes.
Onto the overall enterprise. Our debt expense was $103 million in the fourth quarter, which is a good run rate for a debt expense in future quarters. Our income attributable to noncontrolling interests was $40 million.
Next, our effective tax rate for income attributable to DaVita HealthCare Partners in the fourth quarter was 36% and for the year was 38.2%. And we expect the full year tax rate for 2016 to be in the range of 40% to 41%.
We have also repurchased $151 million of our common stock in the fourth quarter, and we also repurchased an additional $249 million in the month of January. As a result of these transactions, we now have approximately $259 million remaining under our current board authorization.
As you think about modeling the first quarter, here are a few things that you should keep in mind. In our dialysis business, Q1 2015 contains -- or '16 contains 1 fewer day than this past quarter. So you should expect lower revenues and higher fixed costs per treatment. 
Second, our payroll tax cap is reset at the beginning of the year, which leads to higher costs of $1 to $1.50 per treatment. At HCP, OI fluctuates from quarter-to-quarter due to the seasonal needs of patients, and Q1 tends to be a bit lighter than the full year average.
Now turning to cash flow. We continue to generate strong cash flows as operating cash flow was $437 million in the fourth quarter and $1.861 billion for all of 2015, excluding the Vainer settlement. The strong cash flows in 2015 are borrowing a bit from 2016 operating cash flow, mostly due to the timing of cash tax payments and other working capital items. But despite that, we still expect 2016 operating cash flows to be $1.55 billion to $1.75 billion, showing that we continue to generate strong cash flows. As always, this guidance range captures a majority of probabilistic outcomes, but we could be above or below this range. 
And with that, operator, let's go ahead and open it up for Q&A."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question comes from Mr. Matthew Borsch with Goldman Sachs.",13,"[Operator Instructions] Our first question comes from Mr. Matthew Borsch with Goldman Sachs."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Could you maybe just address the areas of operating performance improvement that you're expecting in the HCP business? Maybe just -- I don't know if there's any kind of granularity that you're prepared to give at this point, whether it's by geography or f",64,"Could you maybe just address the areas of operating performance improvement that you're expecting in the HCP business? Maybe just -- I don't know if there's any kind of granularity that you're prepared to give at this point, whether it's by geography or function. I'm just curious the types of things that you think are going to be better this year versus last."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Matthew, this is Kent. It's -- thanks for getting on the call. It's pretty broad-based, so there's nothing, really, that jumps out. There's no dramatic disparity in unit growth or margin enhancement either through MOR improvement or G&A savings or revenue",49,"Matthew, this is Kent. It's -- thanks for getting on the call. It's pretty broad-based, so there's nothing, really, that jumps out. There's no dramatic disparity in unit growth or margin enhancement either through MOR improvement or G&A savings or revenue enhancements. So it's pretty mixed across the portfolio."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","And let me ask on a different front, still related to HCP. As you look at things that are potentially for sale, and you mentioned prices are high, is that still principally because of the major hospital systems that are bidding up? Is it, I mean, more the",61,"And let me ask on a different front, still related to HCP. As you look at things that are potentially for sale, and you mentioned prices are high, is that still principally because of the major hospital systems that are bidding up? Is it, I mean, more the same hospitals? How much is hospitals? How much is managed care versus other?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. Certainly, health system is a bit sometimes breathtaking amounts for these medical groups, but we have been surprised by some of the other players, including some of the health insurance entities and the offers that they've put on the table as well",43,"Right. Certainly, health system is a bit sometimes breathtaking amounts for these medical groups, but we have been surprised by some of the other players, including some of the health insurance entities and the offers that they've put on the table as well."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Kevin Ellich with Piper Jaffray.",11,"Our next question comes from Mr. Kevin Ellich with Piper Jaffray."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Kent, I guess, just kind of big picture. Thinking about the guidance, which historically, you've had a track record of being conservative. But if you look over the last few years, we haven't seen much growth in operating income. I guess, clearly, there's",64,"Kent, I guess, just kind of big picture. Thinking about the guidance, which historically, you've had a track record of being conservative. But if you look over the last few years, we haven't seen much growth in operating income. I guess, clearly, there's been some issues with HealthCare Partners, but I guess, broadly speaking, what will it take before -- to get growth reaccelerating?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","A very fair question, Kevin, and one that we are pretty intense about on the inside. On the kidney care front, with that flat Medicare reimbursement, that's just a real problem that we've got to get addressed. And then hopefully, through a new partner or",152,"A very fair question, Kevin, and one that we are pretty intense about on the inside. On the kidney care front, with that flat Medicare reimbursement, that's just a real problem that we've got to get addressed. And then hopefully, through a new partner or the same partner and a new partnership with the SAs, or getting some integrated care runway, we can start to break out of the current trend. On the HCP side, of course, some of the declines have taken away their kidney care gains. And so if we just stopped that and get back to reasonable steady growth on HCP, that, together with the normal growth in kidney care, could start to generate some much more interesting numbers. And then lastly, international is, unfortunately, just a couple of years away from being able to really help. Although once it starts helping, it could be a long-term big deal."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Got it. Okay. And then going back to your comments on kidney care and the potential downside and 3 factors for a potential upside, in the ESA component, you said that contract expires in 2018. Should we expect to see something happen in the next year or 2",48,"Got it. Okay. And then going back to your comments on kidney care and the potential downside and 3 factors for a potential upside, in the ESA component, you said that contract expires in 2018. Should we expect to see something happen in the next year or 2?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","We would like to develop the right kind of long-term win-win partnership sooner rather than later. We have the contract we have with Amgen, and so if they don't want to do anything new with us, we certainly can't force them to. Having said that, there are",160,"We would like to develop the right kind of long-term win-win partnership sooner rather than later. We have the contract we have with Amgen, and so if they don't want to do anything new with us, we certainly can't force them to. Having said that, there are other people that we can create agreements with that just wouldn't kick in until the day after the Amgen agreement expired. So our point is pretty simple. That we think we can be a great partner for someone for the next 5 to 10 years in that area, and we're eager to find that party and start working towards that long-term future. Necessarily, even if we got very serious with someone tomorrow, these deals are pretty complicated and nothing would be signed for some time. But that's one of the reasons why we want to start working on them now because it takes a while to put them together. Is that responsive?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","It is. And can you remind us, I think in the contract, you had the ability for 10% of your ESA supply to come from someone else. Are you guys testing other options out right now? And if so, how's that going?",42,"It is. And can you remind us, I think in the contract, you had the ability for 10% of your ESA supply to come from someone else. Are you guys testing other options out right now? And if so, how's that going?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","LeAnne, you want to talk about that?",7,"LeAnne, you want to talk about that?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly. We do plan to do some pilots over the next year.",12,"Certainly. We do plan to do some pilots over the next year."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. Will you go with one source? Or will you try different options, LeAnne?",14,"Okay. Will you go with one source? Or will you try different options, LeAnne?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Certainly, we'll try multiple options.",5,"Certainly, we'll try multiple options."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, great. And then, I guess, going to hammer -- going to the share repurchase, you guys were very active in January. I think you said you have $259 million remaining. Should we expect to see continued share repurchase activity maybe get -- are you guys",77,"Okay, great. And then, I guess, going to hammer -- going to the share repurchase, you guys were very active in January. I think you said you have $259 million remaining. Should we expect to see continued share repurchase activity maybe get -- are you guys going to go back to the board to get a -- to re-up the authorization? And even though you don't provide EPS guidance, is that part of your outlook for 2016?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes, I'll go ahead and take that one. We're going to apply the same sort of measured calculus we've always applied, that looking at the alternative deployments, looking at the different scenarios going forward, looking at interest rates, looking at the st",164,"Yes, I'll go ahead and take that one. We're going to apply the same sort of measured calculus we've always applied, that looking at the alternative deployments, looking at the different scenarios going forward, looking at interest rates, looking at the stock price, as a CEO, I'm feeling a little sheepish about the fact that we bought back quite a bit when the stock was a fair amount higher than it is today, and we would have done more value for -- created more value for our long-term shareholders by waiting a little bit as opposed to buying when we were at above historical average EBITDA multiple. So we bring our normal sort of intellectual calculus to it. But certainly, we've demonstrated over the last year, and certainly, many of you were actively engaged in encouraging us to, certainly we've demonstrated, as we have at different types in our history, the willingness to go into the market and take some shares out of play."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Kevin Fischbeck of Bank of America Merrill Lynch.",14,"Our next question comes from Mr. Kevin Fischbeck of Bank of America Merrill Lynch."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","This is actually in Joanna Gajuk, filling in for Kevin today. So on HCP guidance and the breakdown on different elements that are impacting the output income, specifically, I recall the company mentioned on the last call Medicaid headwinds of $20 million?",66,"This is actually in Joanna Gajuk, filling in for Kevin today. So on HCP guidance and the breakdown on different elements that are impacting the output income, specifically, I recall the company mentioned on the last call Medicaid headwinds of $20 million? So should we assume that you'd no longer include that headwind? Or it's just all that if you don't -- you didn't disclose it?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","When it happened, we thought it would be Medicaid at $20 million. It turns out, Medicaid is $8 million. And so when we talked about $58 million, $50 million was that RAF model at Medicare, $8 million was Medicaid.",39,"When it happened, we thought it would be Medicaid at $20 million. It turns out, Medicaid is $8 million. And so when we talked about $58 million, $50 million was that RAF model at Medicare, $8 million was Medicaid."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, that makes sense. So then I know you mentioned that those headwinds, you expect to be offered by a broad, I guess, base operating improvement. But are you willing to talk about the legacy markets performance 2015? I don't know whether specific numbe",65,"Okay, that makes sense. So then I know you mentioned that those headwinds, you expect to be offered by a broad, I guess, base operating improvement. But are you willing to talk about the legacy markets performance 2015? I don't know whether specific numbers are up or down or the magnitude of improvement? And then what do you think this would be 2016 versus '15?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. In 2015, our legacy markets contributed to the profit growth, the OI growth, as did our new markets. So both were contributors to our ability to offset the bad stuff that happened in normal medical cost inflation and our big investments. In 2016, w",69,"Right. In 2015, our legacy markets contributed to the profit growth, the OI growth, as did our new markets. So both were contributors to our ability to offset the bad stuff that happened in normal medical cost inflation and our big investments. In 2016, we anticipate the same, that independent of the rate cuts, that both legacy markets and new markets will do better than they did in '15."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And then just a follow-up on your comment around the dialysis business and the pricing, that you expect the pricing to be positive in first half, but there's less visibility for the second half of the year. So can you shed a little more light why y",50,"Great. And then just a follow-up on your comment around the dialysis business and the pricing, that you expect the pricing to be positive in first half, but there's less visibility for the second half of the year. So can you shed a little more light why you think that?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's not because of any particular normal negotiation between us and the payer. It's just because of all the noise in the air with everything going on with exchanges, regulatory ambiguity and those areas, what some of the new payers are going to do in ter",73,"It's not because of any particular normal negotiation between us and the payer. It's just because of all the noise in the air with everything going on with exchanges, regulatory ambiguity and those areas, what some of the new payers are going to do in terms of getting in and out of exchanges. So it's just so much going on that we're uneasy, increasingly uneasy, and we thought we should share that."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","So there's nothing specific across -- because I want to say, you mentioned something about a specific contract? Or I guess, maybe there was rather, on the HCP side, so maybe that's irrelevant. And I think that's all from me now.",42,"So there's nothing specific across -- because I want to say, you mentioned something about a specific contract? Or I guess, maybe there was rather, on the HCP side, so maybe that's irrelevant. And I think that's all from me now."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Okay, thank you. I think you might be referring to the DaVita Rx renewals I referred to.",17,"Okay, thank you. I think you might be referring to the DaVita Rx renewals I referred to."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Right.",1,"Right."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","But that is an independent point separate from what's going on in mainstream kidney care.",16,"But that is an independent point separate from what's going on in mainstream kidney care."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Ms. Margaret Kaczor with William Blair.",11,"Our next question comes from Ms. Margaret Kaczor with William Blair."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","First of all, thanks for all the details in terms of where you guys are investing in HCP. So maybe a question on that. What impact should we expect these investments to have? I might assume it's better outcomes that are going to lead to these higher patie",78,"First of all, thanks for all the details in terms of where you guys are investing in HCP. So maybe a question on that. What impact should we expect these investments to have? I might assume it's better outcomes that are going to lead to these higher patient adds. But even more specifically, over what time frame should we see the fruits of these investments? Is it as early as '17? Or is it more '18, '19, '20?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Right. Well, Margaret, we knew this question was going to come and dreaded it because it's going to be the answer you hate. It's not going to happen right away. For example, in technology space, it'll take a year, 1 to 2 years to get a lot of that stuff d",169,"Right. Well, Margaret, we knew this question was going to come and dreaded it because it's going to be the answer you hate. It's not going to happen right away. For example, in technology space, it'll take a year, 1 to 2 years to get a lot of that stuff done, and then the benefit has -- does not immediately leap off the P&L. In terms of our NexGen care management and change management group, that's got some near-term upside. When you're managing $4 billion of medical cost, the -- spending that extra, whatever it is, $20 million, with some new talent, with some new analytics and with some new approaches, you can get a pretty good payback on that pretty quickly. But the whole team is so new and the processes we're putting in place are so new that we would just hate to create expectations and then fail. We're very bullish on the impact they're going to have, but it just is not going to be overnight."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. So maybe to take that even further, and I'm sure you'll appreciate this question as well. But you talked about profitability in HCP maybe improving in '17, and part of that is that the reimbursement cuts from the RAF model go away. And so that shoul",100,"Okay. So maybe to take that even further, and I'm sure you'll appreciate this question as well. But you talked about profitability in HCP maybe improving in '17, and part of that is that the reimbursement cuts from the RAF model go away. And so that should be, if I'm thinking of it right, about a $60 million tailwind. But then are you going to increase investments further in '17 to offset that? And then also, the final bucket in terms of the OI performance. Should that improve in '17 as Centura and Everett start to have a larger impact?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. Well, you're -- you do know us well. The elimination of the RAF model that's been hanging our heads, that's certainly the elimination of a headwind. It doesn't lead to a tailwind. It just leads to the absence of wind, which, for us right now, would f",108,"Yes. Well, you're -- you do know us well. The elimination of the RAF model that's been hanging our heads, that's certainly the elimination of a headwind. It doesn't lead to a tailwind. It just leads to the absence of wind, which, for us right now, would feel pretty good assuming that benchmark rate increases would be, roughly speaking, equivalent to what goes on with medical cost inflation. And so we do want 2017 OI to be nicely higher than 2016 OI because of the elimination of those headwinds and a lot of the other stuff hopefully kicking in. But did I miss a part of your question?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes. So the operating performance in Centura and Everett, what kind of impact will they have in '17 and '18?",20,"Yes. So the operating performance in Centura and Everett, what kind of impact will they have in '17 and '18?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Oh, thank you. On Everett, we would also expect '17 to be better than '16. '16 has some integration expenses. '16 has some adding talent to take on risk pools, so we have that expense. We have some additional amortization from the deal. And we have some s",180,"Oh, thank you. On Everett, we would also expect '17 to be better than '16. '16 has some integration expenses. '16 has some adding talent to take on risk pools, so we have that expense. We have some additional amortization from the deal. And we have some special additional expenses that exists for the first year or 2 of the deal and then go away. And so we are counting on -- we're expecting a nice operating income trajectory at The Everett Clinic in '17 versus '16 and '18 versus '17 and '19 versus '18. We have high hopes for the significant growth of the business there. And then on Centura, that is a tougher one. We certainly expect it to do better in '17 than '16. It really depends on if we get a quality risk contract, what the effective date is and then how quickly we can make a difference. So that one could stretch out a little bit based on the timing of all that. We're making nice progress, but right now, there's nothing locked and loaded."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay, great. And then just one more for me. You guys were nice enough to provide kind of the nouveau clinics that were waiting for regulatory approval last quarter. How are those looking this quarter? And should we expect they're still being -- they're st",62,"Okay, great. And then just one more for me. You guys were nice enough to provide kind of the nouveau clinics that were waiting for regulatory approval last quarter. How are those looking this quarter? And should we expect they're still being -- they're still to be able as with clinics that we'll see open in the first half of the year?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","The DeNovo backlog is still about the same as what it was last quarter. But what we're seeing is a much better improvement in opening new clinics. So that's where we'll see improvement in the first half of the year.",40,"The DeNovo backlog is still about the same as what it was last quarter. But what we're seeing is a much better improvement in opening new clinics. So that's where we'll see improvement in the first half of the year."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","And that person speaking is Patrick McKinnon, Chief Financial Officer of Kidney Care.",13,"And that person speaking is Patrick McKinnon, Chief Financial Officer of Kidney Care."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Gary Lieberman with Wells Fargo.",11,"Our next question comes from Mr. Gary Lieberman with Wells Fargo."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Sticking with HCP for a second. Is it possible to get some color on Albuquerque, maybe just how it's -- how the recovery has gone and where it is today versus where it was, say, a year or 2 years ago?",41,"Sticking with HCP for a second. Is it possible to get some color on Albuquerque, maybe just how it's -- how the recovery has gone and where it is today versus where it was, say, a year or 2 years ago?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is KT. I'll handle that. The difference between a year or 2 ago is night and day. It's just huge orders of magnitude better. So that's the high-level answer. The operations have been stabilized. We're in very constructive risk pool conversations with",126,"This is KT. I'll handle that. The difference between a year or 2 ago is night and day. It's just huge orders of magnitude better. So that's the high-level answer. The operations have been stabilized. We're in very constructive risk pool conversations with one of the major payers. We're in healthy collaboration discussions with 2 other significant health systems. The leadership has been stabilized. The management team has been improved. So there hasn't been any -- I mean, the numbers are certainly way better than 2 years ago, but I'm not wanting to represent this as we're on some stunningly steep trajectory of profit improvement. But all the fundamentals are better. And now we'll see what we can get done in the next couple of years."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then how much of your time are you spending on HCP versus on the Kidney Care business?",19,"Okay. And then how much of your time are you spending on HCP versus on the Kidney Care business?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I spend significantly more time on HCP than on domestic Kidney Care.",12,"I spend significantly more time on HCP than on domestic Kidney Care."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe just talking about the self-disclosure and the CID, both happening on the same day. Is that just coincidence? Or is there something else that we could read into from that?",34,"Okay. And then maybe just talking about the self-disclosure and the CID, both happening on the same day. Is that just coincidence? Or is there something else that we could read into from that?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's just totally coincidence.",5,"It's just totally coincidence."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then is there any additional color you could give us around it?",14,"Okay. And then is there any additional color you could give us around it?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I don't think so, Gary. We just don't know much yet. We -- the good news is that through our own internal normal compliance processes, we uncovered some issues. And we did the right thing in investigating them. We did the right thing in reporting to the g",150,"I don't think so, Gary. We just don't know much yet. We -- the good news is that through our own internal normal compliance processes, we uncovered some issues. And we did the right thing in investigating them. We did the right thing in reporting to the government. We did the right thing in doing some refunds. All of these were small dollar issues and transactions that were a tiny, tiny percentage of overall transactions. And we kept the OIG up to date along the way as to the work we were doing but not completed, and then we sent off our formal self-disclosure document. And it just so happened that very same day that we got the CID from the Department of Justice, and we have no idea if the Department of Justice had any idea that we were already 9 months down the track with the OIG."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And I think you said your analysis went back to 2010. And it looks like their inquiry goes back to 2006. Is there anything to read into that?",29,"Okay. And I think you said your analysis went back to 2010. And it looks like their inquiry goes back to 2006. Is there anything to read into that?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No. I guess, it would suggest again that there -- the 2 things aren't at all linked because clearly, they were coming up with their own set of issues and their own set of dates. But beyond that, we don't know. As you know, in many instances, when they're",71,"No. I guess, it would suggest again that there -- the 2 things aren't at all linked because clearly, they were coming up with their own set of issues and their own set of dates. But beyond that, we don't know. As you know, in many instances, when they're -- once they've decide to take a look, they -- they often, that first document is very, very broad because why not?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on your comments regarding negotiating an ESA contract, it sounds like you've talked -- you're talking about it more than I think you had in the past on new contract. Is there anything tangible you can share with us? Or any hope that it cou",54,"Okay. And then on your comments regarding negotiating an ESA contract, it sounds like you've talked -- you're talking about it more than I think you had in the past on new contract. Is there anything tangible you can share with us? Or any hope that it could get done in the near term?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No idea. This is -- we are eager -- I'll be redundant, but we are eager to have a long-term partner and a long-term plan, and we just think there's a lot of opportunity. But getting there, we'll take either our current partner, deciding they want to creat",105,"No idea. This is -- we are eager -- I'll be redundant, but we are eager to have a long-term partner and a long-term plan, and we just think there's a lot of opportunity. But getting there, we'll take either our current partner, deciding they want to create the next generation together, or us doing it with someone else, in which case, the implementation, of course, would have to wait. But the reason we're talking about it more is people are getting more serious because it's just not that far away anymore, and $800 million a year and growing is a lot to play with."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","And then I guess, well, maybe just the last point on that. Is there anything that you can share with us or that you're aware of, of the one short-term biosimilar that has been expected to come to market but has not yet?",43,"And then I guess, well, maybe just the last point on that. Is there anything that you can share with us or that you're aware of, of the one short-term biosimilar that has been expected to come to market but has not yet?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I don't -- I personally don't think it makes much sense for us to start talking about individual biosimilars and what exactly is going on. And so, LeAnne, I don't know if there's anything you'd like to get out on the table. I -- anything I do would just b",55,"I don't -- I personally don't think it makes much sense for us to start talking about individual biosimilars and what exactly is going on. And so, LeAnne, I don't know if there's anything you'd like to get out on the table. I -- anything I do would just be repeating publicly known information."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","No, Kent. I think you answered that correctly.",8,"No, Kent. I think you answered that correctly."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Chris Rigg with Susquehanna.",10,"Our next question comes from Mr. Chris Rigg with Susquehanna."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","We're going to get the advance notice for 2017 MA rates next week. And obviously, I don't want to -- it's hard for you guys to predict what's going to be in there, but one thing that's been kicked around is potentially adjusting the risk model to better c",86,"We're going to get the advance notice for 2017 MA rates next week. And obviously, I don't want to -- it's hard for you guys to predict what's going to be in there, but one thing that's been kicked around is potentially adjusting the risk model to better code for duals. Do you have any thoughts on that, particularly if there was budget-neutral? And if not, can you at least give us a sense for, within the HCP pool of enrollment, how many are duals?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. Like you observed, we don't have any idea what they're going to do. And we do believe that currently, in Medicare Advantage, the sickest people we get under-reimbursed for and the healthiest people, they over-reimburse for. And for people like us, wh",110,"Yes. Like you observed, we don't have any idea what they're going to do. And we do believe that currently, in Medicare Advantage, the sickest people we get under-reimbursed for and the healthiest people, they over-reimburse for. And for people like us, who are not insurance companies, and we want to keep the patients we have, we do keep them, we can't really determine which new ones come to us, the current reality works to our disadvantage. And then with respect to duals in particular, while we have a bunch, it's impossible to say whether we would benefit materially or not until you know whatever the heck they would do."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Got you. And then changing gears here. Just with regard to the seamless care organization rollout or pilots last fall, can you give us a sense for some initial feedback from patients? Or just anything with regard to that would be helpful.",42,"Got you. And then changing gears here. Just with regard to the seamless care organization rollout or pilots last fall, can you give us a sense for some initial feedback from patients? Or just anything with regard to that would be helpful."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is regarding ESCOs?",4,"This is regarding ESCOs?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes, yes.",2,"Yes, yes."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","It's just too soon, but I -- we can tell you, though, we've been in a globally capitated pilot with CMS for 7, 8 years now, and it's pretty significant. There's 800 patients there or so, and then we have another 800, 900 globally capitated patients within",131,"It's just too soon, but I -- we can tell you, though, we've been in a globally capitated pilot with CMS for 7, 8 years now, and it's pretty significant. There's 800 patients there or so, and then we have another 800, 900 globally capitated patients within our HealthCare Partners universe. And in general, and in particular on the kidney care side were they SNP plan, Special Needs Plan is focused just on these kidney care patients, it's spectacular. The patients get extra services. The doctors have extra support. The referring doctors get better information. The nurses get to provide coordinated care. The patient and family get support at home. So I can tell you in our mature other work where we're globally capitated, it's a spectacular beautiful transparent victory."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Whit Mayo with Robert W. Baird.",12,"Our next question comes from Mr. Whit Mayo with Robert W. Baird."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Kent, you've discussed in the past your desire to reengage in productive conversations with your health plan partners to ensure that your incentives are aligned with their incentives, and they treat you as a good partner with the MA rate cuts. And are the",59,"Kent, you've discussed in the past your desire to reengage in productive conversations with your health plan partners to ensure that your incentives are aligned with their incentives, and they treat you as a good partner with the MA rate cuts. And are there just any developments along the recontracting front that would be of any interest to us?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes is the short answer. Every -- I'm not going to get the mix right, but if you ask on Capital Markets Day, we'll have it, and Jim Rechtin is not here right now. But a -- I would say a healthy percentage of our renewals end up with a new agreement where",137,"Yes is the short answer. Every -- I'm not going to get the mix right, but if you ask on Capital Markets Day, we'll have it, and Jim Rechtin is not here right now. But a -- I would say a healthy percentage of our renewals end up with a new agreement where our interests are much more aligned. And that's been true every year with a big shift from what existed before. And the same statement is true with respect to health systems and hospitals, where a very solid percentage of our new contracts there create a lot more alignment than the old ones, which were so 0 sum. So I would say it's steady progress, nothing dramatic, but it's really healthy in reducing downside risk, and over the long term will create some shared upside."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Great. And just on Renal Ventures. I don't think I've heard an update. Just -- maybe I should know this, but just divestitures, FTC and any sense for the contribution this year?",32,"Great. And just on Renal Ventures. I don't think I've heard an update. Just -- maybe I should know this, but just divestitures, FTC and any sense for the contribution this year?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","This is Javier Rodriguez, CEO of Kidney Care. There is no update. We're still anticipating a Q2 close.",18,"This is Javier Rodriguez, CEO of Kidney Care. There is no update. We're still anticipating a Q2 close."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Okay. And maybe one last one is just any way to get a sense of the size of DaVita Rx now either by patients or revenue?",26,"Okay. And maybe one last one is just any way to get a sense of the size of DaVita Rx now either by patients or revenue?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Boy, I don't remember what our historical policy has been. It is -- it has certainly grown. It is making some money. It's not losing money anymore. And I'm going to have to turn to Jim Gustafson so I don't violate any policy. Go ahead, Jim.",46,"Boy, I don't remember what our historical policy has been. It is -- it has certainly grown. It is making some money. It's not losing money anymore. And I'm going to have to turn to Jim Gustafson so I don't violate any policy. Go ahead, Jim."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes. We disclosed -- we're serving in various capacities 165,000 patients, and that includes both internal and external.",18,"Yes. We disclosed -- we're serving in various capacities 165,000 patients, and that includes both internal and external."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from Mr. Ryan Newman with Promus Capital.",11,"Our next question comes from Mr. Ryan Newman with Promus Capital."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","You spoke a little bit about softness in some of the international markets and how other players were attracted to those assets as well [ph]. So while I know you expanded a little bit in Colombia and Portugal and China, Germany. Can you just talk about a",54,"You spoke a little bit about softness in some of the international markets and how other players were attracted to those assets as well [ph]. So while I know you expanded a little bit in Colombia and Portugal and China, Germany. Can you just talk about a bit how where the most softness occurred?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Where the most of what has occurred?",7,"Where the most of what has occurred?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Where the softest conditions exist internationally.",6,"Where the softest conditions exist internationally."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Softness conditions?",2,"Softness conditions?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Yes.",1,"Yes."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","So soft as in...",5,"So soft as in..."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","The worst performance.",3,"The worst performance."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Poor performance? Okay. Thank you. Sorry for my...",8,"Poor performance? Okay. Thank you. Sorry for my..."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","No, I misworded the question. I apologize.",7,"No, I misworded the question. I apologize."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","I'd say the softest performance from a profit point of view -- I mean, my mind is racing as to how much I should disclose.",26,"I'd say the softest performance from a profit point of view -- I mean, my mind is racing as to how much I should disclose."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Analysts","Sure.",1,"Sure."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","We've had some profit problems in Colombia. That probably sticks out as one of the softest. In Saudi, we've been growing a little bit behind plan, but the microeconomics appear to be solid. And I think beyond that, I'd have to get into so many nuances. In",156,"We've had some profit problems in Colombia. That probably sticks out as one of the softest. In Saudi, we've been growing a little bit behind plan, but the microeconomics appear to be solid. And I think beyond that, I'd have to get into so many nuances. In China, we still put in the R&D category where we're very steadily consistently investing to look for the winning formula, and we don't have it yet, but we're not discouraged. We've got some stuff that's working there. We have some stuff that's not working, and that's kind of the hit rate we expected. India, we know is a long-haul kind of thing, an immense market, but we're not ever going to start doing anything big there quickly because the microeconomics are just too tiny. So there's a little bit of flavor across 3 or 4, and I'm probably giving Jim Gustafson a heart attack by providing all this."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","At this time, we no longer have further questions on queue. [Operator Instructions]",13,"At this time, we no longer have further questions on queue. [Operator Instructions]"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Well, we -- the Capital Markets are May 18th, correct, Jim?",11,"Well, we -- the Capital Markets are May 18th, correct, Jim?"
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Executives","In New York. We're going to nail down the location. There's a lot to talk about. We look forward to going into more detail. We're going to have a longer general session than we normally do, so that we hopefully give you a very comprehensive and analytical",101,"In New York. We're going to nail down the location. There's a lot to talk about. We look forward to going into more detail. We're going to have a longer general session than we normally do, so that we hopefully give you a very comprehensive and analytically thoughtful, not only reiteration of our strategy, but our progress and the right kind of leading indicators to stare at. So we're looking forward to a real high-intensity extended exchange, and we'll do our best in between now and then to get through '16 and start growing again in '17. Thank you very much."
35644,324689788,933170,"DaVita HealthCare Partners Inc., Q4 2015 Earnings Call, Feb 11, 2016",2016-02-11,"Earnings Calls","DaVita Inc.","Operator","Thank you. So that concludes today's conference call. Thank you all for participating. You may now disconnect.",17,"Thank you. So that concludes today's conference call. Thank you all for participating. You may now disconnect."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you all for standing by. [Operator Instructions] Now I will turn the meeting over to your host, Mr. Jim Gustafson. Sir, you may begin.",27,"Welcome, and thank you all for standing by. [Operator Instructions] Now I will turn the meeting over to your host, Mr. Jim Gustafson. Sir, you may begin."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you, JR, and welcome, everyone, to the DaVita HealthCare Partners First Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations, and with me today are Kent T",240,"Thank you, JR, and welcome, everyone, to the DaVita HealthCare Partners First Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations, and with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO of DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of HealthCare Partners; Jim Hilger, our Interim CFO and Chief Accounting Officer; and LeAnne Zumwalt, Group Vice President.
I'd like to could start with our forward-looking disclosure statements. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based on information currently available to us, and we do not intend and undertake no duty to update these statements for any reason. Additionally, I'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website. 
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, Jim, and welcome to all. In the quarter, we delivered solid operating income and strong cash flow. The total adjusted operating income, as you've seen in the release, $458 million and the operating cash flows of $429 million. In the cours",257,"Okay. Thank you, Jim, and welcome to all. In the quarter, we delivered solid operating income and strong cash flow. The total adjusted operating income, as you've seen in the release, $458 million and the operating cash flows of $429 million. In the course of this call, before Q&A, we'll cover the clinical outcomes. We'll talk about U.S. Kidney Care. We'll provide an international update, including talking a little bit about the deal announced today. We'll cover HealthCare Partners results. HealthCare Partners we now refer to as the DaVita Medical Group, and then we'll provide a few additional financial details. 
After clinical outcomes, we'll discuss them first as we always do because of that is what comes first. We are, first and foremost, a caregiving company. And the Kidney Care side is where we'll focus our clinical comments on this call. We'll probably rotate back and forth between the various parts of the enterprise each quarter. We have about 178,000 dialysis patients now in the U.S. That's about 35% of all the patients in the U.S. And from a vaccination point of view, our outcomes relative to the community are very strong. Pneumonia vaccinations at 92% for patients; influenza vaccinations, 92% for patients; and influenza vaccinations at 84%. And as many of you know, improving performance in vaccinations also leads to fewer hospitalizations and, as always, in our areas around the enterprise, our improved clinical outcomes are also very good for the taxpayer. For more color on U.S. Kidney Care financial results, let's hear from Javier Rodriguez."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you, Kent. I'll divide my comments into 2 sections. First, I'll cover the quarter, and then secondly, I will cover full year guidance. For the quarter, we had a strong operating income of $422 million, and let me cover some of the highlights. Number",557,"Thank you, Kent. I'll divide my comments into 2 sections. First, I'll cover the quarter, and then secondly, I will cover full year guidance. For the quarter, we had a strong operating income of $422 million, and let me cover some of the highlights. Number one, normalized NAG was 4.1, which represented continued improvement over the prior quarters, and it is consistent with our guidance that we gave last year for our 3 years of 3.5% to 4.5%. Our rate per treatment increased by $2.34 per treatment, and it was mainly driven through higher acute mix and improved commercial mix. These improvements were partially offset by fewer treatment days, which is normal in Q1. And as a reminder, the quarter benefited from an extra date due to a leap year. And seasonally higher cost and treatment, number one, primarily due to higher personnel costs from payroll taxes and higher pharma costs from seasonally higher people utilization due to the delay of the flu. Happy with the quarter. 
Our guidance for Kidney Care remains unchanged at $1.625 billion to $1.75 billion. And as always, arranged in total captures the majority of that probabilistic outcomes. And based on where we are today, we are more likely to be on the top half of the guidance range. 
The primary reason for leaving our guidance unchanged is driven by some economic uncertainties surrounding the exchange plans of the ACA. Let me summarize with 4 points on our experience on the ACA. Number one, it is working for patients. Americans who otherwise would not have insurance are now insured. Number two, many patients are far better insured and have better coverage than they had before, including many of our patients that are benefiting from the insurance coverage. Number three, the regulatory environment around exchanges is still being built. While many pairs are living up to the spirit of the ACA, others are changing their fine print and their plan designs to avoid paying for expensive chronic diseases, either by cost shifting to the patient or by making the plans unattractive for the expensive chronically ill in other ways. It might be helpful to give an example. We had in 1 state a plan that tried to limit dialysis benefits and shifted significant economic responsibility to the patient, which as many of you know, these patients can clearly not afford. Once we alerted the regulatory agencies the plans were instructed to remedy their behavior. That being said, we're seeing more effort by some of the payers to improve their economics in the exchange plan by making it more difficult for dialysis patients to enroll. This is a complicated issue, which will require regulatory environment. As you know, it happened to be a tough year because the election and many are distracted. Therefore, the dynamics around enforcement are hard for us to predict. I'll state the obvious, patients and providers will continue to work with regulators as this unfold. 
Lastly, as you know, not unique to us, there are larger macroeconomics and political risks that are clouding the future of the exchanges. Therefore, it's hard to handicap with certainty how this will play out for us. We'll talk about some of these issues in our longer-term outlook in 2 weeks as we see you in Capital Markets. 
I'll pass it back to you, Kent."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","All right. Thanks, JR. I'm going to cover international now. The losses, as you've seen, were $10 million in the quarter year, and this is in line with our guidance of approximately $40 million on the year. The most noteworthy new news on the internationa",353,"All right. Thanks, JR. I'm going to cover international now. The losses, as you've seen, were $10 million in the quarter year, and this is in line with our guidance of approximately $40 million on the year. The most noteworthy new news on the international front is our definitive agreement to form a joint venture to grow our Kidney Care business in Asia with 2 partners: Kazana and Mitsui. Kazana is a highly respected sovereign wealth fund of the government of Malaysia with an investment portfolio greater than $30 billion. And Mitsui, as many of you know, one of the largest oldest business groups in Japan with about $45 billion in annual revenue. And it recently designated health care as a key strategic domain for themselves corporately going forward. They are both experienced in health care already and are value-added partners for us, not just investors. One of their noteworthy successes in the Asian health care scene is they have a majority stake, approximately 60% stake in IHH HealthCare, which many don't realize, is the second-largest hospital company in the world by market cap. That market cap is about $13 billion at this point, and we're very excited to have them as our partners. 
The financial terms, just to the summary level, each of Kazana and Mitsui will invest $150 million over the next few years, and each will receive in return a 20% ownership stake. We -- well, of course, still majority owner therefore, and we will be running the enterprise with them as our very active partners. 
Just to give you a sense of the current scope of the business, we have 64 clinics that serve about 3,300 patients across 5 countries in that part of the world. The definitive agreement is subject to a few closing conditions, so it could take some time to complete. But all 3 parties are working to make that happen as soon as it's possible. 
And now let's turn to what has historically been called HealthCare Partners, but is now, at least internally, referred to as DaVita Medical Group, Vijay Kotte, the Chief Financial Officer."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. We'll first start with a review of the HCP Q1 performance. Operating income for the quarter, adjusted for the $77 million goodwill impairment and the $16 million Nevada hospice reserve, gets us to $36 million on a non-GAAP basis. Included in",508,"Thanks, Kent. We'll first start with a review of the HCP Q1 performance. Operating income for the quarter, adjusted for the $77 million goodwill impairment and the $16 million Nevada hospice reserve, gets us to $36 million on a non-GAAP basis. Included in the $36 million are approximately $9 million of onetime costs. When adjusted for these onetime costs, we get a normalized operating income of $45 million for the quarter. 
One question you will likely ask is to reconcile this with the first quarter of last year. To do this, we start with 2015 Q1 OI of $60 million, subtract 1/4 of the $58 million in MA and Medicaid rate cuts we had previously disclosed or $15 million and that gets you to $45 million, demonstrating a relatively flat underlying performance year-over-year. 
Now let's break down some of the drivers of performance for the quarter. There's some good things and some bad things. We'll start with the bad things. In addition to the rate cuts, Medicare Advantage enrollment in our legacy geographies grew less than in prior years, and we grew in line with our geographies. Additionally, our commercial membership continues to decline with the market. 
Now let's turn to some good stuff. We continue to close transactions. Earlier in the quarter, we closed on The Everett Clinic, a nationally recognized physician group that adds over 500 clinicians across 20-plus clinics, serving over 300,000 patients with an expected annual revenue of over $400 million. In addition, within our existing geographies, we have a healthy pipeline of opportunities, including a number of small tuck-ins as well as a few larger acquisitions in process. One example is our prior announcement of our intent to combine with Mountainview Medical Group, which has 50 clinicians across 14 clinics, serving over 80,000 patients, which, if closed, will strengthen our already healthy capabilities in Colorado Springs. 
As we have said before, we continue building capabilities. There are a couple of examples, one clinical and one operational. On the clinical side, we're expanding our very successful home care program from other geographies to Nevada, focusing on the needs of our high-risk patients in order to avoid unnecessary hospitalizations and readmissions. On the operational front, we are centralizing national operations and expect to realize savings from scale and vendor consolidation. Just to remind you, there's been a significant transformation of the leadership team, and that group is picking up new momentum every month. The progress in all these activities, we have a good shot at adding approximately $30 million to OI and the remaining 3 quarters of 2016, above the Q1 normalized rate of $170 million, bringing us to approximately $200 million for the year, the midpoint of our guidance range. So we are maintaining our guidance range of $175 million $225 million, although we acknowledge that achieving the high end may be less likely. We'll provide more details on our ongoing investments and operational capabilities and our longer-term outlook at Capital Markets Day in 2 weeks. 
Now I'll turn it over to Jim Hilger."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. In regards to the overall enterprise, our debt expense was $103 million in the first quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 40% in the quarter when you adjust fo",316,"Thanks, Vijay. In regards to the overall enterprise, our debt expense was $103 million in the first quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 40% in the quarter when you adjust for the nondeductible goodwill impairment charge in the HCP Nevada Hospice accrual. For the full year, we now expect the 2016 effective tax rate attributable to DaVita HealthCare Partners to be in the range of 39.5 to 40.5. 
Now turning to cash flow. We continue to generate strong cash flows. Operating cash flow was $429 million in the first quarter and on an adjusted basis, $1.88 billion for the 12 months. As we've discussed before, over time, Kidney Care contribute about 75% of our operating cash flows. HCP contributes about 25%, notably higher than its contribution percentage to our enterprise operating income. 
Regarding capital deployment. The first quarter -- during the first quarter, we purchased 3.7 million shares for $249 million at an average price of $67.61, but we've not made any additional repurchases since our last earnings call. Please note that we continuously weigh capital deployment opportunities across growth investment, share repurchases, debt repayment and holding cash. 
And now finally on to outlook, I'd just like to restate our outlook. We are still expecting our consolidated operating income for 2016 to be in the range of $1.8 billion to $1.95 billion. We expect our operating income for Kidney Care to be in the range of $1.625 billion to $1.725 billion, and we expect income for HCP to be in the range of $175 million to $225 million. And our cash flow -- our operating cash flow expectation is in the range of $1.55 billion to $1.75 billion. As always, these guidance ranges capture majority of the probabilistic outcomes that we can foresee. 
And with that, operator, let's go ahead and open it up for Q&A."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first questions from the line of Mr. Kevin Fischbeck.",12,"[Operator Instructions] Our first questions from the line of Mr. Kevin Fischbeck."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Can you talk a little bit about the $9 million of onetime costs in HCP those relate to?",18,"Can you talk a little bit about the $9 million of onetime costs in HCP those relate to?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Sure. The onetime cost, Kevin, were related to 3 primary things. One was the move of our California headquarters. Two is some compensation-related accruals, and the third is just some spend true-ups for prior periods.",35,"Sure. The onetime cost, Kevin, were related to 3 primary things. One was the move of our California headquarters. Two is some compensation-related accruals, and the third is just some spend true-ups for prior periods."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And then you guys earlier kind of quantified the 2017 MA rate headwind of $25 million. I guess, how do you think about offsetting that? And any tailwinds you think about into next year versus this year?",37,"And then you guys earlier kind of quantified the 2017 MA rate headwind of $25 million. I guess, how do you think about offsetting that? And any tailwinds you think about into next year versus this year?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We're not going to give full 2017 guidance or that information. But related to the rate headwinds themselves, there are some things related to the health insurer tax that will give some tailwind, but not enough to overcome those headwinds here. And beyond",63,"We're not going to give full 2017 guidance or that information. But related to the rate headwinds themselves, there are some things related to the health insurer tax that will give some tailwind, but not enough to overcome those headwinds here. And beyond that, we'll give more detail of operational expectations some other things at Capital Markets in a couple of weeks."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Just is that explicitly built into your contracts as a flow-through or is that something that you have to go back and kind of renegotiate as an offset?",29,"Just is that explicitly built into your contracts as a flow-through or is that something that you have to go back and kind of renegotiate as an offset?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It varies by contract and so we'll -- we've already addressed it with most of our payers.",18,"It varies by contract and so we'll -- we've already addressed it with most of our payers."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And I guess, maybe last question. I guess, as far as people cost for the year, I guess, was pushing through rate increase and encouraging people to move over to there any thoughts there about kind of how you guys are dealing with at? Is that the mov",62,"Okay. And I guess, maybe last question. I guess, as far as people cost for the year, I guess, was pushing through rate increase and encouraging people to move over to there any thoughts there about kind of how you guys are dealing with at? Is that the move that you've done or do you expect that you pressure through the year?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","LeeAnn, would you like to go ahead and take that one, please?",12,"LeeAnn, would you like to go ahead and take that one, please?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","You may need to clarify if I don't answer your question correctly. As it relates to Epogen pricing, we did not experience a price increase this year. So I don't know if that answers your question your for referring to our nest?",43,"You may need to clarify if I don't answer your question correctly. As it relates to Epogen pricing, we did not experience a price increase this year. So I don't know if that answers your question your for referring to our nest?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I guess, my understanding was that trying to move to the longer-lasting Epo product as generally speaking contract might be different than others. But sure if that was something that you guys were looking to do whether that was going to be a cost advantag",52,"I guess, my understanding was that trying to move to the longer-lasting Epo product as generally speaking contract might be different than others. But sure if that was something that you guys were looking to do whether that was going to be a cost advantage to you under your contract this year."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We certainly use some Aranesp now and the population and we -- both products are very clinically appropriate for patients. And so we just use whichever the physician is ordering at this point in time. And there's not a contractual difference.",41,"We certainly use some Aranesp now and the population and we -- both products are very clinically appropriate for patients. And so we just use whichever the physician is ordering at this point in time. And there's not a contractual difference."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Matthew Borsch of Goldman Sachs.",14,"Our next question is from the line of Mr. Matthew Borsch of Goldman Sachs."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Just first question I was curious your perspective on the slowdown. A realize it's a much broader dynamic than just DaVita Medical Group. But the slowdown in Medicare Advantage enrollment and if there's anything that the DaVita Medical Group physicians ar",53,"Just first question I was curious your perspective on the slowdown. A realize it's a much broader dynamic than just DaVita Medical Group. But the slowdown in Medicare Advantage enrollment and if there's anything that the DaVita Medical Group physicians are seeing on the front lines that might help inform what's going on."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","At this point, we don't have a good sense of what '17, '18, '19 are going to look like. We still think Medicare Advantage is going to be growing in our markets as in the country overall. We and a lot of other people continue to add more services and capab",123,"At this point, we don't have a good sense of what '17, '18, '19 are going to look like. We still think Medicare Advantage is going to be growing in our markets as in the country overall. We and a lot of other people continue to add more services and capabilities that will fuel that fire. At the same time, if the payers decide in any given period to leave benefits statement or, in fact, even pull back a little bit, that has a big impact. And so we remain very bullish on fundamental growth. But at this point, the notion of sort of guesstimating what's going to happen in '17 and '18, we're not feeling certain enough to add any value there."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Yes. That makes sense. And just curious, when the medical group sees MA patients, is there any distinction in terms of the financials, if that's an employer group MA member or a regular, I guess, you'd say retail member.",39,"Yes. That makes sense. And just curious, when the medical group sees MA patients, is there any distinction in terms of the financials, if that's an employer group MA member or a regular, I guess, you'd say retail member."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Can you restate the question? I'm not understanding.",8,"Can you restate the question? I'm not understanding."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Well, I guess, you think about the major Medicare Advantage plans, they typically have for every 800 individual MA members, they may be have another 200 that come from employer groups that are doing retiree coverage. It's all Medicare Advantage. I'm just",64,"Well, I guess, you think about the major Medicare Advantage plans, they typically have for every 800 individual MA members, they may be have another 200 that come from employer groups that are doing retiree coverage. It's all Medicare Advantage. I'm just wondering if there's any distinction in the medical group sees in terms of the financial arrangements, risk-taking arrangements between group and individual."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","No, we have not seen significant in that word.",9,"No, we have not seen significant in that word."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And you don't really know how many is one or the other? Is that correct?",16,"Okay. And you don't really know how many is one or the other? Is that correct?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, I don't think of anything useful to say about this, Matthew. But by capital markets, if there's anything useful to say, we'll be prepared to say it.",28,"Yes, I don't think of anything useful to say about this, Matthew. But by capital markets, if there's anything useful to say, we'll be prepared to say it."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. That sounds great. Just one last question on the ACA exchange plan dynamic. Can you give us some sense of how to think about what the numbers are? In other words, is this -- I wouldn't think it would be the numbers would be very big in terms of your",74,"Okay. That sounds great. Just one last question on the ACA exchange plan dynamic. Can you give us some sense of how to think about what the numbers are? In other words, is this -- I wouldn't think it would be the numbers would be very big in terms of your overall patient base. But is there a higher concentration relative to, say, how the ACA exchange enrollment compares to the overall insured population?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Let me take a stab at that, Matthew, and then you tell me if I'm hitting the right thing. Exchanges are a tiny percentage of what we're about. At the same time, when we have exchange business that's private insurance, that is additive in the same way that",102,"Let me take a stab at that, Matthew, and then you tell me if I'm hitting the right thing. Exchanges are a tiny percentage of what we're about. At the same time, when we have exchange business that's private insurance, that is additive in the same way that our private insurance patients are in general. Since as you know, the 10% or so of patients we have private subsidized the 90% that are government at which we lose money on the margin. And so exchanges are a tiny percentage, but just like with the rest of private pay, little movements add up."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And have you ever contemplated starting your own exchange plans to get around the problems that you have had with the payers?",22,"And have you ever contemplated starting your own exchange plans to get around the problems that you have had with the payers?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","After this point, we have not.",6,"After this point, we have not."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","At this point, I would like to open the line",10,"At this point, I would like to open the line"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Maybe talk about the joint venture and kind of the expectations for growth and maybe some of the startup losses that we should expect.",24,"Maybe talk about the joint venture and kind of the expectations for growth and maybe some of the startup losses that we should expect."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'm sorry, Gary, could you -- there was still some noise can you go ahead repeat the question.",19,"I'm sorry, Gary, could you -- there was still some noise can you go ahead repeat the question."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Maybe talk about the joint venture a little bit and the expectation for growth and what if any startup losses we would expect to see from it.",27,"Maybe talk about the joint venture a little bit and the expectation for growth and what if any startup losses we would expect to see from it."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Well, we are still losing money in the Asia market. And that's not going to change in the near term. Because if anything, the addition of these 2 partners is going to accelerate some of our growth, which in the short term, could actually increase our loss",80,"Well, we are still losing money in the Asia market. And that's not going to change in the near term. Because if anything, the addition of these 2 partners is going to accelerate some of our growth, which in the short term, could actually increase our losses kind of depends which countries we're growing the most in. So I don't know how much useful I can say beyond that, but go ahead and fire off another question if you'd like."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I guess, in terms of little different topic just foreign exchange rates, any thoughts there any plans to hedge or is it too small to really worry about it?",29,"I guess, in terms of little different topic just foreign exchange rates, any thoughts there any plans to hedge or is it too small to really worry about it?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Up to this point, we've done little or no hedging. we're paying a lot of attention, but the numbers are so small. And in particular, given we're spread across 10 different countries, 11 different countries and you kind of do the math, it just isn't that h",81,"Up to this point, we've done little or no hedging. we're paying a lot of attention, but the numbers are so small. And in particular, given we're spread across 10 different countries, 11 different countries and you kind of do the math, it just isn't that helpful at this point. But we're making sure we're talking to people who are more thoughtful and sophisticated than we are and trying to figure out exactly when we should start doing more of that."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. On to the ESAs. Is it possible for you to tell us what percentage of patients are currently using Aranesp?",21,"Okay. On to the ESAs. Is it possible for you to tell us what percentage of patients are currently using Aranesp?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I can answer that. We're predominantly an Epo people quite small.",11,"I can answer that. We're predominantly an Epo people quite small."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Is it the 10% that you're allowed to use other ESAs or does that not count if it's Aranesp.",19,"Is it the 10% that you're allowed to use other ESAs or does that not count if it's Aranesp."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, Aranesp does not count against us.",7,"Yes, Aranesp does not count against us."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then the pricing -- the lack of pricing increase on Epo, does that have something to do with you moving some number of patients onto Aranesp?",28,"Okay. And then the pricing -- the lack of pricing increase on Epo, does that have something to do with you moving some number of patients onto Aranesp?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","No, that's not the case and since I have the floor here, I'm being corrected that we did take a 1% price increase in January, and so I apologize for that mistake.",32,"No, that's not the case and since I have the floor here, I'm being corrected that we did take a 1% price increase in January, and so I apologize for that mistake."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Ms. Margaret Kaczor from William Barrett.",14,"Our next question is from the line of Ms. Margaret Kaczor from William Barrett."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","First question for me, there's a lot of moving pieces in HCP, and I'm sure you'll address a lot of them in your Capital Markets Day in a few weeks. But that said, as a look at HCP and its trajectory, really over the next couple of years, maybe 3 years, ho",91,"First question for me, there's a lot of moving pieces in HCP, and I'm sure you'll address a lot of them in your Capital Markets Day in a few weeks. But that said, as a look at HCP and its trajectory, really over the next couple of years, maybe 3 years, how important is that patient and revenue growth compared to that profitability improvement. And where do you see that going? Can the newer market revenues exceed the legacy markets since those appear to be slowing legacy markets reaccelerate from here?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, a very fair question. And certainly, we are going to that card in the Capital Markets or at least to the best of our ability. We do think in a couple of our new markets the growth prospects over the next 2, 3 years and revenue EBITDA and OI basis is",106,"Yes, a very fair question. And certainly, we are going to that card in the Capital Markets or at least to the best of our ability. We do think in a couple of our new markets the growth prospects over the next 2, 3 years and revenue EBITDA and OI basis is material. But at the same time, we actually have a lot of growth opportunities in the 3 inherited markets. And so which has more potential, I think, we'd probably say they're pretty equivalent and if anything, the legacy markets have more, but it'd be nice to see them in a bit of a race."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And just maybe take a little bit more at that. We saw the senior revenues in the mid-single-digit range in 2015. But as we look out again over that 2 to 3-year time horizon, what would you be happy with seeing in terms of that kind of new patient gr",57,"Okay. And just maybe take a little bit more at that. We saw the senior revenues in the mid-single-digit range in 2015. But as we look out again over that 2 to 3-year time horizon, what would you be happy with seeing in terms of that kind of new patient growth as well as the revenue growth?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. What would be happy to see? I would say if you give us the gift of reflecting on that, and we're going to talk about the range that we expect to see at Capital Markets and then maybe address the happiness thing. But we'll definitely give you our sen",62,"Okay. What would be happy to see? I would say if you give us the gift of reflecting on that, and we're going to talk about the range that we expect to see at Capital Markets and then maybe address the happiness thing. But we'll definitely give you our sense of the range of likely outcomes here in a couple of weeks."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","All right. Fair enough. And then on the Kidney Care side a number of clinics you guys are opening our growing a little bit faster than they have been the last few quarters, and rightfully so. But should we expect a similar pace of net new centers opening",100,"All right. Fair enough. And then on the Kidney Care side a number of clinics you guys are opening our growing a little bit faster than they have been the last few quarters, and rightfully so. But should we expect a similar pace of net new centers opening throughout 2016 as you guys catch up with those longer approval time frames from last year so are you going to reach 120 new clinics for the year? And how quickly can these new clinics help get your NAG back up to that 4.5% or maybe even higher over the near term?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'll turn that one over to Javier.",8,"I'll turn that one over to Javier."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you. We had a 30 centers opened in the first quarter arranged for the year, 90 to 110. The last part of your question on NEG. We're still comfortable with a multiyear range that we addressed earlier, so 3.5 to 4.5.",42,"Thank you. We had a 30 centers opened in the first quarter arranged for the year, 90 to 110. The last part of your question on NEG. We're still comfortable with a multiyear range that we addressed earlier, so 3.5 to 4.5."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then last one for me. How's the acquisition of Renal Ventures coming along? When should we see kind of the initial impact and results and how long is it going to take for that change to more closely resemble maybe the financial structure of the",49,"Okay. And then last one for me. How's the acquisition of Renal Ventures coming along? When should we see kind of the initial impact and results and how long is it going to take for that change to more closely resemble maybe the financial structure of the DaVita clinics?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","JR, can you take that one, please?",7,"JR, can you take that one, please?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It's still going through the FTC, so the short answer is we don't know.",15,"It's still going through the FTC, so the short answer is we don't know."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Gary Taylor of JP MC.",14,"Our next question is from the line of Mr. Gary Taylor of JP MC."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Couple of questions. I wanted to go back to the international JV for a second and just make sure I understand what you said. Each of these investing $150 million over several years for 20% that was for each of those, right? So $300 million investment comb",53,"Couple of questions. I wanted to go back to the international JV for a second and just make sure I understand what you said. Each of these investing $150 million over several years for 20% that was for each of those, right? So $300 million investment combined by [ph] 40% of the venture."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Correct.",1,"Correct."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","So that implies something with equity value of $750 million. Does the DaVita make commensurate capital contribution? Or is this capital-light to you because you're contributing your market operational intelligence, know-how, et cetera? What's your contrib",36,"So that implies something with equity value of $750 million. Does the DaVita make commensurate capital contribution? Or is this capital-light to you because you're contributing your market operational intelligence, know-how, et cetera? What's your contribution?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Right. This investment will be the growth capital for the entity. And what we're submitting into the partnership is the entity itself, which is the kind of things that you mentioned.",31,"Right. This investment will be the growth capital for the entity. And what we're submitting into the partnership is the entity itself, which is the kind of things that you mentioned."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And are you contributing your existing centers in those 5 countries into the JV?",15,"Okay. And are you contributing your existing centers in those 5 countries into the JV?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Correct. So our entire business in Kidney Care in that geographic area, that's the asset which we're contributing into the partnership. What they're contributing is the $150 million each of growth capital.",32,"Correct. So our entire business in Kidney Care in that geographic area, that's the asset which we're contributing into the partnership. What they're contributing is the $150 million each of growth capital."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And it implies pretty sizable capital deployment to that part of the world, I guess, compared to what you've invested thus far. So are there existing centers to acquire? Is this primarily development or will be both?",37,"And it implies pretty sizable capital deployment to that part of the world, I guess, compared to what you've invested thus far. So are there existing centers to acquire? Is this primarily development or will be both?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It will be both, but we're expecting that more of it will be acquisition than de novo. But it almost gets difficult to use some of the labels because in some of these countries, for example, China, you could end up with deal arrangements that are kind of",50,"It will be both, but we're expecting that more of it will be acquisition than de novo. But it almost gets difficult to use some of the labels because in some of these countries, for example, China, you could end up with deal arrangements that are kind of a hybrid."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And then my other questions, just want to go back to commercial mix. I was taking notes, but I don't know if I missed this comment. Did you make a comment about commercial mix of patients, which I think was actually grew year-over-year in '15 for I think",61,"And then my other questions, just want to go back to commercial mix. I was taking notes, but I don't know if I missed this comment. Did you make a comment about commercial mix of patients, which I think was actually grew year-over-year in '15 for I think the first time in some time so 1Q of '16 does that change?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It did grow in '15 for the first time in a long time, and so we're pretty pleased with it where we're at. I think we disclosed in the 10-K 12% mix. We're rounded up to 12%. Sorry, we were 11% rounded to 11% in 2015.",46,"It did grow in '15 for the first time in a long time, and so we're pretty pleased with it where we're at. I think we disclosed in the 10-K 12% mix. We're rounded up to 12%. Sorry, we were 11% rounded to 11% in 2015."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","11% of our total patients.",5,"11% of our total patients."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Give that annually, I believe, is that right?",8,"Give that annually, I believe, is that right?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","That is correct. We disclose it annually.",7,"That is correct. We disclose it annually."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. So the commercial mix continue to improve year-over-year in 1Q of '16 or has that leveled out?",18,"Okay. So the commercial mix continue to improve year-over-year in 1Q of '16 or has that leveled out?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We continue to improve in the quarter.",7,"We continue to improve in the quarter."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And is most of that -- is that improvement being driven by exchanges or...",14,"And is most of that -- is that improvement being driven by exchanges or..."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","That is a portion of the improvement. The improvement we've seen over multiple quarter period is in part due to exchanges and in part due to improving economy. And in some cases, it's difficult to discern what -- which is where. We know where the exchange",52,"That is a portion of the improvement. The improvement we've seen over multiple quarter period is in part due to exchanges and in part due to improving economy. And in some cases, it's difficult to discern what -- which is where. We know where the exchanges are, but also is some cannibalization."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Yes, obviously it's powerful trend. Now my last question, stealing out good couple of weeks here Capital Markets, but what is your average commercial rate increase you're expecting for 2016 that's baked into guidance?",34,"Yes, obviously it's powerful trend. Now my last question, stealing out good couple of weeks here Capital Markets, but what is your average commercial rate increase you're expecting for 2016 that's baked into guidance?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, we will go over expectations on the RPT side at Capital Markets, and we may or may not get quite to that level of granularity. But, as always, we'll give you a 3-year outlook on what we think about RPT or revenue per treatment.",45,"Yes, we will go over expectations on the RPT side at Capital Markets, and we may or may not get quite to that level of granularity. But, as always, we'll give you a 3-year outlook on what we think about RPT or revenue per treatment."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","At this point, I would like to open the line for Ms. Lisa Clive of Bernstein.",16,"At this point, I would like to open the line for Ms. Lisa Clive of Bernstein."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I have 3 for you. First of all, sorry, if I missed the details on this, but could you give us some color on the accrual for HCP the hospice business in Nevada? Am I right that is about $16 million? Second, on dialysis, could you comment on the program in",135,"I have 3 for you. First of all, sorry, if I missed the details on this, but could you give us some color on the accrual for HCP the hospice business in Nevada? Am I right that is about $16 million? Second, on dialysis, could you comment on the program in your experience with it so far? I believe you have something like 3,000 or 4,000 patients. And according to your competitor, Medicare's just recently suggested the program could be expanded. Would you want to participate on a larger scale? Or if not, why not? And then lastly, looking further into Kidney Care, FMC has actually started a Medicare Advantage dialysis snip. Could you comment on what your integrated care platform looks like beyond ESCO and if you have an initiatives ongoing to grow this?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Let's go ahead and start with the first one. Go ahead, Vijay.",13,"Let's go ahead and start with the first one. Go ahead, Vijay."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","So on the hospice, it's related to the Nevada hospice business. The reserve is for damages and liabilities associated with our potential eligibility to terminations. The majority of which predates our acquisition of that business in 2013.",37,"So on the hospice, it's related to the Nevada hospice business. The reserve is for damages and liabilities associated with our potential eligibility to terminations. The majority of which predates our acquisition of that business in 2013."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And let's go ahead, and we can always come back to that, Lisa, but let's go ahead and hit the second question on ESCOs. And Javier, you want to hit that, please?",33,"And let's go ahead, and we can always come back to that, Lisa, but let's go ahead and hit the second question on ESCOs. And Javier, you want to hit that, please?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Sure. We have about 4,000 patients in our ESCOs right now. It covers 4 states, 3 markets. And it's too early to tell how these are going to turn out in our excitement on expansion or not. We've only been at it for a couple of months, so it's too early to",99,"Sure. We have about 4,000 patients in our ESCOs right now. It covers 4 states, 3 markets. And it's too early to tell how these are going to turn out in our excitement on expansion or not. We've only been at it for a couple of months, so it's too early to go through that. As it relates to the sea snips, we now have 5 C snips and we continue to find it a good growth vehicle that is really great for integration of transition of care for the patient. So we'll continue to grow on that side."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Sorry, those sea snips, are you partnered with insurers on that? Or is that something you're doing unilaterally?",18,"Sorry, those sea snips, are you partnered with insurers on that? Or is that something you're doing unilaterally?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We do have partnerships.",4,"We do have partnerships."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And maybe, Lisa, I'll add a couple of comments since some of these items, KT here. First, regarding integrated care beyond ESCOs. We remain as intensely positive about that as we have been for years and think that more and more payers as well as more peop",142,"And maybe, Lisa, I'll add a couple of comments since some of these items, KT here. First, regarding integrated care beyond ESCOs. We remain as intensely positive about that as we have been for years and think that more and more payers as well as more people in Congress are starting to understand the clinical and economic upside. And so we will continue to push integrated care outside of ESCOs, both for private pay and for Medicaid and for Medicare. Impossible to predict when there might be an inflection point. But certainly, we're in the lot higher-quality conversations and doing a lot more deals of different sorts with payers now than any time before. And then going back to the hospice, we necessarily have to be pretty circumspect there because there's some active litigation, which is why our commentary is quite sketchy."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Whit Mayo of Robert Baird.",14,"Our next question is from the line of Mr. Whit Mayo of Robert Baird."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","For treatment in dialysis it's trended a lot better than I would've thought for a much longer period of time. Can you remind me just what's driving that improvement in the long we can probably expect to see those declines?",41,"For treatment in dialysis it's trended a lot better than I would've thought for a much longer period of time. Can you remind me just what's driving that improvement in the long we can probably expect to see those declines?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","First part of your question for some reason, the phone cut off and so we only heard the last half. Could you redo it, please?",25,"First part of your question for some reason, the phone cut off and so we only heard the last half. Could you redo it, please?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Oh yes, that question was just the G&A trends in dialysis. It's just trended much more favorably than we thought. Just wanted to know what's driving that and how long we can continue to see improvement.",36,"Oh yes, that question was just the G&A trends in dialysis. It's just trended much more favorably than we thought. Just wanted to know what's driving that and how long we can continue to see improvement."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Well, I can tell you it's driven by excellent work by Javier and his team. But I'll let him complete the answer. JR?",23,"Well, I can tell you it's driven by excellent work by Javier and his team. But I'll let him complete the answer. JR?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, and unfortunately, less powerful but due to some seasonality, we expect G&A to be flat year-over-year.",17,"Yes, and unfortunately, less powerful but due to some seasonality, we expect G&A to be flat year-over-year."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","On a dollar basis or per treatment?",7,"On a dollar basis or per treatment?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Per treatment basis.",3,"Per treatment basis."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And on HCP, I think you referenced in the last quarter that we shouldn't anticipate about $10 million of incremental investments this year. Is there any update around that number? And does that include any of the corporate changes relocating the cor",51,"Okay. And on HCP, I think you referenced in the last quarter that we shouldn't anticipate about $10 million of incremental investments this year. Is there any update around that number? And does that include any of the corporate changes relocating the corporate headquarter that you referenced in your prepared remarks?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'm sorry. Could you do that one again?",9,"I'm sorry. Could you do that one again?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Sorry. Last quarter, you communicated that we should expect about $10 million of incremental investments into HCP, and I wanted to know if that was still there great number for 2016. And does it include the corporate headquarter change that you referenced",42,"Sorry. Last quarter, you communicated that we should expect about $10 million of incremental investments into HCP, and I wanted to know if that was still there great number for 2016. And does it include the corporate headquarter change that you referenced?"
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","So one, it did not include the corporate headquarters, and what we had planned to invest are still in our plans. There's no significant changes to that. They were intended to be in the later part of the year. And as we continue to the year, we'll see if t",62,"So one, it did not include the corporate headquarters, and what we had planned to invest are still in our plans. There's no significant changes to that. They were intended to be in the later part of the year. And as we continue to the year, we'll see if that changes. But right now, we have no changes -- plans to change."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And the $10 million are all investments that would be of a recurring nature.",14,"And the $10 million are all investments that would be of a recurring nature."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. One last one. Just looking beyond ESAs, are there any other interesting therapies potentially coming to market, whether there's an iron drug, vitamin D? Just wondering if there are any drugs that we haven't been paying attention to that you find to",45,"Okay. One last one. Just looking beyond ESAs, are there any other interesting therapies potentially coming to market, whether there's an iron drug, vitamin D? Just wondering if there are any drugs that we haven't been paying attention to that you find to be interesting."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I don't think there's any right now that would affect your 3-year forecasts. The big variable in that near and intermediate term is what kind of partnership we establish on the ESA front, which everybody is, of course, already aware of. And we're looking",65,"I don't think there's any right now that would affect your 3-year forecasts. The big variable in that near and intermediate term is what kind of partnership we establish on the ESA front, which everybody is, of course, already aware of. And we're looking forward to wrapping up a good partnership with someone. But outside of that, there's really nothing to handicap right now."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Right now, we do not have any additional questions in queue.",13,"[Operator Instructions] 
Right now, we do not have any additional questions in queue."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. We will look forward to saying a bunch of you and talking to the rest of you at our annual Capital Markets session where we can obviously go into all this stuff with much more intensity and analysis. So we look forward to that. Take care.",47,"Okay. We will look forward to saying a bunch of you and talking to the rest of you at our annual Capital Markets session where we can obviously go into all this stuff with much more intensity and analysis. So we look forward to that. Take care."
35644,332021620,972947,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","And that concludes today's conference. Thank you all for joining. You may now disconnect.",15,"And that concludes today's conference. Thank you all for joining. You may now disconnect."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you, all, for standing by. [Operator Instructions] Now I will turn the meeting over to your host, Mr. Jim Gustafson. Sir, you may begin.",27,"Welcome, and thank you, all, for standing by. [Operator Instructions] Now I will turn the meeting over to your host, Mr. Jim Gustafson. Sir, you may begin."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you, JR, and welcome, everyone, to the DaVita HealthCare Partners First Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations, and with me today are Kent T",239,"Thank you, JR, and welcome, everyone, to the DaVita HealthCare Partners First Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations, and with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO of DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of HealthCare Partners; Jim Hilger, our Interim CFO and Chief Accounting Officer; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statements. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based on information currently available to us, and we do not intend and undertake no duty to update these statements for any reason. Additionally, I'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website. 
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, Jim, and welcome to all. In the quarter, we delivered solid operating income and strong cash flow. The total adjusted operating income, as you've seen in the release, $458 million and the operating cash flows of $429 million. In the cours",259,"Okay. Thank you, Jim, and welcome to all. In the quarter, we delivered solid operating income and strong cash flow. The total adjusted operating income, as you've seen in the release, $458 million and the operating cash flows of $429 million. In the course of this call, before Q&A, we'll cover clinical outcomes, we'll talk about U.S. Kidney Care, we'll provide an international update, including talking a little bit about the deal announced today, we'll cover HealthCare Partners results; HealthCare Partners we now refer to as the DaVita Medical Group, and then we'll provide a few additional financial details. 
As to clinical outcomes, we'll discuss them first as we always do because that is what comes first. We are, first and foremost, a caregiving company. And the Kidney Care side is where we'll focus our clinical comments on this call. We'll probably rotate back and forth between the various parts of the enterprise each quarter. We have about 178,000 dialysis patients now in the U.S. That's about 35% of all the patients in the U.S. And from a vaccination point of view, our outcomes relative to the community are very strong. Pneumonia vaccinations at 92% for patients; influenza vaccinations, 92% for patients; and Team A [ph] influenza vaccinations at 84%. And as many of you know, improving performance in vaccinations also leads to fewer hospitalizations and, as always, in our areas around the enterprise, our improved clinical outcomes are also very good for the taxpayer. For more color on U.S. Kidney Care financial results, let's hear from Javier Rodriguez."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you, Kent. And I'll divide my comments into 2 sections. First, I'll cover the quarter, and then secondly, I will cover full year guidance. For the quarter, we had a strong operating income of $422 million, and let me cover some of the highlights: Nu",560,"Thank you, Kent. And I'll divide my comments into 2 sections. First, I'll cover the quarter, and then secondly, I will cover full year guidance. For the quarter, we had a strong operating income of $422 million, and let me cover some of the highlights: Number one, normalized NAG was 4.1%, which represented continued improvement over the prior quarters, and it is consistent with our guidance that we gave last year for our 3 years of 3.5% to 4.5%. Our rate per treatment increased by $2.34 per treatment, and it was mainly driven through higher acute mix and improved commercial mix. These improvements were partially offset by fewer treatment days, which is normal in Q1. And as a reminder, the quarter benefited from an extra date due to a leap year, and seasonally higher cost and treatment, number one, primarily due to higher personnel costs from payroll taxes and higher pharma costs from seasonally higher EPO utilization due to the delay of the flu. Happy with the quarter. 
Our guidance for Kidney Care remains unchanged at $1.625 billion to $1.725 [ph] billion. And as always, arrange in total captures the majority of the probabilistic outcomes. And based on where we are today, we are more likely to be on the top half of the guidance range. 
The primary reason for leaving our guidance unchanged is driven by some economic uncertainties surrounding the exchange plans of the ACA. Let me summarize with 4 points on our experience on the ACA: Number one, it is working for patients. Americans, who otherwise would not have insurance, are now insured; number two, many people are far better insured and have better coverage than they had before, including many of our patients that are benefiting from the insurance coverage; number three, the regulatory environment around exchanges is still being built. While many pairs are living up to the spirit of the ACA, others are changing their fine print and their plan designs to avoid paying for expensive chronic diseases, either by cost shifting to the patient or by making the plans unattractive for the expensive chronically ill in other ways. It might be helpful to give an example. We had in one state a plan that tried to limit dialysis benefits and shifted significant economic responsibility to the patient, which, as many of you know, these patients can clearly not afford. Once we alerted the regulatory agencies, the plans were instructed to remedy their behavior. That being said, we're seeing more effort by some of the payers to improve their economics in the exchange plan by making it more difficult for dialysis patients to enroll. This is a complicated issue, which will require regulatory environment. As you know, it happens to be a tough year because of the election and many are distracted. Therefore, the dynamics around enforcement are hard for us to predict. I'll state the obvious, patients and providers will continue to work with regulators as this unfolds. 
Lastly, as you know, not unique to us, there are larger macroeconomics and political risks that are clouding the future of the exchanges. Therefore, it's hard to handicap, with certainty, how this will play out for us. We'll talk about some of these issues in our longer-term outlook in 2 weeks, as we see you in Capital Markets. 
I'll pass it back to you, Kent."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","All right. Thanks, JR. I'm going to cover international now. The losses, as you've seen, were $10 million in the quarter, and this is in line with our guidance of approximately $40 million on the year. The most noteworthy new news on the international fro",354,"All right. Thanks, JR. I'm going to cover international now. The losses, as you've seen, were $10 million in the quarter, and this is in line with our guidance of approximately $40 million on the year. The most noteworthy new news on the international front is our definitive agreement to form a joint venture to grow our Kidney Care business in Asia with 2 partners: Khazanah and Mitsui. Khazanah is a highly respected sovereign wealth fund of the government of Malaysia with an investment portfolio greater than $30 billion. And Mitsui, as many of you know, one of the largest oldest business groups in Japan with about $45 billion in annual revenue, and it recently designated health care as a key strategic domain for themselves corporately going forward. They are both experienced in health care already and are value-added partners for us, not just investors. One of their noteworthy successes in the Asian health care scene is they have a majority stake, approximately 60% stake in IHH Healthcare, which many don't realize, is the second-largest hospital company in the world by market cap. Their market cap is about $13 billion at this point, and we're very excited to have them as our partners. 
The financial terms, just to the summary level, each of Khazanah and Mitsui will invest $150 million over the next few years, and each will receive in return a 20% ownership stake. We will, of course, still be the majority owner therefore, and we will be running the enterprise with them as our very active partners. 
Just to give you a sense of the current scope of the business, we have 64 clinics that serve about 3,300 patients across 5 countries in that part of the world. The definitive agreement is subject to a few closing conditions, so it could take some time to complete, but all 3 parties are working to make that happen as soon as it's possible. 
And now let's turn to what has historically been called HealthCare Partners, but is now, at least internally, referred to as a DaVita Medical Group, Vijay Kotte, the Chief Financial Officer."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. We'll first start with a review of the HCP Q1 performance. Operating income for the quarter, adjusted for the $77 million goodwill impairment and the $16 million Nevada hospice reserve, gets us to $36 million on a non-GAAP basis. Included in",508,"Thanks, Kent. We'll first start with a review of the HCP Q1 performance. Operating income for the quarter, adjusted for the $77 million goodwill impairment and the $16 million Nevada hospice reserve, gets us to $36 million on a non-GAAP basis. Included in the $36 million are approximately $9 million of onetime costs. When adjusted for these onetime costs, we get a normalized operating income of $45 million for the quarter. 
One question you will likely ask is to reconcile this with the first quarter of last year. To do this, we start with 2015 Q1 OI of $60 million, subtract 1/4 of the $58 million in MA and Medicaid rate cuts we had previously disclosed are $15 million and that gets you to $45 million, demonstrating a relatively flat underlying performance year-over-year. 
Now let's break down some of the drivers of performance for the quarter. There's some good things and some bad things. We'll start with the bad things. In addition to the rate cuts, Medicare Advantage enrollment in our legacy geographies grew less than in prior years, and we grew in line with our geographies. Additionally, our commercial membership continues to decline with the market. 
Now let's turn to some good stuff. We continue to close transactions. Earlier in the quarter, we closed on The Everett Clinic, a nationally recognized physician group that adds over 500 clinicians across 20-plus clinics, serving over 300,000 patients with an expected annual revenue of over $400 million. In addition, within our existing geographies, we have a healthy pipeline of opportunities, including a number of small tuck-ins, as well as a few larger acquisitions in process. One example is our prior announcement of our intent to combine with Mountain View Medical Group, which has 50 clinicians across 14 clinics, serving over 80,000 patients, which, if closed, will strengthen our already healthy capabilities in Colorado Springs. 
As we have said before, we continue building capabilities. There are a couple of examples, one clinical and one operational. On the clinical side, we're expanding our very successful Home Care program from other geographies to Nevada, focusing on the needs of our high-risk patients in order to avoid unnecessary hospitalizations and readmissions. On the operational front, we're centralizing national operations and expect to realize savings from scale and vendor consolidation. To remind you, there's been a significant transformation of the leadership team, and that group is picking up new momentum every month. To progress on all these activities, we have a good shot at adding approximately $30 million to OI in the remaining 3 quarters of 2016, above the Q1 normalized rate of $170 million, bringing us to approximately $200 million for the year, the midpoint of our guidance range. So we are maintaining our guidance range of $175 million to $225 million, although we acknowledge that achieving the high end may be less likely. We'll provide more details on our ongoing investments and operational capabilities and a longer-term outlook at Capital Markets Day in 2 weeks. 
Now I'll turn it over to Jim Hilger."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. In regards to the overall enterprise, our debt expense was $103 million in the first quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 40% in the quarter when you adjust fo",316,"Thanks, Vijay. In regards to the overall enterprise, our debt expense was $103 million in the first quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 40% in the quarter when you adjust for the nondeductible goodwill impairment charge in the HCP Nevada hospice accrual. For the full year, we now expect the 2016 effective tax rate attributable to DaVita HealthCare Partners to be in the range of 39.5% to 40.5%. 
Now turning to cash flow. We continue to generate strong cash flows. Operating cash flow was $429 million in the first quarter and on an adjusted basis, $1.88 billion for the 12 months. As we've discussed before, over time, Kidney Care contributes about 75% of our operating cash flows. HCP contributes about 25%, notably higher than its contribution percentage to our enterprise operating income. 
Regarding capital deployment. The first quarter -- during the first quarter, we purchased 3.7 million shares for $249 million at an average price of $67.61, but we've not made any additional repurchases since our last earnings call. Please note that we continuously weigh capital deployment opportunities across growth investment, share repurchases, debt repayment and holding cash. 
And now, finally, on to outlook. I'd just like to restate our outlook. We are still expecting our consolidated operating income for 2016 to be in the range of $1.8 billion to $1.95 billion. We expect our operating income for Kidney Care to be in the range of $1.625 billion to $1.725 billion, and we expect income for HCP to be in the range of $175 million to $225 million. And our cash flow -- our operating cash flow expectation is in the range of $1.55 billion to $1.75 billion. As always, these guidance ranges capture majority of the probabilistic outcomes that we can foresee. 
And with that, operator, let's go ahead and open it up for Q&A."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question is from the line of Mr. Kevin Fischbeck.",13,"[Operator Instructions] Our first question is from the line of Mr. Kevin Fischbeck."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Could you talk a little bit about the $9 million of onetime costs in HCP what those relate to?",19,"Could you talk a little bit about the $9 million of onetime costs in HCP what those relate to?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Sure. The onetime costs, Kevin, were related to 3 primary things: One was the move of our California headquarters; two is some compensation-related accruals; and the third is just some expense true-ups for prior periods.",35,"Sure. The onetime costs, Kevin, were related to 3 primary things: One was the move of our California headquarters; two is some compensation-related accruals; and the third is just some expense true-ups for prior periods."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And then you guys earlier kind of quantified the 2017 MA rate headwind of $25 million. I guess, how do you think about offsetting that? And any kind of tailwinds you think about into next year versus this year?",39,"And then you guys earlier kind of quantified the 2017 MA rate headwind of $25 million. I guess, how do you think about offsetting that? And any kind of tailwinds you think about into next year versus this year?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We're not going to give full 2017 guidance or that information, but related to the rate headwinds themselves, there are some things related to the health insurer tax that will give some tailwind, but not enough to overcome those headwinds. And beyond that",66,"We're not going to give full 2017 guidance or that information, but related to the rate headwinds themselves, there are some things related to the health insurer tax that will give some tailwind, but not enough to overcome those headwinds. And beyond that, we'll give more detail of our operational expectations and some of our other things at Capital Markets in a couple of weeks."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Actually [indiscernible] insurance fees, is that explicitly built into your contracts as a flow-through? Or is that something that you have to go back and kind of renegotiate as an offset?",31,"Actually [indiscernible] insurance fees, is that explicitly built into your contracts as a flow-through? Or is that something that you have to go back and kind of renegotiate as an offset?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It varies by contract and so we'll. We've already addressed it with most of our payers.",17,"It varies by contract and so we'll. We've already addressed it with most of our payers."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, I guess, maybe last question. I guess, as far as EPO costs for the year, I guess, Amgen is pushing through rate increase on EPO and then encouraging people to move over to Aranesp. Is there any thoughts there about kind of how you guys are",69,"Okay. And then, I guess, maybe last question. I guess, as far as EPO costs for the year, I guess, Amgen is pushing through rate increase on EPO and then encouraging people to move over to Aranesp. Is there any thoughts there about kind of how you guys are dealing with that? Is that the move that you're done? Or do you expect the EPO pressure through the year?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","LeAnne, would you like to go ahead and take that one, please?",12,"LeAnne, would you like to go ahead and take that one, please?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, and you may need to clarify if I don't answer your question correctly. As it relates to Epogen pricing, we did not experience a price increase this year. So I don't know if that answers your question or you refer to Aranesp?",43,"Yes, and you may need to clarify if I don't answer your question correctly. As it relates to Epogen pricing, we did not experience a price increase this year. So I don't know if that answers your question or you refer to Aranesp?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I guess, my understanding was that the Amgen was trying to move people to the longer-lasting EPO product. As generally speaking, you favor your contract might be different than others. But I want to be sure if that was something that you guys were looking",64,"I guess, my understanding was that the Amgen was trying to move people to the longer-lasting EPO product. As generally speaking, you favor your contract might be different than others. But I want to be sure if that was something that you guys were looking to do and whether that was going to be a cost advantage to you under your contract this year?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We certainly use some Aranesp now in the population and we -- both products are both -- very clinically appropriate for patients. And so we just use whichever the physician is ordering at this point in time. And there's not a contractual difference.",43,"We certainly use some Aranesp now in the population and we -- both products are both -- very clinically appropriate for patients. And so we just use whichever the physician is ordering at this point in time. And there's not a contractual difference."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Matthew Borsch of Goldman Sachs.",14,"Our next question is from the line of Mr. Matthew Borsch of Goldman Sachs."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Just first question, I was curious your perspective on the slowdown. I realize it's a much broader dynamic than just DaVita Medical Group. But the slowdown in Medicare Advantage enrollment and if there's anything that the DaVita Medical Group physicians a",53,"Just first question, I was curious your perspective on the slowdown. I realize it's a much broader dynamic than just DaVita Medical Group. But the slowdown in Medicare Advantage enrollment and if there's anything that the DaVita Medical Group physicians are seeing on the front lines that might help inform what's going on?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","At this point, we don't have a good sense of what '17, '18, '19 are going to look like. We still think Medicare Advantage is going to be growing in our markets, as in the country overall. We and a lot of other people continue to add more services and capa",123,"At this point, we don't have a good sense of what '17, '18, '19 are going to look like. We still think Medicare Advantage is going to be growing in our markets, as in the country overall. We and a lot of other people continue to add more services and capabilities that will fuel that fire. At the same time, if the payers decide in any given period to leave benefits stagnant or, in fact, even pull back a little bit, that has a big impact. And so we remain very bullish on fundamental growth. But at this point, the notion of sort of guesstimating what's going to happen in '17 and '18, we're not feeling certain enough to add any value there."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Yes, that makes sense. And just curious, when the medical group sees MA patients, is there any distinction in terms of the financials, if that's an employer group MA member or a regular, I guess, you'd say retail MA member?",40,"Yes, that makes sense. And just curious, when the medical group sees MA patients, is there any distinction in terms of the financials, if that's an employer group MA member or a regular, I guess, you'd say retail MA member?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Can you restate the question, Matthew? I'm not understanding.",9,"Can you restate the question, Matthew? I'm not understanding."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Well, I guess, you think about the major Medicare Advantage plans, they typically have for every 800 individual MA members, they may be have another 200 that come from employer groups that are doing retiree coverage. It's all Medicare Advantage. I'm just",65,"Well, I guess, you think about the major Medicare Advantage plans, they typically have for every 800 individual MA members, they may be have another 200 that come from employer groups that are doing retiree coverage. It's all Medicare Advantage. I'm just wondering if there's any distinction in that the medical group sees in terms of the financial arrangements, risk-taking arrangements between group and individual."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","No, we have not seen anything significant in that [indiscernible].",10,"No, we have not seen anything significant in that [indiscernible]."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And you don't really know how many is one or the other? Is that correct?",16,"Okay. And you don't really know how many is one or the other? Is that correct?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, I think -- I don't think we've anything useful to say about this, Matthew. But by Capital Markets, if there's anything useful to say, we'll be prepared to say it.",31,"Yes, I think -- I don't think we've anything useful to say about this, Matthew. But by Capital Markets, if there's anything useful to say, we'll be prepared to say it."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. That sounds great. Just one last question on the ACA exchange plan dynamic. Can you give us some sense of how to think about what the numbers are? In other words, is this -- I wouldn't think it would be the numbers would be very big in terms of your",74,"Okay. That sounds great. Just one last question on the ACA exchange plan dynamic. Can you give us some sense of how to think about what the numbers are? In other words, is this -- I wouldn't think it would be the numbers would be very big in terms of your overall patient base. But is there a higher concentration relative to, say, how the ACA exchange enrollment compares to the overall insured population?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Let me take a stab at that, Matthew, and then you tell me if I'm hitting the right thing. Exchanges are a tiny percentage of what we're about. At the same time, when we have exchange business that's private insurance, that is additive in the same way that",103,"Let me take a stab at that, Matthew, and then you tell me if I'm hitting the right thing. Exchanges are a tiny percentage of what we're about. At the same time, when we have exchange business that's private insurance, that is additive in the same way that our private insurance patients are in general, since, as you know, the 10% or so of patients we have are private subsidized, the 90% that are government on which we lose money on the margin. And so exchanges are a tiny percentage, but just like with the rest of private pay, little movements add up."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And have you ever contemplated starting your own exchange plans to get around the problems that you have had, had with the payers?",23,"And have you ever contemplated starting your own exchange plans to get around the problems that you have had, had with the payers?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Up to this point, we have not.",7,"Up to this point, we have not."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","At this point, I would like to open the line for Mr. Gary Lieberman of Wells Fargo.",17,"At this point, I would like to open the line for Mr. Gary Lieberman of Wells Fargo."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Maybe talk about the joint venture and kind of the expectations for growth and maybe some of the start-up losses that we should expect.",25,"Maybe talk about the joint venture and kind of the expectations for growth and maybe some of the start-up losses that we should expect."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'm sorry, Gary, could you -- there was still some noise on this end. Could you go ahead and repeat the question? My bet.",25,"I'm sorry, Gary, could you -- there was still some noise on this end. Could you go ahead and repeat the question? My bet."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Maybe talk about the joint venture a little bit and the expectation for growth, and what if any start-up losses we would expect to see from it?",27,"Maybe talk about the joint venture a little bit and the expectation for growth, and what if any start-up losses we would expect to see from it?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Well, we are still losing money in the Asia market. And that's not going to change in the near term because if anything, the addition of these 2 partners is going to accelerate some of our growth, which in the short term, could actually increase our losse",80,"Well, we are still losing money in the Asia market. And that's not going to change in the near term because if anything, the addition of these 2 partners is going to accelerate some of our growth, which in the short term, could actually increase our losses, kind of depends which countries we're growing the most in. So I don't know how much useful I can say beyond that, but go ahead and fire off another question if you'd like."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I guess, in terms of -- little different topic, just foreign exchange rates, any thoughts there? [indiscernible] any plans to hedge them? Or is it too small to really worry about it?",32,"I guess, in terms of -- little different topic, just foreign exchange rates, any thoughts there? [indiscernible] any plans to hedge them? Or is it too small to really worry about it?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Up to this point, we've done little or no hedging. We're paying a lot of attention, but the numbers are so small. And in particular, given we're spread across 10 different countries -- 11 different countries and you kind of do the math, it just isn't that",82,"Up to this point, we've done little or no hedging. We're paying a lot of attention, but the numbers are so small. And in particular, given we're spread across 10 different countries -- 11 different countries and you kind of do the math, it just isn't that helpful at this point. But we're making sure we're talking to people who are more thoughtful and sophisticated than we are and trying to figure out exactly when we should start doing more of that."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. On to the ESAs, is it possible for you to tell us what percentage of patients are currently using Aranesp?",21,"Okay. On to the ESAs, is it possible for you to tell us what percentage of patients are currently using Aranesp?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I can answer that. We're predominantly an EPO shot, but quite small.",12,"I can answer that. We're predominantly an EPO shot, but quite small."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Is it the 10% that you're allowed to use other ESAs? Or does that not count, I guess, here if it's Aranesp?",22,"Is it the 10% that you're allowed to use other ESAs? Or does that not count, I guess, here if it's Aranesp?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, Aranesp does not count against us.",7,"Yes, Aranesp does not count against us."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then the pricing -- the lack of pricing increase on EPO, does that have something to do with you moving some number of patients onto Aranesp?",28,"Okay. And then the pricing -- the lack of pricing increase on EPO, does that have something to do with you moving some number of patients onto Aranesp?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","No, that's not the case and since I have the floor here, I'm being corrected that we did take a 1% price increase in January, and so I apologize for that mistake.",32,"No, that's not the case and since I have the floor here, I'm being corrected that we did take a 1% price increase in January, and so I apologize for that mistake."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Ms. Margaret Kaczor of William Blair.",14,"Our next question is from the line of Ms. Margaret Kaczor of William Blair."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","First question for me, there's a lot of moving pieces in HCP, and I'm sure you'll address a lot of them at your Capital Markets Day in a few weeks. But that said, if you look at HCP and its trajectory, really over the next couple of years, maybe 3 years,",96,"First question for me, there's a lot of moving pieces in HCP, and I'm sure you'll address a lot of them at your Capital Markets Day in a few weeks. But that said, if you look at HCP and its trajectory, really over the next couple of years, maybe 3 years, how important is that patient and revenue growth compared to that profitability improvement? And where do you see that going? Can the newer market revenues exceed the legacy markets since those appear to be slowing in kind of legacy markets even we accelerate from here?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, a very fair question. And certainly, we are going to hit that hard in the Capital Markets or at least to the best of our ability. We do think in a couple of our new markets the growth prospects over the next 2, 3 years and revenue, EBITDA and OI basi",107,"Yes, a very fair question. And certainly, we are going to hit that hard in the Capital Markets or at least to the best of our ability. We do think in a couple of our new markets the growth prospects over the next 2, 3 years and revenue, EBITDA and OI basis is material. But at the same time, we actually have a lot of growth opportunities in the 3 inherited markets. And so which has more potential, I think, we'd probably say they're pretty equivalent and if anything, the legacy markets have more, but it'd be nice to see them in a bit of a race."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And just maybe pick a little bit more at that. We saw the senior revenues in the mid-single-digit range in 2015. But as we look out again over that 2- to 3-year time horizon, what would you be happy with seeing in terms of that kind of new patient g",57,"Okay. And just maybe pick a little bit more at that. We saw the senior revenues in the mid-single-digit range in 2015. But as we look out again over that 2- to 3-year time horizon, what would you be happy with seeing in terms of that kind of new patient growth as well as the revenue growth?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. What would we be happy to see? I would say if you give us the gift of reflecting on that, and we're going to talk about the range that we expect to see at Capital Markets, and then maybe address the happiness thing. But we'll definitely give you our",63,"Okay. What would we be happy to see? I would say if you give us the gift of reflecting on that, and we're going to talk about the range that we expect to see at Capital Markets, and then maybe address the happiness thing. But we'll definitely give you our sense of the range of likely outcomes here in a couple of weeks."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","All right. Fair enough. And then on the Kidney Care side, number of clinics that you guys are opening or growing a little bit faster than they have been the last few quarters, and rightfully so. But should we expect a similar pace of net new centers openi",99,"All right. Fair enough. And then on the Kidney Care side, number of clinics that you guys are opening or growing a little bit faster than they have been the last few quarters, and rightfully so. But should we expect a similar pace of net new centers opening throughout 2016 as you guys catch up with those longer approval time frames from last year. So are you going to reach 120 new clinics for the year? And how quickly can these new clinics help get your NAG back up to that 4.5% or maybe even higher over the near-term?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'll turn that one over to Javier.",8,"I'll turn that one over to Javier."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you. We had 30 centers opened in the first quarter. Range for the year is 90 to 110. The last part of your question on NAG, we're still comfortable with a multiyear range that we addressed earlier, so 3.5% to 4.5%.",42,"Thank you. We had 30 centers opened in the first quarter. Range for the year is 90 to 110. The last part of your question on NAG, we're still comfortable with a multiyear range that we addressed earlier, so 3.5% to 4.5%."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And last one for me. How is the acquisition of Renal Ventures coming along? When should we see kind of the initial impact on results, and how long is it going to take for that change to more closely resemble maybe the financial structure of the DaVi",49,"Okay. And last one for me. How is the acquisition of Renal Ventures coming along? When should we see kind of the initial impact on results, and how long is it going to take for that change to more closely resemble maybe the financial structure of the DaVita-owned clinics?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","JR, can you take that one, please?",7,"JR, can you take that one, please?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes. It's still going through the FTC, so the short answer is we don't know.",15,"Yes. It's still going through the FTC, so the short answer is we don't know."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Gary Taylor of JP MC.",14,"Our next question is from the line of Mr. Gary Taylor of JP MC."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Couple of questions. I wanted to go back to the international JV for a second and just make sure I understand what you said. Each of these investing $150 million over several years for 20%, so -- that was for each of those, right? So the $300 million inve",55,"Couple of questions. I wanted to go back to the international JV for a second and just make sure I understand what you said. Each of these investing $150 million over several years for 20%, so -- that was for each of those, right? So the $300 million investment combined along 40% of the venture."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Correct.",1,"Correct."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","So that implies something with equity value of $750 million. Does the DaVita make commensurate capital contribution? Or is this capital-light to you because you're contributing your market operational intelligence, know-how, et cetera? What's your contrib",36,"So that implies something with equity value of $750 million. Does the DaVita make commensurate capital contribution? Or is this capital-light to you because you're contributing your market operational intelligence, know-how, et cetera? What's your contribution?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Right. This investment will be the growth capital for the entity. And what we're submitting into the partnership is the entity itself, which is the kind of things that you mentioned.",31,"Right. This investment will be the growth capital for the entity. And what we're submitting into the partnership is the entity itself, which is the kind of things that you mentioned."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And are you contributing your existing centers in those 5 countries into the JV?",15,"Okay. And are you contributing your existing centers in those 5 countries into the JV?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Correct. So our entire business in Kidney Care in that geographic area, that's the asset which we're contributing into the partnership. What they're contributing is the $150 million each of growth capital.",32,"Correct. So our entire business in Kidney Care in that geographic area, that's the asset which we're contributing into the partnership. What they're contributing is the $150 million each of growth capital."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And it implies pretty sizable capital deployment to that part of the world, I guess, compared to what you've invested thus far. So are there existing centers to acquire? Is this primarily development or will be both?",37,"And it implies pretty sizable capital deployment to that part of the world, I guess, compared to what you've invested thus far. So are there existing centers to acquire? Is this primarily development or will be both?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It will be both, but we're expecting that more of it will be acquisition than de novo. But it almost gets difficult to use some of the labels because in some of these countries, for example, China, you could end up with deal arrangements that are kind of",50,"It will be both, but we're expecting that more of it will be acquisition than de novo. But it almost gets difficult to use some of the labels because in some of these countries, for example, China, you could end up with deal arrangements that are kind of a hybrid."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And then my another question, I just want to go back to commercial mix. I was taking notes, but I don't know if I missed this comment. Did you make a comment about commercial mix of patients, which I think was actually grew year-over-year in '15 for, I th",62,"And then my another question, I just want to go back to commercial mix. I was taking notes, but I don't know if I missed this comment. Did you make a comment about commercial mix of patients, which I think was actually grew year-over-year in '15 for, I think, the first time in some time, so 1Q of '16. Did that change?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It did grow in '15 for the first time in a long time, and so we're pretty pleased with it where we're at. I think we disclosed in the 10-K 12% mix. We're rounding up to 12% -- excuse me, 11% of our total patients.",45,"It did grow in '15 for the first time in a long time, and so we're pretty pleased with it where we're at. I think we disclosed in the 10-K 12% mix. We're rounding up to 12% -- excuse me, 11% of our total patients."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Sorry, we were 11%, rounded to 11% in 2015.",9,"Sorry, we were 11%, rounded to 11% in 2015."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","You only give that annually, I believe, is that right?",10,"You only give that annually, I believe, is that right?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","That is correct. We disclose it annually.",7,"That is correct. We disclose it annually."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. So the commercial mix continue to improve year-over-year in 1Q of '16? Or has that leveled out?",18,"Okay. So the commercial mix continue to improve year-over-year in 1Q of '16? Or has that leveled out?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We continue to improve in the quarter.",7,"We continue to improve in the quarter."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And is most of that -- is that improvement being driven by exchanges or...",14,"And is most of that -- is that improvement being driven by exchanges or..."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","That is a portion of the improvement. The improvement we've seen over multiple quarter period is in part due to exchanges and in part due to improving economy. And in some cases, it's difficult to discern what -- which is where. We know where the exchange",53,"That is a portion of the improvement. The improvement we've seen over multiple quarter period is in part due to exchanges and in part due to improving economy. And in some cases, it's difficult to discern what -- which is where. We know where the exchanges are, but there also is some cannibalization."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Yes, obviously, it's powerful trend. Now my last question, what's in the [indiscernible] I'll get [indiscernible] couple of weeks here at Capital Markets, but what is your average commercial rate increase you're expecting for 2016 that's baked into guidan",39,"Yes, obviously, it's powerful trend. Now my last question, what's in the [indiscernible] I'll get [indiscernible] couple of weeks here at Capital Markets, but what is your average commercial rate increase you're expecting for 2016 that's baked into guidance?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, we will go over our expectations on the RPT side at Capital Markets, and we may or may not get quite to that level of granularity. But, as always, we'll give you a 3-year outlook on what we think about RPT, or revenue per treatment.",46,"Yes, we will go over our expectations on the RPT side at Capital Markets, and we may or may not get quite to that level of granularity. But, as always, we'll give you a 3-year outlook on what we think about RPT, or revenue per treatment."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","At this point, I would like to open the line for Ms. Lisa Clive of Bernstein.",16,"At this point, I would like to open the line for Ms. Lisa Clive of Bernstein."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I have 3 for you. First of all, sorry, if I missed the details on this, but could you give us some color on the accrual for HCP, the hospice business in Nevada? Am I right this is about $16 million? Second, on dialysis, could you comment on the ESCO progr",138,"I have 3 for you. First of all, sorry, if I missed the details on this, but could you give us some color on the accrual for HCP, the hospice business in Nevada? Am I right this is about $16 million? Second, on dialysis, could you comment on the ESCO program in your experience with it so far? I believe you have something like 3,000 or 4,000 patients. And according to your competitor, Medicare has just recently suggested the program could be expanded. Would you want to participate on a larger scale? Or if not, why not? And then lastly, looking further in integrated care, FMC has actually just started a Medicare Advantage dialysis snip. Could you comment on what your integrated care platform looks like beyond ESCO, and if you have any initiatives ongoing to grow this?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Let's go ahead and start with the first one. Go ahead, Vijay.",13,"Let's go ahead and start with the first one. Go ahead, Vijay."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","So on the hospice, it's related to the Nevada hospice business. The reserve is for damages and liabilities associated with our potential eligibility to terminations. The majority of which predates our acquisition of that business in 2013.",37,"So on the hospice, it's related to the Nevada hospice business. The reserve is for damages and liabilities associated with our potential eligibility to terminations. The majority of which predates our acquisition of that business in 2013."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And let's go ahead, and we can always come back to that, Lisa, but let's go ahead and hit the second question on ESCOs. And Javier, you want to hit that, please?",33,"And let's go ahead, and we can always come back to that, Lisa, but let's go ahead and hit the second question on ESCOs. And Javier, you want to hit that, please?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Sure. We have about 4,000 patients in our ESCOs right now. It covers 4 states, 3 markets. And it's too early to tell how these are going to turn out in our excitement on expansion or not. We've only been at it for a couple of months, so it's too early to",97,"Sure. We have about 4,000 patients in our ESCOs right now. It covers 4 states, 3 markets. And it's too early to tell how these are going to turn out in our excitement on expansion or not. We've only been at it for a couple of months, so it's too early to go through that. As it relates to the C-SNIPs, we now have 5 C-SNIPs, and we continue to find it a good growth vehicle that is really great for integration of transitions of care for the patient. So we'll continue to grow on that side."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Sorry, those C-SNIPs are you partnered with insurers on that? Or is that something you're doing unilaterally?",17,"Sorry, those C-SNIPs are you partnered with insurers on that? Or is that something you're doing unilaterally?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We do have partnerships.",4,"We do have partnerships."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And maybe, Lisa, I'll add a couple of comments since some of these items, KT here. First, regarding integrated care beyond ESCOs. We remain as intensely positive about that, as we have been for years, and think that more and more payers as well as more pe",142,"And maybe, Lisa, I'll add a couple of comments since some of these items, KT here. First, regarding integrated care beyond ESCOs. We remain as intensely positive about that, as we have been for years, and think that more and more payers as well as more people in Congress are starting to understand the clinical and economic upside. And so we will continue to push integrated care outside of ESCOs, both for private pay and for Medicaid and for Medicare. Impossible to predict when there might be an inflection point. But certainly, we're in a lot higher-quality conversations and doing a lot more deals of different sorts with payers now than any time before. And then going back to the hospice, we necessarily have to be pretty circumspect there because there's some active litigation, which is why our commentary is quite sketchy."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Whit Mayo of Robert Baird.",14,"Our next question is from the line of Mr. Whit Mayo of Robert Baird."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","For treatment in dialysis, it's trended a lot better than I would've thought for a much longer period of time. Can you remind me just what's driving that improvement in the long we can probably expect to see those declines?",40,"For treatment in dialysis, it's trended a lot better than I would've thought for a much longer period of time. Can you remind me just what's driving that improvement in the long we can probably expect to see those declines?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","But could you -- the first part of your question for some reason, the phone cut off and so we only heard the last half. Could you redo it, please?",30,"But could you -- the first part of your question for some reason, the phone cut off and so we only heard the last half. Could you redo it, please?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Yes. The question was just the G&A trends in dialysis. It's just trended much more favorably than we thought. Just wanted to know what's driving that, and how long we can continue to see improvement?",35,"Yes. The question was just the G&A trends in dialysis. It's just trended much more favorably than we thought. Just wanted to know what's driving that, and how long we can continue to see improvement?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","What I can tell you it's driven by excellent work by Javier and his team, but I'll let him complete the answer. JR?",24,"What I can tell you it's driven by excellent work by Javier and his team, but I'll let him complete the answer. JR?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, and unfortunately, less powerful but due to some seasonality, we expect G&A to be flat year-over-year.",17,"Yes, and unfortunately, less powerful but due to some seasonality, we expect G&A to be flat year-over-year."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","On a dollar basis or per treatment?",7,"On a dollar basis or per treatment?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Per treatment basis.",3,"Per treatment basis."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And on HCP, I think you referenced in the last quarter that we shouldn't anticipate about $10 million of incremental investments this year. Is there any update around that number? And does that include any of the corporate changes, relocating the co",51,"Okay. And on HCP, I think you referenced in the last quarter that we shouldn't anticipate about $10 million of incremental investments this year. Is there any update around that number? And does that include any of the corporate changes, relocating the corporate headquarter that you referenced in your prepared remarks?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'm sorry. Could you do that one again?",9,"I'm sorry. Could you do that one again?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Sorry. Last quarter, you communicated that we should expect about $10 million of incremental investments into HCP, and I wanted to know if that was still the right number for 2016? And does it include the corporate headquarter change that you referenced?",42,"Sorry. Last quarter, you communicated that we should expect about $10 million of incremental investments into HCP, and I wanted to know if that was still the right number for 2016? And does it include the corporate headquarter change that you referenced?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","So one, it did not include the corporate headquarters, and what we had planned to invest are still in our plans. There's no significant changes to that. They were intended to be in the later part of the year. And as we continue to assess the year, we'll s",63,"So one, it did not include the corporate headquarters, and what we had planned to invest are still in our plans. There's no significant changes to that. They were intended to be in the later part of the year. And as we continue to assess the year, we'll see if that changes. But right now, we have no changes -- plans to change."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And the $10 million are all investments that would be of a recurring nature.",14,"And the $10 million are all investments that would be of a recurring nature."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. One last one. Just looking beyond ESAs, are there any other interesting therapies potentially coming to market, whether there's an iron drug, vitamin D? Just wondering if there are any other drugs that we haven't been paying attention to that you fi",46,"Okay. One last one. Just looking beyond ESAs, are there any other interesting therapies potentially coming to market, whether there's an iron drug, vitamin D? Just wondering if there are any other drugs that we haven't been paying attention to that you find to be interesting?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I don't think there's any right now that would affect your 3-year forecasts. The big variable in that near and intermediate term is what kind of partnership we establish on the ESA front, which everybody is, of course, already aware of. And we're looking",65,"I don't think there's any right now that would affect your 3-year forecasts. The big variable in that near and intermediate term is what kind of partnership we establish on the ESA front, which everybody is, of course, already aware of. And we're looking forward to wrapping up a good partnership with someone. But outside of that, there's really nothing to handicap right now."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","At this time, speakers, there are no additional questions in queue. [Operator Instructions]",13,"At this time, speakers, there are no additional questions in queue. [Operator Instructions]"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Operator, that's -- well, you've already gotten somebody else, have you?",11,"Operator, that's -- well, you've already gotten somebody else, have you?"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","All right. No, we do not have any additional questions in queue",12,"All right. No, we do not have any additional questions in queue"
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. We will look forward to seeing a bunch of you and talking to the rest of you at our Annual Capital Markets session where we can obviously go into all this stuff with much more intensity and analysis. So we look forward to that. Take care.",47,"Okay. We will look forward to seeing a bunch of you and talking to the rest of you at our Annual Capital Markets session where we can obviously go into all this stuff with much more intensity and analysis. So we look forward to that. Take care."
35644,332021620,973230,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","And that concludes today's conference. Thank you, all, for joining. You may now disconnect.",15,"And that concludes today's conference. Thank you, all, for joining. You may now disconnect."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you, all, for standing by. [Operator Instructions] Now I will turn the meeting over to your host, Mr. Jim Gustafson. Sir, you may begin.",27,"Welcome, and thank you, all, for standing by. [Operator Instructions] Now I will turn the meeting over to your host, Mr. Jim Gustafson. Sir, you may begin."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you, JR, and welcome, everyone, to the DaVita HealthCare Partners First Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations, and with me today are Kent T",239,"Thank you, JR, and welcome, everyone, to the DaVita HealthCare Partners First Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations, and with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO of DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of HealthCare Partners; Jim Hilger, our Interim CFO and Chief Accounting Officer; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statements. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based on information currently available to us, and we do not intend and undertake no duty to update these statements for any reason. Additionally, I'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website. 
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, Jim, and welcome to all. In the quarter, we delivered solid operating income and strong cash flow. The total adjusted operating income, as you've seen in the release, $458 million and the operating cash flows of $429 million. In the cours",257,"Okay. Thank you, Jim, and welcome to all. In the quarter, we delivered solid operating income and strong cash flow. The total adjusted operating income, as you've seen in the release, $458 million and the operating cash flows of $429 million. In the course of this call, before Q&A, we'll cover clinical outcomes, we'll talk about U.S. Kidney Care, we'll provide an international update, including talking a little bit about the deal announced today, we'll cover HealthCare Partners results, HealthCare Partners we now refer to as the DaVita Medical Group; and then we'll provide a few additional financial details. 
As to clinical outcomes, we'll discuss them first as we always do because that is what comes first. We are, first and foremost, a caregiving company. On the Kidney Care side is where we'll focus our clinical comments on this call. We'll probably rotate back and forth between the various parts of the enterprise each quarter. We have about 178,000 dialysis patients now in the U.S. That's about 35% of all the patients in the U.S. And from a vaccination point of view, our outcomes relative to the community are very strong. Pneumonia vaccinations at 92% for patients; influenza vaccinations, 92% for patients; and teammate influenza vaccinations at 84%. And as many of you know, improving performance in vaccinations also leads to fewer hospitalizations and, as always, in our areas around the enterprise, our improved clinical outcomes are also very good for the taxpayer. For more color on U.S. Kidney Care financial results, let's hear from Javier Rodriguez."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you, Kent. And I'll divide my comments into 2 sections. First, I'll cover the quarter, and then secondly, I will cover full year guidance. For the quarter, we had a strong operating income of $422 million, and let me cover some of the highlights: Nu",560,"Thank you, Kent. And I'll divide my comments into 2 sections. First, I'll cover the quarter, and then secondly, I will cover full year guidance. For the quarter, we had a strong operating income of $422 million, and let me cover some of the highlights: Number one, normalized NAG was 4.1%, which represented continued improvement over the prior quarters, and it is consistent with our guidance that we gave last year for our 3 years of 3.5% to 4.5%. Our rate per treatment increased by $2.34 per treatment, and it was mainly driven through higher acute mix and improved commercial mix. These improvements were partially offset by fewer treatment days, which is normal in Q1. And as a reminder, the quarter benefited from an extra day due to a leap year, and seasonally higher cost and treatment, number one, primarily due to higher personnel costs from payroll taxes and higher pharma costs from seasonally higher EPO utilization due to the delay of the flu. Happy with the quarter. 
Our guidance for Kidney Care remains unchanged at $1.625 billion to $1.75 billion. And as always, our range in total captures the majority of the probabilistic outcomes. And based on where we are today, we are more likely to be on the top half of the guidance range. 
The primary reason for leaving our guidance unchanged is driven by some economic uncertainties surrounding the exchange plans of the ACA. Let me summarize with 4 points on our experience on the ACA: Number one, it is working for patients. Americans, who otherwise would not have insurance, are now insured; number two, many people are far better insured and have better coverage than they had before, including many of our patients that are benefiting from the insurance coverage; number three, the regulatory environment around exchanges is still being built. While many payers are living up to the spirit of the ACA, others are changing their fine print in their plan designs to avoid paying for expensive chronic diseases, either by cost shifting to the patient or by making the plans unattractive for the expensive chronically ill in other ways. It might be helpful to give an example. We had in one state a plan that tried to limit dialysis benefits and shifted significant economic responsibility to the patient, which, as many of you know, these patients can clearly not afford. Once we alerted the regulatory agencies, the plans were instructed to remedy their behavior. That being said, we're seeing more effort by some of the payers to improve their economics in the exchange plan by making it more difficult for dialysis patients to enroll. This is a complicated issue, which will require regulatory environment. As you know, it happens to be a tough year because of the election and many are distracted. Therefore, the dynamics around enforcement are hard for us to predict. I'll state the obvious, patients and providers will continue to work with regulators as this unfolds. 
Lastly, as you know, not unique to us, there are larger macroeconomics and political risks that are clouding the future of the exchanges. Therefore, it's hard to handicap, with certainty, how this will play out for us. We'll talk about some of these issues in our longer-term outlook in 2 weeks, as we see you in Capital Markets. 
I'll pass it back to you, Kent."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","All right. Thanks, JR. I'm going to cover international now. The losses, as you've seen, were $10 million in the quarter, and this is in line with our guidance of approximately $40 million on the year. The most noteworthy new news on the international fro",354,"All right. Thanks, JR. I'm going to cover international now. The losses, as you've seen, were $10 million in the quarter, and this is in line with our guidance of approximately $40 million on the year. The most noteworthy new news on the international front is our definitive agreement to form a joint venture to grow our Kidney Care business in Asia with 2 partners: Khazanah and Mitsui. Khazanah is a highly respected sovereign wealth fund of the government of Malaysia with an investment portfolio greater than $30 billion. And Mitsui, as many of you know, one of the largest oldest business groups in Japan with about $45 billion in annual revenue, and it recently designated health care as a key strategic domain for themselves corporately going forward. They are both experienced in health care already and are value-added partners for us, not just investors. One of their noteworthy successes in the Asian health care scene is they have a majority stake, approximately 60% stake in IHH Healthcare, which many don't realize, is the second-largest hospital company in the world by market cap. Their market cap is about $13 billion at this point, and we're very excited to have them as our partners. 
The financial terms, just at a summary level, each of Khazanah and Mitsui will invest $150 million over the next few years, and each will receive in return a 20% ownership stake. We will, of course, still be the majority owner therefore, and we will be running the enterprise with them as our very active partners. 
Just to give you a sense of the current scope of the business, we have 64 clinics that serve about 3,300 patients across 5 countries in that part of the world. The definitive agreement is subject to a few closing conditions, so it could take some time to complete, but all 3 parties are working to make that happen as soon as is possible. 
And now let's turn to what has historically been called HealthCare Partners, but is now, at least internally, referred to as the DaVita Medical Group, Vijay Kotte, the Chief Financial Officer."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. We'll first start with a review of the HCP Q1 performance. Operating income for the quarter, adjusted for the $77 million goodwill impairment and the $16 million Nevada hospice reserve, gets us to $36 million on a non-GAAP basis. Included in",509,"Thanks, Kent. We'll first start with a review of the HCP Q1 performance. Operating income for the quarter, adjusted for the $77 million goodwill impairment and the $16 million Nevada hospice reserve, gets us to $36 million on a non-GAAP basis. Included in the $36 million are approximately $9 million of onetime costs. When adjusted for these onetime costs, we get a normalized operating income of $45 million for the quarter. 
One question you will likely ask is to reconcile this with the first quarter of last year. To do this, we start with 2015 Q1 OI of $60 million, subtract one quarter of the $58 million in MA and Medicaid rate cuts we had previously disclosed, or $15 million, and that gets you to $45 million, demonstrating a relatively flat underlying performance year-over-year. 
Now let's break down some of the drivers of performance for the quarter. There's some good things and some bad things. We'll start with the bad things. In addition to the rate cuts, Medicare Advantage enrollment in our legacy geographies grew less than in prior years, and we grew in line with our geographies. Additionally, our commercial membership continues to decline with the market. 
Now let's turn to some good stuff. We continue to close transactions. Earlier in the quarter, we closed on The Everett Clinic, a nationally recognized physician group that adds over 500 clinicians across 20-plus clinics, serving over 300,000 patients with an expected annual revenue of over $400 million. In addition, within our existing geographies, we have a healthy pipeline of opportunities, including a number of small tuck-ins, as well as a few larger acquisitions in process. One example is our prior announcement of our intent to combine with Mountain View Medical Group, which has 50 clinicians across 14 clinics, serving over 80,000 patients, which, if closed, will strengthen our already healthy capabilities in Colorado Springs. 
As we have said before, we continue building capabilities. There are a couple of examples, one clinical and one operational. On the clinical side, we're expanding our very successful Home Care program from other geographies to Nevada, focusing on the needs of our high-risk patients in order to avoid unnecessary hospitalizations and readmissions. On the operational front, we're centralizing national operations and expect to realize savings from scale and vendor consolidation. To remind you, there's been a significant transformation of the leadership team, and that group is picking up new momentum every month. To progress on all these activities, we have a good shot at adding approximately $30 million to OI in the remaining 3 quarters of 2016, above the Q1 normalized rate of $170 million, bringing us to approximately $200 million for the year, the midpoint of our guidance range. So we are maintaining our guidance range of $175 million to $225 million, although we acknowledge that achieving the high end may be less likely. We'll provide more details on our ongoing investments and operational capabilities and a longer-term outlook at Capital Markets Day in 2 weeks. 
Now I'll turn it over to Jim Hilger."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. In regards to the overall enterprise, our debt expense was $103 million in the first quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 40% in the quarter when you adjust fo",318,"Thanks, Vijay. In regards to the overall enterprise, our debt expense was $103 million in the first quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 40% in the quarter when you adjust for the nondeductible goodwill impairment charge in the HCP Nevada hospice accrual. For the full year, we now expect the 2016 effective tax rate attributable to DaVita HealthCare Partners to be in the range of 39.5% to 40.5%. 
Now turning to cash flow. We continue to generate strong cash flows. Operating cash flow was $429 million in the first quarter and on an adjusted basis, $1.88 billion for the 12 months. As we've discussed before, over time, Kidney Care contributes about 75% of our operating cash flows. HCP contributes about 25%, notably higher than its contribution percentage to our enterprise operating income. 
Regarding capital deployment. The first quarter -- during the first quarter, we purchased 3.7 million shares for $249 million at an average price of $67.61, but we have not made any additional repurchases since our last earnings call. Please note that we continuously weigh capital deployment opportunities across growth investment, share repurchases, debt repayment and holding cash. 
And now, finally, on to outlook. I'd just like to restate our outlook. We are still expecting our consolidated operating income for 2016 to be in the range of $1.8 billion to $1.95 billion. We expect our operating income for Kidney Care to be in the range of $1.625 billion to $1.725 billion, and we expect income for HCP to be in the range of $175 million to $225 million. And our cash flow -- our operating cash flow expectation is in the range of $1.55 billion to $1.75 billion. As always, these guidance ranges capture a majority of the probabilistic outcomes that we can foresee. 
And with that, operator, let's go ahead and open it up for Q&A."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question is from the line of Mr. Kevin Fischbeck.",13,"[Operator Instructions] Our first question is from the line of Mr. Kevin Fischbeck."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Could you talk a little bit about the $9 million of onetime costs in HCP what those relate to?",19,"Could you talk a little bit about the $9 million of onetime costs in HCP what those relate to?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Sure. The onetime costs, Kevin, were related to 3 primary things: One was the move of our California headquarters; two, is some compensation-related accruals; and the third is just some expense true-ups for prior periods.",35,"Sure. The onetime costs, Kevin, were related to 3 primary things: One was the move of our California headquarters; two, is some compensation-related accruals; and the third is just some expense true-ups for prior periods."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And then you guys earlier kind of quantified the 2017 MA rate headwind of $25 million. I guess, how do you think about offsetting that? And any kind of tailwinds you think about into next year versus this year?",39,"And then you guys earlier kind of quantified the 2017 MA rate headwind of $25 million. I guess, how do you think about offsetting that? And any kind of tailwinds you think about into next year versus this year?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We're not going to give full 2017 guidance or that information, but related to the rate headwinds themselves, there are some things related to the health insurer tax that will give some tailwind, but not enough to overcome those headwinds. And beyond that",66,"We're not going to give full 2017 guidance or that information, but related to the rate headwinds themselves, there are some things related to the health insurer tax that will give some tailwind, but not enough to overcome those headwinds. And beyond that, we'll give more detail of our operational expectations and some of our other things at Capital Markets in a couple of weeks."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Actually I was going to -- one of my follow up questions to that, the health insurance fee, is that explicitly built into your contracts as a flow-through? Or is that something that you have to go back and kind of renegotiate as an offset?",45,"Actually I was going to -- one of my follow up questions to that, the health insurance fee, is that explicitly built into your contracts as a flow-through? Or is that something that you have to go back and kind of renegotiate as an offset?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It varies by contract and so we'll -- we've already addressed it with most of our payers.",18,"It varies by contract and so we'll -- we've already addressed it with most of our payers."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, I guess, maybe last question. I guess, as far as EPO costs for the year, I guess, Amgen is pushing through rate increase on EPO and then encouraging people to move over to Aranesp. Is there any thoughts there about kind of how you guys are",69,"Okay. And then, I guess, maybe last question. I guess, as far as EPO costs for the year, I guess, Amgen is pushing through rate increase on EPO and then encouraging people to move over to Aranesp. Is there any thoughts there about kind of how you guys are dealing with that? Is that the move that you're done? Or do you expect the EPO pressure through the year?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","LeAnne, would you like to go ahead and take that one, please?",12,"LeAnne, would you like to go ahead and take that one, please?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, and you may need to clarify if I don't answer your question correctly. As it relates to Epogen pricing, we did not experience a price increase this year. So I don't know if that answers your question, or you referred to Aranesp?",43,"Yes, and you may need to clarify if I don't answer your question correctly. As it relates to Epogen pricing, we did not experience a price increase this year. So I don't know if that answers your question, or you referred to Aranesp?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I guess, my understanding was that the Amgen was trying to move people to the longer-lasting EPO product. As generally speaking, if maybe your contract might be different than others. But I want to be sure if that was something that you guys were looking",64,"I guess, my understanding was that the Amgen was trying to move people to the longer-lasting EPO product. As generally speaking, if maybe your contract might be different than others. But I want to be sure if that was something that you guys were looking to do and whether that was going to be a cost advantage to you under your contract this year?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We certainly use some Aranesp now in the population and we -- both products are both very clinically appropriate for patients. And so we just use whichever the physician is ordering at this point in time. And there's not a contractual difference.",42,"We certainly use some Aranesp now in the population and we -- both products are both very clinically appropriate for patients. And so we just use whichever the physician is ordering at this point in time. And there's not a contractual difference."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Matthew Borsch of Goldman Sachs.",14,"Our next question is from the line of Mr. Matthew Borsch of Goldman Sachs."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Just first question, I was curious your perspective on the slowdown. I realize it's a much broader dynamic than just DaVita Medical Group. But the slowdown in Medicare Advantage enrollment and if there's anything that the DaVita Medical Group physicians a",53,"Just first question, I was curious your perspective on the slowdown. I realize it's a much broader dynamic than just DaVita Medical Group. But the slowdown in Medicare Advantage enrollment and if there's anything that the DaVita Medical Group physicians are seeing on the front lines that might help inform what's going on?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","At this point, we don't have a good sense of what '17, '18, '19 are going to look like. We still think Medicare Advantage is going to be growing in our markets, as in the country overall. We, and a lot of other people, continue to add more services and ca",123,"At this point, we don't have a good sense of what '17, '18, '19 are going to look like. We still think Medicare Advantage is going to be growing in our markets, as in the country overall. We, and a lot of other people, continue to add more services and capabilities that will fuel that fire. At the same time, if the payers decide in any given period to leave benefits stagnant or, in fact, even pull back a little bit, that has a big impact. And so we remain very bullish on fundamental growth. But at this point, the notion of sort of guesstimating what's going to happen in '17 and '18, we're not feeling certain enough to add any value there."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Yes, that makes sense. And just curious, when the medical group sees MA patients, is there any distinction in terms of the financials, if that's an employer group MA member or a regular, I guess, you'd say retail MA member?",40,"Yes, that makes sense. And just curious, when the medical group sees MA patients, is there any distinction in terms of the financials, if that's an employer group MA member or a regular, I guess, you'd say retail MA member?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Can you restate the question, Matthew? I'm not understanding.",9,"Can you restate the question, Matthew? I'm not understanding."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Well, I guess, you think about the major Medicare Advantage plans, they typically have for every 800 individual MA members, they may be have another 200 that come from employer groups that are doing retiree coverage. It's all Medicare Advantage. I'm just",65,"Well, I guess, you think about the major Medicare Advantage plans, they typically have for every 800 individual MA members, they may be have another 200 that come from employer groups that are doing retiree coverage. It's all Medicare Advantage. I'm just wondering if there's any distinction in that the medical group sees in terms of the financial arrangements, risk-taking arrangements between group and individual."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","No we don't, we have not seen anything significant in that significant in that sense [ph].",17,"No we don't, we have not seen anything significant in that significant in that sense [ph]."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And you don't really know how many is one or the other? Is that correct?",16,"Okay. And you don't really know how many is one or the other? Is that correct?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, I think -- I don't think we've anything useful to say about this, Matthew. But by Capital Markets, if there is anything useful to say, we'll be prepared to say it.",32,"Yes, I think -- I don't think we've anything useful to say about this, Matthew. But by Capital Markets, if there is anything useful to say, we'll be prepared to say it."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. That sounds great. Just one last question on the ACA exchange plan dynamic. Can you give us some sense of how to think about what the numbers are? In other words, is this -- I wouldn't think it would be -- the numbers would be very big in terms of y",75,"Okay. That sounds great. Just one last question on the ACA exchange plan dynamic. Can you give us some sense of how to think about what the numbers are? In other words, is this -- I wouldn't think it would be -- the numbers would be very big in terms of your overall patient base. But is there a higher concentration relative to, say, how the ACA exchange enrollment compares to the overall insured population?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Let me take a stab at that, Matthew, and then you tell me if I'm hitting the right thing. Exchanges are a tiny percentage of what we're about. At the same time, when we have exchange business that's private insurance, that is additive in the same way that",103,"Let me take a stab at that, Matthew, and then you tell me if I'm hitting the right thing. Exchanges are a tiny percentage of what we're about. At the same time, when we have exchange business that's private insurance, that is additive in the same way that our private insurance patients are in general, since, as you know, the 10% or so of patients we have are private subsidized, the 90% that are government on which we lose money on the margin. And so exchanges are a tiny percentage, but just like with the rest of private pay, little movements add up."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And have you ever contemplated starting your own exchange plans to get around the problems that you have had, had with the payers?",23,"And have you ever contemplated starting your own exchange plans to get around the problems that you have had, had with the payers?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Up to this point, we have not.",7,"Up to this point, we have not."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","At this point, I would like to open the line for Mr. Gary Lieberman of Wells Fargo.",17,"At this point, I would like to open the line for Mr. Gary Lieberman of Wells Fargo."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Maybe talk about the joint venture and kind of the expectations for growth and maybe some of the start-up losses that we should expect.",25,"Maybe talk about the joint venture and kind of the expectations for growth and maybe some of the start-up losses that we should expect."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'm sorry, Gary, could you -- there was still some noise on this end. Could you go ahead and repeat the question? My bad.",25,"I'm sorry, Gary, could you -- there was still some noise on this end. Could you go ahead and repeat the question? My bad."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Maybe talk about the joint venture a little bit and the expectation for growth, and what if any start-up losses we would expect to see from it?",27,"Maybe talk about the joint venture a little bit and the expectation for growth, and what if any start-up losses we would expect to see from it?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Well, we are still losing money in the Asia market. And that's not going to change in the near term because if anything, the addition of these 2 partners is going to accelerate some of our growth, which in the short term, could actually increase our losse",80,"Well, we are still losing money in the Asia market. And that's not going to change in the near term because if anything, the addition of these 2 partners is going to accelerate some of our growth, which in the short term, could actually increase our losses, kind of depends which countries we're growing the most in. So I don't know how much useful I can say beyond that, but go ahead and fire off another question if you'd like."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I guess, in terms of -- little different topic, just foreign exchange rates, any thoughts there? They've been somewhat volatile, any plans to hedge them? Or is it too small to really worry about it?",35,"I guess, in terms of -- little different topic, just foreign exchange rates, any thoughts there? They've been somewhat volatile, any plans to hedge them? Or is it too small to really worry about it?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Up to this point, we've done little or no hedging. We're paying a lot of attention, but the numbers are so small. And in particular, given we're spread across 10 different countries -- 11 different countries and you kind of do the math, it just isn't that",82,"Up to this point, we've done little or no hedging. We're paying a lot of attention, but the numbers are so small. And in particular, given we're spread across 10 different countries -- 11 different countries and you kind of do the math, it just isn't that helpful at this point. But we're making sure we're talking to people who are more thoughtful and sophisticated than we are and trying to figure out exactly when we should start doing more of that."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. On to the ESAs, is it possible for you to tell us what percentage of patients are currently using Aranesp?",21,"Okay. On to the ESAs, is it possible for you to tell us what percentage of patients are currently using Aranesp?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I can answer that. We're predominantly an EPO shot, so it's quite small.",13,"I can answer that. We're predominantly an EPO shot, so it's quite small."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Is it the 10% that you're allowed to use other ESAs? Or does that not count against you if it's Aranesp?",21,"Is it the 10% that you're allowed to use other ESAs? Or does that not count against you if it's Aranesp?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, Aranesp does not count against us.",7,"Yes, Aranesp does not count against us."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then the pricing -- the lack of pricing increase on EPO, does that have something to do with you moving some number of patients onto Aranesp?",28,"Okay. And then the pricing -- the lack of pricing increase on EPO, does that have something to do with you moving some number of patients onto Aranesp?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","No, that's not the case and since I have the floor here, I'm being corrected that we did take a 1% price increase in January, and so I apologize for that mistake.",32,"No, that's not the case and since I have the floor here, I'm being corrected that we did take a 1% price increase in January, and so I apologize for that mistake."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Ms. Margaret Kaczor of William Blair.",14,"Our next question is from the line of Ms. Margaret Kaczor of William Blair."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","First question for me, there's a lot of moving pieces in HCP, and I'm sure you'll address a lot of them at your Capital Markets Day in a few weeks. But that said, if you look at HCP and its trajectory, really over the next couple of years, maybe 3 years,",95,"First question for me, there's a lot of moving pieces in HCP, and I'm sure you'll address a lot of them at your Capital Markets Day in a few weeks. But that said, if you look at HCP and its trajectory, really over the next couple of years, maybe 3 years, how important is that patient and revenue growth compared to that profitability improvement? And where do you see that going? Can the newer market revenues exceed the legacy markets since those appear to be slowing and can those legacy markets even reaccelerate from here?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, a very fair question. And certainly, we are going to hit that hard in the Capital Markets, or at least to the best of our ability. We do think in a couple of our new markets the growth prospects over the next 2, 3 years on revenue, EBITDA and OI basi",107,"Yes, a very fair question. And certainly, we are going to hit that hard in the Capital Markets, or at least to the best of our ability. We do think in a couple of our new markets the growth prospects over the next 2, 3 years on revenue, EBITDA and OI basis is material. But at the same time, we actually have a lot of growth opportunities in the 3 inherited markets. And so which has more potential, I think, we'd probably say they're pretty equivalent and if anything, the legacy markets have more, but it'd be nice to see them in a bit of a race."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And just maybe pick a little bit more at that. We saw the senior revenues in the mid-single-digit range in 2015. But as we look out again over that 2- to 3-year time horizon, what would you be happy with seeing in terms of that kind of new patient g",57,"Okay. And just maybe pick a little bit more at that. We saw the senior revenues in the mid-single-digit range in 2015. But as we look out again over that 2- to 3-year time horizon, what would you be happy with seeing in terms of that kind of new patient growth as well as the revenue growth?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. What would we be happy to see? I would say if you give us the gift of reflecting on that, and we're going to talk about the range that we expect to see at Capital Markets, and then maybe address the happiness thing. But we'll definitely give you our",63,"Okay. What would we be happy to see? I would say if you give us the gift of reflecting on that, and we're going to talk about the range that we expect to see at Capital Markets, and then maybe address the happiness thing. But we'll definitely give you our sense of the range of likely outcomes here in a couple of weeks."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","All right. Fair enough. And then on the Kidney Care side, the number of clinics that you guys are opening or growing a little bit faster than they have been the last few quarters, and rightfully so. But should we expect a similar pace of net new centers o",100,"All right. Fair enough. And then on the Kidney Care side, the number of clinics that you guys are opening or growing a little bit faster than they have been the last few quarters, and rightfully so. But should we expect a similar pace of net new centers opening throughout 2016 as you guys catch up with those longer approval time frames from last year. So are you going to reach 120 new clinics for the year? And how quickly can these new clinics help get your NAG back up to that 4.5% or maybe even higher over the near-term?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'll turn that one over to Javier.",8,"I'll turn that one over to Javier."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Thank you. We had 30 centers opened in the first quarter. Our range for the year is 90 to 110. The last part of your question on NAG, we're still comfortable with a multiyear range that we addressed earlier, so 3.5% to 4.5%.",43,"Thank you. We had 30 centers opened in the first quarter. Our range for the year is 90 to 110. The last part of your question on NAG, we're still comfortable with a multiyear range that we addressed earlier, so 3.5% to 4.5%."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And last one for me. How is the acquisition of Renal Ventures coming along? When should we see kind of the initial impact on results, and how long is it going to take for that change to more closely resemble maybe the financial structure of the DaVi",49,"Okay. And last one for me. How is the acquisition of Renal Ventures coming along? When should we see kind of the initial impact on results, and how long is it going to take for that change to more closely resemble maybe the financial structure of the DaVita-owned clinics?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","JR, can you take that one, please?",7,"JR, can you take that one, please?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes. It's still going through the FTC, so the short answer is we don't know.",15,"Yes. It's still going through the FTC, so the short answer is we don't know."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Gary Taylor of JPMC.",13,"Our next question is from the line of Mr. Gary Taylor of JPMC."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Couple of questions. I wanted to go back to the international JV for a second and just make sure I understand what you said. Each of these investing $150 million over several years for 20%, so -- that was for each of those, right? So the $300 million inve",56,"Couple of questions. I wanted to go back to the international JV for a second and just make sure I understand what you said. Each of these investing $150 million over several years for 20%, so -- that was for each of those, right? So the $300 million investment combined to own 40% of the venture."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Correct.",1,"Correct."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","So that implies something with equity value of $750 million. Does the DaVita make commensurate capital contribution? Or is this capital-light to you because you're contributing your market operational intelligence, know-how, et cetera? What's your contrib",36,"So that implies something with equity value of $750 million. Does the DaVita make commensurate capital contribution? Or is this capital-light to you because you're contributing your market operational intelligence, know-how, et cetera? What's your contribution?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Right. This investment will be the growth capital for the entity. And what we're submitting into the partnership is the entity itself, which is the kind of things that you mentioned.",31,"Right. This investment will be the growth capital for the entity. And what we're submitting into the partnership is the entity itself, which is the kind of things that you mentioned."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And are you contributing your existing centers in those 5 countries into the JV?",15,"Okay. And are you contributing your existing centers in those 5 countries into the JV?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Correct. So our entire business in Kidney Care in that geographic area, that's the asset which we're contributing into the partnership. What they're contributing is the $150 million each of growth capital.",32,"Correct. So our entire business in Kidney Care in that geographic area, that's the asset which we're contributing into the partnership. What they're contributing is the $150 million each of growth capital."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And it implies pretty sizable capital deployment to that part of the world, I guess, compared to what you've invested thus far. So are there existing centers to acquire? Is this primarily development or will it be both?",38,"And it implies pretty sizable capital deployment to that part of the world, I guess, compared to what you've invested thus far. So are there existing centers to acquire? Is this primarily development or will it be both?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It will be both, but we're expecting that more of it will be acquisition than de novo. But it almost gets difficult to use some of the labels because in some of these countries, for example, China, you could end up with deal arrangements that are kind of",50,"It will be both, but we're expecting that more of it will be acquisition than de novo. But it almost gets difficult to use some of the labels because in some of these countries, for example, China, you could end up with deal arrangements that are kind of a hybrid."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And then my another question, I just want to go back to commercial mix. I was taking notes, but I don't know if I missed this comment. Did you make a comment about commercial mix of patients, which I think was actually grew year-over-year in '15 for, I th",62,"And then my another question, I just want to go back to commercial mix. I was taking notes, but I don't know if I missed this comment. Did you make a comment about commercial mix of patients, which I think was actually grew year-over-year in '15 for, I think, the first time in some time, so 1Q of '16. Did that change?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","It did grow in '15 for the first time in a long time, and so we're pretty pleased with it where we're at. I think we disclosed in the 10-K a 12% mix. We're rounding up to 12% --",39,"It did grow in '15 for the first time in a long time, and so we're pretty pleased with it where we're at. I think we disclosed in the 10-K a 12% mix. We're rounding up to 12% --"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Sorry, we were 11%, rounded to 11% in 2015.",9,"Sorry, we were 11%, rounded to 11% in 2015."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","-- excuse me, 11% of our total patients.",8,"-- excuse me, 11% of our total patients."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","You only give that annually, I believe, is that right?",10,"You only give that annually, I believe, is that right?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","That is correct. We disclose it annually.",7,"That is correct. We disclose it annually."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. So the commercial mix continued to improve year-over-year in 1Q of '16? Or has that leveled out?",18,"Okay. So the commercial mix continued to improve year-over-year in 1Q of '16? Or has that leveled out?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We continued to improve in the quarter.",7,"We continued to improve in the quarter."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","And is most of that -- is that improvement being driven by exchanges or...",14,"And is most of that -- is that improvement being driven by exchanges or..."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","That is a portion of the improvement. The improvement we've seen over multiple quarter period is in part due to exchanges and in part due to improving economy. And in some cases, it's difficult to discern what -- which is where. We know where the exchange",53,"That is a portion of the improvement. The improvement we've seen over multiple quarter period is in part due to exchanges and in part due to improving economy. And in some cases, it's difficult to discern what -- which is where. We know where the exchanges are, but there also is some cannibalization."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Yes, obviously, it's powerful trend. Now my last question, what's -- and I have a feeling maybe I'll get kicked down the curb a couple of weeks until Capital Markets, but what is your average commercial rate increase you're expecting for 2016 that's baked",46,"Yes, obviously, it's powerful trend. Now my last question, what's -- and I have a feeling maybe I'll get kicked down the curb a couple of weeks until Capital Markets, but what is your average commercial rate increase you're expecting for 2016 that's baked into guidance?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, we will go over our expectations on the RPT side at Capital Markets, and we may or may not get quite to that level of granularity. But, as always, we'll give you a 3-year outlook on what we think about RPT, or revenue per treatment.",46,"Yes, we will go over our expectations on the RPT side at Capital Markets, and we may or may not get quite to that level of granularity. But, as always, we'll give you a 3-year outlook on what we think about RPT, or revenue per treatment."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","At this point, I would like to open the line for Ms. Lisa Clive of Bernstein.",16,"At this point, I would like to open the line for Ms. Lisa Clive of Bernstein."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","I have 3 for you. First of all, sorry, if I missed the details on this, but could you give us some color on the accrual for HCP, the hospice business in Nevada? Am I right this is about $16 million? Second, on dialysis, could you comment on the ESCO pro",138,"I have 3 for you. First of all, sorry, if I missed the details on this, but could you give us some color on the accrual for HCP, the hospice business in Nevada? Am I right this is about $16 million? 
Second, on dialysis, could you comment on the ESCO program in your experience with it so far? I believe you have something like 3,000 or 4,000 patients. And according to your competitor, Medicare has just recently suggested the program could be expanded. Would you want to participate on a larger scale? Or if not, why not? 
And then lastly, looking further in integrated care, FMC has actually just started a Medicare Advantage dialysis SNP. Could you comment on what your integrated care platform looks like beyond ESCO, and if you have any initiatives ongoing to grow this?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Let's go ahead and start with the first one. Go ahead, Vijay.",13,"Let's go ahead and start with the first one. Go ahead, Vijay."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","So on the hospice, it's related to the Nevada hospice business. The reserve is for damages and liabilities associated with our potential eligibility to terminations. The majority of which predates our acquisition of that business in 2013.",37,"So on the hospice, it's related to the Nevada hospice business. The reserve is for damages and liabilities associated with our potential eligibility to terminations. The majority of which predates our acquisition of that business in 2013."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And let's go ahead, and we can always come back to that, Lisa, but let's go ahead and hit the second question on ESCOs. And Javier, you want to hit that, please?",33,"And let's go ahead, and we can always come back to that, Lisa, but let's go ahead and hit the second question on ESCOs. And Javier, you want to hit that, please?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Sure. We have about 4,000 patients in our ESCOs right now. It covers 4 states, 3 markets. And it's too early to tell how these are going to turn out in our excitement on expansion or not. We've only been at it for a couple of months, so it's too early to",97,"Sure. We have about 4,000 patients in our ESCOs right now. It covers 4 states, 3 markets. And it's too early to tell how these are going to turn out in our excitement on expansion or not. We've only been at it for a couple of months, so it's too early to go through that. As it relates to the C-SNPs, we now have 5 C-SNPs, and we continue to find it a good growth vehicle that is really great for integration of transitions of care for the patient. So we'll continue to grow on that side."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Sorry, those C-SNPs are you partnered with insurers on that? Or is that something you're doing unilaterally?",17,"Sorry, those C-SNPs are you partnered with insurers on that? Or is that something you're doing unilaterally?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","We do have partnerships.",4,"We do have partnerships."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And maybe, Lisa, I'll add a couple of comments since some of these items, KT here. First, regarding integrated care beyond ESCOs. We remain as intensely positive about that, as we have been for years, and think that more and more payers as well as more pe",142,"And maybe, Lisa, I'll add a couple of comments since some of these items, KT here. First, regarding integrated care beyond ESCOs. We remain as intensely positive about that, as we have been for years, and think that more and more payers as well as more people in Congress are starting to understand the clinical and economic upside. And so we will continue to push integrated care outside of ESCOs, both for private pay and for Medicaid and for Medicare. Impossible to predict when there might be an inflection point. But certainly, we're in a lot higher-quality conversations and doing a lot more deals of different sorts with payers now than any time before. 
And then going back to the hospice, we necessarily have to be pretty circumspect there because there's some active litigation, which is why our commentary is quite sketchy."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Our next question is from the line of Mr. Whit Mayo of Robert Baird.",14,"Our next question is from the line of Mr. Whit Mayo of Robert Baird."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","-- for treatment in dialysis, it's trended a lot better than I would've thought for a much longer period of time. Can you remind me just what's driving that improvement in the long we can probably expect to see those declines?",41,"-- for treatment in dialysis, it's trended a lot better than I would've thought for a much longer period of time. Can you remind me just what's driving that improvement in the long we can probably expect to see those declines?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","But could you -- the first part of your question for some reason, the phone cut off and so we only heard the last half. Could you redo it, please?",30,"But could you -- the first part of your question for some reason, the phone cut off and so we only heard the last half. Could you redo it, please?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Yes. The question was just the G&A trends in dialysis. It's just trended much more favorably than we thought. Just wanted to know what's driving that, and how long we can continue to see improvement?",35,"Yes. The question was just the G&A trends in dialysis. It's just trended much more favorably than we thought. Just wanted to know what's driving that, and how long we can continue to see improvement?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Well I can tell you it's driven by excellent work by Javier and his team, but I'll let him complete the answer. JR?",24,"Well I can tell you it's driven by excellent work by Javier and his team, but I'll let him complete the answer. JR?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Yes, and unfortunately, less powerful but due to some seasonality, we expect G&A to be flat year-over-year.",17,"Yes, and unfortunately, less powerful but due to some seasonality, we expect G&A to be flat year-over-year."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","On a dollar basis or per treatment?",7,"On a dollar basis or per treatment?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Per treatment basis.",3,"Per treatment basis."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. And on HCP, I think you referenced in the last quarter that we shouldn't anticipate about $10 million of incremental investments this year. Is there any update around that number? And does that include any of the corporate changes, relocating the co",51,"Okay. And on HCP, I think you referenced in the last quarter that we shouldn't anticipate about $10 million of incremental investments this year. Is there any update around that number? And does that include any of the corporate changes, relocating the corporate headquarter that you referenced in your prepared remarks?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I'm sorry. Could you do that one again?",9,"I'm sorry. Could you do that one again?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Sorry. Last quarter, you communicated that we should expect about $10 million of incremental investments into HCP, and I wanted to know if that was still the right number for 2016? And does it include the corporate headquarter change that you referenced?",42,"Sorry. Last quarter, you communicated that we should expect about $10 million of incremental investments into HCP, and I wanted to know if that was still the right number for 2016? And does it include the corporate headquarter change that you referenced?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","So one, it did not include the corporate headquarters, and what we had planned to invest are still in our plans. There's no significant changes to that. They were intended to be in the later part of the year. And as we continue to assess the year, we'll s",63,"So one, it did not include the corporate headquarters, and what we had planned to invest are still in our plans. There's no significant changes to that. They were intended to be in the later part of the year. And as we continue to assess the year, we'll see if that changes. But right now, we have no changes -- plans to change."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","And the $10 million are all investments that would be of a recurring nature.",14,"And the $10 million are all investments that would be of a recurring nature."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Analysts","Okay. One last one. Just looking beyond ESAs, are there any other interesting therapies potentially coming to market, whether there's an iron drug, vitamin D? Just wondering if there are any other drugs that we haven't been paying attention to that you fi",46,"Okay. One last one. Just looking beyond ESAs, are there any other interesting therapies potentially coming to market, whether there's an iron drug, vitamin D? Just wondering if there are any other drugs that we haven't been paying attention to that you find to be interesting?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","I don't think there's any right now that would affect your 3-year forecasts. The big variable in that near and intermediate term is what kind of partnership we establish on the ESA front, which everybody is, of course, already aware of. And we're looking",65,"I don't think there's any right now that would affect your 3-year forecasts. The big variable in that near and intermediate term is what kind of partnership we establish on the ESA front, which everybody is, of course, already aware of. And we're looking forward to wrapping up a good partnership with someone. But outside of that, there's really nothing to handicap right now."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","At this time, speakers, there are no additional questions in queue. [Operator Instructions]",13,"At this time, speakers, there are no additional questions in queue. [Operator Instructions]"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Operator, that's -- well, unless you've already gotten somebody else -- have you?",13,"Operator, that's -- well, unless you've already gotten somebody else -- have you?"
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","Right now we do not have any additional questions in queue.",11,"Right now we do not have any additional questions in queue."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Executives","Okay. We will look forward to seeing a bunch of you and talking to the rest of you at our Annual Capital Markets session where we can obviously go into all this stuff with much more intensity and analysis. So we look forward to that. Take care.",47,"Okay. We will look forward to seeing a bunch of you and talking to the rest of you at our Annual Capital Markets session where we can obviously go into all this stuff with much more intensity and analysis. So we look forward to that. Take care."
35644,332021620,973357,"DaVita HealthCare Partners Inc., Q1 2016 Earnings Call, May 04, 2016",2016-05-04,"Earnings Calls","DaVita Inc.","Operator","And that concludes today's conference. Thank you, all, for joining. You may now disconnect.",15,"And that concludes today's conference. Thank you, all, for joining. You may now disconnect."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you for standing by. [Operator Instructions] Now I will turn the meeting over to one of your hosts, Mr. Jim Gustafson. Sir, you may begin.",28,"Welcome, and thank you for standing by. [Operator Instructions] Now I will turn the meeting over to one of your hosts, Mr. Jim Gustafson. Sir, you may begin."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Joel, and welcome, everyone, to the DaVita HealthCare Partners Second Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Ken",243,"Thank you, Joel, and welcome, everyone, to the DaVita HealthCare Partners Second Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, the CEO of DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of DaVita Medical Group; Jim Hilger, our Interim CFO and Chief Accounting Officer; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statement. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based on information currently available to us, and we do not intend and undertake no duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website.
I will now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Jim, and welcome to all. We delivered solid adjusted operating income and strong cash flows in this particular quarter. The total adjusted operating income was $475 million, as many of you have already seen, which were driven by the strong Kidn",393,"Thank you, Jim, and welcome to all. We delivered solid adjusted operating income and strong cash flows in this particular quarter. The total adjusted operating income was $475 million, as many of you have already seen, which were driven by the strong Kidney Care results at $431 million and a disappointing DaVita Medical Group trajectory reflected with $44 million on a non-GAAP basis there. Operating cash flow's another bright spot of $517 million as we continue to successfully convert your earnings into your cash.
We'll discuss several topics here before we get into Q&A to. Number 2 is clinical outcomes; number 2 is DMG results; number 3 is U.S. Kidney Care; number 4, a little bit of an update on international; and number 5 is just some additional financial enterprise-level details.
Let's start with clinical outcomes. As we always do, we are first and foremost, a caregiving company and quite good at it. Now about 185,000 patients in the U.S. alone, about 35% of all dialysis patients in America. One of the areas where we've increased our focus is in reducing bloodstream infections, a very big deal to our patients, a very big deal to their families, a very big deal to the taxpayer. It's important because this keeps patients out of the hospital. Bloodstream infections are one of the top 5 causes of hospitalizations for these patients, and this impacts both Quip [ph] and 5-Star [ph]. We are now performing blood-pressure tests on more than 90% of the situations when a patient is present or assigned with symptoms of bloodstream infections. We'll never get to 100, but 90 is remarkably higher than where we were x years ago and where some aid dialysis centers are today.
Despite testing a greater percentage of all the patients, we've actually decreased our blood stream infection rate by 16% over the last 12 months, and we're working both sides of the equation with tenacity and some success. 
On the DMG side, the DaVita Medical Group year-to-date, we've outperformed on the focus HEDIS measures that CMS uses to track medicare advantage clinical quality to compared to the same period last year. And as a result, we are on track to achieve greater than 4 stars in all of our planned relationships. For some more detail on the DaVita Medical Group, I'll turn it over to Vijay Kotte."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. Turning to this quarter's performance, operating income was $44 million, excluding non-GAAP items as detailed in our earnings release. Unfortunately, year-to-date, we have financially underperformed relative to plan, and we expect this gap t",355,"Thanks, Kent. Turning to this quarter's performance, operating income was $44 million, excluding non-GAAP items as detailed in our earnings release. Unfortunately, year-to-date, we have financially underperformed relative to plan, and we expect this gap to increase in the second half of this year. As a result, we are lowering our 2016 full year guidance to $110 million to $150 [ph] million. The decrease in guidance has 4 primary drivers: We preserve its growth, Medicare Advantage growth, and rebranding effort. To provide a little more color, let me walk you through those.
First, our fee-for-service revenue growth has not met our expectation. Our target with 6% year-over-year, but we're achieving 3%. Second, we made a mistake forecasting 2016 operating profit by overestimating expected reconciliation payments for prior year Medicare Advantage revenue. Third, while our in-year [ph] Medicare Advantage of growth has been in line with broader enrollment trends in the geographies we operate in, it's lower than we've previously expected. Fourth, as we stated on our last call, we are rebranding from healthcare partners to the DaVita Medical Group. To accomplish this, we expect to spend $5 million to $10 million this year that wasn't previously included in our forecast. In addition, we will need to accelerate the noncash amortization of $110 million worth of existing trademark intangibles associated with the legacy healthcare partners band. This accelerated amortization has been excluded from our revised 2016 and long-term guidance. Despite these disappointments, we are making good progress on the key items we identified at Capital Markets.
In terms of fee-for-service to value conversion, we are progressing and contracting discussions with health plan while developing value-based care capabilities in our newer markets. Additionally, we continue to invest in the business, which we believe will fuel our long-term success. One example is our investment in 7 new DeNovo clinics, which are capital-efficient growth platform similar to what you are used to seeing in Kidney Care.
Finally, as we look towards our long-term outlook, our 2019 OI target remained $250 million.
Now I will turn it over to Javier Rodriguez to speak a little bit more about Kidney Care."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Vijay, and hello, everyone. Before I talk about the quarter, I'd like to highlight a recent development that we're very excited about. In our Capital Markets Day, we talked about the powerful benefit of integrated care for chronic populations,",436,"Thank you, Vijay, and hello, everyone. Before I talk about the quarter, I'd like to highlight a recent development that we're very excited about. In our Capital Markets Day, we talked about the powerful benefit of integrated care for chronic populations, including our own ESRD patients. Since then, 2 new pieces of legislations that are supported by the dialysis community have been introduced in Congress. 
The first is called the Dialysis Patient Demonstration Act, and that provides for true integrated care model for Kidney Care patients. The second is called the ESRD Choice Act of 2016, and that was finally allowed for ESRD patients to enroll an MA plans. Was of the sex will be a great gift to ESRD patients and play to our long-term strategy of integrated care.
We're hopeful about their prospects in Congress due to the strong bipartisan support, and we will continue to work hard to pursue integrated care for our patients. 
Now on to our quarterly results. Overall, DaVita Kidney Care had a strong and reasonably straightforward quarter, so I won't go into much detail here. As Kent said, we delivered strong operating income of $431 million due to a slight improvement in revenue per treatment over Q1 as well as slight reduction in cost for its treatment. With respect to growth, our normalized non-acquired growth for the quarter was 4.3%, which falls within our long-term target range of 3.5% to 4.5%.
With the first half of the year now behind us, we're raising the bottom end of our 2016 guidance range by $50 million. This is consistent with our comments from last quarter that we're more likely to be in the top half of our original guidance. With this change, our new Kidney Care operating income guidance for 2016 is now $1.675 billion to $1.725 billion. As for next year, we plan to provide 2017 guidance during our fourth quarter earnings call. We made this change last year because ACA plans have become a more meaningful part of our commercial mix. This has added some new drivers of upside and downside to our business and our industry as well as some seasonality. Providing guidance on our fourth quarter call allows us to incorporate the additional visibility we gained during open enrollment period.
Before I turn it back to KT, I want to close by saying we remain excited about the fundamentals of our business, the gradual shift towards integrated care and the fact that our teammates are recognized for providing the best outcomes and quality of life for kidney patients.
Now back to Kent to discuss our international business."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, JR. International losses, $13 million in the quarter, which is pretty much in line with our guidance for approximately $40 million in losses on the full year. We continue to maintain what we told you -- when I think about a year ago that",201,"Okay. Thank you, JR. International losses, $13 million in the quarter, which is pretty much in line with our guidance for approximately $40 million in losses on the full year. We continue to maintain what we told you -- when I think about a year ago that we committed [indiscernible] to achieve breakeven by 2018 in our current market portfolio actually in any new countries, and we're standing by that. And a number of you probably sell out we did, in fact, close the transaction that we had to announce 4 to 5 to 6 weeks ago, that being our JV transaction with Khazanah and Mitsui on August 1. Just to refresh year memory, Khazanah and Mitsui have each subscribed to acquire 20% share of ownership over time. At the closing, each provided $50 million of funding to the JV in return for each receiving a 6.7% stake. We're excited to have them as partners. We have a very long-term point of view about the opportunity in that part of the world as today, and we think they're going to help us accelerate and deepen our growth.
Now I'll turn it over to Jim Hilger to cover some more enterprise financials."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent, and just a little more about our Asia Pacific joint venture. In regards to the JV with Khazanah and Mitsui, please note that we expect that this joint venture will be deconsolidated from our financials and thus, future operating results will",470,"Thanks, Kent, and just a little more about our Asia Pacific joint venture. In regards to the JV with Khazanah and Mitsui, please note that we expect that this joint venture will be deconsolidated from our financials and thus, future operating results will run through equity investment income for our pro rata share of ownership in the joint venture. Please note that we expect to record a material noncash onetime gain in connection with the formation of this JV, and this gain is excluded from our guidance.
Now onto the overall enterprise. Our debt expense was $103 million in the second quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 37.2% in the quarter when adjusted for the nondeductible goodwill impairment charge and recognition of a state tax -- income tax benefit. We expect the full year effective tax rate attributable to DaVita HealthCare Partners on our adjusted income for 2016 to be in the range of 39% to 40%.
Now turning to cash flow. We continue to generate strong cash flows. Operating cash flow was $517 million in the quarter and $2.06 billion for the last 12 months. The last 12 months benefited from the timing of tax payments. We expect full year 2016 operating cash flow to be between $1.6 billion and $1.75 billion.
One thing to keep in mind when thinking about the cash flows of our individual operating segments is that DMG generates a disproportionately higher share of our cash flows than its share of our adjusted operating income. While the midpoint of our DMG guidance for adjusted operating income is $130 million, the business has a year-to-date annual run rate of $200 million in noncash depreciation and amortization expense. In addition, as you will recall, there is a cash tax reduction of approximately $100 million per year, which is the equivalent to $167 million improvement in pretax operating income. This cash tax benefit is due to the tax rates of step-up created when we acquired the medical group.
And finally, as the vast majority of GMG's business is capitated care, where we are paid before in current expenses, it has favorable cash flow characteristics with low to negative working capital. Thus, DMG contributes more to our operating cash flows than its first apparent when looking at operating income.
We continue to have a very strong cash balance with $1.68 billion [ph] in cash and short-term investments as of June 30. We continue to weigh capital deployment opportunities across growth investment, share repurchases, debt repayment and holding cash. Additionally, as disclosed in our earnings release, our Board of Directors just increased our share repurchase authorization from the remaining $259 million to now $1.5 billion. 
And with that, I will now turn the call back over to Ken Kent Thiry."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I'll just have make a piece some other comments before we go to Q&A. Number one, with the DaVita Medical Group, we're certainly sorry that we had to reduce the guidance. In fact, that it will take even more time to get it to where we think we can be regul",200,"I'll just have make a piece some other comments before we go to Q&A. Number one, with the DaVita Medical Group, we're certainly sorry that we had to reduce the guidance. In fact, that it will take even more time to get it to where we think we can be regularly growing earnings and we're intentionally intent on doing, but it will take sometime. Number two, DaVita Kidney Care, a wonderfully solid results yet again, probably even better than that. At the same time, as JR has talked about recently, we could have some choppiness at the high levels. And we are [indiscernible] continuing to invest in becoming even more differentiated than we are today in quality, in service, in physician experience, in IT, et cetera. Third or [ph] fourth is the cash flow, your cash flow, continues to be a powerful weapon to be deployed in your defense and on offense. And lastly, fourth, we continue to have a lot of belief in our overall business platform, and we think from our geographic footprint to our capabilities by function, et cetera, et cetera.
So thank you all very much and, Joel, could you please open up for Q&A?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions]",2,"[Operator Instructions]"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Operator, are you having any problems?",6,"Operator, are you having any problems?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","I'm just waiting for the participants if they will -- if they would be pressing solid line to ask a question. But at the moment, we don't have an incoming question. [Operator Instructions]",34,"I'm just waiting for the participants if they will -- if they would be pressing solid line to ask a question. But at the moment, we don't have an incoming question. [Operator Instructions]"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Joe, I show 7 [ph] people in the queue.",9,"Joe, I show 7 [ph] people in the queue."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Joel, there might be something wrong with the equipment that you're looking at. So perhaps while the first person ask the question, you can do some checking with one of the other people there.",34,"Joel, there might be something wrong with the equipment that you're looking at. So perhaps while the first person ask the question, you can do some checking with one of the other people there."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Yes, I will double check, sir, because those people that are on the queue, they pressed star 1 at the beginning of the presentation, but let me open up your line. Hold on.",33,"Yes, I will double check, sir, because those people that are on the queue, they pressed star 1 at the beginning of the presentation, but let me open up your line. Hold on."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","But that's okay to let them in, Joe, because we know there's a number of people that ask questions each and every call. So it's okay if they do that.",31,"But that's okay to let them in, Joe, because we know there's a number of people that ask questions each and every call. So it's okay if they do that."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","So we have the first question from the line of Mr. Chris Greg.",13,"So we have the first question from the line of Mr. Chris Greg."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I just want to ask about DMG here. I guess, just with regard to the fee-for-service revenue only growing at 3% versus 6%, is that tied to The Everett Clinic? Or is that something completely different?",36,"I just want to ask about DMG here. I guess, just with regard to the fee-for-service revenue only growing at 3% versus 6%, is that tied to The Everett Clinic? Or is that something completely different?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's pity much across the board, although, of course, The Everett Clinic is the biggest single stars. We're just a little bit soft in a number of different areas, and the good news or bad news, depending on how you look at it is we can operate some parts",90,"It's pity much across the board, although, of course, The Everett Clinic is the biggest single stars. We're just a little bit soft in a number of different areas, and the good news or bad news, depending on how you look at it is we can operate some parts of that much better outside of The Everett Clinic and within The Everett Clinic, which operates. So accidentally, they had kind of an uncharacteristic stumble. And so it's a mix of all of our fee-for-service locations, nothing really jumping out."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just a little bit forward thinking on the ESRD choice legislation that you guys highlighted. I mean, how would that -- at least at a high level work in your guys' opinion, would you get better rates from the MA plans than you currently get",61,"Okay. And then just a little bit forward thinking on the ESRD choice legislation that you guys highlighted. I mean, how would that -- at least at a high level work in your guys' opinion, would you get better rates from the MA plans than you currently get on the fee-for-service side? Is that the right way to think about it?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","There's a couple of ways about it, and I'll chime in, it's Javier, and then Leanne if you want to supplement. The main thing is that the lives will be attributed to the dialysis clinics. And so therefore, this dialysis clinic will become the medical home,",109,"There's a couple of ways about it, and I'll chime in, it's Javier, and then Leanne if you want to supplement. The main thing is that the lives will be attributed to the dialysis clinics. And so therefore, this dialysis clinic will become the medical home, sort of de facto medical home because we have the patient for 12 hours. The other important thing is on the revenue side. Instead of having a benchmark, which is a little of a black box thing, you got a number, it would be linked to MA. And so the revenues would be a lot more predictable. Does that answer your question?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes. Thanks a lot.",4,"Yes. Thanks a lot."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. Matthew Borsch.",11,"The next question comes from the line of Mr. Matthew Borsch."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","This is Stacy joining on for Mark. There's been some recent articles about insurers focusing on third-party payments from sureties like American Kidney Fund and even across other such sureties as well. I think it's been a long-standing practice for dialys",76,"This is Stacy joining on for Mark. There's been some recent articles about insurers focusing on third-party payments from sureties like American Kidney Fund and even across other such sureties as well. I think it's been a long-standing practice for dialysis companies to donate to these charities. But for those of us less familiar, can you provide some color on how a [indiscernible] fits into your real strategy? And any dynamics a play regarding increased focus?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Before we do that, before Javier does that, this is KT just coming back again, I want to make sure we cover all aspect of the previous questioner's question. And in general, we do get paid more for an MA dialysis patient than the Medicare fee-for-service",142,"Before we do that, before Javier does that, this is KT just coming back again, I want to make sure we cover all aspect of the previous questioner's question. And in general, we do get paid more for an MA dialysis patient than the Medicare fee-for-service patient. It's totally intuitively to be expected because if you have MA risks, if you're in MA plan, you care a lot more about aggregate integrated care because you're at risk on the entire expense for the patient. And so coming to us where you get some of what we provide and therefore, lower hospitalizations and happier repeat patients/customers, it's natural that given our more robust value proposition that the payer pays us more and in fact, is happier and they would be paying less for fee-for-service type service. Now on to the next question. Javier?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure, Matthew. Thank you for the question. First of all, it's probably worth stepping back and reviewing level setting here. We believe that it is vital for patients of all different disease states to have premium assistance. It is a critical part of our",152,"Sure, Matthew. Thank you for the question. First of all, it's probably worth stepping back and reviewing level setting here. We believe that it is vital for patients of all different disease states to have premium assistance. It is a critical part of our healthcare system and had been so for decades. And of course, we've got have appropriate rules, so those need to be reviewed periodically. In Kidney Care, we have been donating, so have all other providers, to help patients with end-stage renal disease for decades in order to be assisted with their premiums. The OIG has reviewed that framework more than once and actually just did it over a year ago or so. And so that framework has been valid and of course, we have to make sure that we all stay and abide by the rules that were outlined by the OIG. Did I get to what you're..."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That was very helpful. And just a quick kind of follow-up modeling question. For the G&A in the quarter, looks like [indiscernible] was that associated with the accelerated amortization from the rebranding?",32,"That was very helpful. And just a quick kind of follow-up modeling question. For the G&A in the quarter, looks like [indiscernible] was that associated with the accelerated amortization from the rebranding?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","No, it was not. We have not started the acceleration. That's a forward-looking event, but we will keep you informed about that matter as we determine the final amortization periods.",30,"No, it was not. We have not started the acceleration. That's a forward-looking event, but we will keep you informed about that matter as we determine the final amortization periods."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","But perhaps we can explain...",6,"But perhaps we can explain..."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. Can you comment on the uptick though?",8,"Okay. Can you comment on the uptick though?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Why don't you give us...",6,"Why don't you give us..."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's primarily -- excuse me, it's primarily The Everett Clinic.",11,"It's primarily -- excuse me, it's primarily The Everett Clinic."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","And so we'll check and if there's any answer that should be appended to, primarily The Everett Clinic, we'll get it back out in the next 5 to 10 minutes. But next one please, Joe?",36,"And so we'll check and if there's any answer that should be appended to, primarily The Everett Clinic, we'll get it back out in the next 5 to 10 minutes. But next one please, Joe?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. Kevin Fischbeck.",11,"The next question comes from the line of Mr. Kevin Fischbeck."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","This is actually Joanna Gajuk filling in for Kevin. So question here on the transaction that you entered with [indiscernible] over a portion of it, the question here is who did you sell the interest to? And the question [indiscernible] who would like to k",67,"This is actually Joanna Gajuk filling in for Kevin. So question here on the transaction that you entered with [indiscernible] over a portion of it, the question here is who did you sell the interest to? And the question [indiscernible] who would like to know and whether this was a strategic player maybe could potentially help save money there? Or was it pretty done for financial reasons?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","On Tandigm, what we did is sold a part of our stake back to IBC, Independence Blue Cross, who has been our partner in Tandigm since day 1. And what both sides agreed was to do this in order to create more alignment between IBC and Tandigm. Otherwise, we'r",132,"On Tandigm, what we did is sold a part of our stake back to IBC, Independence Blue Cross, who has been our partner in Tandigm since day 1. And what both sides agreed was to do this in order to create more alignment between IBC and Tandigm. Otherwise, we're in a situation where IBC got 100% of the profits in their non-Tandigm business, only 50% in the Tandigm part of the business. And this lack of alignment that was getting of the way of some of the glass breaking that needed to go on in order to move the entire organization forward. And so we agreed to be bought out in part to get that alignment. And who knows, perhaps we'll get to go back up to a higher percentage over time."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. That's helpful. And staying a little bit on that front and specifically on the reduction in, I guess, outlook for operating income for that part of the business, HCP or DaVita Medical Group. And specifically, how should we think about this reduction",103,"Okay. That's helpful. And staying a little bit on that front and specifically on the reduction in, I guess, outlook for operating income for that part of the business, HCP or DaVita Medical Group. And specifically, how should we think about this reduction as it relates to the sale [indiscernible] and also the exit in Arizona market? So is that the guidance changed to reflect those 2 things? Or there's a change to core performance as well? And then if it is and if you could please quantify the 2 different sort of the asset sales versus the core performance of the business?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay, I'm going to turn that to Vijay. There was a part in Arizona and then perhaps the relationship with Arizona with Tandigm and then core performance, separate from those 2, if I heard.",34,"Okay, I'm going to turn that to Vijay. There was a part in Arizona and then perhaps the relationship with Arizona with Tandigm and then core performance, separate from those 2, if I heard."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Correct.",1,"Correct."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Were those the 3 parts, please?",6,"Were those the 3 parts, please?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes, exactly. Thank you.",4,"Yes, exactly. Thank you."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","So Joanna, I think the first question was related to does the guidance change, is that reflective -- or is that driven by the change in ownership in Arizona and in Tandigm? So it is incorporated. It's not a driving component. The 4 items that we called ou",61,"So Joanna, I think the first question was related to does the guidance change, is that reflective -- or is that driven by the change in ownership in Arizona and in Tandigm? So it is incorporated. It's not a driving component. The 4 items that we called out are the primary factors that are changing our guidance expectations for the year."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","So is there a way to quantify those? I've heard you said see $5 million to $6 million of these additional costs are from rebranding. So I guess, there are other -- I guess, the other delta. The other part of the delta is [indiscernible] for service in MA,",50,"So is there a way to quantify those? I've heard you said see $5 million to $6 million of these additional costs are from rebranding. So I guess, there are other -- I guess, the other delta. The other part of the delta is [indiscernible] for service in MA, right?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, one is the fee-for-service growth being only 3% versus our expected 6% and then the in-year MA growth and then the -- mistaken our estimate on the prior year revenue reconciliation amount.",33,"Yes, one is the fee-for-service growth being only 3% versus our expected 6% and then the in-year MA growth and then the -- mistaken our estimate on the prior year revenue reconciliation amount."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","But is there a way to sort of out of those 4 things versus the change in -- coming from the sale of Tandigm and Arizona?",26,"But is there a way to sort of out of those 4 things versus the change in -- coming from the sale of Tandigm and Arizona?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I would...",3,"I would..."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think -- let me take a stab at the answer to the question, I think, you're asking. Those 4 factors explain the change in guidance, and the Tandigm Arizona transactions had little to no impact on go forward guidance.",40,"I think -- let me take a stab at the answer to the question, I think, you're asking. Those 4 factors explain the change in guidance, and the Tandigm Arizona transactions had little to no impact on go forward guidance."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's what I was getting at, yes, exactly. Thank you so much.",13,"That's what I was getting at, yes, exactly. Thank you so much."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","So the next question comes from the line of Mr. Garry Lieberman.",12,"So the next question comes from the line of Mr. Garry Lieberman."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I guess, maybe to stay with that last question for a second. Is it possible to break out those 4 components to put a dollar number on each one of those for the impact? Because it was a fairly large change to the guidance.",44,"I guess, maybe to stay with that last question for a second. Is it possible to break out those 4 components to put a dollar number on each one of those for the impact? Because it was a fairly large change to the guidance."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. I think all 4 are pretty significant meaty parts of it, and we're not going to attribute out each 1 individually but each one is significant.",27,"Yes. I think all 4 are pretty significant meaty parts of it, and we're not going to attribute out each 1 individually but each one is significant."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, I guess, maybe just going back to the explanation for the sale of Tandigm. Could you just walk us through that? In other words, it wasn't entirely clear kind of exactly what the driver was there.",39,"Okay. And then, I guess, maybe just going back to the explanation for the sale of Tandigm. Could you just walk us through that? In other words, it wasn't entirely clear kind of exactly what the driver was there."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure, I can. In establishing Tandigm, where you know that IBC and DaVita together stood up a 100,000 member at risk HMOs essentially in a year. And so an exceptionally aggressive implementation, it is necessary for us to work for a lot of the home departm",198,"Sure, I can. In establishing Tandigm, where you know that IBC and DaVita together stood up a 100,000 member at risk HMOs essentially in a year. And so an exceptionally aggressive implementation, it is necessary for us to work for a lot of the home departments within IBC and also to be negotiating with the same hospitals that IBC's negotiating with further other products. And what we found is IBC teammates, as you would rationally expect, say, ""Hey, an extra dollar of hospital rate relief goes 100% to IBC if I put it in this product negotiated for here and only 50% if I negotiate for it there."" Now the fact is those perceptions are going to change over time because of the offense of potential off and Tandigm and because more and more IBC people are becoming a part of Tandigm. But in the meantime, rather than try to deal with the some of that understandable organizational friction, we said the simplest way to deal with it in the near term is to let us be bought down, and so all of IBC could see that they have a significant majority of the profits in either case."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then you mentioned the opportunity to benefit increase your ownership stake back up. How would that work?",19,"Okay. And then you mentioned the opportunity to benefit increase your ownership stake back up. How would that work?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Correct. Without going into a lot of detail, we have some rights with respect to buying back up to our prior position.",22,"Correct. Without going into a lot of detail, we have some rights with respect to buying back up to our prior position."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. So you're still committed to Tandigm? And it's going well compared to when you initially got the deal? Or how would you characterize that?",25,"Okay. So you're still committed to Tandigm? And it's going well compared to when you initially got the deal? Or how would you characterize that?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, we're still committed to Tandigm. On the doing well, I kind of hate saying yes or no to something like that. It's a young company. We're making progress every quarter. If we hit plan, then it sounds like you're doing well but it could have been you m",170,"Yes, we're still committed to Tandigm. On the doing well, I kind of hate saying yes or no to something like that. It's a young company. We're making progress every quarter. If we hit plan, then it sounds like you're doing well but it could have been you make too soft a plan. If you're missing it, it can sound like you're doing poorly but it could have been you sent a good aggressive plan or had a little bad luck. And so all I can say is that we're a lot better today than we were 4 months ago. We are better 4 months ago than 8 months ago. We've got some new executives on board, and so we're feeling pretty darn good. But we also set out to do something that really hasn't been done very often, and so we just don't have a lot of illusions about skipping up the mountain we know we're never going to skin our knees a couple of times along the way."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And maybe turning toward the comments by some of the management care companies this quarter regarding the premiums from the American Kidney Fund. It sounds like some of them may actually be talking to state insurance commissioners or pushing back in",72,"Okay. And maybe turning toward the comments by some of the management care companies this quarter regarding the premiums from the American Kidney Fund. It sounds like some of them may actually be talking to state insurance commissioners or pushing back in other ways to maybe get out of taking those premiums. Can you talk about any conversations that you've had your thoughts generally speaking about how any of this might transpire?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure Garry, this is Javier and again, it's probably useful to step back a bit. And so in a world right now where in 2014, the exchanges came into play, we've heard so much about the risk pools and how they're not well-funded. And so a new product comes in",274,"Sure Garry, this is Javier and again, it's probably useful to step back a bit. And so in a world right now where in 2014, the exchanges came into play, we've heard so much about the risk pools and how they're not well-funded. And so a new product comes into market, our dialysis patients and our social workers worked really hard to make sure that they explain and understand the new product. And at that time, the patient and the patient alone makes a decision on what's right for them. As you know, many of the chronic in high-cost disease states have costs these risk pools to be challenging to the payers. I think that they've -- in some instances, have highlighted the ESRD expense but the reality is it's pretty much all chronic diseases. So CMS is evaluating third-party premium assistance to see what their stance, is but it's complicated around the healthcare continuum. And so right now they're evaluating because the last thing they want to do is use a broad brush and then have consequences on 1 disease state versus another. So right now what's going on is that in every state, people are trying to lobby to get one thing or another. What we have found is that regulators, once they really hear our patients' needs and what they literally need is choice, they're quite sympathetic to the cost, and so it will play out state-by-state. And of course, the patients and ourselves will do the best we can to make sure that they have rights to these products regardless of the fact that they end up being expensive patients."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's very helpful. And then maybe final question just on the Kidney Care front. It looks like patient care costs for premium was down marginally in the quarter. Any changes specifically on use of drugs? And then to the extent that you guys are willing t",61,"That's very helpful. And then maybe final question just on the Kidney Care front. It looks like patient care costs for premium was down marginally in the quarter. Any changes specifically on use of drugs? And then to the extent that you guys are willing to comment on renegotiations or conversations with alternative providers of ESA or your current supplier?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Garry, thanks for the question. No big change on the utilization of meds, and there's nothing new to update. The negotiations continue, and all the dynamics that we've explained before are the same.",33,"Garry, thanks for the question. No big change on the utilization of meds, and there's nothing new to update. The negotiations continue, and all the dynamics that we've explained before are the same."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. John Ransom.",11,"The next question comes from the line of Mr. John Ransom."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","A couple of things. Kent, let's kind of step back and think big picture on HCP, HealthCare Partners, now remained. You've been in this for 4 years. Clearly, the numbers haven't been what we all thought they would be. How much of that do you attribute to s",102,"A couple of things. Kent, let's kind of step back and think big picture on HCP, HealthCare Partners, now remained. You've been in this for 4 years. Clearly, the numbers haven't been what we all thought they would be. How much of that do you attribute to structural factors? And what I would say about that is maybe not as many markets were ready for this revolution as we thought. Or secondly, how much of it do you say, ""Well, gosh, maybe we didn't execute as well as we thought have -- or we could have."" Is it possible to do that?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. That's a very fair point. Maybe I'd refer to 4 chapters. Chapter 1 was huge reimbursement cut. $200 [ph] million of OI lost because of HealthCare Partners was more adept than others at capturing acuity codes, which we new going in but didn't anticipa",322,"Yes. That's a very fair point. Maybe I'd refer to 4 chapters. Chapter 1 was huge reimbursement cut. $200 [ph] million of OI lost because of HealthCare Partners was more adept than others at capturing acuity codes, which we new going in but didn't anticipate that dramatic change in policy. We knew there would be some softening there and some compression and we knew it wouldn't be small, but we did not expect it would happen so much and so quickly and therefore, we own that. So chapter 1 was breathtaking reimbursement cuts, $200 million annually. Chapter 2 was pretty much total displacement of the leadership. California, Nevada, Florida, the 3 markets essentially at 100% change. And that took time. And of course, while you're doing it at does get in the way of things getting done and it thus create some transitional. Chapter 3 is bring in the new infrastructure. You can buy the house on the best lot with the best architectural bonds, but if it needs new heating, ventilating, air-conditioning, you've got a lot of work to do. That doesn't really start showing up until it's done, but it makes a hell of a difference as to the experience of going inside. And so that's a chapter where in the midst of right now. Chapter 4 is the one we're just starting to feel in some places where we're bringing a new level of operating excellence, a new level of innovation and an enhanced value proposition, new levels of creative activity and contracting, but these are just little. little saplings breaking through the surface right now. The good news is they're there and we're ready to take care of them. So I would divide the world into 4 chapters and then I would offer up my empathy for the fact that so many of the shareholders have had to live through the excruciating burden of chapters 1 through 3."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's a great answer. And I have a follow-up for Javier. I mean, just to push back a little bit on this foundation issue. I mean, these patients will be covered by Medicare. It's not as though they would be [indiscernible] to health insurance. And I thin",176,"That's a great answer. And I have a follow-up for Javier. I mean, just to push back a little bit on this foundation issue. I mean, these patients will be covered by Medicare. It's not as though they would be [indiscernible] to health insurance. And I think I've read 5,500 or so patients are now on the exchanges being paid for by the foundations. I mean, aren't you arguing that UnitedHealthcare and Anthem should take, I don't know, $5,000, $10,000 in premium and have a care costs of over $100,000? I mean, how can we make that argument to these plans when they could be covered under the public plans? And that's -- I would assume you just have your proportional share of the 5,500. I guess, stepping back from that of a public policy standpoint how do you -- at a time when the plans are losing money in the exchanges, how do you argue to them that they should cover people that could be covered for a fraction of the cost under Medicare?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Couple of things. If you're on Medicare, you're not eligible to go on the exchange, and so that is the benefit that you have. For the patients that switch, I don't know if the number you cited is whether or not we haven't disclosed those numbers, it is a",128,"Couple of things. If you're on Medicare, you're not eligible to go on the exchange, and so that is the benefit that you have. For the patients that switch, I don't know if the number you cited is whether or not we haven't disclosed those numbers, it is a very personal decision that is based on access to specialists, drugs and other things, so the patient actually do get differentiated care. And so the reality of this thing is that the system set it up for individuals to make their choices forward their best coverage is. And so patients made that choice, and it's a very personal decision and I can't decide whether that's right or wrong for the system but rather, they get to make the choice."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","One might well also ask the question how appropriate it is for plans to make multiple times the magnitude of profit on MA patients that all the providers in America do combine? That might be another philosophical question to ask. The fact that it gets so",178,"One might well also ask the question how appropriate it is for plans to make multiple times the magnitude of profit on MA patients that all the providers in America do combine? That might be another philosophical question to ask. The fact that it gets so interesting. There's pockets of profitability within healthcare and then you have pockets of loss, for example, for us, about 80% of our patients are Medicare fee-for-service and we lose money on every one of them. It really doesn't make any sense, and so you end up having to think of it as an ecosystem where the plans have what might look like excessive margin somewhere and then have losses elsewhere. Where we take care of some patients, an absolute significant and ambiguous loss and other cases have higher margins than you expect us to, so you sort of have to end up looking at it as an ecosystem and see if anyone part of it is getting out of balance because it's hard to get each individual part of it exactly right."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","We have another question from the line of Mr. Whit Mayo.",11,"We have another question from the line of Mr. Whit Mayo."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Maybe I missed this but can you go back to the prior year revenue headwind within DMG and -- or DMG? Was that prior issue in the quarter? Or is this something that you expect to hit in the second half?",41,"Maybe I missed this but can you go back to the prior year revenue headwind within DMG and -- or DMG? Was that prior issue in the quarter? Or is this something that you expect to hit in the second half?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It was something that we expected to receive and recognize in the second half of the year.",17,"It was something that we expected to receive and recognize in the second half of the year."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Maybe just help us understand the process around identifying insuring up those claims and what specifically this is?",18,"Maybe just help us understand the process around identifying insuring up those claims and what specifically this is?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","This is not related to claims. This is about revenue and the finalization of revenue with CMS, and you typically bring that in on a cash basis in the second part of the year, and our estimate of that was higher than what we now believe that amount to be t",58,"This is not related to claims. This is about revenue and the finalization of revenue with CMS, and you typically bring that in on a cash basis in the second part of the year, and our estimate of that was higher than what we now believe that amount to be that we would receive in the back half."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then if you just look at the 4 buckets that you've outlined, I guess, the sources of underperformance, if you will, within the DaVita Medical Group, the rebranding doesn't seem to be an issue that's probably going to recur into 2017, maybe it do",87,"Okay. And then if you just look at the 4 buckets that you've outlined, I guess, the sources of underperformance, if you will, within the DaVita Medical Group, the rebranding doesn't seem to be an issue that's probably going to recur into 2017, maybe it does to some extent. The prior year revenue, that stuff happens but I would imagine that's probably something that doesn't recur next year. So how much of the guide down would you call to be -- would be more from transient factors?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think the way you think about it is about right, and I -- we don't want to go any further into what 2017 would look like but I think the way you think about it is right.",38,"I think the way you think about it is about right, and I -- we don't want to go any further into what 2017 would look like but I think the way you think about it is right."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I'd go a traditional further than that because you're right on the mistake we made in forecasting and fortunately caught it before we were into that forecasted period. We certainly hope that, that doesn't recur. We like everyone else hope that MA in enrol",155,"I'd go a traditional further than that because you're right on the mistake we made in forecasting and fortunately caught it before we were into that forecasted period. We certainly hope that, that doesn't recur. We like everyone else hope that MA in enrollment growth is higher the next couple of years than the last couple. That's not entirely under our control. Of course, it depends on what government policy comes out in terms of rates to a great extent. We're working hard to not jump that fee-for-service growth so we don't want that to be recurring, and we don't expect it to be recurring in the long run, but we don't know how quickly we're going to be able to either bump it up or take out some of the expenses associated with not having higher growth. And I'm missing the fourth one, but I think he also nailed that one. Enough said."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And maybe just remind us, Renal Ventures, is this included in your guidance at this point? And it feels like maybe this deal's taking a little bit longer than maybe we anticipated. Just an update with the timing of that.",41,"Okay. And maybe just remind us, Renal Ventures, is this included in your guidance at this point? And it feels like maybe this deal's taking a little bit longer than maybe we anticipated. Just an update with the timing of that."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure. The answer to the first question is it is not included. As to the timing, we are equally as frustrated and are moving as quickly as we can. We anticipate back in fourth quarter closing. [indiscernible] now but as you know, that is a moving target.",47,"Sure. The answer to the first question is it is not included. As to the timing, we are equally as frustrated and are moving as quickly as we can. We anticipate back in fourth quarter closing. [indiscernible] now but as you know, that is a moving target."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Got it. Any specific reason that just for the hold up on the deal? Or is this just one of those things that's out of everyone's control?",27,"Got it. Any specific reason that just for the hold up on the deal? Or is this just one of those things that's out of everyone's control?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's normal process, but no. I'll tell you just the normal process but it just gone below. It seems that every step of the process.",26,"It's normal process, but no. I'll tell you just the normal process but it just gone below. It seems that every step of the process."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from the line of Mr. Garry Taylor.",11,"Our next question comes from the line of Mr. Garry Taylor."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","A couple of questions. First on California, I'm sorry -- the Arizona divestiture. Will that close in third quarter?",19,"A couple of questions. First on California, I'm sorry -- the Arizona divestiture. Will that close in third quarter?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It was already. That closed within Q2.",7,"It was already. That closed within Q2."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","So it's included in the cash flow statement proceeds for 6 months, which is not very much. Can you just remind us then of, in that market, what the revenue model was in the membership?",36,"So it's included in the cash flow statement proceeds for 6 months, which is not very much. Can you just remind us then of, in that market, what the revenue model was in the membership?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We don't typically disclose our numbers on a market basis, so I'd refrain from giving you that level of detail. Is there more specific question you could ask?",29,"We don't typically disclose our numbers on a market basis, so I'd refrain from giving you that level of detail. Is there more specific question you could ask?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Well, I guess, I'm trying to understand what it was you sold and who you sold it to and what the revenues come out for HCP? Obviously, you said it won't have much an impact on operating income. So apparently, it was in that profitable but we do need to mo",64,"Well, I guess, I'm trying to understand what it was you sold and who you sold it to and what the revenues come out for HCP? Obviously, you said it won't have much an impact on operating income. So apparently, it was in that profitable but we do need to model HCP revenues on a go-forward basis so any help there would be good."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Gary, absolutely fair questions, and we didn't think of that one ahead of time and we don't want to establish -- on one hand, we don't want to establish new precedent for disclosing things. And on the other hand, we don't want to keep it from being able t",99,"Gary, absolutely fair questions, and we didn't think of that one ahead of time and we don't want to establish -- on one hand, we don't want to establish new precedent for disclosing things. And on the other hand, we don't want to keep it from being able to take care of your model. So why don't you just -- we'll work on it so everybody who has a follow-up call can figure out what we can say or not say about the [indiscernible] on a particular, but for us to do it spontaneously is a little too nerve-racking."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. On commercial mix, improved about 100 basis points last year, I believe, and I did note the revenue per treatment growth slowed this quarter year-over-year. So I didn't hear you call anything out, so I'm presuming you're just comping that growth of",62,"Okay. On commercial mix, improved about 100 basis points last year, I believe, and I did note the revenue per treatment growth slowed this quarter year-over-year. So I didn't hear you call anything out, so I'm presuming you're just comping that growth of commercial mix. And is it right to think that maybe commercial mix is pretty stable year-over-year? Is it down?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's Javier again. So I think you're alluding 2014, we disclosed 10% and [ph] revenue per treatment was 3 42 in 2015. We disclosed 11%; revenue, 3 48. As you saw, we're 3 51. We haven't disclosed mix. So it's fair to say that's stable with a slight bump.",50,"It's Javier again. So I think you're alluding 2014, we disclosed 10% and [ph] revenue per treatment was 3 42 in 2015. We disclosed 11%; revenue, 3 48. As you saw, we're 3 51. We haven't disclosed mix. So it's fair to say that's stable with a slight bump."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. On the HCP side, question. Are any of the rates contractually tied to the health industry fee holiday? In other words, referred from some plans that as they get released in '17 and not have to pay this industry fee holiday, some of their capitated [",99,"Okay. On the HCP side, question. Are any of the rates contractually tied to the health industry fee holiday? In other words, referred from some plans that as they get released in '17 and not have to pay this industry fee holiday, some of their capitated [ph] groups contractually get a bump because they effectively had to eat as you did some rate cuts over the last few years. So this is effectively a net -- on the rate increase of the plans and not have to pay those fees. Will HCP benefit contractually from then [ph] in '17?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Again, as it relates to our contracts, there is some expect some of our contracts will have it flow through, others won't. But in those where it does flow through, there maybe some slight pickups there for the onetime period as you know all the details ar",47,"Again, as it relates to our contracts, there is some expect some of our contracts will have it flow through, others won't. But in those where it does flow through, there maybe some slight pickups there for the onetime period as you know all the details around."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","And last question. I believe at Investor Day, you had sized a $25 million Medicare headwind for HCP in '17. And I wonder if there was any update to that. Obviously, we're thinking about potential negative impact of the dual risk model change in some marke",75,"And last question. I believe at Investor Day, you had sized a $25 million Medicare headwind for HCP in '17. And I wonder if there was any update to that. Obviously, we're thinking about potential negative impact of the dual risk model change in some markets but positive in others and then may be a little bit of benefit from this industry fee holiday. At this point, is that $25 million still the best number?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","That's still the best number, including all the things you just described.",13,"That's still the best number, including all the things you just described."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Ms. Lisa Clive.",11,"The next question comes from the line of Ms. Lisa Clive."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Three questions. Just the HCP Arizona sale, could you talk to the rationale for that? Second question, some of the write-down that we had on HCP over the last few quarters, have we hit the bottom here? Or are there potentially more to come? I mean, obviou",85,"Three questions. Just the HCP Arizona sale, could you talk to the rationale for that? Second question, some of the write-down that we had on HCP over the last few quarters, have we hit the bottom here? Or are there potentially more to come? I mean, obviously, it depends on what your accounting say, but it will just be helpful to think through that. And then the third question is international business, you mentioned goodwill impairment charge, just wondering what the source of that was."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Let me first start on the Arizona divestiture. In short, we' got a good offer that was presented to us. And as we look at the alternatives the way that we did invest or deploy our resources for a greater value that was the right trade-off. So we decided t",63,"Let me first start on the Arizona divestiture. In short, we' got a good offer that was presented to us. And as we look at the alternatives the way that we did invest or deploy our resources for a greater value that was the right trade-off. So we decided to accept that offer and divest. Jim, you want to touch on the [indiscernible]"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","In regard to the goodwill impairment that we took in the quarter. As we look forward, there is a chance that we will have another impairment if -- as we disclosed in our 10-Q, we have a negative cushion on -- in our Nevada and Florida markets and there is",162,"In regard to the goodwill impairment that we took in the quarter. As we look forward, there is a chance that we will have another impairment if -- as we disclosed in our 10-Q, we have a negative cushion on -- in our Nevada and Florida markets and there is a very kind of new ones and detailed accounting rules around impairment accounting. And so when you have a negative cushion, that means that your fair value is less than your booked value. And so if there is any further deterioration performance or an outlook of those markets, we could see a further impairment. Additionally, [indiscernible] is looking at changing the rules around accounting for goodwill impairments. When they do that, there maybe an effect related to the adoption of those new rules. And then the final part of your question was an international impairment. We did have a small international impairment last year. Well, we did not have 1 this year."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Just one follow-up on the Arizona deal. Who did you actually sell to?",14,"Just one follow-up on the Arizona deal. Who did you actually sell to?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I don't know if we're authorized to say. Does anybody here in the table know for sure? I don't know the contracts by [indiscernible]. If you could call in and we'll check in now if it's fine. It's also relatively commonly known in the market in case you k",69,"I don't know if we're authorized to say. Does anybody here in the table know for sure? I don't know the contracts by [indiscernible]. If you could call in and we'll check in now if it's fine. It's also relatively commonly known in the market in case you know anyone there, but we'd be happy to give the answer once we confirm that we were legally allowed to."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. I was just sort of curious as to what sort of event would give you a good deal to take off your hand.",24,"Okay. I was just sort of curious as to what sort of event would give you a good deal to take off your hand."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","For us, it was better for us to focus on other markets than that one.",15,"For us, it was better for us to focus on other markets than that one."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","We have another question from the line of Margaret Kaser.",10,"We have another question from the line of Margaret Kaser."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I was hoping to start out with exchange plans. Over the last couple of calls, this has been a popular topic for you guys but now that we're in August, half way through the year, are you seeing the regulatory environment improving, stabilizing or patients",64,"I was hoping to start out with exchange plans. Over the last couple of calls, this has been a popular topic for you guys but now that we're in August, half way through the year, are you seeing the regulatory environment improving, stabilizing or patients receiving adequate access to care, especially near term? Any trend data that you guys may have will be helpful."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. We actually don't have any significant change. The patients are receiving great care. And right now, as we stated earlier in the call, there's a lot to be played. So a lot of rules and enforcement is still to be played, but right now, there's nothing",58,"Yes. We actually don't have any significant change. The patients are receiving great care. And right now, as we stated earlier in the call, there's a lot to be played. So a lot of rules and enforcement is still to be played, but right now, there's nothing different report than what we told you in Capital Markets Day."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think the way I would put it is that the regulatory agencies capacity to enforce the regulations with respect to changes remained weak, either by virtue of lack of motivation, because they're worried about the exchanges financial liability or because th",47,"I think the way I would put it is that the regulatory agencies capacity to enforce the regulations with respect to changes remained weak, either by virtue of lack of motivation, because they're worried about the exchanges financial liability or because they just don't have the resources."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Is that something that can change at some point over the next 6, 12, 18 months?",16,"Is that something that can change at some point over the next 6, 12, 18 months?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, it could change, and it's likely to change some, but one wouldn't want to depend once hope when it's changing a lot.",23,"Yes, it could change, and it's likely to change some, but one wouldn't want to depend once hope when it's changing a lot."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay and then for international ventures, how is Asia developing some of these other countries like Saudi Arabia developing? And then how do you compare this business us versus some of your clinics in Germany, both in terms of patients, investments going",46,"Okay and then for international ventures, how is Asia developing some of these other countries like Saudi Arabia developing? And then how do you compare this business us versus some of your clinics in Germany, both in terms of patients, investments going forward and profitability profile?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We're in 11 other countries now and the microeconomics and growth trajectory are different in every 1. The good news is that in virtually every 1, the microeconomics work at a very reasonable market share position. So even if we're losing money now in a c",114,"We're in 11 other countries now and the microeconomics and growth trajectory are different in every 1. The good news is that in virtually every 1, the microeconomics work at a very reasonable market share position. So even if we're losing money now in a country, just by increasing our scale with the existing achieve your macroeconomics of our current sellers, we know we're in the path to the promise land of first thing profitable and then second, having an adequate [indiscernible] return. But the differences are quite large, and Germany and Saudi are 2 of our more successful markets from many perspectives, including the microeconomics. But am I getting to your question?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Well, and part of it becomes how do you guys [indiscernible] to that profitability gap you talked about at the Capital Markets Day? And what impact and how many years really will it take for China to either be material as well as profitable?",44,"Well, and part of it becomes how do you guys [indiscernible] to that profitability gap you talked about at the Capital Markets Day? And what impact and how many years really will it take for China to either be material as well as profitable?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I don't know is the answer. With respect to China, that day is almost certainly outside your investment time horizon and yet the only way to become a leader in China is to get into China and learn it. Very difficult to try to transplant your way in x year",180,"I don't know is the answer. With respect to China, that day is almost certainly outside your investment time horizon and yet the only way to become a leader in China is to get into China and learn it. Very difficult to try to transplant your way in x years later. In China, we'll probably end up with a few partners is the right way to do it. Just as we concluded in Asia, despite the fact that we were doing well in Southeast Asia, partnering with Khazanah and Mitsui we thought was going to help us grow faster and better everything from helping us recruit more talent, helping us oversee what we have, helping us interact with the government more and the regulators. So in all sorts of ways, we learned important lessons, which should make the next 5 years very different from the last 5. But having said all that, in China, in particular, you want to be very careful before you start talking about any bullish forecasts, because it is one tough place to do business."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then one last question. We're trying to balance some of the growth within dialysis again some of the other companies that cover it. And what we're noticing is some of the acute care demand at least for equipment is growing a little bit faster. Y",82,"Okay. And then one last question. We're trying to balance some of the growth within dialysis again some of the other companies that cover it. And what we're noticing is some of the acute care demand at least for equipment is growing a little bit faster. You're seeing PD growth a little bit faster. So maybe what are you guys seeing in the field? Are you actually seeing acute-care patients improve i PD? And how does that end up benefiting you guys?"
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Margaret. We're seeing RPD grow similarly than our non-acquired growth in center, so we're not seeing a disproportionate growth there. And so as it relates to our acute business, there's nothing that stands out to our historical trends. So it c",112,"Thank you, Margaret. We're seeing RPD grow similarly than our non-acquired growth in center, so we're not seeing a disproportionate growth there. And so as it relates to our acute business, there's nothing that stands out to our historical trends. So it could be that equipment, of course, is misaligned with services and that equipment could be old or someone decides that they want to do some treatments in their hospital and/or change of staffing ratios instead of having a room they conduct dialysis, they want to go bed to bed in the hospital. So it's really hard to predict the alignment there, but we're not seeing anything different in our business."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","At the moment, speakers, we have no more questions over the phone.",12,"At the moment, speakers, we have no more questions over the phone."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","All right. Thank you very much, everyone, for your interest in DaVita. We'll do our best for you between now and our next call. Take care.",26,"All right. Thank you very much, everyone, for your interest in DaVita. We'll do our best for you between now and our next call. Take care."
35644,377729485,1030231,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Thank you all, speakers. So that concludes today's conference. Thank you all for participating. You may now disconnect.",18,"Thank you all, speakers. So that concludes today's conference. Thank you all for participating. You may now disconnect."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you for standing by. [Operator Instructions] Now I will turn the meeting over to one of your hosts, Mr. Jim Gustafson. Sir, you may begin.",28,"Welcome, and thank you for standing by. [Operator Instructions] Now I will turn the meeting over to one of your hosts, Mr. Jim Gustafson. Sir, you may begin."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Joel, and welcome, everyone, to the DaVita HealthCare Partners Second Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Ken",243,"Thank you, Joel, and welcome, everyone, to the DaVita HealthCare Partners Second Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, the CEO of DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of DaVita Medical Group; Jim Hilger, our Interim CFO and Chief Accounting Officer; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statement. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based upon information currently available to us, and we do not intend and undertake no duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website.
I will now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Jim, and welcome to all. We delivered solid adjusted operating income and strong cash flows in this particular quarter. The total adjusted operating income was $475 million, as many of you have already seen, which were driven by the strong Kidn",388,"Thank you, Jim, and welcome to all. We delivered solid adjusted operating income and strong cash flows in this particular quarter. The total adjusted operating income was $475 million, as many of you have already seen, which were driven by the strong Kidney Care results at $431 million and a disappointing DaVita Medical Group trajectory reflected with $44 million on a non-GAAP basis there. Operating cash flow is another bright spot of $517 million as we continue to successfully convert your earnings into your cash.
We'll discuss several topics here before we get into Q&A. Number one is clinical outcomes; number two is DMG results; number three is U.S. Kidney Care; number four, a little bit of an update on international; and number five is just some additional financial enterprise-level details.
Let's start with clinical outcomes. As we always do, we are, first and foremost, a caregiving company and quite good at it. Now about 185,000 patients in the U.S. alone, about 35% of all dialysis patients in America. One of the areas where we've increased our focus is on reducing bloodstream infections, a very big deal to our patients, a very big deal to their families, a very big deal to the taxpayer. It's important because this keeps patients out of the hospital. Bloodstream infections are one of the top 5 causes of hospitalizations for these patients, and this impacts both QIP and 5-Star. We are now performing blood-culture test on more than 90% of the situations when a patient is present with signs and symptoms of bloodstream infections. We'll never get to 100, but 90 is remarkably higher than where we were x years ago and where so many dialysis centers are today.
Despite testing a greater percentage of eligible patients, we've actually decreased our bloodstream infection rate by 16% over the last 12 months, and we're working both sides of the equation with tenacity and some success. 
On the DMG side, the DaVita Medical Group, year-to-date, we've outperformed on the focused HEDIS measures that CMS uses to track Medicare advantage clinical quality compared to the same period last year. And as a result, we are on track to achieve greater than 4 stars in all of our planned relationships. For some more detail on the DaVita Medical Group, I turn it over to Vijay Kotte."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. Turning to this quarter's performance, operating income was $44 million, excluding non-GAAP items as detailed in our earnings release. Unfortunately, year-to-date, we have financially underperformed relative to plan, and we expect this gap t",357,"Thanks, Kent. Turning to this quarter's performance, operating income was $44 million, excluding non-GAAP items as detailed in our earnings release. Unfortunately, year-to-date, we have financially underperformed relative to plan, and we expect this gap to increase in the second half of the year. As a result, we are lowering our 2016 full year guidance to $110 million to $150 million. The decrease in guidance has 4 primary drivers: We preserve its growth, Medicare Advantage growth, and rebranding effort. To provide a little more color, let me walk you through those.
First, our fee-for-service revenue growth has not met our expectations. Our target with 6% year-over-year, but we're achieving 3%. Second, we made a mistake forecasting 2016 operating profit by overestimating expected reconciliation payments for prior year Medicare Advantage revenue. Third, while our in-year Medicare Advantage membership growth has been in line with broader enrollment trends in the geographies we operate in, it is lower than we've previously expected. Fourth, as we stated on our last call, we are rebranding from healthcare partners to the DaVita Medical Group. To accomplish this, we expect to spend $5 million to $10 million this year that wasn't previously included in our forecast. In addition, we will need to accelerate the noncash amortization of $110 million worth of existing trademark intangibles associated with the legacy healthcare partners brand. This accelerated amortization has been excluded from our revised 2016 and long-term guidance. Despite these disappointments, we are making good progress on the key items we identified at Capital Market.
In terms of fee for service to value conversion, we are progressing and contracting discussions with health plan while developing value-based care capabilities in our newer markets. Additionally, we continue to invest in the business, which we believe will fuel our long-term success. One example is our investment in 7 new de novo clinics, which are capital-efficient growth platform similar to what you are used to seeing in Kidney Care.
Finally, as we look towards our long-term outlook, our 2019 OI target remained $250 million.
Now I will turn it over to Javier Rodriguez to speak a little bit more about Kidney Care."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Vijay, and hello, everyone. Before I talk about the quarter, I'd like to highlight a recent development that we're very excited about. At our Capital Markets Day, we talked about the powerful benefits of integrated care for chronic populations,",436,"Thank you, Vijay, and hello, everyone. Before I talk about the quarter, I'd like to highlight a recent development that we're very excited about. At our Capital Markets Day, we talked about the powerful benefits of integrated care for chronic populations, including our own ESRD patients. Since then, 2 new pieces of legislation that are supported by the dialysis community have been introduced in Congress. 
The first is called the Dialysis PATIENT Demonstration Act, and that provides for true integrated care model for kidney care patients. The second is called the ESRD Choice Act of 2016, and that would finally allow for ESRD patients to enroll in MA plans. Both of these acts would be a great gift to ESRD patients and play to our long-term strategy of integrated care.
We're hopeful about their prospects in Congress due to the strong bipartisan support, and we will continue to work hard to pursue integrated care for our patients. 
Now on to our quarterly results. Overall, DaVita Kidney Care had a strong and reasonably straightforward quarter, so I won't go into much detail here. As Kent said, we delivered strong operating income of $431 million due to a slight improvement in revenue per treatment over Q1 as well as slight reduction in cost for its treatment. With respect to growth, our normalized Non-Acquired growth for the quarter was 4.3%, which falls within our long-term target range of 3.5% to 4.5%.
With the first half of the year now behind us, we're raising the bottom end of our 2016 guidance range by $50 million. This is consistent with our comments from last quarter that we're more likely to be in the top half of our original guidance. With this change, our new Kidney Care operating income guidance for 2016 is now $1.675 billion to $1.725 billion. As for next year, we plan to provide 2017 guidance during our fourth quarter earnings call. We made this change last year because ACA plans have become a more meaningful part of our commercial mix. This has added some new drivers of upside and downside to our business and our industry as well as some seasonality. Providing guidance on our fourth quarter call allows us to incorporate the additional visibility we gained during open enrollment period.
Before I turn it back to KT, I want to close by saying we remain excited about the fundamentals of our business, the gradual shift toward integrated care, and the fact that our teammates are recognized for providing the best outcomes and quality of life for kidney patients.
Now back to Kent to discuss our international business."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, JR. International losses, $13 million in the quarter, which is pretty much in line with our guidance for approximately $40 million in losses on the full year. We continue to maintain what we told you -- when I think about a year ago that",204,"Okay. Thank you, JR. International losses, $13 million in the quarter, which is pretty much in line with our guidance for approximately $40 million in losses on the full year. We continue to maintain what we told you -- when I think about a year ago that we committed to try to achieve breakeven by 2018 in our current market portfolio actually in any new countries, and we're standing by that. And a number of you probably saw it that we did, in fact, close the transaction that we had to announce 4 to 5 to 6 weeks ago, that being our JV transaction with Khazanah and Mitsui on August 1. 
Just to refresh year memory, Khazanah and Mitsui have each subscribed to acquire 20% share of ownership over time. At the closing, each provided $50 million of funding to the JV in return for each receiving a 6.7% stake. We're excited to have them as partners. We have a very long-term point of view about the opportunity in that part of the world as do they, and we think they're going to help us accelerate and deepen our growth.
Now I'll turn it over to Jim Hilger to cover some more enterprise financials."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent, and just a little more about our Asia Pacific joint venture. In regards to the JV with Khazanah and Mitsui, please note that we expect that this joint venture will be deconsolidated from our financials and thus, future operating results will",467,"Thanks, Kent, and just a little more about our Asia Pacific joint venture. In regards to the JV with Khazanah and Mitsui, please note that we expect that this joint venture will be deconsolidated from our financials and thus, future operating results will run through equity investment income for our pro rata share of ownership in the joint venture. Please note that we expect to record a material noncash onetime gain in connection with the formation of this JV, and this gain is excluded from our guidance.
Now onto the overall enterprise. Our debt expense was $103 million in the second quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 37.2% in the quarter when adjusted for the nondeductible goodwill impairment charge and recognition of a state income tax benefit. We expect the full year effective tax rate attributable to DaVita HealthCare Partners on our adjusted income for 2016 to be in the range of 39% to 40%.
Now turning to cash flow. We continue to generate strong cash flows. Operating cash flow was $517 million in the quarter and $2.06 billion for the last 12 months. The last 12 months benefited from the timing of tax payments. We expect full year 2016 operating cash flow to be between $1.6 billion and $1.75 billion.
One thing to keep in mind when thinking about the cash flows of our individual operating segments is that DMG generates a disproportionately higher share of our cash flows than its share of our adjusted operating income. While the midpoint of our DMG guidance for adjusted operating income is $130 million, the business has a year-to-date annual run rate of $200 million in noncash depreciation and amortization expense. In addition, as you will recall, there is a cash tax reduction of approximately $100 million per year, which is the equivalent to $167 million improvement in pretax operating income. This cash tax benefit is due to the tax rates of step-up created when we acquired the medical group.
And finally, as the vast majority of DMG's business is capitated care, where we are paid before incurring expenses, it has favorable cash flow characteristics with low to negative working capital. Thus, DMG contributes more to our operating cash flows than its first apparent when looking at operating income.
We continue to have a very strong cash balance with $1.68 billion in cash and short-term investments as of June 30. We continue to weigh capital deployment opportunities across growth investment, share repurchases, debt repayment and holding cash. Additionally, as disclosed in our earnings in our release, our Board of Directors just increased our share repurchase authorization from the remaining $259 million to now $1.5 billion. 
And with that, I will now turn the call back over to Kent Thiry."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I'll just make a few summary comments before we go to Q&A. Number one, with the DaVita Medical Group, we're certainly sorry that we had to reduce the guidance. In fact, that it will take even more time to get it to where we think we can be regularly growi",197,"I'll just make a few summary comments before we go to Q&A. Number one, with the DaVita Medical Group, we're certainly sorry that we had to reduce the guidance. In fact, that it will take even more time to get it to where we think we can be regularly growing earnings, and we're intentionally intent on doing, but it will take sometime. Number two, DaVita Kidney Care, wonderfully solid results yet again, probably even better than that. At the same time, as JR has talked about recently, we could have some choppiness at the high levels. And we are maniacally continuing to invest in becoming even more differentiated than we are today in quality, in service, in physician experience, in IT, et cetera. Third or fourth is the cash flow. Your cash flow, continues to be a powerful weapon to be deployed in your defense and on offense. And lastly, fourth, we continue to have a lot of belief in our overall business platform, and we think from our geographic footprint to our capabilities by function, et cetera, et cetera.
So thank you all very much and, Joel, could you please open it up for Q&A?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions]",2,"[Operator Instructions]"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Operator, are you having any problems?",6,"Operator, are you having any problems?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","I'm just waiting for the participants if they will -- if they would be pressing star 1 to ask a question. But at the moment, we don't have an incoming question. [Operator Instructions]",34,"I'm just waiting for the participants if they will -- if they would be pressing star 1 to ask a question. But at the moment, we don't have an incoming question. [Operator Instructions]"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Joel, I show there are 7 people in the queue.",10,"Joel, I show there are 7 people in the queue."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Joel, there might be something wrong with the equipment that you're looking at. So perhaps while the first person ask their question, you can do some checking with one of the other people there.",34,"Joel, there might be something wrong with the equipment that you're looking at. So perhaps while the first person ask their question, you can do some checking with one of the other people there."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Yes, I will double check, sir, because those people that are on the queue, they pressed star 1 at the beginning of the presentation, but let me open up their line. Hold on.",33,"Yes, I will double check, sir, because those people that are on the queue, they pressed star 1 at the beginning of the presentation, but let me open up their line. Hold on."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay. That's okay to let them in, Joel, because we know there's a number of people who ask questions each and every call. So it's okay if they do that.",30,"Okay. That's okay to let them in, Joel, because we know there's a number of people who ask questions each and every call. So it's okay if they do that."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","So we have the first question from the line of Mr. Chris Rigg.",13,"So we have the first question from the line of Mr. Chris Rigg."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Wanting to ask about DMG here. I guess, just with regard to the fee-for-service revenue only growing at 3% versus 6%, is that tied to The Everett Clinic? Or is that something completely different?",34,"Wanting to ask about DMG here. I guess, just with regard to the fee-for-service revenue only growing at 3% versus 6%, is that tied to The Everett Clinic? Or is that something completely different?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's pretty much across the board, although, of course, The Everett Clinic is the biggest single source. But we're just a little bit soft in a number of different areas, and the good news or bad news, depending on how you look at it, is we can operate som",91,"It's pretty much across the board, although, of course, The Everett Clinic is the biggest single source. But we're just a little bit soft in a number of different areas, and the good news or bad news, depending on how you look at it, is we can operate some parts of that much better outside of The Everett Clinic and within The Everett Clinic, which operates so excellently, it had kind of an uncharacteristic stumble. And so it's a mix of all of our fee-for-service locations, nothing really jumping out."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, just a little bit forward thinking on the ESRD Choice legislation that you guys highlighted. I mean, how would that -- at least, at a high level work in your guys' opinion, would you get better rates from the MA plans than you currently ge",61,"Okay. And then, just a little bit forward thinking on the ESRD Choice legislation that you guys highlighted. I mean, how would that -- at least, at a high level work in your guys' opinion, would you get better rates from the MA plans than you currently get on the fee-for-service side? Is that the right way to think about it?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","There's a couple of ways about it, and I'll chime in, this is Javier. And then, LeAnne, if you want to supplement. The main thing is that the lives will be attributed to the dialysis clinic. And so therefore, the dialysis clinic would become the medical h",112,"There's a couple of ways about it, and I'll chime in, this is Javier. And then, LeAnne, if you want to supplement. The main thing is that the lives will be attributed to the dialysis clinic. And so therefore, the dialysis clinic would become the medical home, sort of de facto medical home because we've had the patient for 12 hours. The other important thing is that on the revenue side, instead of having a benchmark, which is a little of a black box thing, and you get a number, it would be linked to MA. And so the revenues would be a lot more predictable. Does that answer your question?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes.",1,"Yes."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. Matthew Borsch.",11,"The next question comes from the line of Mr. Matthew Borsch."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","This is Tejus Ujjani on for Matt. There's been some recent articles about insurers focusing on third-party payments from sureties like American Kidney Fund and even across other sectors as well. I think it's been a long-standing practice for dialysis comp",74,"This is Tejus Ujjani on for Matt. There's been some recent articles about insurers focusing on third-party payments from sureties like American Kidney Fund and even across other sectors as well. I think it's been a long-standing practice for dialysis companies to donate to these charities. But for those of us less familiar, can you provide some color on how AKF fits into your overall strategy? And any dynamics at play regarding increased focus?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Before we do that, before Javier does that, this is KT just coming back again, I want to make sure we cover all aspects of the previous questioner's question. And in general, we do get paid more for an MA dialysis patient than a Medicare fee-for-service p",143,"Before we do that, before Javier does that, this is KT just coming back again, I want to make sure we cover all aspects of the previous questioner's question. And in general, we do get paid more for an MA dialysis patient than a Medicare fee-for-service patient. It's totally intuitively to be expected because if you have MA risks, if you're in MA plan, you care a lot more about aggregate integrated care because you're at risk on the entire expense for the patient. And so coming to us where you get some of what we provide and therefore, lower hospitalizations and happier repeat patients/customers, it is natural that given our more robust value proposition, that the payer pays us more and in fact, is happier than they would be paying less for fee-for-service type service. Now on to the next question. Javier?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure, Matthew (sic) [ Tejus ]. Thank you for the question. First of all, it's probably worth stepping back and reviewing level setting here. We believe that it is vital for patients of all different disease states to have a premium assistance. It is a cri",161,"Sure, Matthew (sic) [ Tejus ]. Thank you for the question. First of all, it's probably worth stepping back and reviewing level setting here. We believe that it is vital for patients of all different disease states to have a premium assistance. It is a critical part of our health care system and has been so for decades. And of course, we got to have appropriate rules. So those need to be reviewed periodically. In Kidney Care, we have been donating, and so have all other providers, to help patients with end-stage renal disease for decades in order to be assisted with their premiums. The OIG has reviewed that framework more than once and actually just did it over a year ago or so. And so that framework has been vetted and of course, we have to make sure that we all stay and abide by the rules that were outlined by the OIG. Did I get to what you're to..."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes. That was very helpful. And just a quick kind of follow-up modeling question. For the G&A in the quarter, it looks like there's an uptick there. Was that associated with the accelerated amortization from the rebranding?",37,"Yes. That was very helpful. And just a quick kind of follow-up modeling question. For the G&A in the quarter, it looks like there's an uptick there. Was that associated with the accelerated amortization from the rebranding?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","No, it was not. We have not started the acceleration. That's a forward-looking event, but we will keep you informed about that matter as we determine the final amortization periods.",30,"No, it was not. We have not started the acceleration. That's a forward-looking event, but we will keep you informed about that matter as we determine the final amortization periods."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","But perhaps we can explain...",6,"But perhaps we can explain..."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. Can you comment on the uptick though?",8,"Okay. Can you comment on the uptick though?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Why don't you give us...",6,"Why don't you give us..."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's primarily -- excuse me, it's primarily The Everett Clinic.",11,"It's primarily -- excuse me, it's primarily The Everett Clinic."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","And so we'll check if there's any answer that should be appended to, primarily, The Everett Clinic. We'll get it back out in the next 5 to 10 minutes. But next one please, Joel?",35,"And so we'll check if there's any answer that should be appended to, primarily, The Everett Clinic. We'll get it back out in the next 5 to 10 minutes. But next one please, Joel?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. Kevin Fischbeck.",11,"The next question comes from the line of Mr. Kevin Fischbeck."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","This is actually Joanna Gajuk filling in for Kevin. So question here on the transaction that you announced with Tandigm or rather selling a portion of it. So the question here is who did you sell the interest to? And the question, since we're [indiscernib",72,"This is actually Joanna Gajuk filling in for Kevin. So question here on the transaction that you announced with Tandigm or rather selling a portion of it. So the question here is who did you sell the interest to? And the question, since we're [indiscernible], we would like to know whether this was a strategic player maybe who could potentially help save money there? Or was it pretty done for financial reasons?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","On Tandigm, what we did is sold a part of our stake back to IBC, Independence Blue Cross, who has been our partner in Tandigm since day 1. And what both sides agreed was to do this in order to create more alignment between IBC and Tandigm. Otherwise, we w",132,"On Tandigm, what we did is sold a part of our stake back to IBC, Independence Blue Cross, who has been our partner in Tandigm since day 1. And what both sides agreed was to do this in order to create more alignment between IBC and Tandigm. Otherwise, we were in a situation where IBC got 100% of the profits in their non-Tandigm business, only 50% in the Tandigm part of the business. And this lack of alignment was getting in the way of some of the glass breaking that needed to go on in order to move the entire organization forward. And so we agreed to be bought out in part to get that alignment. And who knows, perhaps, we'll get to go back up to a higher percentage over time."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. That's helpful. And staying a little bit on that front and specifically on the reduction in, I guess, outlook for operating income for that part of the business, HCP or DaVita Medical Group. And so specifically, how should we think about this reduct",108,"Okay. That's helpful. And staying a little bit on that front and specifically on the reduction in, I guess, outlook for operating income for that part of the business, HCP or DaVita Medical Group. And so specifically, how should we think about this reduction as it relates to the sale in the space and also the exit in Arizona market? So is that -- the guidance changed to reflect those 2 things? Or there's a change to core performance as well? And then, if it is, then if you could please quantify the 2 different sort of buckets, the asset sales versus the core performance of the business?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay, I'm going to turn that to Vijay. There was a part in Arizona and then perhaps the relationship with Arizona with Tandigm and then core performance, separate from those 2, if I heard correctly.",35,"Okay, I'm going to turn that to Vijay. There was a part in Arizona and then perhaps the relationship with Arizona with Tandigm and then core performance, separate from those 2, if I heard correctly."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Correct.",1,"Correct."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Were those the 3 parts, please?",6,"Were those the 3 parts, please?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes, exactly. Yes.",3,"Yes, exactly. Yes."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","So Joanna, I think the first question was related to does the guidance change, is that reflective -- or is that driven by the change in ownership in Arizona and in Tandigm? So it is incorporated. It's not a driving component. The 4 items that we called ou",61,"So Joanna, I think the first question was related to does the guidance change, is that reflective -- or is that driven by the change in ownership in Arizona and in Tandigm? So it is incorporated. It's not a driving component. The 4 items that we called out are the primary factors that are changing our guidance expectations for the year."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","So is there a way to quantify those? I've heard you said $5 million to $6 million of these additional costs are from rebranding. So I guess, there are other, I guess, the other delta. The other part of the delta is [indiscernible] called fee-for-service i",48,"So is there a way to quantify those? I've heard you said $5 million to $6 million of these additional costs are from rebranding. So I guess, there are other, I guess, the other delta. The other part of the delta is [indiscernible] called fee-for-service in MA, right?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, one is the fee-for-service growth being only 3% versus our expected 6%, and then the in-year MA growth and then the -- mistaken our estimate on the prior year revenue reconciliation amount.",33,"Yes, one is the fee-for-service growth being only 3% versus our expected 6%, and then the in-year MA growth and then the -- mistaken our estimate on the prior year revenue reconciliation amount."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","But is there a way to sort of add up those 4 things versus the change in -- coming from the sale of Tandigm and Arizona?",26,"But is there a way to sort of add up those 4 things versus the change in -- coming from the sale of Tandigm and Arizona?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I would...",3,"I would..."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think -- let me take a stab at the answer to the question that, I think, you're asking. Those 4 factors explain the change in guidance, and the Tandigm and Arizona transactions had little to no impact on go-forward guidance.",41,"I think -- let me take a stab at the answer to the question that, I think, you're asking. Those 4 factors explain the change in guidance, and the Tandigm and Arizona transactions had little to no impact on go-forward guidance."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","So the next question comes from the line of Mr. Gary Lieberman.",12,"So the next question comes from the line of Mr. Gary Lieberman."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I guess, maybe to stay with that last question for a second. Is it possible to break out those 4 components to put a dollar number on each one of those for the impact because it was a fairly large change to the guidance?",44,"I guess, maybe to stay with that last question for a second. Is it possible to break out those 4 components to put a dollar number on each one of those for the impact because it was a fairly large change to the guidance?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. I think all 4 are pretty significant meaty parts of it, and we're not going to attribute $1 to each one individually, but each one is significant.",28,"Yes. I think all 4 are pretty significant meaty parts of it, and we're not going to attribute $1 to each one individually, but each one is significant."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, I guess, maybe just going back to the explanation for the sale of Tandigm. Could you just walk us through that? In other words, it wasn't entirely clear kind of exactly what the driver was there.",39,"Okay. And then, I guess, maybe just going back to the explanation for the sale of Tandigm. Could you just walk us through that? In other words, it wasn't entirely clear kind of exactly what the driver was there."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure, I can. In establishing Tandigm, where you know that IBC and DaVita together stood up a 100,000-member at risk HMO essentially in a year. So an exceptionally aggressive implementation. It is necessary for us to work for a lot of the home departments",196,"Sure, I can. In establishing Tandigm, where you know that IBC and DaVita together stood up a 100,000-member at risk HMO essentially in a year. So an exceptionally aggressive implementation. It is necessary for us to work for a lot of the home departments within IBC and also to be negotiating with the same hospitals that IBC's negotiating with for their other products. And what we found is some IBC teammates, as you would rationally expect, say, ""Hey, an extra dollar of hospital rate relief goes 100% to IBC if I put it in this product negotiated for here and only 50% if I negotiate for it there."" Now the fact is those perceptions are going to change over time because of the offensive potential of Tandigm, and because more and more IBC people are becoming a part of Tandigm. But in the meantime, rather than try to deal with the some of that understandable organizational friction, we said the simplest way to deal with it in the near term is to let us be bought down, and so all of IBC could see that they had a significant majority of the profits in either case."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, you mentioned the opportunity to potentially increase your ownership stake back up. How would that work?",19,"Okay. And then, you mentioned the opportunity to potentially increase your ownership stake back up. How would that work?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Correct. Without going into a lot of detail, we have some rights with respect to buying back up to our prior position.",22,"Correct. Without going into a lot of detail, we have some rights with respect to buying back up to our prior position."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. So you're still committed to Tandigm? And it's going well compared to when you initially did the deal? Or how would you characterize that?",25,"Okay. So you're still committed to Tandigm? And it's going well compared to when you initially did the deal? Or how would you characterize that?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We're still committed to Tandigm. On the doing well, I kind of hate saying yes or no to something like that. It's a young company. We're making progress every quarter. If you hit plan, then it sounds like you're doing well, but it could have been you make",169,"We're still committed to Tandigm. On the doing well, I kind of hate saying yes or no to something like that. It's a young company. We're making progress every quarter. If you hit plan, then it sounds like you're doing well, but it could have been you make too soft a plan. If you're missing it, it can sound like you're doing poorly, but it could have been you sent a good aggressive plan or had a little bad luck. And so all I can say is that we're a lot better today than we were 4 months ago. We are better 4 months ago than 8 months ago. We've got some new executives onboard. And so we're feeling pretty darn good. But we also set out to do something that really hasn't been done very often, and so we just don't have a lot of illusions about skipping up the mountain we know we're never going to skin our knees a couple of times on the way."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe turning towards the comments by some of the managed care companies this quarter regarding the premiums from the American Kidney Fund. It sounds like some of them may actually be talking to state insurance commissioners or pushing back",74,"Okay. And then maybe turning towards the comments by some of the managed care companies this quarter regarding the premiums from the American Kidney Fund. It sounds like some of them may actually be talking to state insurance commissioners or pushing back in other ways to maybe get out of taking those premiums. Can you talk about any conversations that you've had or your thoughts, generally speaking, about how any of this might transpire?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure Gary, this is Javier. And again, it's probably useful to step back a bit. And so in a world right now where in 2014, the exchanges came into play, we've heard so much about the risk pools and how they're not well-funded. And so a new product comes in",277,"Sure Gary, this is Javier. And again, it's probably useful to step back a bit. And so in a world right now where in 2014, the exchanges came into play, we've heard so much about the risk pools and how they're not well-funded. And so a new product comes into market, our dialysis patients and our social workers worked really hard to make sure that they explain and understand their new product. And at that time, the patient and the patient alone makes a decision on what's right for them. As you know, many of the chronic and high-cost disease states have caused these risk pools to be challenging to the payers. I think that they've -- in some instances, have highlighted ESRD expense, but the reality is that it's pretty much all chronic diseases. So CMS is evaluating third-party premium assistance to see what their stance is, but it's complicated around the health care continuum. And so right now, they're evaluating because the last thing they want to do is use a broad brush and then have consequences on one disease state versus another. So right now, what's going on is that in every state, people are trying to lobby to get one thing or another. What we have found is that regulators, once they really hear our patients' needs and what they literally need is choice, they're quite sympathetic to the cost, and so it will play out state by state. And of course, the patients and ourself will do the best we can to make sure that they have rights to these products regardless of the fact that they end up being expensive patients."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's very helpful. And then maybe final question just on staying on the Kidney Care front. It looks like patient care cost for premium was down marginally in the quarter. Any changes specifically on use of drugs? And then to the extent that you guys are",64,"That's very helpful. And then maybe final question just on staying on the Kidney Care front. It looks like patient care cost for premium was down marginally in the quarter. Any changes specifically on use of drugs? And then to the extent that you guys are willing to comment on any negotiations or conversations with alternative providers of ESA or your current supplier?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Gary, thanks for the question. No big change on the utilization of meds, and there's nothing new to update. The negotiations continue, and all the dynamics that we've explained before are the same.",33,"Gary, thanks for the question. No big change on the utilization of meds, and there's nothing new to update. The negotiations continue, and all the dynamics that we've explained before are the same."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. John Ransom.",11,"The next question comes from the line of Mr. John Ransom."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","A couple of things. Kent, let's kind of step back and think big picture on HCP, HealthCare Partners, now renamed. You've been in this for 4 years. Clearly, the numbers haven't been what we all hope they would be. How much of that do you attribute to struc",102,"A couple of things. Kent, let's kind of step back and think big picture on HCP, HealthCare Partners, now renamed. You've been in this for 4 years. Clearly, the numbers haven't been what we all hope they would be. How much of that do you attribute to structural factors? And what I would say about that is maybe not as many markets were ready for this revolution as we thought. Or secondly, how much of it do you say, ""Well, gosh, maybe we didn't execute as well as we thought have -- what we could have."" Is this possible to do that?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, it's a very fair point. Maybe I'd refer to -- for the 4 chapters. Chapter 1 was huge reimbursement cut, $200 million of OI lost because HealthCare Partners was more adept than others at capturing acuity codes, which we new going in but didn't anticip",324,"Yes, it's a very fair point. Maybe I'd refer to -- for the 4 chapters. Chapter 1 was huge reimbursement cut, $200 million of OI lost because HealthCare Partners was more adept than others at capturing acuity codes, which we new going in but didn't anticipate the dramatic change in policy. We knew there would be some softening there and some compression, and we knew it wouldn't be small, but we did not expect it would happen so much and so quickly, and therefore, we own that. So chapter 1 was breathtaking reimbursement cuts, $200 million annually. Chapter 2 was pretty much total displacement of the leadership. California, Nevada, Florida, the 3 markets essentially at 100% change. And that took time. And of course, while you're doing it, it does get in the way of things getting done, and it does create some transitional trauma. Chapter 3 is bring in the new infrastructure. You can buy the house on the best lot with the best architectural bonds, but if it needs new heating, ventilating, air conditioning, you got a lot of work to do. But that doesn't really start showing up until it's done, but it makes a hell of a difference as to the experience of going inside. And so that's a chapter we're in the midst of right now. Chapter 4 is the one we're just starting to feel in some places where we're bringing a new level of operating excellence, a new level of innovation and an enhanced value proposition, new levels of creativity in contracting, but these are just little saplings breaking through the surface right now. The good news is they're there, and we're ready to take care of them. So I would divide the world into 4 chapters and then I would offer up my empathy for the fact that so many of these shareholders have had to live through the excruciating burden of chapters 1 through 3."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's a great answer. And I have a follow-up for Javier. I mean, just to push back a little bit on this foundation issue. I mean, these patients will be covered by Medicare. It's not as though they would be bereft to health insurance or -- and I think I'",178,"That's a great answer. And I have a follow-up for Javier. I mean, just to push back a little bit on this foundation issue. I mean, these patients will be covered by Medicare. It's not as though they would be bereft to health insurance or -- and I think I've read 5,500 or so patients are now on the exchanges being paid for by the foundations. I mean, aren't you arguing that UnitedHealthcare and Anthem should take, I don't know, $5,000, $10,000 in premium and have a care cost of over $100,000? I mean, how can we make that argument to these plans when they can be covered under the public plans? That's -- and I would assume you guys have your proportional share of the 5,500. And just stepping back from kind of a public policy standpoint, how do you -- at a time when the plans are losing money in the exchanges, how do you argue to them that they should cover people that could be covered for a fraction of the cost under Medicare?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, a couple of things. If you're on Medicare, you're not eligible to go on the exchange, and so that is the benefit that you have. For the patient that switched, I don't know if the number you cited is whether or not -- we haven't disclosed those number",132,"Yes, a couple of things. If you're on Medicare, you're not eligible to go on the exchange, and so that is the benefit that you have. For the patient that switched, I don't know if the number you cited is whether or not -- we haven't disclosed those numbers, it is a very personal decision that is based on access to specialists, drugs and other things. So the patients actually do get differentiated care. And so the reality of this thing is that the system set it up for individuals to make their choices, to what their best coverage is. And so patients made that choice, and it's a very personal decision that I can't decide whether that's right or wrong for the system but rather, they get to make the choice."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","One might well also ask the question, how appropriate it is for plans to make multiple times the magnitude of profit on MA patients that all the providers in America do combined? That might be another philosophical question to ask. The fact is it gets so",182,"One might well also ask the question, how appropriate it is for plans to make multiple times the magnitude of profit on MA patients that all the providers in America do combined? That might be another philosophical question to ask. The fact is it gets so interesting. There's pockets of profitability within the health care and then you have pockets of loss. For example, for us, about 80% of our patients are Medicare fee-for-service and we lose money on every one of them. It really doesn't make any sense. And so you end up having to kind of think of it as an ecosystem where the plans have what might look like excessive margin somewhere and then have losses elsewhere, where we take care of some patients, an absolute significant and ambiguous loss, and other cases have higher margins than you expect us to. So you sort of have to end up looking at it as an ecosystem and see if anyone, part of it, is getting out of balance because it's hard to get each individual part of it exactly right."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","We have another question from the line of Mr. Whit Mayo.",11,"We have another question from the line of Mr. Whit Mayo."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Maybe I missed this, but can you go back to the prior year revenue headwind within DMG and -- or DMG? Was that a prior issue in the quarter? Or is this something that you expect to hit in the second half?",42,"Maybe I missed this, but can you go back to the prior year revenue headwind within DMG and -- or DMG? Was that a prior issue in the quarter? Or is this something that you expect to hit in the second half?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It was something that we expected to receive and recognize in the second half of the year.",17,"It was something that we expected to receive and recognize in the second half of the year."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Maybe just help us understand the process around identifying and truing up those claims and what specifically this is?",19,"Maybe just help us understand the process around identifying and truing up those claims and what specifically this is?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","This is not related to claims. This is about revenue and the kind of finalization of revenue with CMS. And we typically bring that in on a cash basis in the second part of the year, and our estimate of that was higher than what we now believe that amount",60,"This is not related to claims. This is about revenue and the kind of finalization of revenue with CMS. And we typically bring that in on a cash basis in the second part of the year, and our estimate of that was higher than what we now believe that amount to be that we will receive in the back half."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, if you just look at the 4 buckets that you've outlined, I guess, the sources of underperformance, if you will, within the DaVita Medical Group, the rebranding doesn't seem to be an issue that's probably going to recur into 2017, maybe it d",87,"Okay. And then, if you just look at the 4 buckets that you've outlined, I guess, the sources of underperformance, if you will, within the DaVita Medical Group, the rebranding doesn't seem to be an issue that's probably going to recur into 2017, maybe it does to some extent. The prior year revenue, the stuff happens, but I would imagine that's probably something that doesn't recur next year. So how much of the guide down would you call to be -- would be more from transient factors?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think the way you're thinking about it is about right, and I -- we don't want to go any further into what 2017 would look like, but I think the way you think about it is right.",39,"I think the way you're thinking about it is about right, and I -- we don't want to go any further into what 2017 would look like, but I think the way you think about it is right."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I'll go a tad further than that because you're right on the mistake we made in forecasting and fortunately caught it before we were into that forecasted period. We certainly hope that, that doesn't recur. We, like everyone else, hope that MA enrollment gr",154,"I'll go a tad further than that because you're right on the mistake we made in forecasting and fortunately caught it before we were into that forecasted period. We certainly hope that, that doesn't recur. We, like everyone else, hope that MA enrollment growth is higher the next couple of years than the last couple. That's not entirely under our control. Of course, it depends on what government policy comes out in terms of rates to a great extent. We're working hard to not jump that fee-for-service growth, so we don't want that to be recurring, and we don't expect it to be recurring in the long run, but we don't know how quickly we're going to be able to either bump it up or take out some of the expenses associated with not having higher growth. And I'm missing the fourth one, but I think you also nailed that one. Enough said."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And maybe just remind us, Renal Ventures, is this included in your guidance at this point? And it feels like maybe this deal is taking a little bit longer than maybe we anticipated. Just an update with the timing of that.",42,"Okay. And maybe just remind us, Renal Ventures, is this included in your guidance at this point? And it feels like maybe this deal is taking a little bit longer than maybe we anticipated. Just an update with the timing of that."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure. The answer to the first question is it is not included. As to the timing, we are equally as frustrated and are moving as quickly as we can. We anticipate back in fourth quarter closing as of now but as you know, that is a moving target.",48,"Sure. The answer to the first question is it is not included. As to the timing, we are equally as frustrated and are moving as quickly as we can. We anticipate back in fourth quarter closing as of now but as you know, that is a moving target."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Got it. Any specific reason that -- just for the hold up on the deal? Or is this just one of those things that's out of everyone's control?",28,"Got it. Any specific reason that -- just for the hold up on the deal? Or is this just one of those things that's out of everyone's control?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's normal process, but low for -- I tell you it's just the normal process, but it just gone low, it seems, at every step of the process.",29,"It's normal process, but low for -- I tell you it's just the normal process, but it just gone low, it seems, at every step of the process."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from the line of Mr. Gary Taylor.",11,"Our next question comes from the line of Mr. Gary Taylor."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","A couple of questions. First on California -- California, I'm sorry -- the Arizona divestiture. Will that close in the third quarter?",22,"A couple of questions. First on California -- California, I'm sorry -- the Arizona divestiture. Will that close in the third quarter?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","That was already -- that closed within Q2.",8,"That was already -- that closed within Q2."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","So it's included in the cash flow statement proceeds for 6 months, which is not very much. Can you just remind us then of, in that market, what the revenue model was in the membership?",36,"So it's included in the cash flow statement proceeds for 6 months, which is not very much. Can you just remind us then of, in that market, what the revenue model was in the membership?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We don't typically disclose our numbers on a market basis, so I'd refrain from giving you that level of detail. Is there more specific question you can ask?",29,"We don't typically disclose our numbers on a market basis, so I'd refrain from giving you that level of detail. Is there more specific question you can ask?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Well, I guess, I'm trying to understand what it was you sold and who do you sold it to and what the revenues come out for HCP? Obviously, you said it won't have much impact on operating income. So apparently, it wasn't that profitable. But we do need to m",63,"Well, I guess, I'm trying to understand what it was you sold and who do you sold it to and what the revenues come out for HCP? Obviously, you said it won't have much impact on operating income. So apparently, it wasn't that profitable. But we do need to model HCP revenues on a go-forward basis, so any help there would be good."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Gary, absolutely fair questions, and we didn't think of that one ahead of time, and we don't want to establish -- on one hand, we don't want to establish new precedent for disclosing things. And on the other hand, we don't want to keep it from being able",99,"Gary, absolutely fair questions, and we didn't think of that one ahead of time, and we don't want to establish -- on one hand, we don't want to establish new precedent for disclosing things. And on the other hand, we don't want to keep it from being able to take care of your model. So why don't you just -- we'll work on it. And so everybody who has a follow-up call can figure out what we can say or not say about the years on particulars, but for us to do it spontaneously is a little too nerve-racking."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. On commercial mix, improved about 100 basis points last year, I believe, and I did note the revenue per treatment growth slowed this quarter year-over-year. So I didn't hear you call anything out. So I'm presuming you're just comping that growth of",62,"Okay. On commercial mix, improved about 100 basis points last year, I believe, and I did note the revenue per treatment growth slowed this quarter year-over-year. So I didn't hear you call anything out. So I'm presuming you're just comping that growth of commercial mix. And were we right to think that maybe commercial mix is pretty stable year-over-year? Is it down?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","This is Javier again. So I think you're alluding 2014, we disclosed 10% and revenue per treatment was $342 million in 2015. We disclosed 11%; revenue, $348 million. As you saw, we're at $351 million. We haven't disclosed the mix. So it's fair to say that'",51,"This is Javier again. So I think you're alluding 2014, we disclosed 10% and revenue per treatment was $342 million in 2015. We disclosed 11%; revenue, $348 million. As you saw, we're at $351 million. We haven't disclosed the mix. So it's fair to say that's stable with a slight bump."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. On the HCP side question, are any of the rates contractually tied to the health industry fee holiday? In other words, referred from some plans that as they get released in '17 and not have to pay this industry fee holiday, some of their capitated gr",96,"Okay. On the HCP side question, are any of the rates contractually tied to the health industry fee holiday? In other words, referred from some plans that as they get released in '17 and not have to pay this industry fee holiday, some of their capitated groups contractually get a bump because they effectively had to eat, as you did, some rate cuts over the last few years. So this is effectively a net -- a rate increase to the plans and not have to pay this fee. Will HCP benefit contractually from that in '17?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Again, as it relates to our contracts, there is a -- it's a mixed bag. Some of our contracts will have it flow through, others won't. But in those where it does flow through, there may be some slight pickups there for the onetime period as you know all th",52,"Again, as it relates to our contracts, there is a -- it's a mixed bag. Some of our contracts will have it flow through, others won't. But in those where it does flow through, there may be some slight pickups there for the onetime period as you know all the details around."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","And last question. I believe at Investor Day, you had sized a $25 million Medicare headwind for HCP in '17. And I wonder if there was any update to that. Obviously, we're thinking about potential negative impact of the dual risk core model change in some",75,"And last question. I believe at Investor Day, you had sized a $25 million Medicare headwind for HCP in '17. And I wonder if there was any update to that. Obviously, we're thinking about potential negative impact of the dual risk core model change in some markets but positive in others, and then maybe a little bit of benefit from this industry fee holiday. At this point, is that $25 million still the best number?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","That is still the best number, including all the things you just described.",13,"That is still the best number, including all the things you just described."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Ms. Lisa Clive.",11,"The next question comes from the line of Ms. Lisa Clive."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Three questions. Just the HCP Arizona sale, could you talk to the rationale for that? Second question, some of the write-downs that we've had on HCP over the last few quarters, are we at the bottom here? Or are there potentially more to come? I mean, obvi",89,"Three questions. Just the HCP Arizona sale, could you talk to the rationale for that? Second question, some of the write-downs that we've had on HCP over the last few quarters, are we at the bottom here? Or are there potentially more to come? I mean, obviously, it just depends on what your accounting say, but it will just be helpful to think through that. And then the third question is on the international business, you mentioned a goodwill impairment charge, just wondering what the source of that was."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Let me first start on the Arizona divestiture. In short, we've got a good offer that was presented to us. And as we look at the alternatives the way that we did invest and deploy our resources for a greater value if that was the right trade-off. So we dec",64,"Let me first start on the Arizona divestiture. In short, we've got a good offer that was presented to us. And as we look at the alternatives the way that we did invest and deploy our resources for a greater value if that was the right trade-off. So we decided to accept that offer and divest. Jim, you want to touch on the impairment?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","In regards to the goodwill impairment that we took in the quarter, as we look forward, there is a chance that we will have another impairment if -- as we disclosed in our 10-Q, we have a negative cushion on -- in our Nevada and Florida markets, and there",163,"In regards to the goodwill impairment that we took in the quarter, as we look forward, there is a chance that we will have another impairment if -- as we disclosed in our 10-Q, we have a negative cushion on -- in our Nevada and Florida markets, and there is a very kind of nuanced and detailed accounting rules around impairment accounting. And so when you have a negative cushion, that means that your fair value is less than your book value. And so if there is any further deterioration performance or an outlook of those markets, we could see a further impairment. Additionally, the FASB is looking at changing the rules around accounting for goodwill impairments. When they do that, there may be an effect related to the adoption of those new rules. And then the final part of your question was an international impairment. We did have a small international impairment last year, but we did not have one this year."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. Just one follow-up on the Arizona deal. Who did you actually sell to?",14,"Okay. Just one follow-up on the Arizona deal. Who did you actually sell to?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I don't know if we're authorized to say. Does anybody here on the table know for sure? I don't know the contracts by -- if you could call in and we'll check in now, if it's fine. It's also relatively commonly known in the market in case you know anyone th",69,"I don't know if we're authorized to say. Does anybody here on the table know for sure? I don't know the contracts by -- if you could call in and we'll check in now, if it's fine. It's also relatively commonly known in the market in case you know anyone there, but we'd be happy to give the answer once we confirm that we were legally allowed to."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. I was just sort of curious as to what sort of entity would give you a good deal to take it off your hand.",25,"Okay. I was just sort of curious as to what sort of entity would give you a good deal to take it off your hand."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yeah. For us, it was better for us to focus on other markets than that one.",16,"Yeah. For us, it was better for us to focus on other markets than that one."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","We have another question from the line of Ms. Margaret Kaczor.",11,"We have another question from the line of Ms. Margaret Kaczor."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I was hoping to start out with exchange plans. Over the last couple of calls, this has been a popular topic for you guys. But now that we're in August, halfway through the year, are you seeing the regulatory environment improving, stabilizing or patients",63,"I was hoping to start out with exchange plans. Over the last couple of calls, this has been a popular topic for you guys. But now that we're in August, halfway through the year, are you seeing the regulatory environment improving, stabilizing or patients receiving adequate access to care, especially near term? Any trend data that you guys may have would be helpful."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. We actually don't have any significant change. The patients are receiving great care. And right now, as we stated earlier in the call, there's a lot to be played. So a lot of rules and enforcement is still to be played. But right now, there's nothing",59,"Yes. We actually don't have any significant change. The patients are receiving great care. And right now, as we stated earlier in the call, there's a lot to be played. So a lot of rules and enforcement is still to be played. But right now, there's nothing different to report than what we told you in Capital Markets Day."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think the way I would put it is that the regulatory agencies' capacity to enforce the regulations with respect to changes remained weak, either by virtue of lack of motivation because they're worried about the exchange's financial liability or because t",47,"I think the way I would put it is that the regulatory agencies' capacity to enforce the regulations with respect to changes remained weak, either by virtue of lack of motivation because they're worried about the exchange's financial liability or because they just don't have the resources."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Is that something that can change at some point on the next 6, 12, 18 months?",16,"Is that something that can change at some point on the next 6, 12, 18 months?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, it could change, and it's likely to change some, but one wouldn't want to pin one's hopes on it changing a lot.",23,"Yes, it could change, and it's likely to change some, but one wouldn't want to pin one's hopes on it changing a lot."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on your international ventures, how is Asia developing -- some of these other countries like Saudi Arabia developing? And then how do you compare those businesses versus some of your clinics in Germany, both in terms of patients, investment",47,"Okay. And then on your international ventures, how is Asia developing -- some of these other countries like Saudi Arabia developing? And then how do you compare those businesses versus some of your clinics in Germany, both in terms of patients, investments going forward and profitability profile?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We're in 11 other countries now, and the microeconomics and growth trajectory are different in every one. The good news is that in virtually every one, the microeconomics work at a very reasonable market share position. So even if we're losing money now i",113,"We're in 11 other countries now, and the microeconomics and growth trajectory are different in every one. The good news is that in virtually every one, the microeconomics work at a very reasonable market share position. So even if we're losing money now in a country, just by increasing our scale with the existing achieved microeconomics of our current centers, we know we're on the path to the promise land of, first, being profitable and then second, having an adequate cumulative return. But the differences are quite large. And Germany and Saudi are 2 of our more successful markets from many perspectives, including the microeconomics. But am I getting to your question?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Well, and part of it becomes how do you guys bridge to that profitability gap you talked about at the Capital Markets Day? And what impact and how many years really will it take for China to either be material as well as profitable?",44,"Well, and part of it becomes how do you guys bridge to that profitability gap you talked about at the Capital Markets Day? And what impact and how many years really will it take for China to either be material as well as profitable?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","So I don't know is the answer with respect to China. That day is almost certainly outside your investment time horizon, and yet the only way to become a leader in China is to get into China and learn it. Very difficult to try to transplant your way in x y",181,"So I don't know is the answer with respect to China. That day is almost certainly outside your investment time horizon, and yet the only way to become a leader in China is to get into China and learn it. Very difficult to try to transplant your way in x years later. In China, we'll probably end up with a few partners is the right way to do it. Just as we concluded in Asia, despite the fact that we were doing well in Southeast Asia, partnering with Khazanah and Mitsui, we thought, was going to help us grow faster and better, everything from helping us recruit more talent, helping us oversee what we have, helping us interact with the government more and the regulators. So in all sorts of ways, we learned important lessons, which should make the next 5 years very different from the last 5. But having said all that, in China, in particular, you want to be very careful before you start talking about any bullish forecasts because it is one tough place to do business."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then one last question. We're trying to balance some of the growth within dialysis against some of the other companies we cover. And what we're noticing is some of the acute care demand, at least, for equipment is growing a little bit faster. Yo",82,"Okay. And then one last question. We're trying to balance some of the growth within dialysis against some of the other companies we cover. And what we're noticing is some of the acute care demand, at least, for equipment is growing a little bit faster. You're seeing PD growth a little bit faster. So maybe what are you guys seeing in the field? Are you actually seeing acute care patients improve in PD? And how does that end up benefiting you guys?"
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Margaret. We are seeing our PD grow similarly than our Non-Acquired Growth in center, so we're not seeing a disproportionate growth there. And as it relates to our acute business, there's nothing that stands out to our historical trend. So it c",114,"Thank you, Margaret. We are seeing our PD grow similarly than our Non-Acquired Growth in center, so we're not seeing a disproportionate growth there. And as it relates to our acute business, there's nothing that stands out to our historical trend. So it could be that equipment, of course, is misaligned with services and that equipment could be old or someone decides that they want to do some treatments in their hospital and/or change their staffing ratios instead of having a room where they conduct dialysis, they want to go bed to bed in the hospital. So it's really hard to predict the alignment there, but we're not seeing anything different in our business."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","At the moment, speakers, we have no more questions over the phone.",12,"At the moment, speakers, we have no more questions over the phone."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","All right. Thank you very much, everyone, for your interest in DaVita. We'll do our best for you in between now and our next call. Take care.",27,"All right. Thank you very much, everyone, for your interest in DaVita. We'll do our best for you in between now and our next call. Take care."
35644,377729485,1030444,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Thank you all, speakers. So that concludes today's conference. Thank you all for participating. You may now disconnect.",18,"Thank you all, speakers. So that concludes today's conference. Thank you all for participating. You may now disconnect."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you for standing by. [Operator Instructions] Now I will turn the meeting over to one of your hosts, Mr. Jim Gustafson. Sir, you may begin.",28,"Welcome, and thank you for standing by. [Operator Instructions] Now I will turn the meeting over to one of your hosts, Mr. Jim Gustafson. Sir, you may begin."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Joel, and welcome, everyone, to the DaVita HealthCare Partners Second Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Ken",243,"Thank you, Joel, and welcome, everyone, to the DaVita HealthCare Partners Second Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, the CEO of DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of DaVita Medical Group; Jim Hilger, our Interim CFO and Chief Accounting Officer; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statement. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based upon information currently available to us, and we do not intend and undertake no duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website.
I will now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Jim, and welcome to all. We delivered solid adjusted operating income and strong cash flows in this particular quarter. The total adjusted operating income was $475 million, as many of you have already seen, which were driven by the strong Kidn",388,"Thank you, Jim, and welcome to all. We delivered solid adjusted operating income and strong cash flows in this particular quarter. The total adjusted operating income was $475 million, as many of you have already seen, which were driven by the strong Kidney Care results at $431 million and a disappointing DaVita Medical Group trajectory reflected with $44 million on a non-GAAP basis there. Operating cash flow is another bright spot of $517 million as we continue to successfully convert your earnings into your cash.
We'll discuss several topics here before we get into Q&A. Number one is clinical outcomes; number two is DMG results; number three is U.S. Kidney Care; number four, a little bit of an update on international; and number five is just some additional financial enterprise-level details.
Let's start with clinical outcomes, as we always do. We are, first and foremost, a caregiving company and quite good at it. Now about 185,000 patients in the U.S. alone, about 35% of all dialysis patients in America. One of the areas where we've increased our focus is on reducing bloodstream infections: a very big deal to our patients, a very big deal to their families, a very big deal to the taxpayer. It's important because this keeps patients out of the hospital. Bloodstream infections are one of the top 5 causes of hospitalizations for these patients, and this impacts both QIP and 5-Star. We are now performing blood-culture tests on more than 90% of the situations when a patient is present with signs and symptoms of bloodstream infections. We'll never get to 100, but 90 is remarkably higher than where we were x years ago and where so many dialysis centers are today.
Despite testing a greater percentage of eligible patients, we've actually decreased our bloodstream infection rate by 16% over the last 12 months, and we're working both sides of the equation with tenacity and some success. 
On the DMG side, the DaVita Medical Group, year-to-date, we've outperformed on the focused HEDIS measures that CMS uses to track Medicare advantage clinical quality compared to the same period last year. And as a result, we are on track to achieve greater than 4 stars in all of our plan relationships. For some more detail on the DaVita Medical Group, I turn it over to Vijay Kotte."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. Turning to this quarter's performance, operating income was $44 million, excluding non-GAAP items as detailed in our earnings release. Unfortunately, year-to-date, we have financially underperformed relative to plan, and we expect this gap t",358,"Thanks, Kent. Turning to this quarter's performance, operating income was $44 million, excluding non-GAAP items as detailed in our earnings release. Unfortunately, year-to-date, we have financially underperformed relative to plan, and we expect this gap to increase in the second half of the year. As a result, we are lowering our 2016 full year guidance to $110 million to $150 million. The decrease in guidance has 4 primary drivers: fee for service growth, Medicare Advantage growth, and rebranding effort. To provide a little more color, let me walk you through those.
First, our fee-for-service revenue growth has not met our expectations. Our target was 6% year-over-year, but we're achieving 3%. Second, we made a mistake forecasting 2016 operating profit by overestimating expected reconciliation payments for prior year Medicare Advantage revenue. Third, while our in-year Medicare Advantage membership growth has been in line with broader enrollment trends in the geographies we operate in, it is lower than we've previously expected. Fourth, as we stated on our last call, we are rebranding from Healthcare Partners to the DaVita Medical Group. To accomplish this, we expect to spend $5 million to $10 million this year that wasn't previously included in our forecast. In addition, we will need to accelerate the noncash amortization of $110 million worth of existing trademark intangibles associated with the legacy Healthcare Partners brand. This accelerated amortization has been excluded from our revised 2016 and long-term guidance. Despite these disappointments, we are making good progress on the key items we identified at Capital Markets.
In terms of fee for service to value conversion, we are progressing in contracting discussions with health plan while developing value-based care capabilities in our newer markets. Additionally, we continue to invest in the business, which we believe will fuel our long-term success. One example is our investment in 7 new de novo clinics, which are a capital-efficient growth platform similar to what you are used to seeing in Kidney Care.
Finally, as we look towards our long-term outlook, our 2019 OI target remains $250 million.
Now I will turn it over to Javier Rodriguez to speak a little bit more about Kidney Care."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Vijay, and hello, everyone. Before I talk about the quarter, I'd like to highlight a recent development that we're very excited about. At our Capital Markets Day, we talked about the powerful benefits of integrated care for chronic populations,",436,"Thank you, Vijay, and hello, everyone. Before I talk about the quarter, I'd like to highlight a recent development that we're very excited about. At our Capital Markets Day, we talked about the powerful benefits of integrated care for chronic populations, including our own ESRD patients. Since then, 2 new pieces of legislation that are supported by the dialysis community have been introduced in Congress. 
The first is called the Dialysis PATIENT Demonstration Act, and that provides for true integrated care model for kidney care patients. The second is called the ESRD Choice Act of 2016, and that would finally allow for ESRD patients to enroll in MA plans. Both of these acts would be a great gift to ESRD patients and play to our long-term strategy of integrated care.
We're hopeful about their prospects in Congress due to the strong bipartisan support, and we will continue to work hard to pursue integrated care for our patients. 
Now on to our quarterly results. Overall, DaVita Kidney Care had a strong and reasonably straightforward quarter, so I won't go into much detail here. As Kent said, we delivered strong operating income of $431 million due to a slight improvement in revenue per treatment over Q1 as well as a slight reduction in costs for treatment. With respect to growth, our normalized Non-Acquired growth for the quarter was 4.3%, which falls within our long-term target range of 3.5% to 4.5%.
With the first half of the year now behind us, we're raising the bottom end of our 2016 guidance range by $50 million. This is consistent with our comments from last quarter that we're more likely to be in the top half of our original guidance. With this change, our new Kidney Care operating income guidance for 2016 is now $1.675 billion to $1.725 billion. As for next year, we plan to provide 2017 guidance during our fourth quarter earnings call. We made this change last year because ACA plans have become a more meaningful part of our commercial mix. This has added some new drivers of upside and downside to our business and our industry as well as some seasonality. Providing guidance on our fourth quarter call allows us to incorporate the additional visibility we gained during open enrollment period.
Before I turn it back to KT, I want to close by saying we remain excited about the fundamentals of our business, the gradual shift toward integrated care, and the fact that our teammates are recognized for providing the best outcomes and quality of life for kidney patients.
Now back to Kent to discuss our international business."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, JR. International losses, $13 million in the quarter, which is pretty much in line with our guidance for approximately $40 million in losses on the full year. We continue to maintain what we told you, oh, I think about a year ago that we",201,"Okay. Thank you, JR. International losses, $13 million in the quarter, which is pretty much in line with our guidance for approximately $40 million in losses on the full year. We continue to maintain what we told you, oh, I think about a year ago that we committed to try to achieve breakeven by 2018 in our current market portfolio, excluding any new countries, and we're standing by that. And a number of you probably saw that we did, in fact, close the transaction that we had to announce 4 to 5 to 6 weeks ago, that being our JV transaction with Khazanah and Mitsui on August 1. 
Just to refresh your memory, Khazanah and Mitsui have each subscribed to acquire 20% share of ownership over time. At the closing, each provided $50 million of funding to the JV in return for each receiving a 6.7% stake. We're excited to have them as partners. We have a very long-term point of view about the opportunity in that part of the world as do they, and we think they're going to help us accelerate and deepen our growth.
Now I'll turn it over to Jim Hilger to cover some more enterprise financials."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent, and just a little more about our Asia Pacific joint venture. In regards to the JV with Khazanah and Mitsui, please note that we expect that this joint venture will be deconsolidated from our financials and thus, future operating results will",464,"Thanks, Kent, and just a little more about our Asia Pacific joint venture. In regards to the JV with Khazanah and Mitsui, please note that we expect that this joint venture will be deconsolidated from our financials and thus, future operating results will run through equity investment income for our pro rata share of ownership in the joint venture. Please note that we expect to record a material noncash onetime gain in connection with the formation of this JV, and this gain is excluded from our guidance.
Now onto the overall enterprise. Our debt expense was $103 million in the second quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 37.2% in the quarter when adjusted for the nondeductible goodwill impairment charge and recognition of a state income tax benefit. We expect the full year effective tax rate attributable to DaVita HealthCare Partners on our adjusted income for 2016 to be in the range of 39% to 40%.
Now turning to cash flow. We continue to generate strong cash flows. Operating cash flow was $517 million in the quarter and $2.06 billion for the last 12 months. The last 12 months benefited from the timing of tax payments. We expect full year 2016 operating cash flow to be between $1.6 billion and $1.75 billion.
One thing to keep in mind when thinking about the cash flows of our individual operating segments is that DMG generates a disproportionately higher share of our cash flows than its share of our adjusted operating income. While the midpoint of our DMG guidance for adjusted operating income is $130 million, the business has a year-to-date annual run rate of $200 million in noncash depreciation and amortization expense. In addition, as you will recall, there is a cash tax reduction of approximately $100 million per year, which is the equivalent to $167 million improvement in pretax operating income. This cash tax benefit is due to the tax basis step-up created when we acquired the medical group.
And finally, as the vast majority of DMG's business is capitated care, where we are paid before incurring expenses, it has favorable cash flow characteristics with low to negative working capital. Thus, DMG contributes more to our operating cash flows than is first apparent when looking at operating income.
We continue to have a very strong cash balance with $1.68 billion in cash and short-term investments as of June 30. We continue to weigh capital deployment opportunities across growth investment, share repurchases, debt repayment and holding cash. Additionally, as disclosed in our earnings release, our Board of Directors just increased our share repurchase authorization from the remaining $259 million to now $1.5 billion. 
And with that, I will now turn the call back over to Kent Thiry."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I'll just make a few summary comments before we go to Q&A. Number one, with the DaVita Medical Group, we're certainly sorry that we had to reduce the guidance, and the fact that it will take even more time to get it to where we think we can be regularly g",199,"I'll just make a few summary comments before we go to Q&A. Number one, with the DaVita Medical Group, we're certainly sorry that we had to reduce the guidance, and the fact that it will take even more time to get it to where we think we can be regularly growing earnings. And that's what we're intensely intent on doing, but it will take some time. Number two, DaVita Kidney Care, wonderfully solid results yet again, probably even better than that. At the same time, as JR has talked about recently, we could have some choppiness at the high levels. And we are maniacally continuing to invest in becoming even more differentiated than we are today in quality, in service, in physician experience, in IT, et cetera. Third of four is the cash flow. Your cash flow continues to be a powerful weapon to be deployed in your defense and on offense. And lastly, fourth, we continue to have a lot of belief in our overall business platform, everything from our geographic footprint to our capabilities by function, et cetera, et cetera.
So thank you all very much and, Joel, could you please open it up for Q&A?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] So we have the first question from the line of Mr. Chris Rigg.",15,"[Operator Instructions] So we have the first question from the line of Mr. Chris Rigg."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Wanted to ask about DMG here. I guess, just with regard to the fee-for-service revenue only growing at 3% versus 6%, is that tied to The Everett Clinic? Or is that something completely different?",34,"Wanted to ask about DMG here. I guess, just with regard to the fee-for-service revenue only growing at 3% versus 6%, is that tied to The Everett Clinic? Or is that something completely different?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's pretty much across the board, although, of course, The Everett Clinic is the biggest single source. But we're just a little bit soft in a number of different areas, and the good news or bad news, depending on how you look at it, is we can operate som",91,"It's pretty much across the board, although, of course, The Everett Clinic is the biggest single source. But we're just a little bit soft in a number of different areas, and the good news or bad news, depending on how you look at it, is we can operate some parts of that much better outside of The Everett Clinic. And within The Everett Clinic, which operates so excellently, they had kind of an uncharacteristic stumble. And so it's a mix of all of our fee-for-service locations, nothing really jumping out."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, just a little bit forward thinking on the ESRD Choice legislation that you guys highlighted. I mean, how would that at least at a high level, work, in your guys' opinion? Would you get better rates from the MA plans than you currently get",60,"Okay. And then, just a little bit forward thinking on the ESRD Choice legislation that you guys highlighted. I mean, how would that at least at a high level, work, in your guys' opinion? Would you get better rates from the MA plans than you currently get on the fee-for-service side? Is that the right way to think about it?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","There's a couple of ways about it, and I'll chime in, this is Javier. And then, LeAnne, if you want to supplement. The main thing is that the lives would be attributed to the dialysis clinic. And so therefore, the dialysis clinic would become the medical",112,"There's a couple of ways about it, and I'll chime in, this is Javier. And then, LeAnne, if you want to supplement. The main thing is that the lives would be attributed to the dialysis clinic. And so therefore, the dialysis clinic would become the medical home, sort of de facto medical home because we'd have the patient for 12 hours. The other important thing is that on the revenue side, instead of having a benchmark, which is a little of a black box thing, and you get a number, it would be linked to MA. And so the revenues would be a lot more predictable. Does that answer your question?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes.",1,"Yes."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. Matthew Borsch.",11,"The next question comes from the line of Mr. Matthew Borsch."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","This is Tejus Ujjani on for Matt. There's been some recent articles about insurers focusing on third-party payments from charities like American Kidney Fund and even across other subsectors as well. I think it's been a long-standing practice for dialysis",74,"This is Tejus Ujjani on for Matt. There's been some recent articles about insurers focusing on third-party payments from charities like American Kidney Fund and even across other subsectors as well. I think it's been a long-standing practice for dialysis companies to donate to these charities. But for those of us less familiar, can you provide some color on how AKF fits into your overall strategy? And any dynamics at play regarding increased focus?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Before we do that, before Javier does that, this is KT just coming back again, I want to make sure we covered all aspects of the previous questioner's question. And in general, we do get paid more for an MA dialysis patient than a Medicare fee-for-service",144,"Before we do that, before Javier does that, this is KT just coming back again, I want to make sure we covered all aspects of the previous questioner's question. And in general, we do get paid more for an MA dialysis patient than a Medicare fee-for-service patient. This is totally intuitively to be expected because if you have MA risk, if you're an MA plan, you care a lot more about aggregate integrated care because you're at risk on the entire expense for the patient. And so coming to us where you get some of what we provide and therefore, lower hospitalizations and happier repeat patients/customers, it is natural that given our more robust value proposition, that the payer pays us more and in fact, is happier than they would be paying less for fee-for-service type service. Now on to the next question. Javier?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure, Matthew (sic) [ Tejus ]. Thank you for the question. First of all, it's probably worth stepping back and reviewing level setting here. We believe that it is vital for patients of all different disease states to have premium assistance. It is a criti",161,"Sure, Matthew (sic) [ Tejus ]. Thank you for the question. First of all, it's probably worth stepping back and reviewing level setting here. We believe that it is vital for patients of all different disease states to have premium assistance. It is a critical part of our health care system and has been so for decades. And of course, we got to have appropriate rules. So those need to be reviewed periodically. In Kidney Care, we have been donating, and so have all other providers, to help patients with end-stage renal disease for decades in order to be assisted with their premiums. The OIG has reviewed that framework more than once and actually just did it over a year ago or so. And so that framework has been vetted and of course, we have to make sure that we all stay and abide by the rules that were outlined by the OIG. Did I get to what you were going..."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes. That was very helpful. And just a quick kind of follow-up modeling question. For the D&A in the quarter, it looks like there's an uptick there. Was that associated with the accelerated amortization from the rebranding?",37,"Yes. That was very helpful. And just a quick kind of follow-up modeling question. For the D&A in the quarter, it looks like there's an uptick there. Was that associated with the accelerated amortization from the rebranding?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","No, it was not. We have not started the acceleration. That's a forward-looking event, but we will keep you informed about that matter as we determine the final amortization periods.",30,"No, it was not. We have not started the acceleration. That's a forward-looking event, but we will keep you informed about that matter as we determine the final amortization periods."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","But perhaps we can explain...",6,"But perhaps we can explain..."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. Can you comment on the uptick though?",8,"Okay. Can you comment on the uptick though?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Why don't you give us...",6,"Why don't you give us..."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's primarily -- excuse me, it's primarily The Everett Clinic.",11,"It's primarily -- excuse me, it's primarily The Everett Clinic."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","And so we'll check and if there's any answer that should be appended to, primarily, The Everett Clinic. We'll get it back out in the next 5, 10 minutes. But next one please, Joel?",35,"And so we'll check and if there's any answer that should be appended to, primarily, The Everett Clinic. We'll get it back out in the next 5, 10 minutes. But next one please, Joel?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. Kevin Fischbeck.",11,"The next question comes from the line of Mr. Kevin Fischbeck."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","This is actually Joanna Gajuk filling in for Kevin. So question here on the transaction that you announced with Tandigm or rather selling a portion of it. So the question here is who did you sell the interest to? And the question, since we're at the start",77,"This is actually Joanna Gajuk filling in for Kevin. So question here on the transaction that you announced with Tandigm or rather selling a portion of it. So the question here is who did you sell the interest to? And the question, since we're at the start of it [ph], we would like to know whether this was a strategic player maybe who could potentially help save money there? Or was it purely done for financial reasons?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","On Tandigm, what we did is sold a part of our stake back to IBC, Independence Blue Cross, who has been our partner in Tandigm since day one. And what both sides agreed was to do this in order to create more alignment between IBC and Tandigm. Otherwise, we",132,"On Tandigm, what we did is sold a part of our stake back to IBC, Independence Blue Cross, who has been our partner in Tandigm since day one. And what both sides agreed was to do this in order to create more alignment between IBC and Tandigm. Otherwise, we were in a situation where IBC got 100% of the profits in their non-Tandigm business, only 50% in the Tandigm part of the business. And this lack of alignment was getting in the way of some of the glass breaking that needed to go on in order to move the entire organization forward. And so we agreed to be bought out in part to get that alignment. And who knows, perhaps, we'll get to go back up to a higher percentage over time."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. That's helpful. And staying a little bit on that front and specifically on the reduction in, I guess, outlook for operating income for that part of the business, HCP or DaVita Medical Group. And so specifically, how should we think about this reduct",108,"Okay. That's helpful. And staying a little bit on that front and specifically on the reduction in, I guess, outlook for operating income for that part of the business, HCP or DaVita Medical Group. And so specifically, how should we think about this reduction as it relates to the sale in the space and also the exit in Arizona market? So is that -- the guidance changed to reflect those 2 things? Or there's a change to core performance as well? And then, if it is, then if you could please quantify the 2 different sort of buckets, the asset sales versus the core performance of the business?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay, I'm going to turn that to Vijay. There was a part on Arizona, and then perhaps the relationship of Arizona with Tandigm and then core performance, separate from those 2, if I heard correctly. Were those the 3 parts, please?",41,"Okay, I'm going to turn that to Vijay. There was a part on Arizona, and then perhaps the relationship of Arizona with Tandigm and then core performance, separate from those 2, if I heard correctly. Were those the 3 parts, please?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes, exactly. Yes.",3,"Yes, exactly. Yes."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","So Joanna, I think the first question was related to does the guidance change, is that reflective -- or is that driven by the change in ownership in Arizona and in Tandigm? Though it is incorporated, it is not a driving component. The 4 items that we call",62,"So Joanna, I think the first question was related to does the guidance change, is that reflective -- or is that driven by the change in ownership in Arizona and in Tandigm? Though it is incorporated, it is not a driving component. The 4 items that we called out are the primary factors that are changing our guidance expectations for the year."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","So is there a way to quantify those? I've heard you said $5 million to $6 million of these additional costs are from rebranding. So I guess, there are other, I guess, the other delta. The other part of the delta is the reporting included in [ph] fee-for-s",51,"So is there a way to quantify those? I've heard you said $5 million to $6 million of these additional costs are from rebranding. So I guess, there are other, I guess, the other delta. The other part of the delta is the reporting included in [ph] fee-for-service in MA, right?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, one is the fee-for-service growth being only 3% versus our expected 6%, and then the in-year MA growth and then the mistake in our estimate on the prior year revenue reconciliation amount.",33,"Yes, one is the fee-for-service growth being only 3% versus our expected 6%, and then the in-year MA growth and then the mistake in our estimate on the prior year revenue reconciliation amount."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","But is there a way to sort of add up those 4 things versus the change in -- coming from the sale of Tandigm and Arizona?",26,"But is there a way to sort of add up those 4 things versus the change in -- coming from the sale of Tandigm and Arizona?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I would...",3,"I would..."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think -- let me take a stab at the answer to the question I think you're asking. Those 4 factors explain the change in guidance. And the Tandigm and Arizona transactions had little to no impact on go-forward guidance.",40,"I think -- let me take a stab at the answer to the question I think you're asking. Those 4 factors explain the change in guidance. And the Tandigm and Arizona transactions had little to no impact on go-forward guidance."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","So the next question comes from the line of Mr. Gary Lieberman.",12,"So the next question comes from the line of Mr. Gary Lieberman."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I guess, maybe to stay with that last question for a second. Is it possible to break out those 4 components to put a dollar number on each one of those for the impact? Because it was a fairly large change to the guidance.",44,"I guess, maybe to stay with that last question for a second. Is it possible to break out those 4 components to put a dollar number on each one of those for the impact? Because it was a fairly large change to the guidance."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. I think all 4 are pretty significant meaty parts of it, and we're not going to attribute a dollar to each one individually, but each one is significant.",29,"Yes. I think all 4 are pretty significant meaty parts of it, and we're not going to attribute a dollar to each one individually, but each one is significant."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, I guess, maybe just going back to the explanation for the sale of Tandigm. Could you just walk us through that? In other words, it wasn't entirely clear kind of exactly what the driver was there.",39,"Okay. And then, I guess, maybe just going back to the explanation for the sale of Tandigm. Could you just walk us through that? In other words, it wasn't entirely clear kind of exactly what the driver was there."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure, I can. In establishing Tandigm, where you know that IBC and DaVita together stood up a 100,000-member at-risk HMO, essentially, in a year. So an exceptionally aggressive implementation. It is necessary for us to work for a lot of the home department",195,"Sure, I can. In establishing Tandigm, where you know that IBC and DaVita together stood up a 100,000-member at-risk HMO, essentially, in a year. So an exceptionally aggressive implementation. It is necessary for us to work for a lot of the home departments within IBC and also to be negotiating with the same hospitals that IBC is negotiating with for their other products. And what we found is some IBC teammates, as you would rationally expect, say, ""Hey, an extra dollar of hospital rate relief goes 100% to IBC if I put it in this product, negotiated for here, and only 50% if I negotiate for it there."" Now the fact is those perceptions are going to change over time because of the offensive potential of Tandigm, and because more and more IBC people are becoming a part of Tandigm. But in the meantime, rather than try to deal with some of that understandable organizational friction, we said the simplest way to deal with it in the near term is to let us be bought down, and so all of IBC could see that they had a significant majority of the profits in either case."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then you mentioned the opportunity to potentially increase your ownership stake back up. How would that work?",19,"Okay. And then you mentioned the opportunity to potentially increase your ownership stake back up. How would that work?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Correct. Without going into a lot of detail, we have some rights with respect to buying back up to our prior position.",22,"Correct. Without going into a lot of detail, we have some rights with respect to buying back up to our prior position."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. So you're still committed to Tandigm? And it's going well compared to when you initially did the deal? Or how would you characterize that?",25,"Okay. So you're still committed to Tandigm? And it's going well compared to when you initially did the deal? Or how would you characterize that?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We're still committed to Tandigm. On the doing well, I kind of hate saying yes or no to something like that. It's a young company. We're making progress every quarter. If you hit plan, then it sounds like you're doing well, but it could have been you made",169,"We're still committed to Tandigm. On the doing well, I kind of hate saying yes or no to something like that. It's a young company. We're making progress every quarter. If you hit plan, then it sounds like you're doing well, but it could have been you made too soft a plan. If you're missing it, it can sound like you're doing poorly, but it could have been you set a good aggressive plan or had a little bad luck. And so all I can say is that we're a lot better today than we were 4 months ago. We were better 4 months ago than 8 months ago. We've got some new executives onboard. And so we're feeling pretty darn good. But we also set out to do something that really hasn't been done very often, and so we just don't have a lot of illusions about skipping up the mountain. We know we're never going to skin our knees a couple of times on the way."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe turning towards the comments by some of the managed care companies this quarter regarding the premiums from the American Kidney Fund. It sounds like some of them may actually be talking to state insurance commissioners or pushing back",74,"Okay. And then maybe turning towards the comments by some of the managed care companies this quarter regarding the premiums from the American Kidney Fund. It sounds like some of them may actually be talking to state insurance commissioners or pushing back in other ways to maybe get out of taking those premiums. Can you talk about any conversations that you've had or your thoughts, generally speaking, about how any of this might transpire?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure Gary, this is Javier. And again, it's probably useful to step back a bit. And so in a world right now where in 2014, the exchanges came into play, we've heard so much about the risk pools and how they're not well-funded. And so a new product comes in",277,"Sure Gary, this is Javier. And again, it's probably useful to step back a bit. And so in a world right now where in 2014, the exchanges came into play, we've heard so much about the risk pools and how they're not well-funded. And so a new product comes into market, our dialysis patients and our social workers work really hard to make sure that they explain and understand their new product. And at that time, the patient and the patient alone makes a decision on what's right for them. As you know, many of the chronic and high-cost disease states have caused these risk pools to be challenging to the payers. I think that they've -- in some instances, have highlighted ESRD expense, but the reality is that it's pretty much all chronic diseases. So CMS is evaluating third-party premium assistance to see what their stance is, but it's complicated around the health care continuum. And so right now, they're evaluating because the last thing they want to do is use a broad brush and then have consequences on one disease state versus another. So right now, what's going on is that in every state, people are trying to lobby to get one thing or another. What we have found is that regulators, once they really hear our patients' needs, and what they literally need is choice, they're quite sympathetic to the cause. And so it will play out state by state. And of course, the patients and ourselves will do the best we can to make sure that they have rights to these products regardless of the fact that they end up being expensive patients."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's very helpful. And then maybe final question just on staying on the Kidney Care front. It looks like patient care cost for treatment was down marginally in the quarter. Any changes specifically on use of drugs? And then to the extent that you guys a",64,"That's very helpful. And then maybe final question just on staying on the Kidney Care front. It looks like patient care cost for treatment was down marginally in the quarter. Any changes specifically on use of drugs? And then to the extent that you guys are willing to comment on any negotiations or conversations with alternative providers of ESA or your current supplier?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Gary, no big change on the utilization of meds, and there's nothing new to update. The negotiations continue, and all the dynamics that we've explained before are the same.",29,"Gary, no big change on the utilization of meds, and there's nothing new to update. The negotiations continue, and all the dynamics that we've explained before are the same."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. John Ransom.",11,"The next question comes from the line of Mr. John Ransom."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","A couple of things. Kent, let's kind of step back and think big picture on HCP, HealthCare Partners, now renamed. You've been in this for 4 years. Clearly, the numbers haven't been what we all hoped they would be. How much of that do you attribute to stru",102,"A couple of things. Kent, let's kind of step back and think big picture on HCP, HealthCare Partners, now renamed. You've been in this for 4 years. Clearly, the numbers haven't been what we all hoped they would be. How much of that do you attribute to structural factors? And what I would say about that is maybe not as many markets were ready for this revolution as we thought. Or secondly, how much of it do you say, ""Well, gosh, maybe we didn't execute as well as we thought have -- thought we could have."" If it's possible to do that?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, it's a very fair point. Maybe I'd refer to sort of 4 chapters. Chapter 1 was huge reimbursement cut: $200 million of OI lost because HealthCare Partners was more adept than others at capturing acuity codes, which we knew going in but didn't anticipat",322,"Yes, it's a very fair point. Maybe I'd refer to sort of 4 chapters. Chapter 1 was huge reimbursement cut: $200 million of OI lost because HealthCare Partners was more adept than others at capturing acuity codes, which we knew going in but didn't anticipate the dramatic change in policy. We knew there would be some softening there and some compression. And we knew it wouldn't be small, but we did not expect it would happen so much and so quickly, and therefore, we own that. So chapter 1 was breathtaking reimbursement cuts, $200 million annually. Chapter 2 was pretty much total displacement of the leadership. California, Nevada, Florida, the 3 markets, essentially, a 100% change. And that took time. And of course, while you're doing it, it does get in the way of things getting done, and it does create some transitional trauma. Chapter 3 is bring in the new infrastructure. You can buy the house on the best lot with the best architectural bones, but if it needs new heating, ventilating, air conditioning, you got a lot of work to do. It doesn't really start showing up until it's done, but it makes a hell of a difference as to the experience of going inside. And so that's the chapter we're in the midst of right now. Chapter 4 is the one we're just starting to feel in some places where we're bringing a new level of operating excellence, a new level of innovation and an enhanced value proposition, new levels of creativity in contracting. But these are just little saplings breaking through the surface right now. The good news is they're there, and we're ready to take care of them. So I would divide the world into 4 chapters, and then I would offer up my empathy for the fact that so many of you shareholders have had to live through the excruciating burden of chapters 1 through 3."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's a great answer. And I have a follow-up for Javier. I mean, just to push back a little bit on this foundation issue. I mean, these patients will be covered by Medicare. It's not as though they would be bereft to health insurance or -- and I think I'",178,"That's a great answer. And I have a follow-up for Javier. I mean, just to push back a little bit on this foundation issue. I mean, these patients will be covered by Medicare. It's not as though they would be bereft to health insurance or -- and I think I've read 5,500 or so patients are now on the exchanges being paid for by the foundations. I mean, aren't you arguing that UnitedHealthcare and Anthem should take, I don't know, $5,000, $10,000 in premium and have a care cost of over $100,000? I mean, how can we make that argument to these plans when they could be covered under the public plans? That's -- and I would assume you guys have your proportional share of the 5,500. So just stepping back from kind of a public policy standpoint, how do you -- at a time when the plans are losing money in the exchanges, how do you argue to them that they should cover people that could be covered for a fraction of the cost under Medicare?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, a couple of things. If you're on Medicare, you're not eligible to go on the exchange, and so that is the benefit that you have. For the patient that switched, I don't know if the number you cited is right or not. We haven't disclosed those numbers. I",132,"Yes, a couple of things. If you're on Medicare, you're not eligible to go on the exchange, and so that is the benefit that you have. For the patient that switched, I don't know if the number you cited is right or not. We haven't disclosed those numbers. It is a very personal decision that is based on access to specialists, drugs and other things. So the patients actually do get differentiated care. And so the reality of this thing is that the system set it up for individuals to make a choice as to what their best coverage is. And so patients made that choice, and it's a very personal decision that I can't decide whether that's right or wrong for the system but rather, they get to make the choice."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","One might well also ask the question, how appropriate it is for plans to make multiple times the magnitude of profit on MA patients that all the providers in America do combined? That might be another philosophical question to ask. The fact is it gets so",184,"One might well also ask the question, how appropriate it is for plans to make multiple times the magnitude of profit on MA patients that all the providers in America do combined? That might be another philosophical question to ask. The fact is it gets so interesting. There's pockets of profitability within health care and then you have pockets of loss. For example, for us, about 80% of our patients are Medicare fee-for-service and we lose money on every one of them. It really doesn't make any sense. And so you end up having to kind of think of it as an ecosystem where the plans have what might look like excessive margin somewhere and then have losses elsewhere, where we take care of some patients at an absolute significant and unambiguous loss and in other cases have higher margins than you expect us to. So you sort of have to end up looking at it as an ecosystem and see if any one part of it is getting out of balance because it's hard to get each individual part of it exactly right."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","We have another question from the line of Mr. Whit Mayo.",11,"We have another question from the line of Mr. Whit Mayo."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Maybe I missed this, but can you go back to the prior year revenue headwind within DMG and -- or DMG? Was that prior-year issue in the quarter? Or is this something that you expect to hit in the second half?",41,"Maybe I missed this, but can you go back to the prior year revenue headwind within DMG and -- or DMG? Was that prior-year issue in the quarter? Or is this something that you expect to hit in the second half?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It was something that we expected to receive and recognize in the second half of the year.",17,"It was something that we expected to receive and recognize in the second half of the year."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Maybe just help us understand the process around identifying and truing up those claims and what specifically this is?",19,"Maybe just help us understand the process around identifying and truing up those claims and what specifically this is?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","This is not related to claims. This is about revenue and the kind of finalization of revenue with CMS. And we typically bring that in on a cash basis in the second part of the year, and our estimate of that was higher than what we now believe that amount",60,"This is not related to claims. This is about revenue and the kind of finalization of revenue with CMS. And we typically bring that in on a cash basis in the second part of the year, and our estimate of that was higher than what we now believe that amount to be that we will receive in the back half."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, if you just look at the 4 buckets that you've outlined, I guess, the sources of underperformance, if you will, within the DaVita Medical Group. The rebranding doesn't seem to be an issue that's probably going to recur into 2017, maybe it d",87,"Okay. And then, if you just look at the 4 buckets that you've outlined, I guess, the sources of underperformance, if you will, within the DaVita Medical Group. The rebranding doesn't seem to be an issue that's probably going to recur into 2017, maybe it does to some extent. The prior year revenue, this stuff happens, but I would imagine that's probably something that doesn't recur next year. So how much of the guide down would you call to be -- would be more from transient factors?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think the way you're thinking about it is about right. And I -- we don't want to go any further into what 2017 would look like, but I think the way you're thinking about it is right.",39,"I think the way you're thinking about it is about right. And I -- we don't want to go any further into what 2017 would look like, but I think the way you're thinking about it is right."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I'll go a tad further than that because you're right on the mistake we made in forecasting and fortunately caught it before we were into that forecasted period. We certainly hope that, that doesn't recur. We, like everyone else, hope that MA enrollment gr",154,"I'll go a tad further than that because you're right on the mistake we made in forecasting and fortunately caught it before we were into that forecasted period. We certainly hope that, that doesn't recur. We, like everyone else, hope that MA enrollment growth is higher the next couple of years than the last couple. That's not entirely under our control, of course. It depends on what government policy comes out in terms of rates to a great extent. We're working hard to nudge up that fee-for-service growth, so we don't want that to be recurring, and we don't expect it to be recurring in the long run. But we don't know how quickly we're going to be able to either bump it up or take out some of the expenses associated with not having higher growth. And I'm missing the fourth one, but I think you also nailed that one. Enough said."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And maybe just remind us, Renal Ventures, is this included in your guidance at this point? And it feels like maybe this deal is taking a little bit longer than maybe we anticipated. Just an update with the timing of that.",42,"Okay. And maybe just remind us, Renal Ventures, is this included in your guidance at this point? And it feels like maybe this deal is taking a little bit longer than maybe we anticipated. Just an update with the timing of that."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure. The answer to the first question is it is not included. As to the timing, we are equally as frustrated and are moving as quickly as we can. We anticipate back-end of fourth quarter closing as of now but as you know, that is a moving target.",48,"Sure. The answer to the first question is it is not included. As to the timing, we are equally as frustrated and are moving as quickly as we can. We anticipate back-end of fourth quarter closing as of now but as you know, that is a moving target."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Got it. Any specific reason that -- just for the hold up on the deal? Or is this just one of those things that's out of everyone's control?",28,"Got it. Any specific reason that -- just for the hold up on the deal? Or is this just one of those things that's out of everyone's control?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's normal process, but slow for -- I tell you it's just the normal process, but it just gone slow, it seems, at every step of the process.",29,"It's normal process, but slow for -- I tell you it's just the normal process, but it just gone slow, it seems, at every step of the process."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from the line of Mr. Gary Taylor.",11,"Our next question comes from the line of Mr. Gary Taylor."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","A couple of questions. First on California -- California, I'm sorry -- the Arizona divestiture. Will that close in the third quarter?",22,"A couple of questions. First on California -- California, I'm sorry -- the Arizona divestiture. Will that close in the third quarter?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","That was already -- that closed within Q2.",8,"That was already -- that closed within Q2."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","So it's included in the cash flow statement proceeds for 6 months, which is not very much. Can you just remind us then of, in that market, what the revenue model was in the membership?",36,"So it's included in the cash flow statement proceeds for 6 months, which is not very much. Can you just remind us then of, in that market, what the revenue model was in the membership?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We don't typically disclose our numbers on a market basis, so I'd refrain from giving you that level of detail. Is there more specific question you can ask?",29,"We don't typically disclose our numbers on a market basis, so I'd refrain from giving you that level of detail. Is there more specific question you can ask?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Well, I guess, I'm trying to understand what it was you sold and who you sold it to and what the revenues come out for HCP? Obviously, you said it won't have much impact on operating income. So apparently, it wasn't that profitable. But we do need to mode",62,"Well, I guess, I'm trying to understand what it was you sold and who you sold it to and what the revenues come out for HCP? Obviously, you said it won't have much impact on operating income. So apparently, it wasn't that profitable. But we do need to model HCP revenues on a go-forward basis, so any help there would be good."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Gary, absolutely fair questions, and we didn't think of that one ahead of time, and we don't want to establish -- on one hand, we don't want to establish new precedent for disclosing things. And on the other hand, we don't want to keep you from being able",98,"Gary, absolutely fair questions, and we didn't think of that one ahead of time, and we don't want to establish -- on one hand, we don't want to establish new precedent for disclosing things. And on the other hand, we don't want to keep you from being able to take care of your model. So why don't you just -- we'll work on it. And so everybody who does a follow-up call, can figure out what we can say or not say about the Arizona particulars. But for us to do it spontaneously is a little too nerve-racking."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. On commercial mix, improved about 100 basis points last year, I believe, and I did note the revenue per treatment growth slowed this quarter year-over-year. So I didn't hear you call anything out. So I'm presuming you're just comping that growth of",62,"Okay. On commercial mix, improved about 100 basis points last year, I believe, and I did note the revenue per treatment growth slowed this quarter year-over-year. So I didn't hear you call anything out. So I'm presuming you're just comping that growth of commercial mix. And were we right to think that maybe commercial mix is pretty stable year-over-year? Is it down?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","This is Javier again. So I think you're alluding 2014. We disclosed 10% and revenue per treatment was $342 million. In 2015, we disclosed 11%; revenue, $348 million. As you saw, we're at $351 million. We haven't disclosed mix. So it's fair to say that's s",50,"This is Javier again. So I think you're alluding 2014. We disclosed 10% and revenue per treatment was $342 million. In 2015, we disclosed 11%; revenue, $348 million. As you saw, we're at $351 million. We haven't disclosed mix. So it's fair to say that's stable with a slight bump."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. On the HCP side question, are any of the rates contractually tied to the health industry fee holiday? In other words, we've heard from some plans that as they get released in '17 and not have to pay this industry fee holiday, some of their capitated",97,"Okay. On the HCP side question, are any of the rates contractually tied to the health industry fee holiday? In other words, we've heard from some plans that as they get released in '17 and not have to pay this industry fee holiday, some of their capitated groups contractually get a bump. Because they effectively had to eat, as you did, some rate cuts over the last few years. So this is effectively a net -- a rate increase to the plans to not have to pay this fee. Will HCP benefit contractually from that in '17?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Again, as it relates to our contracts, there is a -- it's a mixed bag. Some of our contracts will have it flow through, others won't. But in those where it does flow through, there may be some slight pickups there for the onetime period as you know all th",52,"Again, as it relates to our contracts, there is a -- it's a mixed bag. Some of our contracts will have it flow through, others won't. But in those where it does flow through, there may be some slight pickups there for the onetime period as you know all the details around."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","And last question. I believe at Investor Day, you had sized a $25 million Medicare headwind for HCP in '17. And I wonder if there was any update to that. Obviously, we're thinking about potential negative impact of the dual risk core model change in some",75,"And last question. I believe at Investor Day, you had sized a $25 million Medicare headwind for HCP in '17. And I wonder if there was any update to that. Obviously, we're thinking about potential negative impact of the dual risk core model change in some markets but positive in others, and then maybe a little bit of benefit from this industry fee holiday. At this point, is that $25 million still the best number?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","That is still the best number, including all the things you just described.",13,"That is still the best number, including all the things you just described."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Ms. Lisa Clive.",11,"The next question comes from the line of Ms. Lisa Clive."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Three questions. Just the HCP Arizona sale, could you talk through the rationale for that? Second question, just on the write-downs that we've had on HCP over the last few quarters, are we at the bottom here? Or are there potentially more to come? I mean,",88,"Three questions. Just the HCP Arizona sale, could you talk through the rationale for that? Second question, just on the write-downs that we've had on HCP over the last few quarters, are we at the bottom here? Or are there potentially more to come? I mean, obviously, it depends on what your accountants say, but it -- just be helpful to think through that. And then the third question is on the international business, you mentioned a goodwill impairment charge, just wondering what the source of that was."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Let me first start on the Arizona divestiture. In short, we got a good offer that was presented to us. And as we looked at the alternatives the weight that we could invest and deploy our resources for a greater value, we thought it was the right trade-off",65,"Let me first start on the Arizona divestiture. In short, we got a good offer that was presented to us. And as we looked at the alternatives the weight that we could invest and deploy our resources for a greater value, we thought it was the right trade-off. So we decided to accept that offer and divest. Jim, you want to touch on the impairment?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","In regards to the goodwill impairment that we took in the quarter, as we look forward, there is a chance that we will have another impairment if -- as we disclosed in our 10-Q, we have a negative cushion in our Nevada and Florida markets. And there is a v",163,"In regards to the goodwill impairment that we took in the quarter, as we look forward, there is a chance that we will have another impairment if -- as we disclosed in our 10-Q, we have a negative cushion in our Nevada and Florida markets. And there is a very kind of nuanced and detailed accounting rules around impairment accounting. And so when you have a negative cushion, that means that your fair value is less than your book value. And so if there is any further deterioration in performance or in our outlook of those markets, we could see a further impairment. Additionally, the FASB is looking at changing the rules around accounting for goodwill impairments. When they do that, there may be an effect related to the adoption of those new rules. And then the final part of your question was an international impairment. We did have a small international impairment last year, but we did not have one this year."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. Just one follow-up on the Arizona deal. Who did you actually sell to?",14,"Okay. Just one follow-up on the Arizona deal. Who did you actually sell to?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I don't know if we're authorized to say. Does anybody here around the table know for sure? I don't know the contract by heart. So if you could call in and we'll check and know if it's fine. It's also relatively commonly known in the market in case you kno",70,"I don't know if we're authorized to say. Does anybody here around the table know for sure? I don't know the contract by heart. So if you could call in and we'll check and know if it's fine. It's also relatively commonly known in the market in case you know anyone there. But we'd be happy to give the answer once we confirm that we were legally allowed to."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. I was just sort of curious as to what sort of entity would give you a good deal to take it off your hand.",25,"Okay. I was just sort of curious as to what sort of entity would give you a good deal to take it off your hand."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yeah. For us, it was better for us to focus on other markets than that one.",16,"Yeah. For us, it was better for us to focus on other markets than that one."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","We have another question from the line of Ms. Margaret Kaczor.",11,"We have another question from the line of Ms. Margaret Kaczor."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I was hoping to start out with exchange plans. Over the last couple of calls, this has been a popular topic for you guys. But now that we're in August, halfway through the year, are you seeing the regulatory environment improving, stabilizing? Are patient",63,"I was hoping to start out with exchange plans. Over the last couple of calls, this has been a popular topic for you guys. But now that we're in August, halfway through the year, are you seeing the regulatory environment improving, stabilizing? Are patients receiving adequate access to care, especially near term? Any trend data that you guys may have would be helpful."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. We actually don't have any significant change. The patients are receiving great care. And right now, as we stated earlier in the call, there's a lot to be played. So a lot of rules and enforcement is still to be played. But right now, there's nothing",59,"Yes. We actually don't have any significant change. The patients are receiving great care. And right now, as we stated earlier in the call, there's a lot to be played. So a lot of rules and enforcement is still to be played. But right now, there's nothing different to report than what we told you in Capital Markets Day."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think the way I would put it is that the regulatory agencies' capacity to enforce the regulations with respect to exchanges remain weak, either by virtue of lack of motivation because they're worried about the exchange's financial viability or because t",47,"I think the way I would put it is that the regulatory agencies' capacity to enforce the regulations with respect to exchanges remain weak, either by virtue of lack of motivation because they're worried about the exchange's financial viability or because they just don't have the resources."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Is that something that can change at some point in the next 6, 12, 18 months?",16,"Is that something that can change at some point in the next 6, 12, 18 months?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, it could change, and it's likely to change some, but one wouldn't want to pin one's hopes on it changing a lot.",23,"Yes, it could change, and it's likely to change some, but one wouldn't want to pin one's hopes on it changing a lot."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on your international ventures, how is Asia developing and some of these other countries like Saudi Arabia developing? And then how do you compare those businesses versus some of your clinics in Germany, both in terms of patients, investmen",47,"Okay. And then on your international ventures, how is Asia developing and some of these other countries like Saudi Arabia developing? And then how do you compare those businesses versus some of your clinics in Germany, both in terms of patients, investments going forward and profitability profile?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We're in 11 other countries now, and the microeconomics and growth trajectory are different in every one. The good news is that in virtually every one, the microeconomics work at a very reasonable market share position. So even if we're losing money now i",113,"We're in 11 other countries now, and the microeconomics and growth trajectory are different in every one. The good news is that in virtually every one, the microeconomics work at a very reasonable market share position. So even if we're losing money now in a country, just by increasing our scale with the existing achieved microeconomics of our current centers, we know we're on the path to the promise land of, first, being profitable and then second, having an adequate cumulative return. But the differences are quite large. And Germany and Saudi are 2 of our more successful markets from many perspectives, including the microeconomics. But am I getting to your question?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Well, and part of it becomes how do you guys bridge to that profitability gap you talked about at the Capital Markets Day? And what impact and how many years really will it take for China to either be material as well as profitable?",44,"Well, and part of it becomes how do you guys bridge to that profitability gap you talked about at the Capital Markets Day? And what impact and how many years really will it take for China to either be material as well as profitable?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","So ""I don't know"" is the answer with respect to China. That day is almost certainly outside your investment time horizon. And yet the only way to become a leader in China is to get into China and learn it. Very difficult to try to transplant your way in x",180,"So ""I don't know"" is the answer with respect to China. That day is almost certainly outside your investment time horizon. And yet the only way to become a leader in China is to get into China and learn it. Very difficult to try to transplant your way in x years later. In China, we'll probably end up with a few partners is the right way to do it. Just as we concluded in Asia, despite the fact that we were doing well in Southeast Asia, partnering with Khazanah and Mitsui, we thought, was going to help us grow faster and better: everything from helping us recruit more talent, helping us oversee what we have, helping us interact with the government more and the regulators. So in all sorts of ways, we learned important lessons, which should make the next 5 years very different from the last 5. But having said all that, in China, in particular, you want to be very careful before you start talking about any bullish forecast because it is one tough place to do business."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then one last question. We're trying to balance some of the growth within dialysis against some of the other companies we cover. And what we're noticing is some of the acute care demand, at least, for equipment is growing a little bit faster. Yo",82,"Okay. And then one last question. We're trying to balance some of the growth within dialysis against some of the other companies we cover. And what we're noticing is some of the acute care demand, at least, for equipment is growing a little bit faster. You're seeing PD growth a little bit faster. So maybe what are you guys seeing in the field? Are you actually seeing acute care patients improve in PD? And how does that end up benefiting you guys?"
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Margaret, we are seeing our PD grow similarly than our Non-Acquired Growth in in-center, so we're not seeing a disproportionate growth there. And as it relates to our acute business, there's nothing that stands out to our historical trend. So it could be",112,"Margaret, we are seeing our PD grow similarly than our Non-Acquired Growth in in-center, so we're not seeing a disproportionate growth there. And as it relates to our acute business, there's nothing that stands out to our historical trend. So it could be that equipment, of course, is misaligned with services in that equipment could be old or someone decides that they want to do some treatments in their hospital and/or change their staffing ratios. Instead of having a room where they conduct dialysis, they want to go bed to bed in the hospital. So it's really hard to predict the alignment there, but we're not seeing anything different in our business."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","At the moment, speakers, we have no more questions over the phone.",12,"At the moment, speakers, we have no more questions over the phone."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","All right. Thank you very much, everyone, for your interest in DaVita. We'll do our best for you in between now and our next call. Take care.",27,"All right. Thank you very much, everyone, for your interest in DaVita. We'll do our best for you in between now and our next call. Take care."
35644,377729485,1030518,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Thank you all, speakers. So that concludes today's conference. Thank you all for participating. You may now disconnect.",18,"Thank you all, speakers. So that concludes today's conference. Thank you all for participating. You may now disconnect."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you for standing by. [Operator Instructions] Now I will turn the meeting over to one of your hosts, Mr. Jim Gustafson. Sir, you may begin.",28,"Welcome, and thank you for standing by. [Operator Instructions] Now I will turn the meeting over to one of your hosts, Mr. Jim Gustafson. Sir, you may begin."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Joel, and welcome, everyone, to the DaVita HealthCare Partners Second Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Ken",243,"Thank you, Joel, and welcome, everyone, to the DaVita HealthCare Partners Second Quarter 2016 Earnings Conference Call. I appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, the CEO of DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of DaVita Medical Group; Jim Hilger, our Interim CFO and Chief Accounting Officer; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statement. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based upon information currently available to us, and we do not intend and undertake no duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website.
I will now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Jim, and welcome to all. We delivered solid adjusted operating income and strong cash flows in this particular quarter. The total adjusted operating income was $475 million, as many of you have already seen, which were driven by the strong Kidn",388,"Thank you, Jim, and welcome to all. We delivered solid adjusted operating income and strong cash flows in this particular quarter. The total adjusted operating income was $475 million, as many of you have already seen, which were driven by the strong Kidney Care results at $431 million and a disappointing DaVita Medical Group trajectory reflected with $44 million on a non-GAAP basis there. Operating cash flow is another bright spot of $517 million as we continue to successfully convert your earnings into your cash.
We'll discuss several topics here before we get into Q&A. Number one is clinical outcomes; number two is DMG results; number three is U.S. Kidney Care; number four, a little bit of an update on international; and number five is just some additional financial enterprise-level details.
Let's start with clinical outcomes, as we always do. We are, first and foremost, a caregiving company and quite good at it. Now about 185,000 patients in the U.S. alone, about 35% of all dialysis patients in America. One of the areas where we've increased our focus is on reducing bloodstream infections: a very big deal to our patients, a very big deal to their families, a very big deal to the taxpayer. It's important because this keeps patients out of the hospital. Bloodstream infections are one of the top 5 causes of hospitalizations for these patients, and this impacts both QIP and 5-Star. We are now performing blood-culture tests on more than 90% of the situations when a patient is present with signs and symptoms of bloodstream infections. We'll never get to 100, but 90 is remarkably higher than where we were x years ago and where so many dialysis centers are today.
Despite testing a greater percentage of eligible patients, we've actually decreased our bloodstream infection rate by 16% over the last 12 months, and we're working both sides of the equation with tenacity and some success. 
On the DMG side, the DaVita Medical Group, year-to-date, we've outperformed on the focused HEDIS measures that CMS uses to track Medicare advantage clinical quality compared to the same period last year. And as a result, we are on track to achieve greater than 4 stars in all of our plan relationships. For some more detail on the DaVita Medical Group, I turn it over to Vijay Kotte."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent. Turning to this quarter's performance, operating income was $44 million, excluding non-GAAP items as detailed in our earnings release. Unfortunately, year-to-date, we have financially underperformed relative to plan, and we expect this gap t",358,"Thanks, Kent. Turning to this quarter's performance, operating income was $44 million, excluding non-GAAP items as detailed in our earnings release. Unfortunately, year-to-date, we have financially underperformed relative to plan, and we expect this gap to increase in the second half of the year. As a result, we are lowering our 2016 full year guidance to $110 million to $150 million. The decrease in guidance has 4 primary drivers: fee for service growth, Medicare Advantage growth, and rebranding effort. To provide a little more color, let me walk you through those.
First, our fee-for-service revenue growth has not met our expectations. Our target was 6% year-over-year, but we're achieving 3%. Second, we made a mistake forecasting 2016 operating profit by overestimating expected reconciliation payments for prior year Medicare Advantage revenue. Third, while our in-year Medicare Advantage membership growth has been in line with broader enrollment trends in the geographies we operate in, it is lower than we've previously expected. Fourth, as we stated on our last call, we are rebranding from Healthcare Partners to the DaVita Medical Group. To accomplish this, we expect to spend $5 million to $10 million this year that wasn't previously included in our forecast. In addition, we will need to accelerate the noncash amortization of $110 million worth of existing trademark intangibles associated with the legacy Healthcare Partners brand. This accelerated amortization has been excluded from our revised 2016 and long-term guidance. Despite these disappointments, we are making good progress on the key items we identified at Capital Markets.
In terms of fee for service to value conversion, we are progressing in contracting discussions with health plan while developing value-based care capabilities in our newer markets. Additionally, we continue to invest in the business, which we believe will fuel our long-term success. One example is our investment in 7 new de novo clinics, which are a capital-efficient growth platform similar to what you are used to seeing in Kidney Care.
Finally, as we look towards our long-term outlook, our 2019 OI target remains $250 million.
Now I will turn it over to Javier Rodriguez to speak a little bit more about Kidney Care."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thank you, Vijay, and hello, everyone. Before I talk about the quarter, I'd like to highlight a recent development that we're very excited about. At our Capital Markets Day, we talked about the powerful benefits of integrated care for chronic populations,",436,"Thank you, Vijay, and hello, everyone. Before I talk about the quarter, I'd like to highlight a recent development that we're very excited about. At our Capital Markets Day, we talked about the powerful benefits of integrated care for chronic populations, including our own ESRD patients. Since then, 2 new pieces of legislation that are supported by the dialysis community have been introduced in Congress. 
The first is called the Dialysis PATIENT Demonstration Act, and that provides for true integrated care model for kidney care patients. The second is called the ESRD Choice Act of 2016, and that would finally allow for ESRD patients to enroll in MA plans. Both of these acts would be a great gift to ESRD patients and play to our long-term strategy of integrated care.
We're hopeful about their prospects in Congress due to the strong bipartisan support, and we will continue to work hard to pursue integrated care for our patients. 
Now on to our quarterly results. Overall, DaVita Kidney Care had a strong and reasonably straightforward quarter, so I won't go into much detail here. As Kent said, we delivered strong operating income of $431 million due to a slight improvement in revenue per treatment over Q1 as well as a slight reduction in costs for treatment. With respect to growth, our normalized Non-Acquired growth for the quarter was 4.3%, which falls within our long-term target range of 3.5% to 4.5%.
With the first half of the year now behind us, we're raising the bottom end of our 2016 guidance range by $50 million. This is consistent with our comments from last quarter that we're more likely to be in the top half of our original guidance. With this change, our new Kidney Care operating income guidance for 2016 is now $1.675 billion to $1.725 billion. As for next year, we plan to provide 2017 guidance during our fourth quarter earnings call. We made this change last year because ACA plans have become a more meaningful part of our commercial mix. This has added some new drivers of upside and downside to our business and our industry as well as some seasonality. Providing guidance on our fourth quarter call allows us to incorporate the additional visibility we gained during open enrollment period.
Before I turn it back to KT, I want to close by saying we remain excited about the fundamentals of our business, the gradual shift toward integrated care, and the fact that our teammates are recognized for providing the best outcomes and quality of life for kidney patients.
Now back to Kent to discuss our international business."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, JR. International losses, $13 million in the quarter, which is pretty much in line with our guidance for approximately $40 million in losses on the full year. We continue to maintain what we told you, oh, I think about a year ago that we",201,"Okay. Thank you, JR. International losses, $13 million in the quarter, which is pretty much in line with our guidance for approximately $40 million in losses on the full year. We continue to maintain what we told you, oh, I think about a year ago that we committed to try to achieve breakeven by 2018 in our current market portfolio, excluding any new countries, and we're standing by that. And a number of you probably saw that we did, in fact, close the transaction that we had to announce 4 to 5 to 6 weeks ago, that being our JV transaction with Khazanah and Mitsui on August 1. 
Just to refresh your memory, Khazanah and Mitsui have each subscribed to acquire 20% share of ownership over time. At the closing, each provided $50 million of funding to the JV in return for each receiving a 6.7% stake. We're excited to have them as partners. We have a very long-term point of view about the opportunity in that part of the world as do they, and we think they're going to help us accelerate and deepen our growth.
Now I'll turn it over to Jim Hilger to cover some more enterprise financials."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Thanks, Kent, and just a little more about our Asia Pacific joint venture. In regards to the JV with Khazanah and Mitsui, please note that we expect that this joint venture will be deconsolidated from our financials and thus, future operating results will",464,"Thanks, Kent, and just a little more about our Asia Pacific joint venture. In regards to the JV with Khazanah and Mitsui, please note that we expect that this joint venture will be deconsolidated from our financials and thus, future operating results will run through equity investment income for our pro rata share of ownership in the joint venture. Please note that we expect to record a material noncash onetime gain in connection with the formation of this JV, and this gain is excluded from our guidance.
Now onto the overall enterprise. Our debt expense was $103 million in the second quarter, consistent with recent quarters. Next, the effective tax rate attributable to DaVita HealthCare Partners was 37.2% in the quarter when adjusted for the nondeductible goodwill impairment charge and recognition of a state income tax benefit. We expect the full year effective tax rate attributable to DaVita HealthCare Partners on our adjusted income for 2016 to be in the range of 39% to 40%.
Now turning to cash flow. We continue to generate strong cash flows. Operating cash flow was $517 million in the quarter and $2.06 billion for the last 12 months. The last 12 months benefited from the timing of tax payments. We expect full year 2016 operating cash flow to be between $1.6 billion and $1.75 billion.
One thing to keep in mind when thinking about the cash flows of our individual operating segments is that DMG generates a disproportionately higher share of our cash flows than its share of our adjusted operating income. While the midpoint of our DMG guidance for adjusted operating income is $130 million, the business has a year-to-date annual run rate of $200 million in noncash depreciation and amortization expense. In addition, as you will recall, there is a cash tax reduction of approximately $100 million per year, which is the equivalent to $167 million improvement in pretax operating income. This cash tax benefit is due to the tax basis step-up created when we acquired the medical group.
And finally, as the vast majority of DMG's business is capitated care, where we are paid before incurring expenses, it has favorable cash flow characteristics with low to negative working capital. Thus, DMG contributes more to our operating cash flows than is first apparent when looking at operating income.
We continue to have a very strong cash balance with $1.68 billion in cash and short-term investments as of June 30. We continue to weigh capital deployment opportunities across growth investment, share repurchases, debt repayment and holding cash. Additionally, as disclosed in our earnings release, our Board of Directors just increased our share repurchase authorization from the remaining $259 million to now $1.5 billion. 
And with that, I will now turn the call back over to Kent Thiry."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I'll just make a few summary comments before we go to Q&A. Number one, with the DaVita Medical Group, we're certainly sorry that we had to reduce the guidance, and the fact that it will take even more time to get it to where we think we can be regularly g",199,"I'll just make a few summary comments before we go to Q&A. Number one, with the DaVita Medical Group, we're certainly sorry that we had to reduce the guidance, and the fact that it will take even more time to get it to where we think we can be regularly growing earnings. And that's what we're intensely intent on doing, but it will take some time. Number two, DaVita Kidney Care, wonderfully solid results yet again, probably even better than that. At the same time, as JR has talked about recently, we could have some choppiness at the high levels. And we are maniacally continuing to invest in becoming even more differentiated than we are today in quality, in service, in physician experience, in IT, et cetera. Third of four is the cash flow. Your cash flow continues to be a powerful weapon to be deployed in your defense and on offense. And lastly, fourth, we continue to have a lot of belief in our overall business platform, everything from our geographic footprint to our capabilities by function, et cetera, et cetera.
So thank you all very much and, Joel, could you please open it up for Q&A?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] So we have the first question from the line of Mr. Chris Rigg.",15,"[Operator Instructions] So we have the first question from the line of Mr. Chris Rigg."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Wanted to ask about DMG here. I guess, just with regard to the fee-for-service revenue only growing at 3% versus 6%, is that tied to The Everett Clinic? Or is that something completely different?",34,"Wanted to ask about DMG here. I guess, just with regard to the fee-for-service revenue only growing at 3% versus 6%, is that tied to The Everett Clinic? Or is that something completely different?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's pretty much across the board, although, of course, The Everett Clinic is the biggest single source. But we're just a little bit soft in a number of different areas, and the good news or bad news, depending on how you look at it, is we can operate som",91,"It's pretty much across the board, although, of course, The Everett Clinic is the biggest single source. But we're just a little bit soft in a number of different areas, and the good news or bad news, depending on how you look at it, is we can operate some parts of that much better outside of The Everett Clinic. And within The Everett Clinic, which operates so excellently, they had kind of an uncharacteristic stumble. And so it's a mix of all of our fee-for-service locations, nothing really jumping out."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, just a little bit forward thinking on the ESRD Choice legislation that you guys highlighted. I mean, how would that at least at a high level, work, in your guys' opinion? Would you get better rates from the MA plans than you currently get",60,"Okay. And then, just a little bit forward thinking on the ESRD Choice legislation that you guys highlighted. I mean, how would that at least at a high level, work, in your guys' opinion? Would you get better rates from the MA plans than you currently get on the fee-for-service side? Is that the right way to think about it?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","There's a couple of ways about it, and I'll chime in, this is Javier. And then, LeAnne, if you want to supplement. The main thing is that the lives would be attributed to the dialysis clinic. And so therefore, the dialysis clinic would become the medical",112,"There's a couple of ways about it, and I'll chime in, this is Javier. And then, LeAnne, if you want to supplement. The main thing is that the lives would be attributed to the dialysis clinic. And so therefore, the dialysis clinic would become the medical home, sort of de facto medical home because we'd have the patient for 12 hours. The other important thing is that on the revenue side, instead of having a benchmark, which is a little of a black box thing, and you get a number, it would be linked to MA. And so the revenues would be a lot more predictable. Does that answer your question?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes.",1,"Yes."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. Matthew Borsch.",11,"The next question comes from the line of Mr. Matthew Borsch."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","This is Tejus Ujjani on for Matt. There's been some recent articles about insurers focusing on third-party payments from charities like American Kidney Fund and even across other subsectors as well. I think it's been a long-standing practice for dialysis",74,"This is Tejus Ujjani on for Matt. There's been some recent articles about insurers focusing on third-party payments from charities like American Kidney Fund and even across other subsectors as well. I think it's been a long-standing practice for dialysis companies to donate to these charities. But for those of us less familiar, can you provide some color on how AKF fits into your overall strategy? And any dynamics at play regarding increased focus?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Before we do that, before Javier does that, this is KT just coming back again, I want to make sure we covered all aspects of the previous questioner's question. And in general, we do get paid more for an MA dialysis patient than a Medicare fee-for-service",144,"Before we do that, before Javier does that, this is KT just coming back again, I want to make sure we covered all aspects of the previous questioner's question. And in general, we do get paid more for an MA dialysis patient than a Medicare fee-for-service patient. This is totally intuitively to be expected because if you have MA risk, if you're an MA plan, you care a lot more about aggregate integrated care because you're at risk on the entire expense for the patient. And so coming to us where you get some of what we provide and therefore, lower hospitalizations and happier repeat patients/customers, it is natural that given our more robust value proposition, that the payer pays us more and in fact, is happier than they would be paying less for fee-for-service type service. Now on to the next question. Javier?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure, Matthew (sic) [ Tejus ]. Thank you for the question. First of all, it's probably worth stepping back and reviewing level setting here. We believe that it is vital for patients of all different disease states to have premium assistance. It is a criti",161,"Sure, Matthew (sic) [ Tejus ]. Thank you for the question. First of all, it's probably worth stepping back and reviewing level setting here. We believe that it is vital for patients of all different disease states to have premium assistance. It is a critical part of our health care system and has been so for decades. And of course, we got to have appropriate rules. So those need to be reviewed periodically. In Kidney Care, we have been donating, and so have all other providers, to help patients with end-stage renal disease for decades in order to be assisted with their premiums. The OIG has reviewed that framework more than once and actually just did it over a year ago or so. And so that framework has been vetted and of course, we have to make sure that we all stay and abide by the rules that were outlined by the OIG. Did I get to what you were going..."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes. That was very helpful. And just a quick kind of follow-up modeling question. For the D&A in the quarter, it looks like there's an uptick there. Was that associated with the accelerated amortization from the rebranding?",37,"Yes. That was very helpful. And just a quick kind of follow-up modeling question. For the D&A in the quarter, it looks like there's an uptick there. Was that associated with the accelerated amortization from the rebranding?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","No, it was not. We have not started the acceleration. That's a forward-looking event, but we will keep you informed about that matter as we determine the final amortization periods.",30,"No, it was not. We have not started the acceleration. That's a forward-looking event, but we will keep you informed about that matter as we determine the final amortization periods."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","But perhaps we can explain...",6,"But perhaps we can explain..."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. Can you comment on the uptick though?",8,"Okay. Can you comment on the uptick though?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Why don't you give us...",6,"Why don't you give us..."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's primarily -- excuse me, it's primarily The Everett Clinic.",11,"It's primarily -- excuse me, it's primarily The Everett Clinic."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","And so we'll check and if there's any answer that should be appended to, primarily, The Everett Clinic. We'll get it back out in the next 5, 10 minutes. But next one please, Joel?",35,"And so we'll check and if there's any answer that should be appended to, primarily, The Everett Clinic. We'll get it back out in the next 5, 10 minutes. But next one please, Joel?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. Kevin Fischbeck.",11,"The next question comes from the line of Mr. Kevin Fischbeck."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","This is actually Joanna Gajuk filling in for Kevin. So question here on the transaction that you announced with Tandigm or rather selling a portion of it. So the question here is who did you sell the interest to? And the question, since we're at the start",77,"This is actually Joanna Gajuk filling in for Kevin. So question here on the transaction that you announced with Tandigm or rather selling a portion of it. So the question here is who did you sell the interest to? And the question, since we're at the start of it [ph], we would like to know whether this was a strategic player maybe who could potentially help save money there? Or was it purely done for financial reasons?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","On Tandigm, what we did is sold a part of our stake back to IBC, Independence Blue Cross, who has been our partner in Tandigm since day one. And what both sides agreed was to do this in order to create more alignment between IBC and Tandigm. Otherwise, we",132,"On Tandigm, what we did is sold a part of our stake back to IBC, Independence Blue Cross, who has been our partner in Tandigm since day one. And what both sides agreed was to do this in order to create more alignment between IBC and Tandigm. Otherwise, we were in a situation where IBC got 100% of the profits in their non-Tandigm business, only 50% in the Tandigm part of the business. And this lack of alignment was getting in the way of some of the glass breaking that needed to go on in order to move the entire organization forward. And so we agreed to be bought out in part to get that alignment. And who knows, perhaps, we'll get to go back up to a higher percentage over time."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. That's helpful. And staying a little bit on that front and specifically on the reduction in, I guess, outlook for operating income for that part of the business, HCP or DaVita Medical Group. And so specifically, how should we think about this reduct",108,"Okay. That's helpful. And staying a little bit on that front and specifically on the reduction in, I guess, outlook for operating income for that part of the business, HCP or DaVita Medical Group. And so specifically, how should we think about this reduction as it relates to the sale in the space and also the exit in Arizona market? So is that -- the guidance changed to reflect those 2 things? Or there's a change to core performance as well? And then, if it is, then if you could please quantify the 2 different sort of buckets, the asset sales versus the core performance of the business?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Okay, I'm going to turn that to Vijay. There was a part on Arizona, and then perhaps the relationship of Arizona with Tandigm and then core performance, separate from those 2, if I heard correctly. Were those the 3 parts, please?",41,"Okay, I'm going to turn that to Vijay. There was a part on Arizona, and then perhaps the relationship of Arizona with Tandigm and then core performance, separate from those 2, if I heard correctly. Were those the 3 parts, please?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Yes, exactly. Yes.",3,"Yes, exactly. Yes."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","So Joanna, I think the first question was related to does the guidance change, is that reflective -- or is that driven by the change in ownership in Arizona and in Tandigm? Though it is incorporated, it is not a driving component. The 4 items that we call",62,"So Joanna, I think the first question was related to does the guidance change, is that reflective -- or is that driven by the change in ownership in Arizona and in Tandigm? Though it is incorporated, it is not a driving component. The 4 items that we called out are the primary factors that are changing our guidance expectations for the year."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","So is there a way to quantify those? I've heard you said $5 million to $6 million of these additional costs are from rebranding. So I guess, there are other, I guess, the other delta. The other part of the delta is the reporting included in [ph] fee-for-s",51,"So is there a way to quantify those? I've heard you said $5 million to $6 million of these additional costs are from rebranding. So I guess, there are other, I guess, the other delta. The other part of the delta is the reporting included in [ph] fee-for-service in MA, right?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, one is the fee-for-service growth being only 3% versus our expected 6%, and then the in-year MA growth and then the mistake in our estimate on the prior year revenue reconciliation amount.",33,"Yes, one is the fee-for-service growth being only 3% versus our expected 6%, and then the in-year MA growth and then the mistake in our estimate on the prior year revenue reconciliation amount."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","But is there a way to sort of add up those 4 things versus the change in -- coming from the sale of Tandigm and Arizona?",26,"But is there a way to sort of add up those 4 things versus the change in -- coming from the sale of Tandigm and Arizona?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I would...",3,"I would..."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think -- let me take a stab at the answer to the question I think you're asking. Those 4 factors explain the change in guidance. And the Tandigm and Arizona transactions had little to no impact on go-forward guidance.",40,"I think -- let me take a stab at the answer to the question I think you're asking. Those 4 factors explain the change in guidance. And the Tandigm and Arizona transactions had little to no impact on go-forward guidance."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","So the next question comes from the line of Mr. Gary Lieberman.",12,"So the next question comes from the line of Mr. Gary Lieberman."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I guess, maybe to stay with that last question for a second. Is it possible to break out those 4 components to put a dollar number on each one of those for the impact? Because it was a fairly large change to the guidance.",44,"I guess, maybe to stay with that last question for a second. Is it possible to break out those 4 components to put a dollar number on each one of those for the impact? Because it was a fairly large change to the guidance."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. I think all 4 are pretty significant meaty parts of it, and we're not going to attribute a dollar to each one individually, but each one is significant.",29,"Yes. I think all 4 are pretty significant meaty parts of it, and we're not going to attribute a dollar to each one individually, but each one is significant."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, I guess, maybe just going back to the explanation for the sale of Tandigm. Could you just walk us through that? In other words, it wasn't entirely clear kind of exactly what the driver was there.",39,"Okay. And then, I guess, maybe just going back to the explanation for the sale of Tandigm. Could you just walk us through that? In other words, it wasn't entirely clear kind of exactly what the driver was there."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure, I can. In establishing Tandigm, where you know that IBC and DaVita together stood up a 100,000-member at-risk HMO, essentially, in a year. So an exceptionally aggressive implementation. It is necessary for us to work for a lot of the home department",195,"Sure, I can. In establishing Tandigm, where you know that IBC and DaVita together stood up a 100,000-member at-risk HMO, essentially, in a year. So an exceptionally aggressive implementation. It is necessary for us to work for a lot of the home departments within IBC and also to be negotiating with the same hospitals that IBC is negotiating with for their other products. And what we found is some IBC teammates, as you would rationally expect, say, ""Hey, an extra dollar of hospital rate relief goes 100% to IBC if I put it in this product, negotiated for here, and only 50% if I negotiate for it there."" Now the fact is those perceptions are going to change over time because of the offensive potential of Tandigm, and because more and more IBC people are becoming a part of Tandigm. But in the meantime, rather than try to deal with some of that understandable organizational friction, we said the simplest way to deal with it in the near term is to let us be bought down, and so all of IBC could see that they had a significant majority of the profits in either case."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then you mentioned the opportunity to potentially increase your ownership stake back up. How would that work?",19,"Okay. And then you mentioned the opportunity to potentially increase your ownership stake back up. How would that work?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Correct. Without going into a lot of detail, we have some rights with respect to buying back up to our prior position.",22,"Correct. Without going into a lot of detail, we have some rights with respect to buying back up to our prior position."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. So you're still committed to Tandigm? And it's going well compared to when you initially did the deal? Or how would you characterize that?",25,"Okay. So you're still committed to Tandigm? And it's going well compared to when you initially did the deal? Or how would you characterize that?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We're still committed to Tandigm. On the doing well, I kind of hate saying yes or no to something like that. It's a young company. We're making progress every quarter. If you hit plan, then it sounds like you're doing well, but it could have been you made",169,"We're still committed to Tandigm. On the doing well, I kind of hate saying yes or no to something like that. It's a young company. We're making progress every quarter. If you hit plan, then it sounds like you're doing well, but it could have been you made too soft a plan. If you're missing it, it can sound like you're doing poorly, but it could have been you set a good aggressive plan or had a little bad luck. And so all I can say is that we're a lot better today than we were 4 months ago. We were better 4 months ago than 8 months ago. We've got some new executives onboard. And so we're feeling pretty darn good. But we also set out to do something that really hasn't been done very often, and so we just don't have a lot of illusions about skipping up the mountain. We know we're never going to skin our knees a couple of times on the way."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe turning towards the comments by some of the managed care companies this quarter regarding the premiums from the American Kidney Fund. It sounds like some of them may actually be talking to state insurance commissioners or pushing back",74,"Okay. And then maybe turning towards the comments by some of the managed care companies this quarter regarding the premiums from the American Kidney Fund. It sounds like some of them may actually be talking to state insurance commissioners or pushing back in other ways to maybe get out of taking those premiums. Can you talk about any conversations that you've had or your thoughts, generally speaking, about how any of this might transpire?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure Gary, this is Javier. And again, it's probably useful to step back a bit. And so in a world right now where in 2014, the exchanges came into play, we've heard so much about the risk pools and how they're not well-funded. And so a new product comes in",277,"Sure Gary, this is Javier. And again, it's probably useful to step back a bit. And so in a world right now where in 2014, the exchanges came into play, we've heard so much about the risk pools and how they're not well-funded. And so a new product comes into market, our dialysis patients and our social workers work really hard to make sure that they explain and understand their new product. And at that time, the patient and the patient alone makes a decision on what's right for them. As you know, many of the chronic and high-cost disease states have caused these risk pools to be challenging to the payers. I think that they've -- in some instances, have highlighted ESRD expense, but the reality is that it's pretty much all chronic diseases. So CMS is evaluating third-party premium assistance to see what their stance is, but it's complicated around the health care continuum. And so right now, they're evaluating because the last thing they want to do is use a broad brush and then have consequences on one disease state versus another. So right now, what's going on is that in every state, people are trying to lobby to get one thing or another. What we have found is that regulators, once they really hear our patients' needs, and what they literally need is choice, they're quite sympathetic to the cause. And so it will play out state by state. And of course, the patients and ourselves will do the best we can to make sure that they have rights to these products regardless of the fact that they end up being expensive patients."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's very helpful. And then maybe final question just on staying on the Kidney Care front. It looks like patient care cost for treatment was down marginally in the quarter. Any changes specifically on use of drugs? And then to the extent that you guys a",64,"That's very helpful. And then maybe final question just on staying on the Kidney Care front. It looks like patient care cost for treatment was down marginally in the quarter. Any changes specifically on use of drugs? And then to the extent that you guys are willing to comment on any negotiations or conversations with alternative providers of ESA or your current supplier?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Gary, no big change on the utilization of meds, and there's nothing new to update. The negotiations continue, and all the dynamics that we've explained before are the same.",29,"Gary, no big change on the utilization of meds, and there's nothing new to update. The negotiations continue, and all the dynamics that we've explained before are the same."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Mr. John Ransom.",11,"The next question comes from the line of Mr. John Ransom."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","A couple of things. Kent, let's kind of step back and think big picture on HCP, HealthCare Partners, now renamed. You've been in this for 4 years. Clearly, the numbers haven't been what we all hoped they would be. How much of that do you attribute to stru",102,"A couple of things. Kent, let's kind of step back and think big picture on HCP, HealthCare Partners, now renamed. You've been in this for 4 years. Clearly, the numbers haven't been what we all hoped they would be. How much of that do you attribute to structural factors? And what I would say about that is maybe not as many markets were ready for this revolution as we thought. Or secondly, how much of it do you say, ""Well, gosh, maybe we didn't execute as well as we thought have -- thought we could have."" If it's possible to do that?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, it's a very fair point. Maybe I'd refer to sort of 4 chapters. Chapter 1 was huge reimbursement cut: $200 million of OI lost because HealthCare Partners was more adept than others at capturing acuity codes, which we knew going in but didn't anticipat",322,"Yes, it's a very fair point. Maybe I'd refer to sort of 4 chapters. Chapter 1 was huge reimbursement cut: $200 million of OI lost because HealthCare Partners was more adept than others at capturing acuity codes, which we knew going in but didn't anticipate the dramatic change in policy. We knew there would be some softening there and some compression. And we knew it wouldn't be small, but we did not expect it would happen so much and so quickly, and therefore, we own that. So chapter 1 was breathtaking reimbursement cuts, $200 million annually. Chapter 2 was pretty much total displacement of the leadership. California, Nevada, Florida, the 3 markets, essentially, a 100% change. And that took time. And of course, while you're doing it, it does get in the way of things getting done, and it does create some transitional trauma. Chapter 3 is bring in the new infrastructure. You can buy the house on the best lot with the best architectural bones, but if it needs new heating, ventilating, air conditioning, you got a lot of work to do. It doesn't really start showing up until it's done, but it makes a hell of a difference as to the experience of going inside. And so that's the chapter we're in the midst of right now. Chapter 4 is the one we're just starting to feel in some places where we're bringing a new level of operating excellence, a new level of innovation and an enhanced value proposition, new levels of creativity in contracting. But these are just little saplings breaking through the surface right now. The good news is they're there, and we're ready to take care of them. So I would divide the world into 4 chapters, and then I would offer up my empathy for the fact that so many of you shareholders have had to live through the excruciating burden of chapters 1 through 3."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","That's a great answer. And I have a follow-up for Javier. I mean, just to push back a little bit on this foundation issue. I mean, these patients will be covered by Medicare. It's not as though they would be bereft to health insurance or -- and I think I'",178,"That's a great answer. And I have a follow-up for Javier. I mean, just to push back a little bit on this foundation issue. I mean, these patients will be covered by Medicare. It's not as though they would be bereft to health insurance or -- and I think I've read 5,500 or so patients are now on the exchanges being paid for by the foundations. I mean, aren't you arguing that UnitedHealthcare and Anthem should take, I don't know, $5,000, $10,000 in premium and have a care cost of over $100,000? I mean, how can we make that argument to these plans when they could be covered under the public plans? That's -- and I would assume you guys have your proportional share of the 5,500. So just stepping back from kind of a public policy standpoint, how do you -- at a time when the plans are losing money in the exchanges, how do you argue to them that they should cover people that could be covered for a fraction of the cost under Medicare?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, a couple of things. If you're on Medicare, you're not eligible to go on the exchange, and so that is the benefit that you have. For the patient that switched, I don't know if the number you cited is right or not. We haven't disclosed those numbers. I",132,"Yes, a couple of things. If you're on Medicare, you're not eligible to go on the exchange, and so that is the benefit that you have. For the patient that switched, I don't know if the number you cited is right or not. We haven't disclosed those numbers. It is a very personal decision that is based on access to specialists, drugs and other things. So the patients actually do get differentiated care. And so the reality of this thing is that the system set it up for individuals to make a choice as to what their best coverage is. And so patients made that choice, and it's a very personal decision that I can't decide whether that's right or wrong for the system but rather, they get to make the choice."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","One might well also ask the question, how appropriate it is for plans to make multiple times the magnitude of profit on MA patients that all the providers in America do combined? That might be another philosophical question to ask. The fact is it gets so",184,"One might well also ask the question, how appropriate it is for plans to make multiple times the magnitude of profit on MA patients that all the providers in America do combined? That might be another philosophical question to ask. The fact is it gets so interesting. There's pockets of profitability within health care and then you have pockets of loss. For example, for us, about 80% of our patients are Medicare fee-for-service and we lose money on every one of them. It really doesn't make any sense. And so you end up having to kind of think of it as an ecosystem where the plans have what might look like excessive margin somewhere and then have losses elsewhere, where we take care of some patients at an absolute significant and unambiguous loss and in other cases have higher margins than you expect us to. So you sort of have to end up looking at it as an ecosystem and see if any one part of it is getting out of balance because it's hard to get each individual part of it exactly right."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","We have another question from the line of Mr. Whit Mayo.",11,"We have another question from the line of Mr. Whit Mayo."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Maybe I missed this, but can you go back to the prior year revenue headwind within DMG and -- or DMG? Was that prior-year issue in the quarter? Or is this something that you expect to hit in the second half?",41,"Maybe I missed this, but can you go back to the prior year revenue headwind within DMG and -- or DMG? Was that prior-year issue in the quarter? Or is this something that you expect to hit in the second half?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It was something that we expected to receive and recognize in the second half of the year.",17,"It was something that we expected to receive and recognize in the second half of the year."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Maybe just help us understand the process around identifying and truing up those claims and what specifically this is?",19,"Maybe just help us understand the process around identifying and truing up those claims and what specifically this is?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","This is not related to claims. This is about revenue and the kind of finalization of revenue with CMS. And we typically bring that in on a cash basis in the second part of the year, and our estimate of that was higher than what we now believe that amount",60,"This is not related to claims. This is about revenue and the kind of finalization of revenue with CMS. And we typically bring that in on a cash basis in the second part of the year, and our estimate of that was higher than what we now believe that amount to be that we will receive in the back half."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then, if you just look at the 4 buckets that you've outlined, I guess, the sources of underperformance, if you will, within the DaVita Medical Group. The rebranding doesn't seem to be an issue that's probably going to recur into 2017, maybe it d",87,"Okay. And then, if you just look at the 4 buckets that you've outlined, I guess, the sources of underperformance, if you will, within the DaVita Medical Group. The rebranding doesn't seem to be an issue that's probably going to recur into 2017, maybe it does to some extent. The prior year revenue, this stuff happens, but I would imagine that's probably something that doesn't recur next year. So how much of the guide down would you call to be -- would be more from transient factors?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think the way you're thinking about it is about right. And I -- we don't want to go any further into what 2017 would look like, but I think the way you're thinking about it is right.",39,"I think the way you're thinking about it is about right. And I -- we don't want to go any further into what 2017 would look like, but I think the way you're thinking about it is right."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I'll go a tad further than that because you're right on the mistake we made in forecasting and fortunately caught it before we were into that forecasted period. We certainly hope that, that doesn't recur. We, like everyone else, hope that MA enrollment gr",154,"I'll go a tad further than that because you're right on the mistake we made in forecasting and fortunately caught it before we were into that forecasted period. We certainly hope that, that doesn't recur. We, like everyone else, hope that MA enrollment growth is higher the next couple of years than the last couple. That's not entirely under our control, of course. It depends on what government policy comes out in terms of rates to a great extent. We're working hard to nudge up that fee-for-service growth, so we don't want that to be recurring, and we don't expect it to be recurring in the long run. But we don't know how quickly we're going to be able to either bump it up or take out some of the expenses associated with not having higher growth. And I'm missing the fourth one, but I think you also nailed that one. Enough said."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And maybe just remind us, Renal Ventures, is this included in your guidance at this point? And it feels like maybe this deal is taking a little bit longer than maybe we anticipated. Just an update with the timing of that.",42,"Okay. And maybe just remind us, Renal Ventures, is this included in your guidance at this point? And it feels like maybe this deal is taking a little bit longer than maybe we anticipated. Just an update with the timing of that."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Sure. The answer to the first question is it is not included. As to the timing, we are equally as frustrated and are moving as quickly as we can. We anticipate back-end of fourth quarter closing as of now but as you know, that is a moving target.",48,"Sure. The answer to the first question is it is not included. As to the timing, we are equally as frustrated and are moving as quickly as we can. We anticipate back-end of fourth quarter closing as of now but as you know, that is a moving target."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Got it. Any specific reason that -- just for the hold up on the deal? Or is this just one of those things that's out of everyone's control?",28,"Got it. Any specific reason that -- just for the hold up on the deal? Or is this just one of those things that's out of everyone's control?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","It's normal process, but slow for -- I tell you it's just the normal process, but it just gone slow, it seems, at every step of the process.",29,"It's normal process, but slow for -- I tell you it's just the normal process, but it just gone slow, it seems, at every step of the process."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Our next question comes from the line of Mr. Gary Taylor.",11,"Our next question comes from the line of Mr. Gary Taylor."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","A couple of questions. First on California -- California, I'm sorry -- the Arizona divestiture. Will that close in the third quarter?",22,"A couple of questions. First on California -- California, I'm sorry -- the Arizona divestiture. Will that close in the third quarter?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","That was already -- that closed within Q2.",8,"That was already -- that closed within Q2."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","So it's included in the cash flow statement proceeds for 6 months, which is not very much. Can you just remind us then of, in that market, what the revenue model was in the membership?",36,"So it's included in the cash flow statement proceeds for 6 months, which is not very much. Can you just remind us then of, in that market, what the revenue model was in the membership?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We don't typically disclose our numbers on a market basis, so I'd refrain from giving you that level of detail. Is there more specific question you can ask?",29,"We don't typically disclose our numbers on a market basis, so I'd refrain from giving you that level of detail. Is there more specific question you can ask?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Well, I guess, I'm trying to understand what it was you sold and who you sold it to and what the revenues come out for HCP? Obviously, you said it won't have much impact on operating income. So apparently, it wasn't that profitable. But we do need to mode",62,"Well, I guess, I'm trying to understand what it was you sold and who you sold it to and what the revenues come out for HCP? Obviously, you said it won't have much impact on operating income. So apparently, it wasn't that profitable. But we do need to model HCP revenues on a go-forward basis, so any help there would be good."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Gary, absolutely fair questions, and we didn't think of that one ahead of time, and we don't want to establish -- on one hand, we don't want to establish new precedent for disclosing things. And on the other hand, we don't want to keep you from being able",98,"Gary, absolutely fair questions, and we didn't think of that one ahead of time, and we don't want to establish -- on one hand, we don't want to establish new precedent for disclosing things. And on the other hand, we don't want to keep you from being able to take care of your model. So why don't you just -- we'll work on it. And so everybody who does a follow-up call, can figure out what we can say or not say about the Arizona particulars. But for us to do it spontaneously is a little too nerve-racking."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. On commercial mix, improved about 100 basis points last year, I believe, and I did note the revenue per treatment growth slowed this quarter year-over-year. So I didn't hear you call anything out. So I'm presuming you're just comping that growth of",62,"Okay. On commercial mix, improved about 100 basis points last year, I believe, and I did note the revenue per treatment growth slowed this quarter year-over-year. So I didn't hear you call anything out. So I'm presuming you're just comping that growth of commercial mix. And were we right to think that maybe commercial mix is pretty stable year-over-year? Is it down?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","This is Javier again. So I think you're alluding 2014. We disclosed 10% and revenue per treatment was $342 million. In 2015, we disclosed 11%; revenue, $348 million. As you saw, we're at $351 million. We haven't disclosed mix. So it's fair to say that's s",50,"This is Javier again. So I think you're alluding 2014. We disclosed 10% and revenue per treatment was $342 million. In 2015, we disclosed 11%; revenue, $348 million. As you saw, we're at $351 million. We haven't disclosed mix. So it's fair to say that's stable with a slight bump."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. On the HCP side question, are any of the rates contractually tied to the health industry fee holiday? In other words, we've heard from some plans that as they get released in '17 and not have to pay this industry fee holiday, some of their capitated",97,"Okay. On the HCP side question, are any of the rates contractually tied to the health industry fee holiday? In other words, we've heard from some plans that as they get released in '17 and not have to pay this industry fee holiday, some of their capitated groups contractually get a bump. Because they effectively had to eat, as you did, some rate cuts over the last few years. So this is effectively a net -- a rate increase to the plans to not have to pay this fee. Will HCP benefit contractually from that in '17?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Again, as it relates to our contracts, there is a -- it's a mixed bag. Some of our contracts will have it flow through, others won't. But in those where it does flow through, there may be some slight pickups there for the onetime period as you know all th",52,"Again, as it relates to our contracts, there is a -- it's a mixed bag. Some of our contracts will have it flow through, others won't. But in those where it does flow through, there may be some slight pickups there for the onetime period as you know all the details around."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","And last question. I believe at Investor Day, you had sized a $25 million Medicare headwind for HCP in '17. And I wonder if there was any update to that. Obviously, we're thinking about potential negative impact of the dual risk core model change in some",75,"And last question. I believe at Investor Day, you had sized a $25 million Medicare headwind for HCP in '17. And I wonder if there was any update to that. Obviously, we're thinking about potential negative impact of the dual risk core model change in some markets but positive in others, and then maybe a little bit of benefit from this industry fee holiday. At this point, is that $25 million still the best number?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","That is still the best number, including all the things you just described.",13,"That is still the best number, including all the things you just described."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","The next question comes from the line of Ms. Lisa Clive.",11,"The next question comes from the line of Ms. Lisa Clive."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Three questions. Just the HCP Arizona sale, could you talk through the rationale for that? Second question, just on the write-downs that we've had on HCP over the last few quarters, are we at the bottom here? Or are there potentially more to come? I mean,",88,"Three questions. Just the HCP Arizona sale, could you talk through the rationale for that? Second question, just on the write-downs that we've had on HCP over the last few quarters, are we at the bottom here? Or are there potentially more to come? I mean, obviously, it depends on what your accountants say, but it -- just be helpful to think through that. And then the third question is on the international business, you mentioned a goodwill impairment charge, just wondering what the source of that was."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Let me first start on the Arizona divestiture. In short, we got a good offer that was presented to us. And as we looked at the alternatives the weight that we could invest and deploy our resources for a greater value, we thought it was the right trade-off",65,"Let me first start on the Arizona divestiture. In short, we got a good offer that was presented to us. And as we looked at the alternatives the weight that we could invest and deploy our resources for a greater value, we thought it was the right trade-off. So we decided to accept that offer and divest. Jim, you want to touch on the impairment?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","In regards to the goodwill impairment that we took in the quarter, as we look forward, there is a chance that we will have another impairment if -- as we disclosed in our 10-Q, we have a negative cushion in our Nevada and Florida markets. And there is a v",163,"In regards to the goodwill impairment that we took in the quarter, as we look forward, there is a chance that we will have another impairment if -- as we disclosed in our 10-Q, we have a negative cushion in our Nevada and Florida markets. And there is a very kind of nuanced and detailed accounting rules around impairment accounting. And so when you have a negative cushion, that means that your fair value is less than your book value. And so if there is any further deterioration in performance or in our outlook of those markets, we could see a further impairment. Additionally, the FASB is looking at changing the rules around accounting for goodwill impairments. When they do that, there may be an effect related to the adoption of those new rules. And then the final part of your question was an international impairment. We did have a small international impairment last year, but we did not have one this year."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. Just one follow-up on the Arizona deal. Who did you actually sell to?",14,"Okay. Just one follow-up on the Arizona deal. Who did you actually sell to?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I don't know if we're authorized to say. Does anybody here around the table know for sure? I don't know the contract by heart. So if you could call in and we'll check and know if it's fine. It's also relatively commonly known in the market in case you kno",70,"I don't know if we're authorized to say. Does anybody here around the table know for sure? I don't know the contract by heart. So if you could call in and we'll check and know if it's fine. It's also relatively commonly known in the market in case you know anyone there. But we'd be happy to give the answer once we confirm that we were legally allowed to."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. I was just sort of curious as to what sort of entity would give you a good deal to take it off your hand.",25,"Okay. I was just sort of curious as to what sort of entity would give you a good deal to take it off your hand."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yeah. For us, it was better for us to focus on other markets than that one.",16,"Yeah. For us, it was better for us to focus on other markets than that one."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","We have another question from the line of Ms. Margaret Kaczor.",11,"We have another question from the line of Ms. Margaret Kaczor."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","I was hoping to start out with exchange plans. Over the last couple of calls, this has been a popular topic for you guys. But now that we're in August, halfway through the year, are you seeing the regulatory environment improving, stabilizing? Are patient",63,"I was hoping to start out with exchange plans. Over the last couple of calls, this has been a popular topic for you guys. But now that we're in August, halfway through the year, are you seeing the regulatory environment improving, stabilizing? Are patients receiving adequate access to care, especially near term? Any trend data that you guys may have would be helpful."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes. We actually don't have any significant change. The patients are receiving great care. And right now, as we stated earlier in the call, there's a lot to be played. So a lot of rules and enforcement is still to be played. But right now, there's nothing",59,"Yes. We actually don't have any significant change. The patients are receiving great care. And right now, as we stated earlier in the call, there's a lot to be played. So a lot of rules and enforcement is still to be played. But right now, there's nothing different to report than what we told you in Capital Markets Day."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","I think the way I would put it is that the regulatory agencies' capacity to enforce the regulations with respect to exchanges remain weak, either by virtue of lack of motivation because they're worried about the exchange's financial viability or because t",47,"I think the way I would put it is that the regulatory agencies' capacity to enforce the regulations with respect to exchanges remain weak, either by virtue of lack of motivation because they're worried about the exchange's financial viability or because they just don't have the resources."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Is that something that can change at some point in the next 6, 12, 18 months?",16,"Is that something that can change at some point in the next 6, 12, 18 months?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Yes, it could change, and it's likely to change some, but one wouldn't want to pin one's hopes on it changing a lot.",23,"Yes, it could change, and it's likely to change some, but one wouldn't want to pin one's hopes on it changing a lot."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on your international ventures, how is Asia developing and some of these other countries like Saudi Arabia developing? And then how do you compare those businesses versus some of your clinics in Germany, both in terms of patients, investmen",47,"Okay. And then on your international ventures, how is Asia developing and some of these other countries like Saudi Arabia developing? And then how do you compare those businesses versus some of your clinics in Germany, both in terms of patients, investments going forward and profitability profile?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","We're in 11 other countries now, and the microeconomics and growth trajectory are different in every one. The good news is that in virtually every one, the microeconomics work at a very reasonable market share position. So even if we're losing money now i",113,"We're in 11 other countries now, and the microeconomics and growth trajectory are different in every one. The good news is that in virtually every one, the microeconomics work at a very reasonable market share position. So even if we're losing money now in a country, just by increasing our scale with the existing achieved microeconomics of our current centers, we know we're on the path to the promise land of, first, being profitable and then second, having an adequate cumulative return. But the differences are quite large. And Germany and Saudi are 2 of our more successful markets from many perspectives, including the microeconomics. But am I getting to your question?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Well, and part of it becomes how do you guys bridge to that profitability gap you talked about at the Capital Markets Day? And what impact and how many years really will it take for China to either be material as well as profitable?",44,"Well, and part of it becomes how do you guys bridge to that profitability gap you talked about at the Capital Markets Day? And what impact and how many years really will it take for China to either be material as well as profitable?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","So ""I don't know"" is the answer with respect to China. That day is almost certainly outside your investment time horizon. And yet the only way to become a leader in China is to get into China and learn it. Very difficult to try to transplant your way in x",180,"So ""I don't know"" is the answer with respect to China. That day is almost certainly outside your investment time horizon. And yet the only way to become a leader in China is to get into China and learn it. Very difficult to try to transplant your way in x years later. In China, we'll probably end up with a few partners is the right way to do it. Just as we concluded in Asia, despite the fact that we were doing well in Southeast Asia, partnering with Khazanah and Mitsui, we thought, was going to help us grow faster and better: everything from helping us recruit more talent, helping us oversee what we have, helping us interact with the government more and the regulators. So in all sorts of ways, we learned important lessons, which should make the next 5 years very different from the last 5. But having said all that, in China, in particular, you want to be very careful before you start talking about any bullish forecast because it is one tough place to do business."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then one last question. We're trying to balance some of the growth within dialysis against some of the other companies we cover. And what we're noticing is some of the acute care demand, at least, for equipment is growing a little bit faster. Yo",82,"Okay. And then one last question. We're trying to balance some of the growth within dialysis against some of the other companies we cover. And what we're noticing is some of the acute care demand, at least, for equipment is growing a little bit faster. You're seeing PD growth a little bit faster. So maybe what are you guys seeing in the field? Are you actually seeing acute care patients improve in PD? And how does that end up benefiting you guys?"
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","Margaret, we are seeing our PD grow similarly than our Non-Acquired Growth in in-center, so we're not seeing a disproportionate growth there. And as it relates to our acute business, there's nothing that stands out to our historical trend. So it could be",112,"Margaret, we are seeing our PD grow similarly than our Non-Acquired Growth in in-center, so we're not seeing a disproportionate growth there. And as it relates to our acute business, there's nothing that stands out to our historical trend. So it could be that equipment, of course, is misaligned with services in that equipment could be old or someone decides that they want to do some treatments in their hospital and/or change their staffing ratios. Instead of having a room where they conduct dialysis, they want to go bed to bed in the hospital. So it's really hard to predict the alignment there, but we're not seeing anything different in our business."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","At the moment, speakers, we have no more questions over the phone.",12,"At the moment, speakers, we have no more questions over the phone."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Executives","All right. Thank you very much, everyone, for your interest in DaVita. We'll do our best for you in between now and our next call. Take care.",27,"All right. Thank you very much, everyone, for your interest in DaVita. We'll do our best for you in between now and our next call. Take care."
35644,377729485,1030678,"DaVita HealthCare Partners Inc., Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","DaVita Inc.","Operator","Thank you all, speakers. So that concludes today's conference. Thank you all for participating. You may now disconnect.",18,"Thank you all, speakers. So that concludes today's conference. Thank you all for participating. You may now disconnect."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you for standing by. [Operator Instructions] And I would now like to turn the call over to Mr. Jim Gustafson. Sir, you may now begin.",28,"Welcome, and thank you for standing by. [Operator Instructions] And I would now like to turn the call over to Mr. Jim Gustafson. Sir, you may now begin."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Jessa, and welcome, everyone, to our third quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO",236,"Thank you, Jessa, and welcome, everyone, to our third quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO of the DaVita Kidney Care; Vijay today, Chief Financial Officer of DaVita Medical Group; Jim Hilger, our Chief Accounting Officer and interim CFO; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statements. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based on information currently available to us, and we do not intend and undertake no duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website.
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, Jim thank you, everyone, for joining on our call. We will start, as we always do, with our clinical performance, and then I will return before Q&A.Within the DaVita Medical Group, we mentioned during our Q2 call that we outperformed in",140,"Okay. Thank you, Jim thank you, everyone, for joining on our call. We will start, as we always do, with our clinical performance, and then I will return before Q&A.
Within the DaVita Medical Group, we mentioned during our Q2 call that we outperformed in clinical quality compared to the same period in the prior year. Our strong performance has continued, and we remain on track to achieve 4 stars or greater for our patients within each of our major health plan relationships.
Within Kidney Care, we continue to focus on vascular access where strong performance significantly improved survival and prevents unnecessary hospitalizations. The publicly reported government data released just this October shows that we have significant outperformed the industry in this important clinical area.
Let's now move onto the nonclinical subjects, and I'll turn it over to Javier Rodriguez."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Kent, and good afternoon. Since we spoke last, a lot has happened. I will cover 3 topics: Number one, Monday's announcement; number two, our Q3 Kidney Care performance; and number three, our outlook. So let's get started.We hope the release o",844,"Thank you, Kent, and good afternoon. Since we spoke last, a lot has happened. I will cover 3 topics: Number one, Monday's announcement; number two, our Q3 Kidney Care performance; and number three, our outlook. So let's get started.
We hope the release on Monday was helpful. I won't be repetitive here, but we've had a lot of questions, so let me take some and if I miss them, please bring them up in Q&A. As a full warning, I'll go into some technical detail because the subject matter requires it.
First, why did we announced the decision on Monday only 2 days before our earning call? It's a simple answer. This is open enrollment that started yesterday, and we needed to provide clarity to our patients and our teammates.
Second, is this a permanent change in policy? No. We have only temporarily suspended support for applications to the American Kidney Fund for patients enrolled in minimum essential Medicaid coverage. When CMS provides guidance, which we expect will be within a couple of weeks, we will evaluate our future policy.
Third, does our announcement signify a concern over our historical practices? No. Our historical practices were illegal and compliant. That said, the language in RFI may confuse some, so I thought it would be useful to clarify further.
The RFI has primarily 3 concerns. One, were the patient enrolled in Medicare purchased an ACA plan that was duplicative in coverage. None of our patients who were enrolled in Medicare enrolled in the ACA plan. The regulations cited in the RFA, which referred to Medicare supplemental plan is not germane to the ACA Plan.
Number two, whether patients lost their Medicaid coverage as a result of purchasing an ACA Plan and therefore, were exposed to additional costs. Our patient did not lose their Medicaid coverage as a result of purchasing an ACA Plan and as a result, were not exposed to additional costs. Consistent with CMS' own education materials, we educated our patients on the ability to pick -- purchase an ACA Plan while retaining Medicaid coverage as a secondary. This patient did not apply for tax credits and subsidies.
And three, whether patients expensed a disruption in continuum of care as a result of purchasing an ACA Plan. Just a small portion of our Medicaid patients made the choice to purchase an ACA Plan, and they did so for their own personal reasons such as to have access to specialists who do not accept Medicaid or increased chance of qualifying for transplantation or other reasons. We are not aware of any patient experiencing a disruption in care likely because those patients who would have had such a disruption made the choice not to enroll in an ACA Plan.
Lastly, there have been some questions around comparing our disclosure of 5,000 patients versus public information from other providers. I believe that the confusion is around some definitions. When refer to individual market plans or ACA Plan, we refer to the full universe of individual plan, whether they're sold on or off the government-run exchanges. A distinction between these types of plans is not relevant because both affect the same risk pools and are generally subject to the same regulation. If you're trying to compare us to other providers, it is important to clarify definitions to ensure that the comparison is an apples-to-apples line.
Now let's discuss our Q3 performance. Overall, DaVita Kidney Care had a solid quarter. We delivered adjusted operating income of $439 million. For U.S. dialysis, our normalized non-acquired growth for the quarter was 4.4%, which falls within our long-term target range of 3.5% to 4.5%. While we're on the topic of volume, we want to share that we signed an amendment to the agreement of Renal Ventures to acquire 100% interest in their dialysis centers for $360 million, which is $55 million less than previously announced purchase price. We expect the transaction will close in the first quarter of 2017.
Our revenue per treatment was up sequentially by 1.7 -- $1.72 per treatment, primarily driven by an increase in seasonal administration of flu vaccine. Our patient care cost per treatment were up versus Q2 by $2.41 per treatment, driven by 2 primary factors: approximately 60% by an increase in labor benefits costs and 40% by an increase in facility costs. We have seen a tightening in labor markets leading to some increase in our labor costs. In the near term, we may see the labor costs remain at higher levels. We expect that our facility costs to come down over the next couple of quarters.
Now onto our outlook. Since we have now visibility to the end of the year, we're updating our 2016 adjusted operating income guidance for Kidney Care to be in the range of $1.695 billion to $1.725 billion. We will provide you with 2017 guidance on our Q4 earnings call when we expect to have additional clarity on several variables, including open enrollment and policy changes from CMS.
Now I'll turn the call to Vijay Kotte for DMG."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Javier. First, financial performance. We noted on the Q2 call that we will see accelerated noncash amortization expense for the ACP brand during the transition to DMG, which would impact our reported operating income. This will run for 30 month",340,"Thank you, Javier. First, financial performance. We noted on the Q2 call that we will see accelerated noncash amortization expense for the ACP brand during the transition to DMG, which would impact our reported operating income. This will run for 30 months at an incremental rate of slightly more than $2 million per month or $26 million on an annualized basis beginning September 2016. Including the impact of this accelerated amortization, operating income for the quarter was $33 million.
As we look at the full year, we are narrowing our 2016 adjusted operating income guidance to a range of $115 million to $145 million. This is effectively a slight increase as our guidance now includes the impact of the $9 million in accelerated brand amortization that was previously excluded.
Another question is how to think about 2017. We're still in the midst of our budget process, and open enrollment plays a big part in our outlook. That being said, there are some things we know. First, $40 million in rate cuts, which includes $30 million related to the Medicare model change and $10 million for Medicaid. Second, we have the $26 million of accelerated brand amortization. And third, we are continuing to make incremental investments in the business. Despite these headwinds, the odds are they will be roughly flat year-over-year, but there are reasonable probabilities on the other side of that. We will go into further detail regarding our expectation for 2017 on the Q4 earnings call.
As we continue to look towards our long-term OI, our 2019 target remain $215 million.
Finally, I want to provide a few highlights on the operating progress we're making at DMG. With regard to claims process without the need for manual intervention, 2015 we're at 26%; and in 2016, 79%. With regards to services getting electronic authorizations, 2015 was 24%, 2016 is 47%. And finally, with regards to new tuck inclination, in 2015, we had 18; and in 2016, we're at 44.
Now to Jim Hilger for some financial details on the quarter."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. I'll first address our international operations. Our international operating income was $368 million in the quarter, which improves the gain on the deconsolidation of the APAC JV of $374 million. We are on track to meet our guidance for app",600,"Thanks, Vijay. I'll first address our international operations. Our international operating income was $368 million in the quarter, which improves the gain on the deconsolidation of the APAC JV of $374 million. We are on track to meet our guidance for approximately $40 million in adjusted losses for 2016.
Our JV transaction with Khazanah and Mitsui closed on August 1. As you will recall, Khazanah and Mitsui have each subscribed to acquire 20% share of ownership of the joint venture. At closing, each partner made their first investment tranche of $50 million in return for a 6.7% ownership in the joint venture. This joint venture has been deconsolidated from our financials. Going forward, our pro rata share of its operating income will run through equity investment income in our income statement. As a result of this deconsolidation, we recorded a onetime noncash gain of $374 million. We are excluding this gain when reporting our adjusted non-GAAP financial results and excluding it from our adjusted operating guidance for 2016. We look forward to continuing our growth in Asia Pacific dialysis with the help of our new partners.
Next. I'd like to talk about a few tax items. In the third quarter, we recorded an adjustment related to tax assets created through the DMG acquisition escrow provisions. This adjustment resulted in a $27 million increase in corporate G&A expense that was offset by an equal reduction in income tax expense and thus, created no change in net earnings or earnings per share. We do not expect any ongoing impact from this adjustment.
Excluding this escrow provision tax adjustment and excluding the gain from the formation of the APAC dialysis joint venture, our tax rate attributable to DaVita was 40% in the quarter and 39% year-to-date. We expect our full year tax rate attributable to DaVita to be approximately 39%, when excluding all non-GAAP items.
Next, our interest expense increased slightly in the quarter to $105 million due to an increase in the interest rate cap amortization as well as the impact of the deconsolidation of the APAC joint venture. This higher level of interest expense reflects our go-forward run rate.
And finally, turning to our continued strong and consistent cash generation. Operating cash flow was $536 million in the third quarter and $1.92 billion for the last 12 months. We expect full year 2016 operating cash flow to be between $1.75 billion and $1.85 billion.
Since our last earnings release, we have repurchased 9.6 million shares for approximately $619 million. And through October, we have repurchased 13.3 million DaVita shares for approximately $868 million, which represents about 6.3% of the outstanding shares at the beginning of the year. Approximately 881 million remains outstanding under our board repurchase authorizations.
We continue to have a strong cash balance with nearly $1.6 billion in cash and short-term investments as of September 30. While $212 million was used in October to repurchase stock, and an additional $360 million will be used in the coming months for the completion of the Renal Venture acquisition, that still leaves us with over $1 billion of cash available before considering our continued strong cash-generating capabilities.
As discussed at our Capital Markets Day earlier this year, we expect to generate well over $5 billion in free cash flow to use for growth and share repurchases from 2016 to 2019. Even assuming a reasonable baseline of $1.5 billion in growth spending for development CapEx and acquisitions, this leaves over $3 billion for additional growth or share repurchase.
And now I'd like to turn it back to Kent for a few closing comments."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thanks, Jim, and I'd actually like to make several additional comments. Some will be a little bit redundant to what JR said, but it's such an important topic. We think it's worthwhile to in order to achieve good clarity. Allow me 8 different points, pleas",1162,"Thanks, Jim, and I'd actually like to make several additional comments. Some will be a little bit redundant to what JR said, but it's such an important topic. We think it's worthwhile to in order to achieve good clarity. Allow me 8 different points, please.
Number one. We fulfilled our regulatory responsibility to provide comprehensive education to our patients. This has been an industry requirement for the last 15 to 20 years, and then ACA was added onto that standard and long-standing process and practice.
Number two. A very small percentage of our Medicaid patients determined that an ACA Plan was better for them, and Javier mentioned some of the very significant reasons why some of those plans were way better for them and/or their families. I won't repeat the examples, but important and often beautiful improvements in care.
Number three. Nonetheless, if you look at the benchmark plan in EGHP plan, you see that total ESRD costs, meaning dialysis and hospital-related costs, et cetera, was about 1.3% of the total medical costs. That again is total ESRD costs in the numerator and then total medical costs for the plan in the denominator. In the ACA Plans, we estimate right now that, that percentage is only up to about 1.6%. And so it is a low absolute number and it's a low increase number.
Number four. We were very sensitive to the fact that some of these patients choosing an ACA Plan meant that we would be paid higher rates, commercial rates versus Medicaid rates. And therefore, we created a very intense oversight process to make sure that we did everything possible to live up to the CMS standards around objective presentation and information and absolutely letting the patient choose.
Number five. We, nonetheless, got swept up in the current huge controversies around the sustainability of the exchanges, and you're all sensitive to the huge political forces in play on that subject.
Number six. Why did dialysis, and in part DaVita, become a visible part of that controversy? Well, a, letter a, we're national, and so our numbers get added up nationally unlike a lot of health systems, which are regional or local.
B, our patients stick out. They're very high cost, very easy to identify, very discreet.
C, there have been abuses by providers in other segments and perhaps some abuses even in ESRD, and so upfront, we started to be painted with that brush by some without data to support.
D, some payers did have very large year-over-year increases in dialysis expense, and it was originally assumed that this must be from the process that I described earlier. But in fact, in many, probably most instances, it was driven by other factors. For example, sometimes, a plan had a differentially attractive product and would gain significant market share literally moving from having 50% of the ESRD patients in a market to 80%, thereby guaranteeing at least a 60% increase in your costs, having nothing to do with anything else other than product design. As we all know, this has been a very dynamic period, probably the most dynamic period ever in terms of alternative product design for insurance plans. And also, people have been struck by how smart the consumers are and how much shopping and switching they do. A second explainer in several markets is when there was a bad actor in the payer world, meaning someone who did inappropriate steering of patients away from themselves, leaving one of their competitors with a disproportionate percentage. And again, we're talking about 30%, 40% shifts in market share in some instances. A third driver out of probably a potential list of 7 or 8, but I'll stop after 3, is areas with relatively poor Medicaid coverage because that would naturally mean that there's a higher probability that a Medicaid patient would find an ACA Plan more attractive. This is just to give you a sense of what kind of things actually drove a lot of those year-over-year increases for particular plans because as we mentioned earlier, the aggregate reality only moved from 1.3 to 1.6.
But letter e, those high examples were taken to CMS and positioned as being reasonably representative of a broader movement. And at that point, CMS did not have the data of the 1.3 and the 1.6.
On to number 7 of 8. CMS is now starting to realize, contrary to initial impressions that, a, some of the numbers were misleading. That's not to say they were inaccurate if they were from a particular plan. They were just misleading. And as you start to stare at a number like a 0.3 increase, and again this is our estimate, but as you compare that to 22% rate increases on average, you can see that we were not a material source of the problem, nor are we a material source of the solution. 
Letter b, our patients made sensible choices, and we provided lots of examples to CMS as have other providers.
C, the fact that enrollment of dialysis patients within the ACA plans looks to be flat or down even without any change in Medicaid access in 2017 and '18, and of course, would be down even more with any restriction on the Medicaid front.
Letter d, CMS now is starting to see some of the reasons for the dramatic disparities in year-over-year dialysis expense increases and seeing how they have to do with product design, competition, et cetera.
And lastly, e, they also have a better sense of how charitable premium assistance has been embedded in the ESRD economic in clinical ecosystem for 20 years with a lot of guardrails and with the OIG's blessing, including blessing the aspect of provider funding.
So number 8 and final comment is, of course, the big question on everyone's mind, including ours, is what exactly is CMS going to decide with respect to this portfolio of decisions. And we don't know. No one knows. I think to their credit, they don't know right now because they're continuing to absorb information, and we are incredibly grateful and respectful that they are doing that.
Moving on to DMG. Just one happy announcement, and that is that Chuck Berg is joining our leadership team as Executive Chair of DaVita Medical Group. He'll report to me in my role as CEO of the enterprise. Chuck's been on our board since 2007. He has a wealth of experience in the health plan world, including having been the very successful executive chair of WealthCare Health Plans and prior to that, the CEO of Oxford Health Plans, where I was his nonexecutive chair. This experience, combined with his brain, makes him uniquely suited to help us evaluate our long-term strategic alternatives at DMG. And he will remain in our board in the meantime, and I and others look forward to working with him.
Operator, if you could please go ahead and open up the line for Q&A."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question is coming from Justin Lake of Wolfe Research.",13,"[Operator Instructions] Our first question is coming from Justin Lake of Wolfe Research."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I guess my first question here is just the company bought back $600 million of stock in the last 4 months at prices that are 15% above the current price. With full knowledge of the issues out there in terms of the concerns around third-party payment for A",135,"I guess my first question here is just the company bought back $600 million of stock in the last 4 months at prices that are 15% above the current price. With full knowledge of the issues out there in terms of the concerns around third-party payment for ACA coverage, right, given the potentially significant impact on earnings here, the downstream impacts of just the government taking a harder look at third-party funding in general, managed care negotiations, et cetera, potentially getting impacted, my question is should we take this as a sign of your comfort level with the potential of downstream impacts on third-party payment changes, et cetera, on the earnings power of the business? And if so, any color you could share on why your level of comfort is that high will be helpful."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Thanks, Justin. I would not say that the reason we chose to buy back was because any particularly distinctive level of confidence on what exactly the outcome was going to be. And certainly, if we could do it over again, we would have preferred to hav",113,"Yes. Thanks, Justin. I would not say that the reason we chose to buy back was because any particularly distinctive level of confidence on what exactly the outcome was going to be. And certainly, if we could do it over again, we would have preferred to have waited and be buying back more of it now. But awfully difficult to predict things. There's a lot of different variables, not only with respect to the issues you mentioned, but other issues, both threats an opportunities. And nonetheless, I would not say that we said, ""Gosh, there's some distinctive near-term downside, and we're going to go ahead and buy anyway."" I wouldn't make that claim."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Then maybe we can just talk about your commercial mix in general given this has been a big area of focus here. We look at the changes and the growth and -- in the commercial mix, and if we back out these 2,000 patients, it looks like it's been flat",166,"Okay. Then maybe we can just talk about your commercial mix in general given this has been a big area of focus here. We look at the changes and the growth and -- in the commercial mix, and if we back out these 2,000 patients, it looks like it's been flat over the last several years. But looking ahead and just thinking about the changes, looks like the -- from USRDS data, there hasn't really been much incidence growth in the pre-65 [ph] population over the last 10 years. And when we couple that with the aging of the baby boomers and the Medicare from kind of commercial years, there's the indication that it could put a fair amount of pressure on commercial mix over time. So I guess my question is can you tell me whether this is a reasonable view? And if so, how should we think about this factor in relation to your typical kind of mid-single-digit long-term growth algorithm for the dialysis?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. It's a very fair question, Justin. And I think if you wanted to identify other worrisome long-term trends, you would also look at improved treatment regimens for diabetics and hypertensives. And commercial patients are more likely to benefit from imp",200,"Yes. It's a very fair question, Justin. And I think if you wanted to identify other worrisome long-term trends, you would also look at improved treatment regimens for diabetics and hypertensives. And commercial patients are more likely to benefit from improved treatment regimens. On the other hand, there's also things pushing in the other direction. We continue to be quite successful with our Non-Acquired Growth, and some of these hard times could lead a lot more small providers to sell or even shut down. In addition, we're very hopeful that Medicare Advantage continues to grow because we radically prefer a customer who cares about total value. And we tend to do much better in terms of both adding value to the system and getting reimbursed for it. In addition, as you know better than most, to the extent that the mix ever starts to put too much pressure on all the independent centers, the government has the easy option of doing that, which it's done 3 or 4 times before, and that's extending the MSP provision from originally 0 to 12 and 12 to 18 and 18 to 30. And so that's a safety valve that's never far away. Justin?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Yes. I -- Kent, if you could give me one more chance. I'll just ask you like does this mean that should we think about within the 6, let's just call it, mid-single-digit CAGR that you look for, for the dialysis business? This mix looks like just the likel",86,"Yes. I -- Kent, if you could give me one more chance. I'll just ask you like does this mean that should we think about within the 6, let's just call it, mid-single-digit CAGR that you look for, for the dialysis business? This mix looks like just the likely pressure that's going to be on commercial mix over the next 10 to 20 years. Is this in that number? Or could this have a negative impact on that number in the way you're looking at it?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, fair question. I would say that at the time we did the last Capital Markets, we incorporated all the variables, although that was a 3-year outlook. When we refresh our Capital Markets outlook at the next one, it will once again incorporate everything",162,"Yes, fair question. I would say that at the time we did the last Capital Markets, we incorporated all the variables, although that was a 3-year outlook. When we refresh our Capital Markets outlook at the next one, it will once again incorporate everything. And while some of the stuff that you're citing is most likely not going to be economically material within the near term, perhaps we should, for the first time in a long time, take a cut that sort of the 4 to 7 year time frame and stare at some of the upsides and downsides, the puts and takes, not only on mix but on cost structure, et cetera, also modality mix and some other things that can have a big impact on cash flow and return on capital. So we don't have anything distinctively thoughtful to say to you today from an analytical point of view, but that's probably a good assignment for the next Capital Markets."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Kevin Fischbeck of Bank of America Merrill Lynch.",14,"Our next question is coming from Kevin Fischbeck of Bank of America Merrill Lynch."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I have a lot of questions kind of similar to that, but I guess I appreciate all the color about the AKF change. I think that was very helpful. I think I understand those parameters. But I guess the question that I'm still struggling with is what the real",228,"I have a lot of questions kind of similar to that, but I guess I appreciate all the color about the AKF change. I think that was very helpful. I think I understand those parameters. But I guess the question that I'm still struggling with is what the real growth rate the company has been over the past 3 years in the dialysis business because if I look at operating income growth over the last 3 years, it's been about 5% per year. But if I were to say that this 1 40 [ph] was either not sustainable or onetime in nature, then I'm getting like a 2% type growth in the dialysis business over the past 3 years. So how do we think about that? And that's the low end of what you guys think you're going to do over the next 3 years going forward. And when I think about the next 3 years versus the last 3 years, Medicare rates have been under pressure and likely will be in the same range. So why is the right way to think about growth over the next 3 years not the low end of that 3 to 7? Like what would cause you to do better than the low end of that range? Or is 4 at the low end the right way to think about it?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Right now, I would say if you wanted to weight the probabilities between the low end, middle and top, you would find the probability skewed to the low end, but it's not by huge amount. And then in addition, of course, unit volume is, for us, in many",115,"Yes. Right now, I would say if you wanted to weight the probabilities between the low end, middle and top, you would find the probability skewed to the low end, but it's not by huge amount. And then in addition, of course, unit volume is, for us, in many ways, of secondary importance with commercial mix and the nature of commercial mix of primary importance. And that number has got a lot of dynamism to it right now, as you well know. And so at this point, we're not revising that guidance, but we do look forward to a very intense analytical discussion at the next Capital Markets about the next generation of 3-year outlook."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Then I guess if we look at commercial mix and take out this maybe 1% that's related to the ACA, it looked like mix has basically been flat over the last 5 years, maybe down a little bit during a time when the economy is improving. So do you think th",117,"Okay. Then I guess if we look at commercial mix and take out this maybe 1% that's related to the ACA, it looked like mix has basically been flat over the last 5 years, maybe down a little bit during a time when the economy is improving. So do you think that, that's really reflective of what the industry has been seeing? Or I know from time to time you raise flags about potentially competitors being aggressive on pricing. Has there been anything where you feel like you've purposely walked away from market share because people got competitive? Or is that kind of how you think mix overall for the industry has looked over that time period?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Our guess is that our trajectory of commercial mix is quite similar to others, and we have not experienced any example of someone in our mind foolishly seeking to gain shares through price reductions in an industry of almost pure variable cost, very stick",70,"Our guess is that our trajectory of commercial mix is quite similar to others, and we have not experienced any example of someone in our mind foolishly seeking to gain shares through price reductions in an industry of almost pure variable cost, very sticky volume and high likelihood of economic retaliation. So we haven't seen any of that go on, and so our guess is that competitor performance is comparable."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just one last question. On HCP, looks like the number of physicians and clinicians went up nicely sequentially, but we still saw a deceleration in revenue in that business for Q2 to Q3. Wanted to see what was going on there. And whether inc",64,"Okay. And then just one last question. On HCP, looks like the number of physicians and clinicians went up nicely sequentially, but we still saw a deceleration in revenue in that business for Q2 to Q3. Wanted to see what was going on there. And whether increase in physicians is a good sign about a ramp-up in revenue over the next couple of quarters."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Over the long term, you should see a positive correlation. Right now in some cases, we were under staffed with physicians. And by adding them, we actually think we can reduce our MLR and the quantity that exceeds the incremental costs that we're addi",166,"Yes. Over the long term, you should see a positive correlation. Right now in some cases, we were under staffed with physicians. And by adding them, we actually think we can reduce our MLR and the quantity that exceeds the incremental costs that we're adding. In other cases, we're adding because we're doing some de novos and other work where we think by adding physician capacity, we're going to get more lives. It's just that there's some lag time. So we're very sensitive to the fact that at a time when the revenue trajectory is what it is, our physician recruiting is ramping up. But the good news is that shows what an attractive place we are for physicians and our hit rate in recruiting is very high. The concerning news for you is we're adding the costs at a time when revenues aren't going up at the same trajectory. And so we hear you, and over time, you should see the positive correlation you expect."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Is the right way to think about that as like a couple of quarter lag? Or a year lag? How long do we think about these doctors adding to the earnings?",32,"Okay. Is the right way to think about that as like a couple of quarter lag? Or a year lag? How long do we think about these doctors adding to the earnings?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, unfortunately, I don't think we're good enough yet to give you an empirical answer for that, and so I won't hazard a guess. Suffice it to say, we know you'll be watching each quarter.",35,"Yes, unfortunately, I don't think we're good enough yet to give you an empirical answer for that, and so I won't hazard a guess. Suffice it to say, we know you'll be watching each quarter."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Gary Lieberman of Wells Fargo.",11,"Our next question is coming from Gary Lieberman of Wells Fargo."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I guess just sticking with the topic of the day. I think there's a broader concern by some investors that potentially the AKF would be restricted more broadly from making premium support payments to historical patients that they would have been doing it f",66,"I guess just sticking with the topic of the day. I think there's a broader concern by some investors that potentially the AKF would be restricted more broadly from making premium support payments to historical patients that they would have been doing it for COBRA or for other factors. Can you talk about that? Do you think that is a risk? And why or why not?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. It is a risk, but the 2 big facts on that big issue are that for private plans to do a broad prohibition of charitable premium assistance is an exceptionally heavy lift because there are hundreds of such organizations all over the country, and thousa",108,"Yes. It is a risk, but the 2 big facts on that big issue are that for private plans to do a broad prohibition of charitable premium assistance is an exceptionally heavy lift because there are hundreds of such organizations all over the country, and thousands of hospitals that like those foundations and charities and the rest. And to try to deploy one that's focused on our patients would be discriminatory and subject to really intense lawsuits. And then separately, CMS does not have authority over the whole EGHP realm. They, of course, have authority over lots of other realms, but not that one. Is that responsive, Gary?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Yes, that's helpful. Any chance you could tell us what percentage of your commercial patients, if you know it, receive premium assistance from the AKF?",25,"Yes, that's helpful. Any chance you could tell us what percentage of your commercial patients, if you know it, receive premium assistance from the AKF?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I think at this point, we've decided that disclosing that is not in your best interest, although we'll continue to stare at that each quarter. But that's our current thinking. Of course, we incorporate all variables into our forecasts, but sometimes, some",48,"I think at this point, we've decided that disclosing that is not in your best interest, although we'll continue to stare at that each quarter. But that's our current thinking. Of course, we incorporate all variables into our forecasts, but sometimes, somebody's swing factors are difficult to calibrate."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on the same topic, I think there are some investors that believe that, in fact, it's illegal to -- for the Medicaid patients to have been given premium support. Can you just talk about that? And your understanding, I assume, from your persp",57,"Okay. And then on the same topic, I think there are some investors that believe that, in fact, it's illegal to -- for the Medicaid patients to have been given premium support. Can you just talk about that? And your understanding, I assume, from your perspective, it's not illegal? Can you just help us think through that?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Sure. I appreciate you bringing it up because we certainly heard the concern. And the very explicit references by CMS to how it is legal are multiple and really clear. And the RFI referred to a part of the statute that didn't apply to the subject at hand.",110,"Sure. I appreciate you bringing it up because we certainly heard the concern. And the very explicit references by CMS to how it is legal are multiple and really clear. And the RFI referred to a part of the statute that didn't apply to the subject at hand. So it was literally not germane to the critical questions that you and others are worried about. And so we have continued to point to the very explicit language supporting our position. We have been in meetings with senior CMS officials and referred to the fact that it's a very clearly legal and have never run into a single objection from anyone."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Gary, let me add one thing, Gary, that might help clear it up. It is the case that Medicaid patients cannot have federal subsidies, and so it's not that there aren't some rules that apply, but it is very clear that there was a conscious decision made to a",123,"Gary, let me add one thing, Gary, that might help clear it up. It is the case that Medicaid patients cannot have federal subsidies, and so it's not that there aren't some rules that apply, but it is very clear that there was a conscious decision made to allow Medicaid patients to make the choices that we made available to them. And I'll even add one other element. Back when the Affordable Care Act was being rolled out, we were encouraged by the administration to promote exchange products. We were even asked to put up signs in our centers promoting the ACA Plans. Now of course, it's 4 years later and a lot of things have changed, but that's the actual historical context."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Great. That's very helpful. And then, Jim, can you just remind us at what point you would have been restricted from purchasing your stock after the end of the quarter?",30,"Great. That's very helpful. And then, Jim, can you just remind us at what point you would have been restricted from purchasing your stock after the end of the quarter?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, we entered -- we typically enter restriction period at -- near the very end of the quarter, and we would be restricted throughout the period of time after the quarter ended until through this call.",36,"Well, we entered -- we typically enter restriction period at -- near the very end of the quarter, and we would be restricted throughout the period of time after the quarter ended until through this call."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Got it. But I thought you guys did, in fact, purchase some stock after the end of the quarter?",19,"Got it. But I thought you guys did, in fact, purchase some stock after the end of the quarter?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, we did, and that was subject to a plan that we put in place before we were blocked out.",20,"Yes, we did, and that was subject to a plan that we put in place before we were blocked out."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","So you did 10b-5 in place before it was blocked out?",12,"So you did 10b-5 in place before it was blocked out?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","That's correct.",3,"That's correct."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Chris Rigg of Susquehanna.",10,"Our next question is coming from Chris Rigg of Susquehanna."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I just wanted to again come back to the AKF issue. Obviously, you're pointing at 140 million of OI this year as that being the potential headwind for next year. But can you give us a sense for how that ramps during the first 2 years of the coverage expans",50,"I just wanted to again come back to the AKF issue. Obviously, you're pointing at 140 million of OI this year as that being the potential headwind for next year. But can you give us a sense for how that ramps during the first 2 years of the coverage expansions?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","How the 140 million ramped up?",6,"How the 140 million ramped up?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Like what was the exposure in 2014 and then in '15? And now you're at 140 million for this year in roughly 2,000-ish patients.",24,"Like what was the exposure in 2014 and then in '15? And now you're at 140 million for this year in roughly 2,000-ish patients."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Okay. I know we didn't calculate that number prior to the call. Why don't -- the people around the table here will see if we can and should generate that and share it before the call is over, but we don't have it at our fingertips.",46,"Okay. I know we didn't calculate that number prior to the call. Why don't -- the people around the table here will see if we can and should generate that and share it before the call is over, but we don't have it at our fingertips."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then sort of another qualitative-type question here on the AKF issue, but obviously, getting to some of the -- at least what's been sort of suggested from the managed care side is that by shifting some of these people from, call it, 100% Medicai",114,"Okay. And then sort of another qualitative-type question here on the AKF issue, but obviously, getting to some of the -- at least what's been sort of suggested from the managed care side is that by shifting some of these people from, call it, 100% Medicaid to sort of Medicaid as a supplemental, there may have been some out-of-pocket exposure here. I guess when you guys did your look back and reviewed the 2,000 or whatever that may have been in '15 and '14, what did you do? I guess I'm just trying to get some comfort here that you guys feel pretty comfortable that in no material way were the individuals harmed financially."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I'll take the first stab and then other people may want to add on. First of all, we dedicated a huge amount of time in developing materials and training our people and so that our historic discipline of presenting objectively was on steroids for this proc",181,"I'll take the first stab and then other people may want to add on. First of all, we dedicated a huge amount of time in developing materials and training our people and so that our historic discipline of presenting objectively was on steroids for this process. And we present very complete information that encompasses premiums, deductibles, co-pays, out-of-pocket stuff, potential federal tax credits, potential charitable premium assistance, individual versus family, high income versus low. And so we're thorough and it's presented to the patients in ways that leaves most of them exceptionally grateful for the help and the clarity, and then they choose. So one can never say that theoretically, you couldn't have a patient choose something that was foolish. I'm sure out of 2,000 patients, there were some, but we have to respect the fact that it's their choice. In general, however, just as we've seen in the exchanges over the last 3 or 4 years, the average patient demonstrates a lot of economic common sense in how they move around between different products, particularly when they are helped."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","And Chris, this is Javier. I'll just add one important point is that they never lose their Medicaid. Medicaid was in the secondary position, so the patients actually didn't incur additional costs.",32,"And Chris, this is Javier. I'll just add one important point is that they never lose their Medicaid. Medicaid was in the secondary position, so the patients actually didn't incur additional costs."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just one last one here on kidney care operating income for next year. You made reference in the Monday press release that there could be some theoretical offsets to the 140 million. If there are, can you give us a sense for what they are? A",67,"Okay. And then just one last one here on kidney care operating income for next year. You made reference in the Monday press release that there could be some theoretical offsets to the 140 million. If there are, can you give us a sense for what they are? And then just can you just give us some general sort of headwinds and tailwinds beyond the AKS issue?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, first of all, on mitigation, we'll be able to do a good job on that the next quarterly call if we're in this scenario where that's the topic of the day. Separate from that, and then someone else may want to add, I mean, on the plus side, we have a w",127,"Well, first of all, on mitigation, we'll be able to do a good job on that the next quarterly call if we're in this scenario where that's the topic of the day. Separate from that, and then someone else may want to add, I mean, on the plus side, we have a wonderful recurring unit growth. We have the potential accelerator of continued Medicare Advantage growth. On the cost structure side, we have the opportunities in the ESA area. And on the capital deployment side, we have the opportunity for more small operators filling any to get out of this ever more complicated and challenging business. On the headwind side, I think we've laid them out with painful detail already and so I won't list them again."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next is coming from John Ransom of Raymond James.",10,"Our next is coming from John Ransom of Raymond James."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I did 1 day of law school and ran off [indiscernible], so my key brain isn't large to understand all these fine points. But to make it simple, one of your competitors said that the [indiscernible] in their opinion wants to switch people off Medicaid, but",122,"I did 1 day of law school and ran off [indiscernible], so my key brain isn't large to understand all these fine points. But to make it simple, one of your competitors said that the [indiscernible] in their opinion wants to switch people off Medicaid, but the ambiguity was when a new patient came in eligible for both Medicaid and an ACA plan, that's where you could present both. Is what you're doing just sort of in line with that, that new patients come in a fair game. They don't have insurance but existing patients to Medicaid you no longer going to try switch them. I know I'm over simplifying but is that a helpful way to think about it? Or no?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Hey, it's LeAnne. I think the -- you're confusing 2 things, so let's talk about patients who find us for ACA coverage made that choice and retained their Medicaid in the secondary. I think that answers the first question. There's no -- we're not substitut",68,"Hey, it's LeAnne. I think the -- you're confusing 2 things, so let's talk about patients who find us for ACA coverage made that choice and retained their Medicaid in the secondary. I think that answers the first question. There's no -- we're not substituting ACA coverage for Medicaid and we're keeping them. They're having both of them, and it's not subsidized by federal tax credits. Does that"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Does that answer the first half of your question, John?",10,"Does that answer the first half of your question, John?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Well, not really but I'll follow up. I don't think there's some crossed financial I don't want to drag this out of the call what about the second senior where a patient can send without any -- maybe not eligible for Medicaid but they do 7 standup ho",85,"Okay. Well, not really but I'll follow up. I don't think there's some crossed financial I don't want to drag this out of the call what about the second senior where a patient can send without any -- maybe not eligible for Medicaid but they do 7 standup how does that work is that something that trigon your competitors to clarify the rules on that patient be that comes that with any insurance I'll give us a I misleading comment by one of your competitors."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. I think we do have patients that come to us that are uninsured and our education and profit with those patients would be to find out all the avenues to which they could purchase coverage, whether they're being Medicare or Medicaid or commercial plan,",82,"No. I think we do have patients that come to us that are uninsured and our education and profit with those patients would be to find out all the avenues to which they could purchase coverage, whether they're being Medicare or Medicaid or commercial plan, an ACA plan, et cetera. So our countless job is to make sure that each of the avenues is presented to that patient, and then the patient chooses what is best for them in their particular circumstance."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","The second question I had was -- I mean, obviously in some of the comments, there were allegedly comments were either current or former DaVita employees who talk about being pressured to sign people up on commercial plans. So I'm sure you saw that stuff.",80,"The second question I had was -- I mean, obviously in some of the comments, there were allegedly comments were either current or former DaVita employees who talk about being pressured to sign people up on commercial plans. So I'm sure you saw that stuff. Just internally, what kind of controls do you have in place to investigate those kinds of comments? And what's your general view on that? True? Not true? Out of context? Or that will be helpful."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","John, thank you. This is Javier. First of all, we'd like to highlight that the numbers are small, but of course, regardless of the size of the number, we take each and everyone very seriously. We did some huge, huge oversight here. We have to train a lot",171,"John, thank you. This is Javier. First of all, we'd like to highlight that the numbers are small, but of course, regardless of the size of the number, we take each and everyone very seriously. We did some huge, huge oversight here. We have to train a lot of people in a very short amount of time, and so we had heavy oversight. And for a small number of people, they might have experienced that as negative. What is do is, of course, if we have any concerns, we give to a third party. We give it to our compliance department, and they look into it and we rectify if there are any mistakes. But the bulk of what we've looked into is now materialized. And actually, when we've gone into some sessions, we've literally asked for evidence to be provided of our wrongdoing and alleged wrongdoing, and we've never been given any specifics because, of course, we would want to correct any mistakes if they were brought to our attention."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. That's great. And then let's switch gears and 2 more quick ones. Let's say, we are in a scenario of a little more austerity on a number of fronts. I mean, there's obviously a big gap between your total CapEx and your maintenance complex. In a more a",159,"Okay. That's great. And then let's switch gears and 2 more quick ones. Let's say, we are in a scenario of a little more austerity on a number of fronts. I mean, there's obviously a big gap between your total CapEx and your maintenance complex. In a more austere scenario, and I'll just make up a number. Let's say, revenue per treatment is $340 to $345 for a bunch of reasons, how should we think about the likely reaction of the company? What levers would be likely to be pulled? And again CapEx is one that would appear to be one where you have a lot of discussion ever. And again, I asked this because there's a debate on The Street about should we look at DaVita on earnings per share? Or should we look at it on free cash flow? And free cash flow requires the assumption that CapEx is closer to maintenance and then there's the actual."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, we hear you. The answer right now will be fairly generic. I mean, in a world where we would suffer some serious revenue compassion, we would do what any responsible businessperson should do and very systematically go through every line item on the P&",105,"Yes, we hear you. The answer right now will be fairly generic. I mean, in a world where we would suffer some serious revenue compassion, we would do what any responsible businessperson should do and very systematically go through every line item on the P&L and every aspect of cash in and cash out. And I -- we would enter into that process with the expectation that we would find some savings in the P&L side and we will find some reductions on the CapEx side. And at the same time, we haven't quantified those, but we certainly do have some serious arranges of discretion."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Was the reduction in price for [indiscernible] is driven by the new thinking around ACA plans? Or was it something else?",22,"Okay. Was the reduction in price for [indiscernible] is driven by the new thinking around ACA plans? Or was it something else?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. It was else. There was a part of the transaction that was contemplated at the beginning. And after further dialog, we are not going to acquire the infusion business so that's why the price was changed.",37,"No. It was else. There was a part of the transaction that was contemplated at the beginning. And after further dialog, we are not going to acquire the infusion business so that's why the price was changed."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I see. And is that -- you still think you might get that done? I know it's been dragging on for over a year. Is that still to be done by the end of the year? Or maybe you never said, but that's our assumption, fair reasonable assumption?",48,"I see. And is that -- you still think you might get that done? I know it's been dragging on for over a year. Is that still to be done by the end of the year? Or maybe you never said, but that's our assumption, fair reasonable assumption?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. We think it will -- there are some change of Q4. But if you were betting, I would probably go with Q1 because there's some regulatory stuff going on. So I think Q1 [indiscernible]",35,"No. We think it will -- there are some change of Q4. But if you were betting, I would probably go with Q1 because there's some regulatory stuff going on. So I think Q1 [indiscernible]"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","[indiscernible] 18 months, is that a record? I don't think 18 months might be a record.",16,"[indiscernible] 18 months, is that a record? I don't think 18 months might be a record."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It is. It's a new record for us anyway.",9,"It is. It's a new record for us anyway."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And lastly, just thinking about potential good guys. ESA costs. Do you have a view of -- you've got your current contract with Amgen obviously. But if you do a market check on what other folks are now paying for ESAs, what's your view on your kind of appl",76,"And lastly, just thinking about potential good guys. ESA costs. Do you have a view of -- you've got your current contract with Amgen obviously. But if you do a market check on what other folks are now paying for ESAs, what's your view on your kind of apples-to-apples cost versus what's currently -- of you are free of that contract, would that be a good guide that could be called out? And I'll stop there."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, it's LeAnne again. I think you have to put it into 2 buckets. Obviously, I think the public announcement by FMC as to their cost reductions associated with their using Mircera gets you in 1 category. So clearly, I think they are enjoying the prices b",137,"Yes, it's LeAnne again. I think you have to put it into 2 buckets. Obviously, I think the public announcement by FMC as to their cost reductions associated with their using Mircera gets you in 1 category. So clearly, I think they are enjoying the prices better than the rest of the marketplace. Then you take the rest of the marketplaces on Amgen products. And I think there was a lot of buzz about the move to [indiscernible] lowered the independent and small providers costs. Well, that's correct, it did. But that's a relative lowering, and our ESA costs has been historically off the bat. And I think that holds true, and so you -- if you want to ask it again at a different way, I think that should give you the answer you're looking for."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","So in short, probably unless somebody opens up the contract, probably not -- it's probably reasonable to assume not much movement on that call, on that line item through the terms of the contract?",34,"So in short, probably unless somebody opens up the contract, probably not -- it's probably reasonable to assume not much movement on that call, on that line item through the terms of the contract?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I don't know if that's necessarily the right conclusion. Of course, when you enter into a long-term contract, both parties will look into it as things change. Amgen, of course, is interested in seeing that we are customer post contract renewal and we want",121,"I don't know if that's necessarily the right conclusion. Of course, when you enter into a long-term contract, both parties will look into it as things change. Amgen, of course, is interested in seeing that we are customer post contract renewal and we want to be talking to all the parties that are out there. And so what we're trying to make sure is that we have the right solution for the long haul, so we're looking at this. You seldom get a chance to look at an $800 million cost line, and so we are very eager in deploying the right level of rigor and resources to make sure that we get the right relationship going forward post '18."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, I've got an answer for the question that Chris brought up, which sort of this $140 million, how did it build over time? It won't be very precise but it will give you directionally what you're seeking. And that is that the bulk of growth came in '15 a",115,"Yes, I've got an answer for the question that Chris brought up, which sort of this $140 million, how did it build over time? It won't be very precise but it will give you directionally what you're seeking. And that is that the bulk of growth came in '15 and '16. '14, it was a small number. I think we had to estimate on the $20 million as a range. In '15, the range is probably somewhere in the -- I don't know, double that give or take. We don't have very precise numbers, but we just wanted to give you directionally that the bulk of it was in '16 with some growth in '15."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Gary Taylor of JPMorgan.",10,"Our next question is coming from Gary Taylor of JPMorgan."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Just a couple of things. Given some of the reports that some of the health plans have already attempted to identify patients with AKF subsidies and even potentially terminate some of those contracts, I just want to check in on commercial mix. I know you d",81,"Just a couple of things. Given some of the reports that some of the health plans have already attempted to identify patients with AKF subsidies and even potentially terminate some of those contracts, I just want to check in on commercial mix. I know you disclosed it annually, not quarterly. But I do think the last quarter, you did acknowledge that it was still trending higher year-over-year. So wanted to see if that was still true for 3Q '16 versus '15."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I'm sorry, Gary, your question is commercial mix? What period to what period?",14,"I'm sorry, Gary, your question is commercial mix? What period to what period?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Q3.",1,"Q3."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Just year-over-year in the third quarter. Is it still trending higher year-over-year in the third quarter?",17,"Just year-over-year in the third quarter. Is it still trending higher year-over-year in the third quarter?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It is, it is up year-on-year, Gary.",7,"It is, it is up year-on-year, Gary."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And sequentially, not probably hasn't done a lot. Is that fair?",11,"And sequentially, not probably hasn't done a lot. Is that fair?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","We've seen it go down slightly in the last quarter.",11,"We've seen it go down slightly in the last quarter."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just back to Renal Ventures. Is that still ballpark 2,300 to 2,400 patients and then anticipating some divestitures? Is that still ballpark?",25,"Okay. And then just back to Renal Ventures. Is that still ballpark 2,300 to 2,400 patients and then anticipating some divestitures? Is that still ballpark?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And then I just want to go to the patient care costs, which you called out and I think you talked about 60%, labor; 40%, facility costs but that was in the context of a couple dollar sequential change given that ESRD OI was down year-over-year and the cos",86,"And then I just want to go to the patient care costs, which you called out and I think you talked about 60%, labor; 40%, facility costs but that was in the context of a couple dollar sequential change given that ESRD OI was down year-over-year and the costs jumped about $6 year-over-year. Is that still the same -- would that still be the same ratio if I look at the year-over-year that more than half of that is labor and the rest is facility costs?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","and when you say facility costs, you said coming down, what exactly is driving that up temporarily?",17,"and when you say facility costs, you said coming down, what exactly is driving that up temporarily?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It was a -- it's a bunch of miscellaneous line items, none of them particularly stick out. So it would just be giving you a very long lists and just cumulatively added up to something this time, and so we're working on it.",43,"It was a -- it's a bunch of miscellaneous line items, none of them particularly stick out. So it would just be giving you a very long lists and just cumulatively added up to something this time, and so we're working on it."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Last question. I believe you were talking about HCP's OI potentially being flat into '17 and you made no comments on consolidated or kidney, and I just wanted to confirm that. That, that was correct.",35,"Last question. I believe you were talking about HCP's OI potentially being flat into '17 and you made no comments on consolidated or kidney, and I just wanted to confirm that. That, that was correct."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. That's correct. We'll be providing guidance on '17 in the next quarterly call for Kidney Care, for U.S. Kidney Care.",21,"Yes. That's correct. We'll be providing guidance on '17 in the next quarterly call for Kidney Care, for U.S. Kidney Care."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next is question is coming from Whit Mayo of Robert W. Baird.",13,"Our next is question is coming from Whit Mayo of Robert W. Baird."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I'll try to keep it quick. But maybe one more on the AKF. It doesn't appear that you implemented this exchange initiative until 2015, at least according to the RFI submission. So one, just looking to confirm that. And the ACA obviously was implemented in",87,"I'll try to keep it quick. But maybe one more on the AKF. It doesn't appear that you implemented this exchange initiative until 2015, at least according to the RFI submission. So one, just looking to confirm that. And the ACA obviously was implemented in 2014 and you knew about it many years prior. So was there something that made you apprehensive about pursuing the strategy with patients? And why perhaps it wasn't implemented in 2013 or '14 open enrollment? Just looking for any additional color."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","There is no conscious delay on our part.",8,"There is no conscious delay on our part."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe just one last one. With the MA star ratings published, how would you characterize your -- how your health plan partners are positioned next year? And what do you think this means for DMG? And maybe the conclusion you see when you look",51,"Okay. And then maybe just one last one. With the MA star ratings published, how would you characterize your -- how your health plan partners are positioned next year? And what do you think this means for DMG? And maybe the conclusion you see when you look at scores like Humana's?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, this is Vijay. Just to be clear, the '17 numbers are already fixed, right? So we don't see much of the change between '16 and '17. The Humana numbers were for payment year of 2018, and the only place where we saw a potential [indiscernible] in 1 mark",107,"Yes, this is Vijay. Just to be clear, the '17 numbers are already fixed, right? So we don't see much of the change between '16 and '17. The Humana numbers were for payment year of 2018, and the only place where we saw a potential [indiscernible] in 1 market. And as you know, the STAR scores are related to a number of factors, but our clinical quality, we did it 4 STAR and above, and we believe that in partnering with our health plan, there's some administrative opportunities to help neutralize some of the impact of the potential hit for 2018 for Humana in that 1 market."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Patrick Wood of Citi.",10,"Our next question is coming from Patrick Wood of Citi."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I'll be very quick and this should be fairly yes or no [indiscernible] of question. I'll ask 3, if I may. The first will be I was very interested to hear about the apples-to-apples comparison in terms of patient numbers in relation to the CMS RFI submissi",166,"I'll be very quick and this should be fairly yes or no [indiscernible] of question. I'll ask 3, if I may. The first will be I was very interested to hear about the apples-to-apples comparison in terms of patient numbers in relation to the CMS RFI submission. I'd be curious to hear what you guys think is an apples-to-apples number vis--vis what your competitors submitted I'd be very curious to hear about. Equally, second question would be when I back off from your operating income sort of impacts you guys kind of give us the $140 million, I get to about a 750-or-so [ph] dollar revenue in part per treatment for the exchange funds. Is that a fair kind of back out? Or is there other noise in that [indiscernible] revenue per treatment number that I got it wrong somehow? And then finally, I'll be very curious to hear of your commercial business. What percentage do you guys feel is out of network, very helpful."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, let me tackle number one and number three, and then someone else can take a stab at number two. On other network, we don't disclose exact percentages but we've successfully, dramatically reduced that number over the last 5 years. And strategically f",190,"Well, let me tackle number one and number three, and then someone else can take a stab at number two. On other network, we don't disclose exact percentages but we've successfully, dramatically reduced that number over the last 5 years. And strategically from a relationship point of view, it's we'd much prefer to be a network and at the same time, of course, the payer's got to make a reasonable offer for that trade-off. And so that's the answer on other network. On the patient count issue, the apples-to-apples issue, all we know is our number and our definition, and we've provided we think the right definition for you to be able to assess the economics associated with this issue. And then if other competitors slice and dice it in different ways, we can't really opine on that. You'll have to really talk to them about why they think it's the right way to do that. Hopefully, we're pretty clear about why we think [indiscernible] on and off exchanges is the right way to look at it for our shareholders, at least. And then on the second one, can somebody?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. On the implied revenue per treatment, you're doing -- you're about right. And of course, there's discrepancies geographically and by payer and product mix, et cetera. But yes, you're in the ZIP Code.",34,"Yes. On the implied revenue per treatment, you're doing -- you're about right. And of course, there's discrepancies geographically and by payer and product mix, et cetera. But yes, you're in the ZIP Code."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our last question is coming from Justin Lake of Wolfe research.",11,"Our last question is coming from Justin Lake of Wolfe research."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I wanted to touch on the -- I think tha people are trying to figure out the other $90 million of potential pressure here. And so I just wanted to walk through, is there any way to think about where those patients came from? Specifically, you've got 3,000",152,"I wanted to touch on the -- I think tha people are trying to figure out the other $90 million of potential pressure here. And so I just wanted to walk through, is there any way to think about where those patients came from? Specifically, you've got 3,000 patients that are on ACA. About half of them are getting [indiscernible] assistance. I assume it's a lot less likely it seems as though something to stop people who came to with commercial to keep what they have or having AKF help keep what they have versus maybe those that come to you uninsured and they're just waiting for the 3-month Medicare period, maybe CMS steps in on that. Is there some way to think about the -- that $90 million and how to think about the risks and maybe break it down to those 2 pools [ph]? Keep what you have versus uninsured?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Let me take a little bit of a stab here, Justin. But I'm not sure we're going to be able to give you what you want. In total, there it is kind of 3 buckets. There's the Medicaid bucket, which, of course, has gotten a huge amount of attention and discussio",220,"Let me take a little bit of a stab here, Justin. But I'm not sure we're going to be able to give you what you want. In total, there it is kind of 3 buckets. There's the Medicaid bucket, which, of course, has gotten a huge amount of attention and discussion. Then there are the uninsured, but that label is kind of misleading, because a very significant number of them came from state high-risk plans that shut down as part of the Affordable Care Act. So while they didn't have classic insurance, they were funded and they were typically funded at rates more like commercial than Medicare or Medicaid. And so for the system, there's no increase in costs from their emergence in the second bucket of ACA plans. And then third, the third bucket, which is substantial, are people who are on private plans before. Before ACA existed, they had individual health insurance plans. And once ACA was there, they switched over and so these are people who've been buying insurance for -- in the same way that everyone now on this call buys insurance [indiscernible] individually as opposed through their employers. So those are the 3 buckets. And then within that second bucket, there's some subsets, but at some point, continued parsing will get to pretty small numbers."
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. So maybe I'll just ask the question this way and jump off. There are people that are going to come to you that are uninsured that can qualify for Medicare for 3 months. If I were thinking about the potential risk bucket here, that would be the 1 whe",105,"Okay. So maybe I'll just ask the question this way and jump off. There are people that are going to come to you that are uninsured that can qualify for Medicare for 3 months. If I were thinking about the potential risk bucket here, that would be the 1 where potentially now you're signing off ACA plans where before, they will just have to wait 3 months uninsured and get Medicare. Is there any way to think about how CMS -- could CMS address that? Or effectively, they're uninsured and they could buy an ACA plan like anybody else. So how do you stop it?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Okay. I may just look on the table. I do not have an answer to that. Does anybody?",19,"Yes. Okay. I may just look on the table. I do not have an answer to that. Does anybody?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, Justin, if I understand you correctly, I think what we're having a little disconnect in the room is we have a population that does not qualify for a Medicare or Medicaid because they haven't worked in a number of quarters or even if you're here and",86,"Well, Justin, if I understand you correctly, I think what we're having a little disconnect in the room is we have a population that does not qualify for a Medicare or Medicaid because they haven't worked in a number of quarters or even if you're here and working through the visa process, you have to wait 5 years before you're eligible for Medicare. So I think there's a genuine population when we discussed it that cannot access the government coverage. Does that explain it for you?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Right. So you're saying there's not really much of this 3,000 population that just had to wait 3 months for Medicare before and is now getting ACA?",27,"Right. So you're saying there's not really much of this 3,000 population that just had to wait 3 months for Medicare before and is now getting ACA?"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Right. specifically [indiscernible] Yes, I hear you, Justin. You're specifically asking about that 3-month waiting period and is anybody -- is anything going on there? Not -- does anyone -- I think, Justin, we'll have to get back to you and the rest of th",89,"Right. specifically [indiscernible] Yes, I hear you, Justin. You're specifically asking about that 3-month waiting period and is anybody -- is anything going on there? Not -- does anyone -- I think, Justin, we'll have to get back to you and the rest of the shareholders on that because it's not a question that I've heard asked and answered.
All right. Thank you very much and thanks, everyone, for your sustained interest, and we look forward to talking to you on all these topics in 90 days. Thank you"
35644,404162533,1070997,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","And that ends today's conference. Thank you all for your participation. You may disconnect at this time.",18,"And that ends today's conference. Thank you all for your participation. You may disconnect at this time."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you for standing by. [Operator Instructions] And I would now like to turn the call over to Mr. Jim Gustafson. Sir, you may now begin.",28,"Welcome, and thank you for standing by. [Operator Instructions] And I would now like to turn the call over to Mr. Jim Gustafson. Sir, you may now begin."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Jess, and welcome, everyone, to our third quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO o",236,"Thank you, Jess, and welcome, everyone, to our third quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO of the DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of DaVita Medical Group; Jim Hilger, our Chief Accounting Officer and interim CFO; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statements. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based upon information currently available to us, and we do not intend and undertake no duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website.
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, Jim, and thank you, everyone, for joining on our call. We will start, as we always do, with our clinical performance, and then I will return before Q&A.Within the DaVita Medical Group, we mentioned during our Q2 call that we outperforme",142,"Okay. Thank you, Jim, and thank you, everyone, for joining on our call. We will start, as we always do, with our clinical performance, and then I will return before Q&A.
Within the DaVita Medical Group, we mentioned during our Q2 call that we outperformed in clinical quality compared to the same period in the prior year. Our strong performance has continued, and we remain on track to achieve 4 Stars or greater for our patients within each of our major health plan relationships.
Within Kidney Care, we continue to focus on vascular access where strong performance significantly improves survival and prevents unnecessary hospitalizations. The publicly reported government data released just this October shows that we have significantly outperformed the industry in this important clinical area.
Let's now move on to the nonclinical subjects, and I'll turn it over to Javier Rodriguez."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Kent, and good afternoon. Since we spoke last, a lot has happened. I will cover 3 topics: number one, Monday's announcement; number two, our Q3 Kidney Care performance; and number three, our outlook. So let's get started.We hope the release o",843,"Thank you, Kent, and good afternoon. Since we spoke last, a lot has happened. I will cover 3 topics: number one, Monday's announcement; number two, our Q3 Kidney Care performance; and number three, our outlook. So let's get started.
We hope the release on Monday was helpful. I won't be repetitive here, but we've had a lot of questions. So let me take some, and if I miss them, please bring them up in Q&A. As a full warning, I'll go into some technical detail because the subject matter requires it.
First, why did we announce the decision on Monday, only 2 days before our earning call? It's a simple answer. This is open enrollment that started yesterday, and we needed to provide clarity to our patients and our teammates.
Second, is this a permanent change in policy? No. We have only temporarily suspended support for applications to the American Kidney Fund for patients enrolled in minimum essential Medicaid coverage. When CMS provides guidance, which we expect will be within a couple of weeks, we will evaluate our future policy.
Third, does our announcement signify a concern over our historical practices? No. Our historical practices were legal and compliant. That said, the language in RFI may confuse some, so I thought it would be useful to clarify further.
The RFI had primarily 3 concerns. One, whether patients enrolled in Medicare purchased an ACA Plan that was duplicative in coverage. None of our patients who were enrolled in Medicare enrolled in the ACA Plan. The regulations cited in the RFA, which referred to Medicare supplemental plan is not germane to the ACA Plan.
Number two, whether patients lost their Medicaid coverage as a result of purchasing an ACA Plan and therefore, were exposed to additional costs. Our patients did not lose their Medicaid coverage as a result of purchasing an ACA Plan and as a result, were not exposed to additional costs. Consistent with CMS' own education materials, we educated our patients on the ability to pick -- purchase an ACA Plan while retaining Medicaid coverage as a secondary. This patient did not apply for tax credits and subsidies.
And three, whether patients expensed a disruption in continuum of care as a result of purchasing an ACA Plan. Just a small portion of our Medicaid patients made the choice to purchase an ACA Plan, and they did so for their own personal reasons such as to have access to specialists who do not accept Medicaid or increased chance of qualifying for transplantation or other reasons. We are not aware of any patient experiencing a disruption in care likely because those patients who would have had such a disruption made the choice not to enroll in an ACA Plan.
Lastly, there have been some questions around comparing our disclosure of 5,000 patients versus public information from other providers. I believe that the confusion is around some definitions. When refer to individual market plans or ACA Plan, we refer to the full universe of individual plan, whether they're sold on or off the government-run exchanges. A distinction between these types of plans is not relevant because both affect the same risk pools and are generally subject to the same regulation. If you're trying to compare us to other providers, it is important to clarify definitions to ensure that the comparison is an apples-to-apples line.
Now let's discuss our Q3 performance. Overall, DaVita Kidney Care had a solid quarter. We delivered adjusted operating income of $439 million. For U.S. dialysis, our normalized non-acquired growth for the quarter was 4.4%, which falls within our long-term target range of 3.5% to 4.5%. While we're on the topic of volume, we want to share that we signed an amendment to the agreement of Renal Ventures to acquire 100% interest in their dialysis centers for $360 million, which is $55 million less than previously announced purchase price. We expect the transaction will close in the first quarter of 2017.
Our revenue per treatment was up sequentially by 1.7 -- $1.72 per treatment, primarily driven by an increase in seasonal administration of flu vaccine. Our patient care cost per treatment were up versus Q2 by $2.41 per treatment, driven by 2 primary factors: approximately 60% by an increase in labor benefits costs and 40% by an increase in facility costs. We have seen a tightening in labor markets leading to some increase in our labor costs. In the near term, we may see the labor costs remain at higher levels. We expect that our facility costs to come down over the next couple of quarters.
Now onto our outlook. Since we have now visibility to the end of the year, we're updating our 2016 adjusted operating income guidance for Kidney Care to be in the range of $1.695 billion to $1.725 billion. We will provide you with 2017 guidance on our Q4 earnings call when we expect to have additional clarity on several variables, including open enrollment and policy changes from CMS.
Now I'll turn the call to Vijay Kotte for DMG."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Javier. First, financial performance. We noted on the Q2 call that we will see accelerated noncash amortization expense for the ACP brand during the transition to DMG, which would impact our reported operating income. This will run for 30 month",341,"Thank you, Javier. First, financial performance. We noted on the Q2 call that we will see accelerated noncash amortization expense for the ACP brand during the transition to DMG, which would impact our reported operating income. This will run for 30 months at an incremental rate of slightly more than $2 million per month or $26 million on an annualized basis beginning September 2016. Including the impact of this accelerated amortization, operating income for the quarter was $33 million.
As we look at the full year, we are narrowing our 2016 adjusted operating income guidance to a range of $115 million to $145 million. This is effectively a slight increase as our guidance now includes the impact of the $9 million in accelerated brand amortization that was previously excluded.
Another question is how to think about 2017. We're still in the midst of our budget process, and open enrollment plays a big part in our outlook. That being said, there are some things we know. First, $40 million in rate cuts, which includes $30 million related to the Medicare model change and $10 million for Medicaid. Second, we have the $26 million of accelerated brand amortization. And third, we are continuing to make incremental investments in the business. Despite these headwinds, the odds are they will be roughly flat year-over-year, but there are reasonable probabilities on the other side of that. We will go into further detail regarding our expectation for 2017 on the Q4 earnings call.
As we continue to look towards our long-term OI, our 2019 target remain $215 million.
Finally, I want to provide a few highlights on the operating progress we're making at DMG. With regard to claims process without the need for manual intervention, 2015 we're at 26%; and in 2016, 79%. With regards to services getting electronic authorizations, 2015 was 24%, 2016 is 47%. And finally, with regards to new tuck-in [ph] clinician, in 2015, we had 18; and in 2016, we're at 44.
Now to Jim Hilger for some financial details on the quarter."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. I'll first address our international operations. Our international operating income was $368 million in the quarter, which improves the gain on the deconsolidation of the APAC JV of $374 million. We are on track to meet our guidance for app",600,"Thanks, Vijay. I'll first address our international operations. Our international operating income was $368 million in the quarter, which improves the gain on the deconsolidation of the APAC JV of $374 million. We are on track to meet our guidance for approximately $40 million in adjusted losses for 2016.
Our JV transaction with Khazanah and Mitsui closed on August 1. As you will recall, Khazanah and Mitsui have each subscribed to acquire 20% share of ownership of the joint venture. At closing, each partner made their first investment tranche of $50 million in return for a 6.7% ownership in the joint venture. This joint venture has been deconsolidated from our financials. Going forward, our pro rata share of its operating income will run through equity investment income in our income statement. As a result of this deconsolidation, we recorded a onetime noncash gain of $374 million. We are excluding this gain when reporting our adjusted non-GAAP financial results and excluding it from our adjusted operating guidance for 2016. We look forward to continuing our growth in Asia Pacific dialysis with the help of our new partners.
Next. I'd like to talk about a few tax items. In the third quarter, we recorded an adjustment related to tax assets created through the DMG acquisition escrow provisions. This adjustment resulted in a $27 million increase in corporate G&A expense that was offset by an equal reduction in income tax expense and thus, created no change in net earnings or earnings per share. We do not expect any ongoing impact from this adjustment.
Excluding this escrow provision tax adjustment and excluding the gain from the formation of the APAC dialysis joint venture, our tax rate attributable to DaVita was 40% in the quarter and 39% year-to-date. We expect our full year tax rate attributable to DaVita to be approximately 39%, when excluding all non-GAAP items.
Next, our interest expense increased slightly in the quarter to $105 million due to an increase in the interest rate cap amortization as well as the impact of the deconsolidation of the APAC joint venture. This higher level of interest expense reflects our go-forward run rate.
And finally, turning to our continued strong and consistent cash generation. Operating cash flow was $536 million in the third quarter and $1.92 billion for the last 12 months. We expect full year 2016 operating cash flow to be between $1.75 billion and $1.85 billion.
Since our last earnings release, we have repurchased 9.6 million shares for approximately $619 million. And through October, we have repurchased 13.3 million DaVita shares for approximately $868 million, which represents about 6.3% of the outstanding shares at the beginning of the year. Approximately 881 million remains outstanding under our board repurchase authorizations.
We continue to have a strong cash balance with nearly $1.6 billion in cash and short-term investments as of September 30. While $212 million was used in October to repurchase stock, and an additional $360 million will be used in the coming months for the completion of the Renal Venture acquisition, that still leaves us with over $1 billion of cash available before considering our continued strong cash-generating capabilities.
As discussed at our Capital Markets Day earlier this year, we expect to generate well over $5 billion in free cash flow to use for growth and share repurchases from 2016 to 2019. Even assuming a reasonable baseline of $1.5 billion in growth spending for development CapEx and acquisitions, this leaves over $3 billion for additional growth or share repurchase.
And now I'd like to turn it back to Kent for a few closing comments."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thanks, Jim, and I'd actually like to make several additional comments. Some will be a little bit redundant to what JR said, but it's such an important topic. We think it's worthwhile to in order to achieve good clarity. Allow me 8 different points, pleas",1162,"Thanks, Jim, and I'd actually like to make several additional comments. Some will be a little bit redundant to what JR said, but it's such an important topic. We think it's worthwhile to in order to achieve good clarity. Allow me 8 different points, please.
Number one. We fulfilled our regulatory responsibility to provide comprehensive education to our patients. This has been an industry requirement for the last 15 to 20 years, and then ACA was added onto that standard and long-standing process and practice.
Number two. A very small percentage of our Medicaid patients determined that an ACA Plan was better for them, and Javier mentioned some of the very significant reasons why some of those plans were way better for them and/or their families. I won't repeat the examples, but important and often beautiful improvements in care.
Number three. Nonetheless, if you look at the benchmark plan in EGHP plan, you see that total ESRD costs, meaning dialysis and hospital-related costs, et cetera, was about 1.3% of the total medical costs. That again is total ESRD costs in the numerator and then total medical costs for the plan in the denominator. In the ACA Plans, we estimate right now that, that percentage is only up to about 1.6%. And so it is a low absolute number and it's a low increase number.
Number four. We were very sensitive to the fact that some of these patients choosing an ACA Plan meant that we would be paid higher rates, commercial rates versus Medicaid rates. And therefore, we created a very intense oversight process to make sure that we did everything possible to live up to the CMS standards around objective presentation and information and absolutely letting the patient choose.
Number five. We, nonetheless, got swept up in the current huge controversies around the sustainability of the exchanges, and you're all sensitive to the huge political forces in play on that subject.
Number six. Why did dialysis, and in part DaVita, become a visible part of that controversy? Well, a, letter a, we're national, and so our numbers get added up nationally unlike a lot of health systems, which are regional or local.
B, our patients stick out. They're very high cost, very easy to identify, very discreet.
C, there have been abuses by providers in other segments and perhaps some abuses even in ESRD, and so upfront, we started to be painted with that brush by some without data to support.
D, some payers did have very large year-over-year increases in dialysis expense, and it was originally assumed that this must be from the process that I described earlier. But in fact, in many, probably most instances, it was driven by other factors. For example, sometimes, a plan had a differentially attractive product and would gain significant market share literally moving from having 50% of the ESRD patients in a market to 80%, thereby guaranteeing at least a 60% increase in your costs, having nothing to do with anything else other than product design. As we all know, this has been a very dynamic period, probably the most dynamic period ever in terms of alternative product design for insurance plans. And also, people have been struck by how smart the consumers are and how much shopping and switching they do. A second explainer in several markets is when there was a bad actor in the payer world, meaning someone who did inappropriate steering of patients away from themselves, leaving one of their competitors with a disproportionate percentage. And again, we're talking about 30%, 40% shifts in market share in some instances. A third driver out of probably a potential list of 7 or 8, but I'll stop after 3, is areas with relatively poor Medicaid coverage because that would naturally mean that there's a higher probability that a Medicaid patient would find an ACA Plan more attractive. This is just to give you a sense of what kind of things actually drove a lot of those year-over-year increases for particular plans because as we mentioned earlier, the aggregate reality only moved from 1.3 to 1.6.
But letter e, those high examples were taken to CMS and positioned as being reasonably representative of a broader movement. And at that point, CMS did not have the data of the 1.3 and the 1.6.
On to number 7 of 8. CMS is now starting to realize, contrary to initial impressions that, a, some of the numbers were misleading. That's not to say they were inaccurate if they were from a particular plan. They were just misleading. And as you start to stare at a number like a 0.3 increase, and again this is our estimate, but as you compare that to 22% rate increases on average, you can see that we were not a material source of the problem, nor are we a material source of the solution. 
Letter b, our patients made sensible choices, and we provided lots of examples to CMS as have other providers.
C, the fact that enrollment of dialysis patients within the ACA plans looks to be flat or down even without any change in Medicaid access in 2017 and '18, and of course, would be down even more with any restriction on the Medicaid front.
Letter d, CMS now is starting to see some of the reasons for the dramatic disparities in year-over-year dialysis expense increases and seeing how they have to do with product design, competition, et cetera.
And lastly, e, they also have a better sense of how charitable premium assistance has been embedded in the ESRD economic in clinical ecosystem for 20 years with a lot of guardrails and with the OIG's blessing, including blessing the aspect of provider funding.
So number 8 and final comment is, of course, the big question on everyone's mind, including ours, is what exactly is CMS going to decide with respect to this portfolio of decisions. And we don't know. No one knows. I think to their credit, they don't know right now because they're continuing to absorb information, and we are incredibly grateful and respectful that they are doing that.
Moving on to DMG. Just one happy announcement, and that is that Chuck Berg is joining our leadership team as Executive Chair of DaVita Medical Group. He'll report to me in my role as CEO of the enterprise. Chuck's been on our board since 2007. He has a wealth of experience in the health plan world, including having been the very successful executive chair of WealthCare Health Plans and prior to that, the CEO of Oxford Health Plans, where I was his nonexecutive chair. This experience, combined with his brain, makes him uniquely suited to help us evaluate our long-term strategic alternatives at DMG. And he will remain in our board in the meantime, and I and others look forward to working with him.
Operator, if you could please go ahead and open up the line for Q&A."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question is coming from Justin Lake of Wolfe Research.",13,"[Operator Instructions] Our first question is coming from Justin Lake of Wolfe Research."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I guess my first question here is just the company bought back $600 million of stock in the last 4 months at prices that are 15% above the current price. With full knowledge of the issues out there in terms of the concerns around third-party payment for A",135,"I guess my first question here is just the company bought back $600 million of stock in the last 4 months at prices that are 15% above the current price. With full knowledge of the issues out there in terms of the concerns around third-party payment for ACA coverage, right, given the potentially significant impact on earnings here, the downstream impacts of just the government taking a harder look at third-party funding in general, managed care negotiations, et cetera, potentially getting impacted, my question is should we take this as a sign of your comfort level with the potential of downstream impacts on third-party payment changes, et cetera, on the earnings power of the business? And if so, any color you could share on why your level of comfort is that high will be helpful."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Thanks, Justin. I would not say that the reason we chose to buy back was because any particularly distinctive level of confidence on what exactly the outcome was going to be. And certainly, if we could do it over again, we would have preferred to hav",113,"Yes. Thanks, Justin. I would not say that the reason we chose to buy back was because any particularly distinctive level of confidence on what exactly the outcome was going to be. And certainly, if we could do it over again, we would have preferred to have waited and be buying back more of it now. But awfully difficult to predict things. There's a lot of different variables, not only with respect to the issues you mentioned, but other issues, both threats and opportunities. And nonetheless, I would not say that we said, ""Gosh, there's some distinctive near-term downside, and we're going to go ahead and buy anyway."" I wouldn't make that claim."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Then maybe we can just talk about your commercial mix in general given this has been a big area of focus here. We look at the changes and the growth and -- in the commercial mix, and if we back out these 2,000 patients, it looks like it's been flat",165,"Okay. Then maybe we can just talk about your commercial mix in general given this has been a big area of focus here. We look at the changes and the growth and -- in the commercial mix, and if we back out these 2,000 patients, it looks like it's been flat over the last several years. But looking ahead and just thinking about the changes, looks like the -- from USRDS data, there hasn't really been much incidence growth in the pre-65 population over the last 10 years. And when we couple that with the aging of the baby boomers and the Medicare from kind of commercial years, there's the indication that it could put a fair amount of pressure on commercial mix over time. So I guess my question is can you tell me whether this is a reasonable view? And if so, how should we think about this factor in relation to your typical kind of mid-single-digit long-term growth algorithm for the dialysis?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. It's a very fair question, Justin. And I think if you wanted to identify other worrisome long-term trends, you would also look at improved treatment regimens for diabetics and hypertensives. And commercial patients are more likely to benefit from imp",200,"Yes. It's a very fair question, Justin. And I think if you wanted to identify other worrisome long-term trends, you would also look at improved treatment regimens for diabetics and hypertensives. And commercial patients are more likely to benefit from improved treatment regimens. On the other hand, there's also things pushing in the other direction. We continue to be quite successful with our Non-Acquired Growth, and some of these hard times could lead a lot more small providers to sell or even shut down. In addition, we're very hopeful that Medicare Advantage continues to grow because we radically prefer a customer who cares about total value. And we tend to do much better in terms of both adding value to the system and getting reimbursed for it. In addition, as you know better than most, to the extent that the mix ever starts to put too much pressure on all the independent centers, the government has the easy option of doing that, which it's done 3 or 4 times before, and that's extending the MSP provision from originally 0 to 12 and 12 to 18 and 18 to 30. And so that's a safety valve that's never far away. Justin?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Yes. I -- Kent, if you could give me one more chance. I'll just ask you like does this mean that should we think about within the 6, let's just call it, mid-single-digit CAGR that you look for, for the dialysis business? This mix looks like just the likel",86,"Yes. I -- Kent, if you could give me one more chance. I'll just ask you like does this mean that should we think about within the 6, let's just call it, mid-single-digit CAGR that you look for, for the dialysis business? This mix looks like just the likely pressure that's going to be on commercial mix over the next 10 to 20 years. Is this in that number? Or could this have a negative impact on that number in the way you're looking at it?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, fair question. I would say that at the time we did the last Capital Markets, we incorporated all the variables, although that was a 3-year outlook. When we refresh our Capital Markets outlook at the next one, it will once again incorporate everything",162,"Yes, fair question. I would say that at the time we did the last Capital Markets, we incorporated all the variables, although that was a 3-year outlook. When we refresh our Capital Markets outlook at the next one, it will once again incorporate everything. And while some of the stuff that you're citing is most likely not going to be economically material within the near term, perhaps we should, for the first time in a long time, take a cut that sort of the 4 to 7 year time frame and stare at some of the upsides and downsides, the puts and takes, not only on mix but on cost structure, et cetera, also modality mix and some other things that can have a big impact on cash flow and return on capital. So we don't have anything distinctively thoughtful to say to you today from an analytical point of view, but that's probably a good assignment for the next Capital Markets."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Kevin Fischbeck of Bank of America Merrill Lynch.",14,"Our next question is coming from Kevin Fischbeck of Bank of America Merrill Lynch."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I have a lot of questions kind of similar to that, but I guess I appreciate all the color about the AKF change. I think that was very helpful. I think I understand those parameters. But I guess the question that I'm still struggling with is what the real",226,"I have a lot of questions kind of similar to that, but I guess I appreciate all the color about the AKF change. I think that was very helpful. I think I understand those parameters. But I guess the question that I'm still struggling with is what the real growth rate the company has been over the past 3 years in the dialysis business because if I look at operating income growth over the last 3 years, it's been about 5% per year. But if I were to say that this 140 was either not sustainable or onetime in nature, then I'm getting like a 2% type growth in the dialysis business over the past 3 years. So how do we think about that? And that's the low end of what you guys think you're going to do over the next 3 years going forward. And when I think about the next 3 years versus the last 3 years, Medicare rates have been under pressure and likely will be in the same range. So why is the right way to think about growth over the next 3 years not the low end of that 3 to 7? Like what would cause you to do better than the low end of that range? Or is 4 at the low end the right way to think about it?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Right now, I would say if you wanted to weight the probabilities between the low end, middle and top, you would find the probability skewed to the low end, but it's not by huge amount. And then in addition, of course, unit volume is, for us, in many",115,"Yes. Right now, I would say if you wanted to weight the probabilities between the low end, middle and top, you would find the probability skewed to the low end, but it's not by huge amount. And then in addition, of course, unit volume is, for us, in many ways, of secondary importance with commercial mix and the nature of commercial mix of primary importance. And that number has got a lot of dynamism to it right now, as you well know. And so at this point, we're not revising that guidance, but we do look forward to a very intense analytical discussion at the next Capital Markets about the next generation of 3-year outlook."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Then I guess if we look at commercial mix and take out this maybe 1% that's related to the ACA, it looked like mix has basically been flat over the last 5 years, maybe down a little bit during a time when the economy is improving. So do you think th",117,"Okay. Then I guess if we look at commercial mix and take out this maybe 1% that's related to the ACA, it looked like mix has basically been flat over the last 5 years, maybe down a little bit during a time when the economy is improving. So do you think that, that's really reflective of what the industry has been seeing? Or I know from time to time you raise flags about potentially competitors being aggressive on pricing. Has there been anything where you feel like you've purposely walked away from market share because people got competitive? Or is that kind of how you think mix overall for the industry has looked over that time period?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Our guess is that our trajectory of commercial mix is quite similar to others, and we have not experienced any example of someone in our mind foolishly seeking to gain shares through price reductions in an industry of almost pure variable cost, very stick",70,"Our guess is that our trajectory of commercial mix is quite similar to others, and we have not experienced any example of someone in our mind foolishly seeking to gain shares through price reductions in an industry of almost pure variable cost, very sticky volume and high likelihood of economic retaliation. So we haven't seen any of that go on, and so our guess is that competitor performance is comparable."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just one last question. On HCP, looks like the number of physicians and clinicians went up nicely sequentially, but we still saw a deceleration in revenue in that business for Q2 to Q3. Wanted to see what was going on there and whether incr",64,"Okay. And then just one last question. On HCP, looks like the number of physicians and clinicians went up nicely sequentially, but we still saw a deceleration in revenue in that business for Q2 to Q3. Wanted to see what was going on there and whether increase in physicians is a good sign about a ramp-up in revenue over the next couple of quarters."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Over the long term, you should see a positive correlation. Right now in some cases, we were under staffed with physicians. And by adding them, we actually think we can reduce our MLR and the quantity that exceeds the incremental costs that we're addi",166,"Yes. Over the long term, you should see a positive correlation. Right now in some cases, we were under staffed with physicians. And by adding them, we actually think we can reduce our MLR and the quantity that exceeds the incremental costs that we're adding. In other cases, we're adding because we're doing some de novos and other work where we think by adding physician capacity, we're going to get more lives. It's just that there's some lag time. So we're very sensitive to the fact that at a time when the revenue trajectory is what it is, our physician recruiting is ramping up. But the good news is that shows what an attractive place we are for physicians and our hit rate in recruiting is very high. The concerning news for you is we're adding the costs at a time when revenues aren't going up at the same trajectory. And so we hear you, and over time, you should see the positive correlation you expect."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Is the right way to think about that as like a couple of quarter lag? Or a year lag? How long do we think about these doctors adding to the earnings?",32,"Okay. Is the right way to think about that as like a couple of quarter lag? Or a year lag? How long do we think about these doctors adding to the earnings?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, unfortunately, I don't think we're good enough yet to give you an empirical answer for that, and so I won't hazard a guess. Suffice it to say, we know you'll be watching each quarter.",35,"Yes, unfortunately, I don't think we're good enough yet to give you an empirical answer for that, and so I won't hazard a guess. Suffice it to say, we know you'll be watching each quarter."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Gary Lieberman of Wells Fargo.",11,"Our next question is coming from Gary Lieberman of Wells Fargo."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I guess just sticking with the topic of the day. I think there's a broader concern by some investors that potentially the AKF would be restricted more broadly from making premium support payments to historical patients that they would have been doing it f",66,"I guess just sticking with the topic of the day. I think there's a broader concern by some investors that potentially the AKF would be restricted more broadly from making premium support payments to historical patients that they would have been doing it for COBRA or for other factors. Can you talk about that? Do you think that is a risk? And why or why not?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. It is a risk, but the 2 big facts on that big issue are that for private plans to do a broad prohibition of charitable premium assistance is an exceptionally heavy lift because there are hundreds of such organizations all over the country, and thousa",108,"Yes. It is a risk, but the 2 big facts on that big issue are that for private plans to do a broad prohibition of charitable premium assistance is an exceptionally heavy lift because there are hundreds of such organizations all over the country, and thousands of hospitals that like those foundations and charities and the rest. And to try to deploy one that's focused on our patients would be discriminatory and subject to really intense lawsuits. And then separately, CMS does not have authority over the whole EGHP realm. They, of course, have authority over lots of other realms, but not that one. Is that responsive, Gary?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Yes, that's helpful. Any chance you could tell us what percentage of your commercial patients, if you know it, receive premium assistance from the AKF?",25,"Yes, that's helpful. Any chance you could tell us what percentage of your commercial patients, if you know it, receive premium assistance from the AKF?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I think at this point, we've decided that disclosing that is not in your best interest, although we'll continue to stare at that each quarter. But that's our current thinking. Of course, we incorporate all variables into our forecasts, but sometimes, some",48,"I think at this point, we've decided that disclosing that is not in your best interest, although we'll continue to stare at that each quarter. But that's our current thinking. Of course, we incorporate all variables into our forecasts, but sometimes, somebody's swing factors are difficult to calibrate."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on the same topic, I think there are some investors that believe that, in fact, it's illegal to -- for the Medicaid patients to have been given premium support. Can you just talk about that? And your understanding, I assume, from your persp",57,"Okay. And then on the same topic, I think there are some investors that believe that, in fact, it's illegal to -- for the Medicaid patients to have been given premium support. Can you just talk about that? And your understanding, I assume, from your perspective, it's not illegal? Can you just help us think through that?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Sure. I appreciate you bringing it up because we certainly heard the concern. And the very explicit references by CMS to how it is legal are multiple and really clear. And the RFI referred to a part of the statute that didn't apply to the subject at hand.",110,"Sure. I appreciate you bringing it up because we certainly heard the concern. And the very explicit references by CMS to how it is legal are multiple and really clear. And the RFI referred to a part of the statute that didn't apply to the subject at hand. So it was literally not germane to the critical questions that you and others are worried about. And so we have continued to point to the very explicit language supporting our position. We have been in meetings with senior CMS officials and referred to the fact that it's a very clearly legal and have never run into a single objection from anyone."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Gary, let me add one thing, Gary, that might help clear it up. It is the case that Medicaid patients cannot have federal subsidies, and so it's not that there aren't some rules that apply, but it is very clear that there was a conscious decision made to a",123,"Gary, let me add one thing, Gary, that might help clear it up. It is the case that Medicaid patients cannot have federal subsidies, and so it's not that there aren't some rules that apply, but it is very clear that there was a conscious decision made to allow Medicaid patients to make the choices that we made available to them. And I'll even add one other element. Back when the Affordable Care Act was being rolled out, we were encouraged by the administration to promote exchange products. We were even asked to put up signs in our centers promoting the ACA Plans. Now of course, it's 4 years later and a lot of things have changed, but that's the actual historical context."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Great. That's very helpful. And then, Jim, can you just remind us at what point you would have been restricted from purchasing your stock after the end of the quarter?",30,"Great. That's very helpful. And then, Jim, can you just remind us at what point you would have been restricted from purchasing your stock after the end of the quarter?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, we entered -- we typically enter restriction period at -- near the very end of the quarter, and we would be restricted throughout the period of time after the quarter ended until through this call.",36,"Well, we entered -- we typically enter restriction period at -- near the very end of the quarter, and we would be restricted throughout the period of time after the quarter ended until through this call."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Got it. But I thought you guys did, in fact, purchase some stock after the end of the quarter?",19,"Got it. But I thought you guys did, in fact, purchase some stock after the end of the quarter?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, we did, and that was subject to a plan that we put in place before we were blocked out.",20,"Yes, we did, and that was subject to a plan that we put in place before we were blocked out."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","So you did 10b-5 in place before it was blocked out?",12,"So you did 10b-5 in place before it was blocked out?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","That's correct.",3,"That's correct."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Chris Rigg of Susquehanna.",10,"Our next question is coming from Chris Rigg of Susquehanna."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I just wanted to again come back to the AKF issue. Obviously, you're pointing at 140 million of OI this year as that being the potential headwind for next year. But can you give us a sense for how that ramps during the first 2 years of the coverage expans",50,"I just wanted to again come back to the AKF issue. Obviously, you're pointing at 140 million of OI this year as that being the potential headwind for next year. But can you give us a sense for how that ramps during the first 2 years of the coverage expansions?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","How the 140 million ramped up?",6,"How the 140 million ramped up?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Like what was the exposure in 2014 and then in '15? And now you're at 140 million for this year in roughly 2,000-ish patients.",24,"Like what was the exposure in 2014 and then in '15? And now you're at 140 million for this year in roughly 2,000-ish patients."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Okay. I know we didn't calculate that number prior to the call. Why don't -- the people around the table here will see if we can and should generate that and share it before the call is over, but we don't have it at our fingertips.",46,"Okay. I know we didn't calculate that number prior to the call. Why don't -- the people around the table here will see if we can and should generate that and share it before the call is over, but we don't have it at our fingertips."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then sort of another qualitative-type question here on the AKF issue, but obviously, getting to some of the -- at least what's been sort of suggested from the managed care side is that by shifting some of these people from, call it, 100% Medicai",114,"Okay. And then sort of another qualitative-type question here on the AKF issue, but obviously, getting to some of the -- at least what's been sort of suggested from the managed care side is that by shifting some of these people from, call it, 100% Medicaid to sort of Medicaid as a supplemental, there may have been some out-of-pocket exposure here. I guess when you guys did your look back and reviewed the 2,000 or whatever that may have been in '15 and '14, what did you do? I guess I'm just trying to get some comfort here that you guys feel pretty comfortable that in no material way were the individuals harmed financially."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I'll take the first stab and then other people may want to add on. First of all, we dedicated a huge amount of time in developing materials and training our people and so that our historic discipline of presenting objectively was on steroids for this proc",181,"I'll take the first stab and then other people may want to add on. First of all, we dedicated a huge amount of time in developing materials and training our people and so that our historic discipline of presenting objectively was on steroids for this process. And we present very complete information that encompasses premiums, deductibles, co-pays, out-of-pocket stuff, potential federal tax credits, potential charitable premium assistance, individual versus family, high income versus low. And so we're thorough, and it's presented to the patients in ways that leaves most of them exceptionally grateful for the help and the clarity, and then they choose. So one can never say that theoretically, you couldn't have a patient choose something that was foolish. I'm sure out of 2,000 patients, there were some. But we have to respect the fact that it's their choice. In general, however, just as we've seen in the exchanges over the last 3 or 4 years, the average patient demonstrates a lot of economic common sense in how they move around between different products, particularly when they are helped."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","And Chris, this is Javier. I'll just add one important point, is that they never lose their Medicaid. Medicaid was in the secondary position, so the patients actually didn't incur additional costs.",32,"And Chris, this is Javier. I'll just add one important point, is that they never lose their Medicaid. Medicaid was in the secondary position, so the patients actually didn't incur additional costs."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay, okay. And then just one last one here on Kidney Care operating income for next year. You made reference in the Monday press release that there could be some theoretical offsets to the 140 million. If there are, can you give us a sense for what they",68,"Okay, okay. And then just one last one here on Kidney Care operating income for next year. You made reference in the Monday press release that there could be some theoretical offsets to the 140 million. If there are, can you give us a sense for what they are? And then just can you just give us some general sort of headwinds and tailwinds beyond the AKF issue?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, first of all, on mitigation, we'll be able to do a good job on that in the next quarterly call if we're in this scenario where that's the topic of the day. Separate from that, and then someone else may want to add, I mean, on the plus side, we have",129,"Well, first of all, on mitigation, we'll be able to do a good job on that in the next quarterly call if we're in this scenario where that's the topic of the day. Separate from that, and then someone else may want to add, I mean, on the plus side, we have a wonderful recurring unit growth. We have the potential accelerator of continued Medicare Advantage growth. On the cost structure side, we have the opportunities in the ESA area. And on the capital deployment side, we have the opportunity for more small operators filling a need to get out of this ever more complicated and challenging business. On the headwind side, I think we've laid them out with painful detail already, and so I won't list them again."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from John Ransom of Raymond James.",11,"Our next question is coming from John Ransom of Raymond James."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I did 1 day of law school and ran off in harp [ph], so my peabrain isn't large to understand all these fine points. But to make it simple, one of your competitors said that the no-no in their opinion was to switch people off Medicaid, but the ambiguity wa",123,"I did 1 day of law school and ran off in harp [ph], so my peabrain isn't large to understand all these fine points. But to make it simple, one of your competitors said that the no-no in their opinion was to switch people off Medicaid, but the ambiguity was when a new patient came in eligible for both Medicaid and an ACA Plan, that's where you could present both. Is what you're doing just sort of in line with that, that new patients come in, a fair game. They don't have insurance, but existing patients with Medicaid, you're no longer going to try switch them. I know I'm over simplifying, but is that a helpful way to think about it? Or no?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It's LeAnne. I think the -- you're confusing 2 things, so let's talk about patients who find us for ACA coverage made that choice and retained their Medicaid in the secondary. I think that answers the first question. There's no -- we're not substituting A",66,"It's LeAnne. I think the -- you're confusing 2 things, so let's talk about patients who find us for ACA coverage made that choice and retained their Medicaid in the secondary. I think that answers the first question. There's no -- we're not substituting ACA coverage for Medicaid. If they're keeping them, they're having both of them, and it's not subsidized by federal tax credits."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Does that answer the first half of your question, John?",10,"Does that answer the first half of your question, John?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Well, not really but I'll follow up. I think there's so many cross-currency [ph]. I don't want to drag this out on the call. And what about the second scenario where a patient comes in without any -- maybe they're eligible for Medicaid but they just",97,"Okay. Well, not really but I'll follow up. I think there's so many cross-currency [ph]. I don't want to drag this out on the call. And what about the second scenario where a patient comes in without any -- maybe they're eligible for Medicaid but they just never signed up. How does that work? And is that something -- again, your competitor said we expect CMS to clarify the rules on that patient B that comes then without any insurance at all. Is that [indiscernible]? Or again, was that a misleading comment by one of your competitors?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. I think we do have patients that come to us that are uninsured, and our education and process with those patients would be to find out all the avenues to which they could purchase coverage, whether they're being Medicare or Medicaid or commercial plan",82,"No. I think we do have patients that come to us that are uninsured, and our education and process with those patients would be to find out all the avenues to which they could purchase coverage, whether they're being Medicare or Medicaid or commercial plan, an ACA Plan, et cetera. So our counselor's job is to make sure that each of the avenues is presented to that patient, and then the patient chooses what is best for them in their particular circumstance."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. LeAnne, hadn't heard from you in a while, so it's good to hear your voice. The second question I had was -- I mean, obviously in some of the comments, there were allegedly comments from were either current or former DaVita employees who talked about",96,"Okay. LeAnne, hadn't heard from you in a while, so it's good to hear your voice. The second question I had was -- I mean, obviously in some of the comments, there were allegedly comments from were either current or former DaVita employees who talked about being pressured to sign people up on commercial plans. So I'm sure you saw that stuff. Just internally, what kind of controls do you have in place to investigate those kinds of comments? And what's your general view on that? True? Not true? Out of context? That will be helpful."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","John, thank you. This is Javier. First of all, we'd like to highlight that the numbers are small. But of course, regardless of the size of the number, we take each and every one very seriously. We did some huge, huge oversight here. We had to train a lot",173,"John, thank you. This is Javier. First of all, we'd like to highlight that the numbers are small. But of course, regardless of the size of the number, we take each and every one very seriously. We did some huge, huge oversight here. We had to train a lot of people in a very short amount of time, and so we had heavy oversight. And for a small number of people, they might have experienced that as negative. What we do is, of course, if we have any concerns, we give it to a third party. We give it to our compliance department. And they look into it and we rectify if there are any mistakes. But the bulk of what we've looked into has now materialized. And actually, when we've gone into some sessions, we've literally asked for evidence to be provided of our wrongdoing and alleged wrongdoing. And we've never been given any specifics because, of course, we would want to correct any mistakes if they were brought to our attention."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. That's great. And then let's switch gears and 2 more quick ones. Let's say we are in a scenario of a little more austerity on a number of fronts. I mean, there's obviously a big gap between your total CapEx and your maintenance complex. In a more au",159,"Okay. That's great. And then let's switch gears and 2 more quick ones. Let's say we are in a scenario of a little more austerity on a number of fronts. I mean, there's obviously a big gap between your total CapEx and your maintenance complex. In a more austere scenario, and I'll just make up a number, let's say revenue per treatment is $340 to $345 for a bunch of reasons. How should we think about the likely reaction of the company? What levers would be likely to be pulled? And again, CapEx is one that would appear to be one where you have a lot of discretion over. And again, I ask this because there's a debate on The Street about should we look at DaVita on earnings per share? Or should we look at it on free cash flow? And free cash flow requires the assumption that CapEx is closer to maintenance and then there's the actual."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, we hear you. The answer right now will be fairly generic. I mean, in a world where we would suffer some serious revenue compression, we would do what any responsible businessperson should do and very systematically go through every line item on the P",103,"Yes, we hear you. The answer right now will be fairly generic. I mean, in a world where we would suffer some serious revenue compression, we would do what any responsible businessperson should do and very systematically go through every line item on the P&L and every aspect of cash in and cash out. And we would enter into that process with the expectation that we would find some savings in the P&L side, and we will find some reductions on the CapEx side. And at the same time, we haven't quantified those, but we certainly do have some serious ranges of discretion."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Was the reduction in price for Renal Ventures driven by the new thinking around ACA Plans? Or was it something else?",22,"Okay. Was the reduction in price for Renal Ventures driven by the new thinking around ACA Plans? Or was it something else?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No, it was something else. There was a part of the transaction that was contemplated at the beginning. And after further dialog, we are not going to acquire their infusion business. So that's why the price was changed.",38,"No, it was something else. There was a part of the transaction that was contemplated at the beginning. And after further dialog, we are not going to acquire their infusion business. So that's why the price was changed."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I see. And is that -- you still think you might get that done? I know it's been dragging on for over a year. Is that still to be done by the end of the year? Or maybe you never said, but that's our assumption, fair, reasonable assumption.",48,"I see. And is that -- you still think you might get that done? I know it's been dragging on for over a year. Is that still to be done by the end of the year? Or maybe you never said, but that's our assumption, fair, reasonable assumption."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. We think it will -- there are some chance of Q4. But if you were betting, I would probably go with Q1 because there's some regulatory stuff going on. So I think Q1 [indiscernible].",35,"No. We think it will -- there are some chance of Q4. But if you were betting, I would probably go with Q1 because there's some regulatory stuff going on. So I think Q1 [indiscernible]."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","[indiscernible] 18 months, is that a record? I don't think 18 months might be a record.",16,"[indiscernible] 18 months, is that a record? I don't think 18 months might be a record."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It is. It's a new record for us anyway.",9,"It is. It's a new record for us anyway."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And lastly, just thinking about potential good guys. ESA costs. Do you have a view of -- you've got your current contract with Amgen, obviously. But if you do a market check on what other folks are now paying for ESAs, what's your view on your kind of app",76,"And lastly, just thinking about potential good guys. ESA costs. Do you have a view of -- you've got your current contract with Amgen, obviously. But if you do a market check on what other folks are now paying for ESAs, what's your view on your kind of apples-to-apples cost versus what's currently -- if you are free of that contract, would that be a good guy that could be called out? And I'll stop there."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, it's LeAnne again. I think you have to put it into 2 buckets. Obviously, I think the public announcement by FMC as to their cost reductions associated with their using Mircera gives you in one category. So clearly, I think they are enjoying the price",140,"Yes, it's LeAnne again. I think you have to put it into 2 buckets. Obviously, I think the public announcement by FMC as to their cost reductions associated with their using Mircera gives you in one category. So clearly, I think they are enjoying the price that is better than the rest of the marketplace. Then you take the rest of the marketplaces on Amgen products. And I think there was a lot of buzz about the move to Aranesp lowered the independent and small providers' costs. Well, that's correct, it did. But that's a relative lowering, and our ESA cost has been historically off the bat. And I think that holds true, and so you -- if you want to ask it again in a different way, but I think that should give you the answer you're looking for."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","So in short, probably unless somebody opens up that contract, probably not -- it's probably reasonable to assume not much movement on that -- on that line item through the terms of the contract?",34,"So in short, probably unless somebody opens up that contract, probably not -- it's probably reasonable to assume not much movement on that -- on that line item through the terms of the contract?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I don't know if that's necessarily the right conclusion. Of course, when you enter into a long-term contract, both parties will look into it as things change. Amgen, of course, is interested in seeing that we are a customer post contract renewal, and we w",123,"I don't know if that's necessarily the right conclusion. Of course, when you enter into a long-term contract, both parties will look into it as things change. Amgen, of course, is interested in seeing that we are a customer post contract renewal, and we want to be talking to all the parties that are out there. And so what we're trying to make sure is that we have the right term solution for the long haul, so we're looking at this. You seldom get a chance to look at an $800 million cost line, and so we are very eager in deploying the right level of rigor and resources to make sure that we get the right relationship going forward post '18."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, and I've got an answer for the question that Chris brought up, which is sort of this $140 million, how did it build over time? It won't be very precise, but it will give you directionally what you're seeking. And that is that the bulk of growth came",116,"Yes, and I've got an answer for the question that Chris brought up, which is sort of this $140 million, how did it build over time? It won't be very precise, but it will give you directionally what you're seeking. And that is that the bulk of growth came in '15 and '16. '14, it was a small number. If we had to estimate, in the $20 million or so range. In '15, the range is probably somewhere in the -- I don't know, double that, give or take. We don't have very precise numbers, but we just wanted to give you directionally that the bulk of it was in '16 with some growth in '15."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Gary Taylor of JPMorgan.",10,"Our next question is coming from Gary Taylor of JPMorgan."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Just a couple of things. Given some of the reports that some of the health plans have already attempted to identify patients with AKF subsidies and even potentially terminate some of those contracts, I just want to check in on commercial mix. I know you d",81,"Just a couple of things. Given some of the reports that some of the health plans have already attempted to identify patients with AKF subsidies and even potentially terminate some of those contracts, I just want to check in on commercial mix. I know you disclosed it annually, not quarterly. But I do think last quarter, you did acknowledge that it was still trending higher year-over-year. So I wanted to see if that was still true for 3Q '16 versus '15."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I'm sorry, Gary, your question is commercial mix? What period to what period?",14,"I'm sorry, Gary, your question is commercial mix? What period to what period?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Q3.",1,"Q3."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Just year-over-year in the third quarter. Is it still trending higher year-over-year in the third quarter?",17,"Just year-over-year in the third quarter. Is it still trending higher year-over-year in the third quarter?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It is. It is up year-on-year, Gary.",7,"It is. It is up year-on-year, Gary."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And sequentially, that probably hasn't done a lot. Is that fair?",11,"And sequentially, that probably hasn't done a lot. Is that fair?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","We've seen it go down slightly in the last quarter.",11,"We've seen it go down slightly in the last quarter."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just back to Renal Ventures. Is that still ballpark 2,300 to 2,400 patients and then anticipating some divestitures? Is that still ballpark?",25,"Okay. And then just back to Renal Ventures. Is that still ballpark 2,300 to 2,400 patients and then anticipating some divestitures? Is that still ballpark?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And then I just want to go to the patient care costs, which you called out. And I think you talked about 60%, labor; 40%, facility costs. But that was in the context of a couple dollar sequential change given that ESRD OI was down year-over-year and the c",86,"And then I just want to go to the patient care costs, which you called out. And I think you talked about 60%, labor; 40%, facility costs. But that was in the context of a couple dollar sequential change given that ESRD OI was down year-over-year and the costs jumped about $6 year-over-year. Is that still the same -- would that still be the same ratio if I look at the year-over-year, that more than half of that is labor and the rest is facility costs?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And when you say facility cost, you said it's coming down, what exactly is driving that up temporarily?",18,"And when you say facility cost, you said it's coming down, what exactly is driving that up temporarily?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It was a -- it's a bunch of miscellaneous line items. None of them particularly stick out. So it would just be giving you a very long list, and they just cumulatively added up to something this time, and so we're working on it.",44,"It was a -- it's a bunch of miscellaneous line items. None of them particularly stick out. So it would just be giving you a very long list, and they just cumulatively added up to something this time, and so we're working on it."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Last question. I believe you were talking about HCP's OI potentially being flat into '17. And you made no comments on consolidated or kidney, and I just wanted to confirm that, that, that was correct.",35,"Last question. I believe you were talking about HCP's OI potentially being flat into '17. And you made no comments on consolidated or kidney, and I just wanted to confirm that, that, that was correct."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, that's correct. We'll be providing guidance on '17 in the next quarterly call for Kidney Care, for U.S. Kidney Care.",21,"Yes, that's correct. We'll be providing guidance on '17 in the next quarterly call for Kidney Care, for U.S. Kidney Care."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next is question is coming from Whit Mayo of Robert W. Baird.",13,"Our next is question is coming from Whit Mayo of Robert W. Baird."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I'll try to keep it quick. But maybe one more on the AKF. It doesn't appear that you implemented this exchange initiative until 2015, at least according to the RFI submission. So one, just looking to confirm that. And the ACA obviously was implemented in",87,"I'll try to keep it quick. But maybe one more on the AKF. It doesn't appear that you implemented this exchange initiative until 2015, at least according to the RFI submission. So one, just looking to confirm that. And the ACA obviously was implemented in 2014, and you knew about it many years prior. So was there something that made you apprehensive about pursuing the strategy with patients and why perhaps it wasn't implemented in 2013 or '14 open enrollment? Just looking for any additional color."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","There was no conscious delay on our part.",8,"There was no conscious delay on our part."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe just one last one. With the MA Star Ratings published, how would you characterize your -- how your health plan partners are positioned next year? And what do you think this means for DMG? And maybe the conclusion when you see -- when",53,"Okay. And then maybe just one last one. With the MA Star Ratings published, how would you characterize your -- how your health plan partners are positioned next year? And what do you think this means for DMG? And maybe the conclusion when you see -- when you look at scores like Humana's?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, this is Vijay. Just to be clear, the '17 numbers are already fixed, right? So we don't see much of a change between '16 and '17. The Humana numbers were for payment year of 2018, and the only place where we saw a potential drop was in one market. And",108,"Yes, this is Vijay. Just to be clear, the '17 numbers are already fixed, right? So we don't see much of a change between '16 and '17. The Humana numbers were for payment year of 2018, and the only place where we saw a potential drop was in one market. And as you know, the Star scores are related to a number of factors. But our clinical quality was at a 4 Star and above, and we believe that in partnering with our health plan, there's some administrative opportunities to help neutralize some of the impact of the potential hit for 2018 for Humana in that one market."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Patrick Wood of Citi.",10,"Our next question is coming from Patrick Wood of Citi."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I'll be very quick, and this should be fairly yes or no [indiscernible] questions. I have 3, if I may. The first will be I was very interested to hear about the apples-to-apples comparison in terms of patient numbers in relation to the CMS RFI submission.",168,"I'll be very quick, and this should be fairly yes or no [indiscernible] questions. I have 3, if I may. The first will be I was very interested to hear about the apples-to-apples comparison in terms of patient numbers in relation to the CMS RFI submission. I'd be curious to hear what you guys think is an apples-to-apples number vis--vis what your competitors submitted. I'd be very curious to hear that. Equally, second question would be when I back off from your operating income sort of impact you guys kind of give us the $140 million, I get to about a 715-or-so dollar revenue implied per treatment for the exchange funds. Is that a fair kind of back out? Or is there other noise in that, that means our revenue per treatment number, that I got it wrong somehow? And then finally, I'll be very curious to hear of your commercial business. What percentage do you guys feel is out of network? It would be very helpful."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, let me tackle number one and number three, and then someone else can take a stab at number two. On out of network, we don't disclose exact percentages, but we've successfully dramatically reduced that number over the last 5 years. And strategically",192,"Well, let me tackle number one and number three, and then someone else can take a stab at number two. On out of network, we don't disclose exact percentages, but we've successfully dramatically reduced that number over the last 5 years. And strategically from a relationship point of view, we'd much prefer to be in network. And at the same time, of course, the payer's got to make a reasonable offer for that trade-off. And so that's the answer on out of network. On the patient count issue, the apples-to-apples issue, all we know is our number and our definition. And we've provided, we think, the right definition for you to be able to assess the economics associated with this issue. And then if other competitors slice and dice it in different ways, we can't really opine on that. You'll have to really talk to them about why they think it's the right way to do that. Hopefully, we're pretty clear about why we think batching [ph] on and off exchanges is the right way to look at it, for our shareholders at least. And then on the second one, can somebody..."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. On the implied revenue per treatment, you're doing -- you're about right. And of course, there's discrepancies geographically and by payer and product mix, et cetera. But yes, you're in the ZIP Code.",34,"Yes. On the implied revenue per treatment, you're doing -- you're about right. And of course, there's discrepancies geographically and by payer and product mix, et cetera. But yes, you're in the ZIP Code."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our last question is coming from Justin Lake of Wolfe Research.",11,"Our last question is coming from Justin Lake of Wolfe Research."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I wanted to touch on the -- I think that people are trying to figure out the other $90 million of potential pressure here. And so I just wanted to walk through. Is there any way to think about where those patients came from? Specifically, you've got 3,000",151,"I wanted to touch on the -- I think that people are trying to figure out the other $90 million of potential pressure here. And so I just wanted to walk through. Is there any way to think about where those patients came from? Specifically, you've got 3,000 patients that are on ACA. About half of them are getting AKF assistance. I assume it's a lot less likely CMS does something to stop people who came to you with commercial to keep what they have or having AKF help them keep what they have versus maybe those that come to you uninsured and they're just waiting for the 3-month Medicare period. Maybe CMS steps in on that. Is there some way to think about the -- that $90 million and how to think about the risk and maybe break it down to those 2 pools, keep what you have versus uninsured?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Let me take a little bit of a stab here, Justin. But I'm not sure we're going to be able to give you what you want. In total, there there's kind of 3 buckets. There's the Medicaid bucket, which, of course, has gotten a huge amount of attention and discuss",222,"Let me take a little bit of a stab here, Justin. But I'm not sure we're going to be able to give you what you want. In total, there there's kind of 3 buckets. There's the Medicaid bucket, which, of course, has gotten a huge amount of attention and discussion. Then there are the uninsured, but that label is kind of misleading because a very significant number of them came from state high-risk plans that shut down as part of the Affordable Care Act. So while they didn't have classic insurance, they were funded and they were typically funded at rates more like commercial than Medicare or Medicaid. And so for the system, there's no increase in cost from their emergence in the second bucket of ACA Plans. And then third, the third bucket, which is substantial, are people who are on private plans before. Before ACA existed, they had individual health insurance plans. And once ACA was there, they switched over. And so these are people who've been buying insurance for -- in the same way that everyone now on this call buys insurance where they're doing it individually as opposed through their employers. So those are the 3 buckets. And then within that second bucket, there's some subsets. But at some point, continued parsing will get to pretty small numbers."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. So maybe I'll just ask the question this way and jump off. There are people that are going to come to you that are uninsured that can qualify for Medicare for 3 months. If I were thinking about the potential risk bucket here, that would be the one w",106,"Okay. So maybe I'll just ask the question this way and jump off. There are people that are going to come to you that are uninsured that can qualify for Medicare for 3 months. If I were thinking about the potential risk bucket here, that would be the one where potentially now you're signing off for ACA plans where before, they will just have to wait 3 months uninsured and get Medicare. Is there any way to think about how CMS -- could CMS address that? Or effectively, they're uninsured and they could buy an ACA Plan like anybody else. So how do you stop it?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Okay. I may just look at it on the table. I do not have an answer to that. Does anybody?",21,"Yes. Okay. I may just look at it on the table. I do not have an answer to that. Does anybody?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, Justin, if I understand you correctly, I think what we're having a little disconnect in the room is we have a population that does not qualify for a Medicare or a Medicaid because they haven't worked in a requisite number of quarters. Or even if you",89,"Well, Justin, if I understand you correctly, I think what we're having a little disconnect in the room is we have a population that does not qualify for a Medicare or a Medicaid because they haven't worked in a requisite number of quarters. Or even if you're here and working through the visa process, you have to wait 5 years before you're eligible for Medicare. So I think there is a genuine population when we discuss it that cannot access the government coverage. Does that explain it for you?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Right. So you're saying there's not really much of this 3,000 population that just had to wait 3 months for Medicare before and is now getting ACA?",27,"Right. So you're saying there's not really much of this 3,000 population that just had to wait 3 months for Medicare before and is now getting ACA?"
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Right. He's specifically ask -- yes, I hear you, Justin. You're specifically asking about that 3-month waiting period and is anybody -- is anything going on there? Not -- does anyone -- I think, Justin, we'll have to get back to you and the rest of the sh",91,"Right. He's specifically ask -- yes, I hear you, Justin. You're specifically asking about that 3-month waiting period and is anybody -- is anything going on there? Not -- does anyone -- I think, Justin, we'll have to get back to you and the rest of the shareholders on that because it's not a question that I've heard asked and answered.
All right. Thank you very much. And thanks, everyone, for your sustained interest, and we look forward to talking to you on all these topics in 90 days. Thank you."
35644,404162533,1071171,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","And that ends today's conference. Thank you all for your participation. You may disconnect at this time.",18,"And that ends today's conference. Thank you all for your participation. You may disconnect at this time."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you for standing by. [Operator Instructions] And I would now like to turn the call over to Mr. Jim Gustafson. Sir, you may now begin.",28,"Welcome, and thank you for standing by. [Operator Instructions] And I would now like to turn the call over to Mr. Jim Gustafson. Sir, you may now begin."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Jess, and welcome, everyone, to our third quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO o",236,"Thank you, Jess, and welcome, everyone, to our third quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO of the DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of DaVita Medical Group; Jim Hilger, our Chief Accounting Officer and interim CFO; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statements. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based upon information currently available to us, and we do not intend and undertake no duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website.
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, Jim, and thank you, everyone, for joining on our call. We will start, as we always do, with our clinical performance, and then I will return before Q&A.Within the DaVita Medical Group, we mentioned during our Q2 call that we outperforme",142,"Okay. Thank you, Jim, and thank you, everyone, for joining on our call. We will start, as we always do, with our clinical performance, and then I will return before Q&A.
Within the DaVita Medical Group, we mentioned during our Q2 call that we outperformed in clinical quality compared to the same period in the prior year. Our strong performance has continued, and we remain on track to achieve 4 Stars or greater for our patients within each of our major health plan relationships.
Within Kidney Care, we continue to focus on vascular access where strong performance significantly improves survival and prevents unnecessary hospitalizations. The publicly reported government data released just this October shows that we have significantly outperformed the industry in this important clinical area.
Let's now move on to the nonclinical subjects, and I'll turn it over to Javier Rodriguez."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Kent, and good afternoon. Since we spoke last, a lot has happened. I will cover 3 topics: number one, Monday's announcement; number two, our Q3 Kidney Care performance; and number three, our outlook. So let's get started.We hope the release o",846,"Thank you, Kent, and good afternoon. Since we spoke last, a lot has happened. I will cover 3 topics: number one, Monday's announcement; number two, our Q3 Kidney Care performance; and number three, our outlook. So let's get started.
We hope the release on Monday was helpful. I won't be repetitive here, but we've had a lot of questions. So let me take some, and if I miss them, please bring them up in Q&A. As a full warning, I'll go into some technical detail because the subject matter requires it.
First, why did we announce the decision on Monday, only 2 days before our earning call? It's a simple answer. This is open enrollment that started yesterday, and we needed to provide clarity to our patients and our teammates.
Second, is this a permanent change in policy? No. We have only temporarily suspended support for applications to the American Kidney Fund for patients enrolled in minimum essential Medicaid coverage. When CMS provides guidance, which we expect will be within a couple of weeks, we will evaluate our future policy.
Third, does our announcement signify a concern over our historical practices? No. Our historical practices were legal and compliant. That said, the language in the RFI may confuse some, so I thought it would be useful to clarify further.
The RFI had primarily 3 concerns. One, whether patients enrolled in Medicare purchased an ACA Plan that was duplicative in coverage. None of our patients who were enrolled in Medicare enrolled in the ACA Plan. The regulations cited in the RFI, which referred to Medicare supplemental plans is not germane to the ACA Plans.
Number two, whether patients lost their Medicaid coverage as a result of purchasing an ACA Plan and therefore, were exposed to additional costs. Our patients did not lose their Medicaid coverage as a result of purchasing an ACA Plan and as a result, were not exposed to additional costs. Consistent with CMS' own education materials, we educated our patients on the ability to pick -- purchase an ACA Plan while retaining Medicaid coverage as a secondary. These patients did not apply for tax credits and subsidies.
And three, whether patients experienced a disruption in continuity of care as a result of purchasing an ACA Plan. Just a small portion of our Medicaid patients made the choice to purchase an ACA Plan, and they did so for their own personal reasons such as to have access to specialists who do not accept Medicaid or increased chance of qualifying for transplantation or other reasons. We are not aware of any patient experiencing a disruption in care likely because those patients who would have had such a disruption, made the choice not to enroll in an ACA Plan.
Lastly, there have been some questions around comparing our disclosure of 5,000 patients versus public information from other providers. I believe that the confusion is around some definitions. When we refer to individual market plans or ACA Plans, we refer to the full universe of individual plans, whether they're sold on or off the government-run exchanges. A distinction between these types of plans is not relevant because both affect the same risk pools and are generally subject to the same regulations. If you're trying to compare us to other providers, it is important to clarify definitions to ensure that the comparison is an apples-to-apples line.
Now let's discuss our Q3 performance. Overall, DaVita Kidney Care had a solid quarter. We delivered adjusted operating income of $439 million. For U.S. dialysis, our normalized non-acquired growth for the quarter was 4.4%, which falls within our long-term target range of 3.5% to 4.5%. While we're on the topic of volume, we want to share that we signed an amendment to the agreement of Renal Ventures to acquire 100% interest in their dialysis centers for $360 million, which is $55 million less than previously announced purchase price. We expect the transaction will close in the first quarter of 2017.
Our revenue per treatment was up sequentially by 1.7 -- $1.72 per treatment, primarily driven by an increase in seasonal administration of flu vaccine. Our patient care cost per treatment were up versus Q2 by $2.41 per treatment, driven by 2 primary factors: approximately 60% by an increase in labor and benefits costs and 40% by an increase in facility costs. We have seen a tightening in labor markets leading to some increase in our labor costs. In the near term, we may see these labor costs remain at higher levels. We expect that our facility costs to come down over the next couple of quarters.
Now onto our outlook. Since we have now visibility to the end of the year, we're updating our 2016 adjusted operating income guidance for Kidney Care to be in the range of $1.695 billion to $1.725 billion. We will provide you with 2017 guidance on our Q4 earnings call when we expect to have additional clarity on several variables, including open enrollment and policy changes from CMS.
Now I'll turn the call to Vijay Kotte for DMG."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Javier. First, financial performance. We noted on the Q2 call that we would see accelerated noncash amortization expense for the ACP brand during the transition to DMG, which would impact our reported operating income. This will run for 30 mont",341,"Thank you, Javier. First, financial performance. We noted on the Q2 call that we would see accelerated noncash amortization expense for the ACP brand during the transition to DMG, which would impact our reported operating income. This will run for 30 months at an incremental rate of slightly more than $2 million per month or $26 million on an annualized basis beginning September 2016. Including the impact of this accelerated amortization, operating income for the quarter was $33 million.
As we look at the full year, we are narrowing our 2016 adjusted operating income guidance to a range of $115 million to $145 million. This is effectively a slight increase as our guidance now includes the impact of the $9 million in accelerated brand amortization that was previously excluded.
A natural question is how to think about 2017. We're still in the midst of our budget process, and open enrollment plays a big part in our outlook. That being said, there are some things we know. First, $40 million in rate cuts, which includes $30 million related to the Medicare model change and $10 million for Medicaid. Second, we have the $26 million of accelerated brand amortization. And third, we are continuing to make incremental investments in the business. Despite these headwinds, the odds are they will be roughly flat year-over-year, but there are reasonable probabilities on the other side of that. We will go into further detail regarding our expectation for 2017 on the Q4 earnings call.
As we continue to look towards our long-term OI, our 2019 target remains $215 million.
Finally, I want to provide a few highlights on the operating progress we're making at DMG. With regard to claims process without the need for manual intervention, 2015 we're at 26%; and in 2016, 79%. With regards to services getting electronic authorizations, 2015 was 24%, 2016 is 47%. And finally, with regards to new tuck-in clinicians, in 2015, we had 18; and in 2016, we're at 44.
Now to Jim Hilger for some financial details on the quarter."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. I'll first address our international operations. Our international operating income was $368 million in the quarter, which includes the gain on the deconsolidation of the APAC JV of $374 million. We are on track to meet our guidance for app",600,"Thanks, Vijay. I'll first address our international operations. Our international operating income was $368 million in the quarter, which includes the gain on the deconsolidation of the APAC JV of $374 million. We are on track to meet our guidance for approximately $40 million in adjusted losses for 2016.
Our JV transaction with Khazanah and Mitsui closed on August 1. As you will recall, Khazanah and Mitsui have each subscribed to acquire 20% share of ownership of the joint venture. At closing, each partner made their first investment tranche of $50 million in return for a 6.7% ownership in the joint venture. This joint venture has been deconsolidated from our financials. Going forward, our pro rata share of its operating income will run through equity investment income in our income statement. As a result of this deconsolidation, we recorded a onetime noncash gain of $374 million. We are excluding this gain when reporting our adjusted non-GAAP financial results and excluding it from our adjusted operating guidance for 2016. We look forward to continuing our growth in Asia Pacific dialysis with the help of our new partners.
Next. I'd like to talk about a few tax items. In the third quarter, we recorded an adjustment related to tax assets created through the DMG acquisition escrow provisions. This adjustment resulted in a $27 million increase in corporate G&A expense that was offset by an equal reduction in income tax expense and thus, created no change in net earnings or earnings per share. We do not expect any ongoing impact from this adjustment.
Excluding this escrow provision tax adjustment and excluding the gain from the formation of the APAC dialysis joint venture, our tax rate attributable to DaVita was 40% in the quarter and 39% year-to-date. We expect our full year tax rate attributable to DaVita to be approximately 39%, when excluding all non-GAAP items.
Next, our interest expense increased slightly in the quarter to $105 million due to an increase in the interest rate cap amortization as well as the impact of the deconsolidation of the APAC joint venture. This higher level of interest expense reflects our go-forward run rate.
And finally, turning to our continued strong and consistent cash generation. Operating cash flow was $536 million in the third quarter and $1.92 billion for the last 12 months. We expect full year 2016 operating cash flow to be between $1.75 billion and $1.85 billion.
Since our last earnings release, we have repurchased 9.6 million shares for approximately $619 million. And through October, we have repurchased 13.3 million DaVita shares for approximately $868 million, which represents about 6.3% of the outstanding shares at the beginning of the year. Approximately 881 million remains outstanding under our board repurchase authorizations.
We continue to have a strong cash balance with nearly $1.6 billion in cash and short-term investments as of September 30. While $212 million was used in October to repurchase stock, and an additional $360 million will be used in the coming months for the completion of the Renal Venture acquisition, that still leaves us with over $1 billion of cash available before considering our continued strong cash-generating capabilities.
As discussed at our Capital Markets Day earlier this year, we expect to generate well over $5 billion in free cash flow to use for growth and share repurchases from 2016 to 2019. Even assuming a reasonable baseline of $1.5 billion in growth spending for development CapEx and acquisitions, this leaves over $3 billion for additional growth or share repurchase.
And now I'd like to turn it back to Kent for a few closing comments."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thanks, Jim, and I'd actually like to make several additional comments. Some will be a little bit redundant to what JR said, but it's such an important topic, we think it's worthwhile in order to achieve good clarity. Allow me 8 different points, please.",1161,"Thanks, Jim, and I'd actually like to make several additional comments. Some will be a little bit redundant to what JR said, but it's such an important topic, we think it's worthwhile in order to achieve good clarity. Allow me 8 different points, please.
Number one. We fulfilled our regulatory responsibility to provide comprehensive education to our patients. This has been an industry requirement for the last 15 to 20 years, and then ACA was added onto that standard and long-standing process and practice.
Number two. A very small percentage of our Medicaid patients determined that an ACA Plan was better for them, and Javier mentioned some of the very significant reasons why some of those plans were way better for them and/or their families. I won't repeat the examples, but important and often beautiful improvements in care.
Number three. Nonetheless, if you look at the benchmark plan, an EGHP plan, you see that total ESRD costs, meaning dialysis and hospital-related costs, et cetera, was about 1.3% of the total medical costs. That again is total ESRD costs in the numerator and then total medical costs for the plan in the denominator. In the ACA Plans, we estimate right now that, that percentage is only up to about 1.6%. And so it is a low absolute number and it's a low increase number.
Number four. We were very sensitive to the fact that some of these patients choosing an ACA Plan meant that we would be paid higher rates, commercial rates versus Medicaid rates. And therefore, we created a very intense oversight process to make sure that we did everything possible to live up to the CMS standards around objective presentation of information and absolutely letting the patient choose.
Number five. We, nonetheless, got swept up in the current huge controversies around the sustainability of the exchanges, and you're all sensitive to the huge political forces in play on that subject.
Number six. Why did dialysis, and in part DaVita, become a visible part of that controversy? Well, a, letter a, we're national, and so our numbers get added up nationally unlike a lot of health systems which are regional or local; b, our patients stick out, they're very high cost, very easy to identify, very discreet; c, there have been abuses by providers in other segments and perhaps some abuses even in ESRD, and so upfront, we started to be painted with that brush by some without data to support; d, some payers did have very large year-over-year increases in dialysis expense, and it was originally assumed that this must be from the process that I described earlier. But in fact, in many, probably most instances, it was driven by other factors. For example, sometimes, a plan had a differentially attractive product and would gain significant market share literally moving from having 50% of the ESRD patients in a market to 80%, thereby guaranteeing at least a 60% increase in your cost, having nothing to do with anything else other than product design. As we all know, this has been a very dynamic period, probably the most dynamic period ever in terms of alternative product design for insurance plans. And also, people have been struck by how smart the consumers are and how much shopping and switching they do. A second explainer in several markets is when there was a bad actor in the payer world, meaning someone who did inappropriate steering of patients away from themselves, leaving one of their competitors with a disproportionate percentage. And again, we're talking about 30%, 40% shifts in market share in some instances. A third driver out of probably a potential list of 7 or 8, but I'll stop after 3, is areas with relatively poor Medicaid coverage because that would naturally mean that there's a higher probability that a Medicaid patient would find an ACA Plan more attractive. This is just to give you a sense of what kind of things actually drove a lot of those year-over-year increases for particular plans because as we mentioned earlier, the aggregate reality only moved from 1.3 to 1.6.
But letter e, those high examples were taken to CMS and positioned as being reasonably representative of a broader movement. And at that point, CMS did not have the data of the 1.3 and the 1.6.
On to number 7 of 8. CMS is now starting to realize, contrary to initial impressions that, a, some of the numbers were misleading. That's not to say they were inaccurate if they were from a particular plan. They were just misleading. And as you start to stare at a number like a 0.3 increase, and again this is our estimate, but as you compare that to 22% rate increases on average, you can see that we were not a material source of the problem, nor are we a material source of the solution. 
Letter b, our patients made sensible choices, and we provided lots of examples to CMS as have other providers.
C, the fact that enrollment of dialysis patients within the ACA plans looks to be flat or down even without any change in Medicaid access in 2017 and '18, and of course, would be down even more with any restriction on the Medicaid front.
Letter d, CMS now is starting to see some of the reasons for the dramatic disparities in year-over-year dialysis expense increases and seeing how they have to do with product design, competition, et cetera.
And lastly, e, they also have a better sense of how charitable premium assistance has been embedded in the ESRD economic and clinical ecosystem for 20 years with a lot of guardrails and with the OIG's blessing, including blessing the aspect of provider funding.
So number 8 and final comment is, of course, the big question on everyone's mind, including ours, is what exactly is CMS going to decide with respect to this portfolio of decisions. And we don't know. No one knows. I think to their credit, they don't know right now because they're continuing to absorb information, and we are incredibly grateful and respectful that they are doing that.
Moving on to DMG. Just one happy announcement, and that is that Chuck Berg is joining our leadership team as Executive Chair of DaVita Medical Group. He'll report to me in my role as CEO of the enterprise. Chuck's been on our board since 2007. He has a wealth of experience in the health plan world, including having been the very successful executive chair of WellCare Health Plans and prior to that, the CEO of Oxford Health Plans, where I was his nonexecutive chair. This experience, combined with his brain, makes him uniquely suited to help us evaluate our long-term strategic alternatives at DMG. And he will remain in our board in the meantime, and I and others look forward to working with him.
Operator, if you could please go ahead and open up the line for Q&A."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question is coming from Justin Lake of Wolfe Research.",13,"[Operator Instructions] Our first question is coming from Justin Lake of Wolfe Research."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I guess my first question here is just the company bought back $600 million of stock in the last 4 months at prices that are 15% above the current price. With full knowledge of the issues out there in terms of the concerns around third-party payment for A",135,"I guess my first question here is just the company bought back $600 million of stock in the last 4 months at prices that are 15% above the current price. With full knowledge of the issues out there in terms of the concerns around third-party payment for ACA coverage, right, given the potentially significant impact on earnings here, the downstream impacts of just the government taking a harder look at third-party funding in general, managed care negotiations, et cetera potentially getting impacted, my question is should we take this as a sign of your comfort level with the potential of downstream impacts on third-party payment changes, et cetera, on the earnings power of the business? And if so, any color you could share on why your level of comfort is that high will be helpful."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Thanks, Justin. I would not say that the reason we chose to buy back was because any particularly distinctive level of confidence on what exactly the outcome was going to be. And certainly, if we could do it over again, we would have preferred to hav",113,"Yes. Thanks, Justin. I would not say that the reason we chose to buy back was because any particularly distinctive level of confidence on what exactly the outcome was going to be. And certainly, if we could do it over again, we would have preferred to have waited and be buying back more of it now. But awfully difficult to predict things. There's a lot of different variables, not only with respect to the issues you mentioned, but other issues, both threats and opportunities. And nonetheless, I would not say that we said, ""Gosh, there's some distinctive near-term downside, and we're going to go ahead and buy anyway."" I wouldn't make that claim."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Then maybe we could just talk about your commercial mix in general given this has been a big area of focus here. We look at the changes and the growth and -- in the commercial mix, and if we back out these 2,000 patients, it looks like it's been fla",165,"Okay. Then maybe we could just talk about your commercial mix in general given this has been a big area of focus here. We look at the changes and the growth and -- in the commercial mix, and if we back out these 2,000 patients, it looks like it's been flat over the last several years. But looking ahead and just thinking about the changes, looks like the -- from USRDS data, there hasn't really been much incidence growth in the pre-65 population over the last 10 years. And when we couple that with the aging of the baby boomers and the Medicare from kind of commercial years, there's the indication that it could put a fair amount of pressure on commercial mix over time. So I guess my question is can you tell me whether this is a reasonable view? And if so, how should we think about this factor in relation to your typical kind of mid-single-digit long-term growth algorithm for the dialysis?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. I think it's a very fair question, Justin. And I think if you wanted to identify other worrisome long-term trends, you would also look at improved treatment regimens for diabetics and hypertensives. And commercial patients are more likely to benefit",202,"Yes. I think it's a very fair question, Justin. And I think if you wanted to identify other worrisome long-term trends, you would also look at improved treatment regimens for diabetics and hypertensives. And commercial patients are more likely to benefit from improved treatment regimens. On the other hand, there's also things pushing in the other direction. We continue to be quite successful with our Non-Acquired Growth, and some of these hard times could lead a lot more small providers to sell or even shut down. In addition, we're very hopeful that Medicare Advantage continues to grow because we radically prefer a customer who cares about total value. And we tend to do much better in terms of both adding value to the system and getting reimbursed for it. In addition, as you know better than most, to the extent that the mix ever starts to put too much pressure on all the independent centers, the government has the easy option of doing that, which it's done 3 or 4 times before, and that's extending the MSP provision from originally 0 to 12 and 12 to 18 and 18 to 30. And so that's a safety valve that's never far away. Justin?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Yes. I -- Kent, if you could give me one more chance. I'll just ask you like does this mean that should we think about within the 6, let's just call it, mid-single-digit CAGR that you look for, for the dialysis business? This mix looks like just the likel",86,"Yes. I -- Kent, if you could give me one more chance. I'll just ask you like does this mean that should we think about within the 6, let's just call it, mid-single-digit CAGR that you look for, for the dialysis business? This mix looks like just the likely pressure that's going to be on commercial mix over the next 10 to 20 years. Is this in that number? Or could this have a negative impact on that number in the way you're looking at it?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, fair question. I would say that at the time we did the last Capital Markets, we incorporated all the variables, although that was a 3-year outlook. When we refresh our Capital Markets outlook at the next one, it will once again incorporate everything",162,"Yes, fair question. I would say that at the time we did the last Capital Markets, we incorporated all the variables, although that was a 3-year outlook. When we refresh our Capital Markets outlook at the next one, it will once again incorporate everything. And while some of the stuff that you're citing is most likely not going to be economically material within the near term, perhaps we should, for the first time in a long time, take a cut at sort of the 4 to 7 year time frame and stare at some of the upsides and downsides, the puts and takes, not only on mix but on cost structure, et cetera, also modality mix and some other things that can have a big impact on cash flow and return on capital. So we don't have anything distinctively thoughtful to say to you today from an analytical point of view, but that's probably a good assignment for the next Capital Markets."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Kevin Fischbeck of Bank of America Merrill Lynch.",14,"Our next question is coming from Kevin Fischbeck of Bank of America Merrill Lynch."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I have a lot of questions kind of similar to that, but I guess I appreciate all the color about the AKF change. I think that was very helpful. I think I understand those parameters. But I guess the question that I'm still struggling with is what the real",227,"I have a lot of questions kind of similar to that, but I guess I appreciate all the color about the AKF change. I think that was very helpful. I think I understand those parameters. But I guess the question that I'm still struggling with is what the real growth rate of the company has been over the past 3 years in the dialysis business because if I look at operating income growth over the last 3 years, it's been about 5% per year. But if I was to say that this 140 was either not sustainable or onetime in nature, then I'm getting like a 2% type growth in the dialysis business over the past 3 years. So how do we think about that? And that's the low end of what you guys think you're going to do over the next few years going forward. And when I think about the next few years versus the last few years, Medicare rates have been under pressure and likely will be in the same range. So why is the right way to think about growth over the next few years not the low end of that 3 to 7? Like what would cause you to do better than the low end of that range? Or is 4 at the low end the right way to think about it?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Right now, I would say if you wanted to weight the probabilities between the low end, middle and top, you would find the probability skewed to the low end, but it's not by a huge amount. And then in addition, of course, unit volume is, for us, in man",116,"Yes. Right now, I would say if you wanted to weight the probabilities between the low end, middle and top, you would find the probability skewed to the low end, but it's not by a huge amount. And then in addition, of course, unit volume is, for us, in many ways, of secondary importance with commercial mix and the nature of commercial mix of primary importance. And that number has got a lot of dynamism to it right now, as you well know. And so at this point, we're not revising that guidance, but we do look forward to a very intense analytical discussion at the next Capital Markets about the next generation of 3-year outlook."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Then I guess if we look at commercial mix and take out this maybe 1% that's related to the ACA, it looked like mix has basically been flat over the last 5 years, maybe down a little bit during a time when the economy is improving. So do you think th",117,"Okay. Then I guess if we look at commercial mix and take out this maybe 1% that's related to the ACA, it looked like mix has basically been flat over the last 5 years, maybe down a little bit during a time when the economy is improving. So do you think that, that's really reflective of what the industry has been seeing? Or I know from time to time you've raised flags about potentially competitors being aggressive on pricing. Has there been anything where you feel like you've purposely walked away from market share because people got competitive? Or is that kind of how you think mix overall for the industry has looked over that time period?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Our guess is that our trajectory of commercial mix is quite similar to others, and we have not experienced any example of someone in our mind foolishly seeking to gain shares through price reductions in an industry of almost pure variable cost, very stick",70,"Our guess is that our trajectory of commercial mix is quite similar to others, and we have not experienced any example of someone in our mind foolishly seeking to gain shares through price reductions in an industry of almost pure variable cost, very sticky volume and high likelihood of economic retaliation. So we haven't seen any of that go on, and so our guess is that competitor performance is comparable."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just one last question. On HCP, looks like the number of physicians and clinicians went up nicely sequentially, but we still saw a deceleration in revenue in that business for Q2 to Q3. Wanted to see what was going on there and whether the",65,"Okay. And then just one last question. On HCP, looks like the number of physicians and clinicians went up nicely sequentially, but we still saw a deceleration in revenue in that business for Q2 to Q3. Wanted to see what was going on there and whether the increase in clinicians is a good sign about a ramp-up in revenue over the next couple of quarters."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Over the long term, you should see a positive correlation. Right now in some cases, we were under staffed with physicians. And by adding them, we actually think we can reduce our MLR and the quantity that exceeds the incremental costs that we're addi",166,"Yes. Over the long term, you should see a positive correlation. Right now in some cases, we were under staffed with physicians. And by adding them, we actually think we can reduce our MLR and the quantity that exceeds the incremental costs that we're adding. In other cases, we're adding because we're doing some de novos and other work where we think by adding physician capacity, we're going to get more lives. It's just that there's some lag time. So we're very sensitive to the fact that at a time when the revenue trajectory is what it is, our physician recruiting is ramping up. But the good news is that shows what an attractive place we are for physicians and our hit rate in recruiting is very high. The concerning news for you is we're adding to costs at a time when revenues aren't going up at the same trajectory. And so we hear you, and over time, you should see the positive correlation you expect."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Is the right way to think about that as like a couple of quarter lag? Or a year lag? How long do we think about these doctors adding to the earnings?",32,"Okay. Is the right way to think about that as like a couple of quarter lag? Or a year lag? How long do we think about these doctors adding to the earnings?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, unfortunately, I don't think we're good enough yet to give you an empirical answer for that, and so I won't hazard a guess. Suffice it to say, we know you'll be watching each quarter.",35,"Yes, unfortunately, I don't think we're good enough yet to give you an empirical answer for that, and so I won't hazard a guess. Suffice it to say, we know you'll be watching each quarter."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Gary Lieberman of Wells Fargo.",11,"Our next question is coming from Gary Lieberman of Wells Fargo."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I guess just sticking with the topic of the day. I think there's a broader concern by some investors that potentially the AKF would be restricted more broadly from making premium support payments to historical patients that they would have been doing it f",66,"I guess just sticking with the topic of the day. I think there's a broader concern by some investors that potentially the AKF would be restricted more broadly from making premium support payments to historical patients that they would have been doing it for COBRA or for other factors. Can you talk about that? Do you think that is a risk? And why or why not?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. It is a risk, but the 2 big facts on that big issue are that for private plans to do a broad prohibition of charitable premium assistance is an exceptionally heavy lift because there are hundreds of such organizations all over the country, and thousa",108,"Yes. It is a risk, but the 2 big facts on that big issue are that for private plans to do a broad prohibition of charitable premium assistance is an exceptionally heavy lift because there are hundreds of such organizations all over the country, and thousands of hospitals that like those foundations and charities and the rest. And to try to deploy one that's focused on our patients would be discriminatory and subject to really intense lawsuits. And then separately, CMS does not have authority over the whole EGHP realm. They, of course, have authority over lots of other realms, but not that one. Is that responsive, Gary?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Yes, that's helpful. Any chance you could tell us what percentage of your commercial patients, if you know it, receive premium assistance from the AKF?",25,"Yes, that's helpful. Any chance you could tell us what percentage of your commercial patients, if you know it, receive premium assistance from the AKF?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I think at this point, we've decided that disclosing that is not in your best interest, although we'll continue to stare at that each quarter. But that's our current thinking. Of course, we incorporate all variables into our forecasts, but sometimes, some",50,"I think at this point, we've decided that disclosing that is not in your best interest, although we'll continue to stare at that each quarter. But that's our current thinking. Of course, we incorporate all variables into our forecasts, but sometimes, some of these swing factors are difficult to calibrate."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on the same topic, I think there are some investors that believe that, in fact, it's illegal to -- for the Medicaid patients to have been given premium support. Can you just talk about that? And your understanding, I assume, from your persp",57,"Okay. And then on the same topic, I think there are some investors that believe that, in fact, it's illegal to -- for the Medicaid patients to have been given premium support. Can you just talk about that? And your understanding, I assume, from your perspective, it's not illegal? Can you just help us think through that?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Sure. I appreciate you bringing it up because we certainly heard the concern. And the very explicit references by CMS to how it is legal are multiple and really clear. And the RFI referred to a part of the statutes that didn't apply to the subject at hand",109,"Sure. I appreciate you bringing it up because we certainly heard the concern. And the very explicit references by CMS to how it is legal are multiple and really clear. And the RFI referred to a part of the statutes that didn't apply to the subject at hand. So it was literally not germane to the critical questions that you and others are worried about. And so we have continued to point to the very explicit language supporting our position. We have been in meetings with senior CMS officials and referred to the fact that it's very clearly legal and have never run into a single objection from anyone."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Gary, let me add one thing, Gary, that might help clear it up. It is the case that Medicaid patients cannot have federal subsidies, and so it's not that there aren't some rules that apply, but it is very clear that there was a conscious decision made to a",123,"Gary, let me add one thing, Gary, that might help clear it up. It is the case that Medicaid patients cannot have federal subsidies, and so it's not that there aren't some rules that apply, but it is very clear that there was a conscious decision made to allow Medicaid patients to make the choices that we made available to them. And I'll even add one other element. Back when the Affordable Care Act was being rolled out, we were encouraged by the administration to promote exchange products. We were even asked to put up signs in our centers promoting the ACA Plans. Now of course, it's 4 years later and a lot of things have changed, but that's the actual historical context."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Great. That's very helpful. And then, Jim, can you just remind us at what point you would have been restricted from purchasing your stock after the end of the quarter?",30,"Great. That's very helpful. And then, Jim, can you just remind us at what point you would have been restricted from purchasing your stock after the end of the quarter?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, we entered -- we typically enter restriction period at -- near the very end of the quarter, and we would be restricted throughout the period of time after the quarter ended until through this call.",36,"Well, we entered -- we typically enter restriction period at -- near the very end of the quarter, and we would be restricted throughout the period of time after the quarter ended until through this call."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Got it. But I thought you guys did, in fact, purchase some stock after the end of the quarter?",19,"Got it. But I thought you guys did, in fact, purchase some stock after the end of the quarter?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, we did, and that was subject to a plan that we put in place before we were blacked out.",20,"Yes, we did, and that was subject to a plan that we put in place before we were blacked out."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","So you did 10b-5 in place before it was blacked out?",12,"So you did 10b-5 in place before it was blacked out?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","That's correct.",3,"That's correct."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Chris Rigg of Susquehanna.",10,"Our next question is coming from Chris Rigg of Susquehanna."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I just wanted to again come back to the AKF issue. Obviously, you're pointing at $140 million of OI this year as that being the potential headwind for next year. But can you give us a sense for how that ramps during the first 2 years of the coverage expan",50,"I just wanted to again come back to the AKF issue. Obviously, you're pointing at $140 million of OI this year as that being the potential headwind for next year. But can you give us a sense for how that ramps during the first 2 years of the coverage expansions?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","How the $140 million ramped up?",6,"How the $140 million ramped up?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Like what was the exposure in 2014, net in '15? And now you're at $140 million for this year in roughly 2,000-ish patients.",23,"Like what was the exposure in 2014, net in '15? And now you're at $140 million for this year in roughly 2,000-ish patients."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Okay. I know we didn't calculate that number prior to the call. Why don't -- the people around the table here will see if we can and should generate that and share it before the call is over, but we don't have it at our fingertips.",46,"Okay. I know we didn't calculate that number prior to the call. Why don't -- the people around the table here will see if we can and should generate that and share it before the call is over, but we don't have it at our fingertips."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then sort of another qualitative-type question here on the AKF issue, but obviously, getting to some of the -- at least what's been sort of suggested from the managed care side is that by shifting some of these people from, call it, 100% Medicai",114,"Okay. And then sort of another qualitative-type question here on the AKF issue, but obviously, getting to some of the -- at least what's been sort of suggested from the managed care side is that by shifting some of these people from, call it, 100% Medicaid to sort of Medicaid as a supplemental, there may have been some out-of-pocket exposure here. I guess when you guys did your look back and reviewed the 2,000 or whatever that may have been in '15 and '14, what did you do? I guess I'm just trying to get some comfort here that you guys feel pretty comfortable that in no material way were the individuals harmed financially."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I'll take a first stab and then other people may want to add on. First of all, we dedicated a huge amount of time in developing materials and training our people and so that our historic discipline of presenting objectively was on steroids for this proces",181,"I'll take a first stab and then other people may want to add on. First of all, we dedicated a huge amount of time in developing materials and training our people and so that our historic discipline of presenting objectively was on steroids for this process. And we present very complete information that encompasses premiums, deductibles, co-pays, out-of-pocket stuff, potential federal tax credits, potential charitable premium assistance, individual versus family, high income versus low. And so we're thorough, and it's presented to the patients in ways that leaves most of them exceptionally grateful for the help and the clarity, and then they choose. So one can never say that theoretically, you couldn't have a patient choose something that was foolish. I'm sure out of 2,000 patients, there were some. But we have to respect the fact that it's their choice. In general, however, just as we've seen in the exchanges over the last 3 or 4 years, the average patient demonstrates a lot of economic common sense in how they move around between different products, particularly when they are helped."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","And Chris, this is Javier. I'll just add one important point, is that they never lose their Medicaid. Medicaid was in the secondary position, so the patients actually didn't incur additional costs.",32,"And Chris, this is Javier. I'll just add one important point, is that they never lose their Medicaid. Medicaid was in the secondary position, so the patients actually didn't incur additional costs."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay, okay. And then just one last one here on Kidney Care operating income for next year. You made reference in the Monday press release that there could be some theoretical offsets to the $140 million. If there are, can you give us a sense for what they",68,"Okay, okay. And then just one last one here on Kidney Care operating income for next year. You made reference in the Monday press release that there could be some theoretical offsets to the $140 million. If there are, can you give us a sense for what they are? And then just can you just give us some general sort of headwinds and tailwinds beyond the AKF issue?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, first of all, on mitigation, we'll be able to do a good job on that in the next quarterly call if we're in this scenario where that's the topic of the day. Separate from that, and then someone else may want to add, I mean, on the plus side, we have",129,"Well, first of all, on mitigation, we'll be able to do a good job on that in the next quarterly call if we're in this scenario where that's the topic of the day. Separate from that, and then someone else may want to add, I mean, on the plus side, we have a wonderful recurring unit growth. We have the potential accelerator of continued Medicare Advantage growth. On the cost structure side, we have the opportunities in the ESA area. And on the capital deployment side, we have the opportunity for more small operators filling a need to get out of this ever more complicated and challenging business. On the headwind side, I think we've laid them out with painful detail already, and so I won't list them again."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from John Ransom of Raymond James.",11,"Our next question is coming from John Ransom of Raymond James."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I did 1 day of law school and ran off in horror, so my peabrain isn't large to understand all these fine points. But to make it simple, one of your competitors said that the no-no in their opinion was to switch people off Medicaid, but that the ambiguity",124,"I did 1 day of law school and ran off in horror, so my peabrain isn't large to understand all these fine points. But to make it simple, one of your competitors said that the no-no in their opinion was to switch people off Medicaid, but that the ambiguity was when a new patient came in eligible for both Medicaid and an ACA Plan, that's where you could present both. Is what you're doing just sort of in line with that, that new patients come in are fair game. They don't have insurance, but existing patients with Medicaid, you're no longer going to try to switch them. I know I'm over simplifying, but is that a helpful way to think about it? Or no?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It's LeAnne. I think the -- you're confusing 2 things, so let's talk about patients who find us for ACA coverage made that choice and retained their Medicaid in the secondary. I think that answers the first question. There's no -- we're not substituting A",66,"It's LeAnne. I think the -- you're confusing 2 things, so let's talk about patients who find us for ACA coverage made that choice and retained their Medicaid in the secondary. I think that answers the first question. There's no -- we're not substituting ACA coverage for Medicaid. If they're keeping them, they're having both of them, and it's not subsidized by federal tax credits."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Does that answer just the first half of your question, John?",11,"Does that answer just the first half of your question, John?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Well, not really, but I'll follow up. I think there's so many cross-currents here, I don't want to drag this out on the call. And what about the second scenario where a patient comes in without any -- maybe they're eligible for Medicaid but they jus",100,"Okay. Well, not really, but I'll follow up. I think there's so many cross-currents here, I don't want to drag this out on the call. And what about the second scenario where a patient comes in without any -- maybe they're eligible for Medicaid but they just never signed up. How does that work? And is that something -- again, your competitor said we expect CMS to clarify the rules on that patient B that comes to them without any insurance at all. Is that a useful way or, again, was that a misleading comment by one of your competitors?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. I think we do have patients that come to us that are uninsured, and our education and process with those patients would be to find out all the avenues to which they could purchase coverage, whether they be Medicare or Medicaid or commercial plan, an A",82,"No. I think we do have patients that come to us that are uninsured, and our education and process with those patients would be to find out all the avenues to which they could purchase coverage, whether they be Medicare or Medicaid or commercial plan, an ACA Plan, et cetera. So our counselor's job is to make sure that each of the avenues is presented to that patient, and then the patient chooses what is best for them in their particular circumstance."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. LeAnne, hadn't heard from you in a while, so it's good to hear your voice. The second question I had was -- I mean, obviously in some of the comments, there were allegedly comments from either current or former DaVita employees who talked about bein",96,"Okay. LeAnne, hadn't heard from you in a while, so it's good to hear your voice. The second question I had was -- I mean, obviously in some of the comments, there were allegedly comments from either current or former DaVita employees who talked about being pressured to sign people up on commercial plans. So I'm sure you saw all that stuff. Just internally, what kind of controls do you have in place to investigate those kinds of comments? And what's your general view on that? True? Not true? Out of context? That would be helpful."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","John, thank you. This is Javier. First of all, would like to highlight that the numbers are small. But of course, regardless of the size of the numbers, we take each and every one very seriously. We did some huge, huge oversight here. We had to train a lo",173,"John, thank you. This is Javier. First of all, would like to highlight that the numbers are small. But of course, regardless of the size of the numbers, we take each and every one very seriously. We did some huge, huge oversight here. We had to train a lot of people in a very short amount of time, and so we had heavy oversight. And for a small number of people, they might have experienced that as negative. What we do is, of course, if we have any concerns, we give it to a third party. We give it to our compliance department. And they look into it and we rectify if there are any mistakes. But the bulk of what we've looked into has now materialized. And actually, when we've gone into some sessions, we've literally asked for evidence to be provided of our wrongdoing and alleged wrongdoing. And we've never been given any specifics because, of course, we would want to correct any mistakes if they were brought to our attention."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. That's great. And then let's switch gears and 2 more quick ones. Let's say we are in a scenario of a little more austerity on a number of fronts. I mean, there's obviously a big gap between your total CapEx and your maintenance CapEx. In a more aust",159,"Okay. That's great. And then let's switch gears and 2 more quick ones. Let's say we are in a scenario of a little more austerity on a number of fronts. I mean, there's obviously a big gap between your total CapEx and your maintenance CapEx. In a more austere scenario, and I'll just make up a number, let's say revenue per treatment is $340 to $345 for a bunch of reasons. How should we think about the likely reaction of the company? What levers would be likely to be pulled? And again, CapEx is one that would appear to be one where you have a lot of discretion over. And again, I ask this because there's a debate on the Street about should we look at DaVita on earnings per share? Or should we look at it on free cash flow? And free cash flow requires the assumption that CapEx is closer to maintenance than it is to actual."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, we hear you. The answer right now will be fairly generic. I mean, in a world where we would suffer some serious revenue compression, we would do what any responsible businessperson should do and very systematically go through every line item on the P",103,"Yes, we hear you. The answer right now will be fairly generic. I mean, in a world where we would suffer some serious revenue compression, we would do what any responsible businessperson should do and very systematically go through every line item on the P&L and every aspect of cash in and cash out. And we would enter into that process with the expectation that we would find some savings in the P&L side, and we would find some reductions on the CapEx side. And at the same time, we haven't quantified those, but we certainly do have some serious ranges of discretion."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Was the reduction in price for Renal Ventures driven by the new thinking around ACA Plans? Or was it something else?",22,"Okay. Was the reduction in price for Renal Ventures driven by the new thinking around ACA Plans? Or was it something else?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No, it was something else. There was a part of the transaction that was contemplated at the beginning. And after further dialog, we are not going to acquire their infusion business. So that's why the price was changed.",38,"No, it was something else. There was a part of the transaction that was contemplated at the beginning. And after further dialog, we are not going to acquire their infusion business. So that's why the price was changed."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I see. And is that -- you still think you might get that done? I know it's been dragging on for over a year. Is that still to be done by the end of the year? Or maybe you never said, but that's our assumption. Is that a reasonable assumption?",50,"I see. And is that -- you still think you might get that done? I know it's been dragging on for over a year. Is that still to be done by the end of the year? Or maybe you never said, but that's our assumption. Is that a reasonable assumption?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. We think it will -- there are some chance of Q4. But if you were betting, I would probably go with Q1 because there's some regulatory stuff going on. So I think Q1 is [indiscernible]",36,"No. We think it will -- there are some chance of Q4. But if you were betting, I would probably go with Q1 because there's some regulatory stuff going on. So I think Q1 is [indiscernible]"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","[indiscernible] 18 months, is that a record? I would think 18 months might be a record.",16,"[indiscernible] 18 months, is that a record? I would think 18 months might be a record."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It is. It's a new record for us anyway.",9,"It is. It's a new record for us anyway."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And lastly, just thinking about potential good guys. ESA costs. Do you have a view of -- you've got your current contract with Amgen, obviously. But if you do a market check on what other folks are now paying for ESAs, what's your view on your kind of app",76,"And lastly, just thinking about potential good guys. ESA costs. Do you have a view of -- you've got your current contract with Amgen, obviously. But if you do a market check on what other folks are now paying for ESAs, what's your view on your kind of apples-to-apples cost versus what's currently -- if you were free of that contract, would that be a good guy that could be called out? And I'll stop there."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, it's LeAnne again. I think you have to put it into 2 buckets. Obviously, I think the public announcement by FMC as to their cost reductions associated with their using Mircera gives you one category. So clearly, I think they are enjoying a price that",139,"Yes, it's LeAnne again. I think you have to put it into 2 buckets. Obviously, I think the public announcement by FMC as to their cost reductions associated with their using Mircera gives you one category. So clearly, I think they are enjoying a price that is better than the rest of the marketplace. Then you take the rest of the marketplaces on Amgen products. And I think there was a lot of buzz about the move to Aranesp lowered the independents' and small providers' costs. Well, that's correct, it did. But that's a relative lowering, and our ESA cost has been historically off the best. And I think that holds true, and so you -- if you want to ask it again in a different way, but I think that should give you the answer you're looking for."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","So in short, probably unless somebody opens up that contract, probably not -- it's probably reasonable to assume not much movement on that -- on that line item through the terms of the contract?",34,"So in short, probably unless somebody opens up that contract, probably not -- it's probably reasonable to assume not much movement on that -- on that line item through the terms of the contract?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I don't know if that's necessarily the right conclusion. Of course, when you enter into a long-term contract, both parties will look into it as things change. Amgen, of course, is interested in seeing that we are a customer post contract renewal, and we w",123,"I don't know if that's necessarily the right conclusion. Of course, when you enter into a long-term contract, both parties will look into it as things change. Amgen, of course, is interested in seeing that we are a customer post contract renewal, and we want to be talking to all the parties that are out there. And so what we're trying to make sure is that we have the right term solution for the long haul, so we're looking at this. You seldom get a chance to look at an $800 million cost line, and so we are very eager in deploying the right level of rigor and resources to make sure that we get the right relationship going forward post '18."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, and I've got an answer for the question that Chris brought up, which is sort of this $140 million, how did it build over time? It won't be very precise, but it will give you directionally what you're seeking. And that is that the bulk of the growth c",117,"Yes, and I've got an answer for the question that Chris brought up, which is sort of this $140 million, how did it build over time? It won't be very precise, but it will give you directionally what you're seeking. And that is that the bulk of the growth came in '15 and '16. '14, it was a small number. If we had to estimate, in the $20 million or so range. In '15, the range is probably somewhere in the -- I don't know, double that, give or take. We don't have very precise numbers, but we just wanted to give you directionally that the bulk of it was in '16 with some growth in '15."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Gary Taylor of JPMorgan.",10,"Our next question is coming from Gary Taylor of JPMorgan."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Just a couple of things. Given some of the reports that some of the health plans have already attempted to identify patients with AKF subsidies and even potentially terminate some of those contracts, I just wanted to check in on commercial mix. I know you",81,"Just a couple of things. Given some of the reports that some of the health plans have already attempted to identify patients with AKF subsidies and even potentially terminate some of those contracts, I just wanted to check in on commercial mix. I know you disclosed it annually, not quarterly. But I do think last quarter, you did acknowledge that it was still trending higher year-over-year. So I wanted to see if that was still true for 3Q '16 versus '15."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I'm sorry, Gary, your question is commercial mix? What period to what period?",14,"I'm sorry, Gary, your question is commercial mix? What period to what period?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Q3.",1,"Q3."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Just year-over-year in the third quarter. Is it still trending higher year-over-year in the third quarter?",17,"Just year-over-year in the third quarter. Is it still trending higher year-over-year in the third quarter?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It is. It is up year-on-year, Gary.",7,"It is. It is up year-on-year, Gary."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And sequentially, that probably hasn't done a lot. Is that fair?",11,"And sequentially, that probably hasn't done a lot. Is that fair?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","We've seen it go down slightly in the last quarter.",11,"We've seen it go down slightly in the last quarter."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just back to Renal Ventures. Is that still ballpark 2,300 to 2,400 patients and then anticipating some divestitures? Is that still ballpark?",25,"Okay. And then just back to Renal Ventures. Is that still ballpark 2,300 to 2,400 patients and then anticipating some divestitures? Is that still ballpark?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And then I just want to go to the patient care costs, which you called out. And I think you talked about 60%, labor; 40%, facility costs. But that was in the context of a couple dollar sequential change given that ESRD OI was down year-over-year and the c",85,"And then I just want to go to the patient care costs, which you called out. And I think you talked about 60%, labor; 40%, facility costs. But that was in the context of a couple dollar sequential change given that ESRD OI was down year-over-year and the costs jumped about $6 year-over-year. Is that still the same -- would that still be the same ratio if I look at the year-over-year, that more than half of that's labor and the rest is facility cost?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And when you say facility cost, you said it's coming down, what exactly is driving that up temporarily?",18,"And when you say facility cost, you said it's coming down, what exactly is driving that up temporarily?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It was a -- it's a bunch of miscellaneous line items. None of them particularly stick out. So it would just be giving you a very long list, and they just cumulatively added up to something this time, and so we're working on it.",44,"It was a -- it's a bunch of miscellaneous line items. None of them particularly stick out. So it would just be giving you a very long list, and they just cumulatively added up to something this time, and so we're working on it."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Last question. I believe you were talking about HCP's OI potentially being flat into '17. And you made no comments on consolidated or kidney, and I just wanted to confirm that, that, that was correct.",35,"Last question. I believe you were talking about HCP's OI potentially being flat into '17. And you made no comments on consolidated or kidney, and I just wanted to confirm that, that, that was correct."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, that's correct. We'll be providing guidance on '17 in the next quarterly call for Kidney Care, for U.S. Kidney Care.",21,"Yes, that's correct. We'll be providing guidance on '17 in the next quarterly call for Kidney Care, for U.S. Kidney Care."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Whit Mayo of Robert W. Baird.",12,"Our next question is coming from Whit Mayo of Robert W. Baird."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I'll try to keep it quick. But maybe one more on the AKF. It doesn't appear that you implemented this exchange initiative until 2015, at least according to the RFI submission. So one, just looking to confirm that. And the ACA obviously was implemented in",87,"I'll try to keep it quick. But maybe one more on the AKF. It doesn't appear that you implemented this exchange initiative until 2015, at least according to the RFI submission. So one, just looking to confirm that. And the ACA obviously was implemented in 2014, and you knew about it many years prior. So was there something that made you apprehensive about pursuing the strategy with patients and why perhaps it wasn't implemented in 2013 or '14 open enrollment? Just looking for any additional color."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","There was no conscious delay on our part.",8,"There was no conscious delay on our part."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe just one last one. With the MA Star Ratings published, how would you characterize your -- how your health plan partners are positioned next year? And what do you think this means for DMG? And maybe the conclusion when you see -- when",53,"Okay. And then maybe just one last one. With the MA Star Ratings published, how would you characterize your -- how your health plan partners are positioned next year? And what do you think this means for DMG? And maybe the conclusion when you see -- when you look at scores like Humana's?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, this is Vijay. Just to be clear, the '17 numbers are already fixed, right? So we don't see much of a change between '16 and '17. The Humana numbers were for payment year of 2018, and the only place where we saw a potential drop was in one market. And",108,"Yes, this is Vijay. Just to be clear, the '17 numbers are already fixed, right? So we don't see much of a change between '16 and '17. The Humana numbers were for payment year of 2018, and the only place where we saw a potential drop was in one market. And as you know, the Star scores are related to a number of factors. But our clinical quality was at a 4 Star and above, and we believe that in partnering with our health plans, there's some administrative opportunities to help neutralize some of the impact of the potential hit for 2018 for Humana in that one market."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Patrick Wood of Citi.",10,"Our next question is coming from Patrick Wood of Citi."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I'll be very quick, and this should be fairly yes or no sort of small questions. I have 3, if I may. The first will be I was very interested to hear about the apples-to-apples comparison in terms of patient numbers in relation to the CMS RFI submission. I",170,"I'll be very quick, and this should be fairly yes or no sort of small questions. I have 3, if I may. The first will be I was very interested to hear about the apples-to-apples comparison in terms of patient numbers in relation to the CMS RFI submission. I'd be curious to hear what you guys think is an apples-to-apples number vis--vis what your competitors submitted. I'd be very curious to hear that. Equally, second question would be when I back off from your operating income sort of impact you guys kind of give us the $140 million, I get to about a 715-or-so dollar revenue implied per treatment for the exchange funds. Is that a fair kind of back out? Or is there other noise in that, that means our revenue per treatment number, that I got it wrong somehow? And then finally, I'll be very curious to hear of your commercial business. What percentage do you guys feel is out of network? It would be very helpful."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, let me tackle number one and number three, and then someone else can take a stab at number two. On out of network, we don't disclose exact percentages, but we've successfully dramatically reduced that number over the last 5 years. And strategically",191,"Well, let me tackle number one and number three, and then someone else can take a stab at number two. On out of network, we don't disclose exact percentages, but we've successfully dramatically reduced that number over the last 5 years. And strategically from a relationship point of view, we'd much prefer to be in network. And at the same time, of course, the payer's got to make a reasonable offer for that trade-off. And so that's the answer on out of network. On the patient count issue, the apples-to-apples issue, all we know is our number and our definition. And we've provided, we think, the right definition for you to be able to assess the economics associated with this issue. And then if other competitors slice and dice it in different ways, we can't really opine on that. You'll have to really talk to them about why they think it's the right way to do that. Hopefully, we're pretty clear about why we think batching on and off exchanges is the right way to look at it, for our shareholders at least. And then on the second one, can somebody..."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. On the implied revenue per treatment, you're doing -- you're about right. And of course, there's discrepancies geographically and by payer and product mix, et cetera. But yes, you're in the ZIP Code.",34,"Yes. On the implied revenue per treatment, you're doing -- you're about right. And of course, there's discrepancies geographically and by payer and product mix, et cetera. But yes, you're in the ZIP Code."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our last question is coming from Justin Lake of Wolfe Research.",11,"Our last question is coming from Justin Lake of Wolfe Research."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I wanted to touch on the -- I think that people are trying to figure out the other $90 million of potential pressure here. And so I just wanted to walk through. Is there any way to think about where those patients came from? Specifically, you've got 3,000",151,"I wanted to touch on the -- I think that people are trying to figure out the other $90 million of potential pressure here. And so I just wanted to walk through. Is there any way to think about where those patients came from? Specifically, you've got 3,000 patients that are on ACA. About half of them are getting AKF assistance. I assume it's a lot less likely CMS does something to stop people who came to you with commercial to keep what they have or having AKF help them keep what they have versus maybe those that come to you uninsured and are just waiting for the 3-month Medicare period. Maybe CMS steps in on that. Is there some way to think about the -- that $90 million and how to think about the risk and maybe break it down to those 2 pools, keep what you have versus uninsured?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Let me take a little bit of a stab here, Justin. But I'm not sure we're going to be able to give you what you want. In total, there's kind of 3 buckets. There's the Medicaid bucket, which, of course, has gotten a huge amount of attention and discussion. T",222,"Let me take a little bit of a stab here, Justin. But I'm not sure we're going to be able to give you what you want. In total, there's kind of 3 buckets. There's the Medicaid bucket, which, of course, has gotten a huge amount of attention and discussion. Then there are the uninsured, but that label is kind of misleading because a very significant number of them came from state high-risk plans that shut down as part of the Affordable Care Act. So while they didn't have classic insurance, they were funded and they were typically funded at rates more like commercial than Medicare or Medicaid. And so for the system, there's no increase in cost from their emergence in the second bucket of ACA Plans. And then third, the third bucket, which is substantial, are people who are on private plans before. Before ACA existed, they had individual health insurance plans. And once ACA was there, they switched over. And so these are people who've been buying insurance for -- in the same way that everyone now on this call buys insurance where they're doing it individually as opposed to through their employer. So those are the 3 buckets. And then within that second bucket, there's some subsets. But at some point, continued parsing will get to pretty small numbers."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. So maybe I'll just ask the question this way and jump off. There are people that are going to come to you that are uninsured that can qualify for Medicare for 3 months. If I were thinking about the potential risk bucket here, that would be the one w",106,"Okay. So maybe I'll just ask the question this way and jump off. There are people that are going to come to you that are uninsured that can qualify for Medicare for 3 months. If I were thinking about the potential risk bucket here, that would be the one where potentially now you're signing off for ACA plans where before, they would just have to wait 3 months uninsured and get Medicare. Is there any way to think about how CMS -- could CMS address that? Or effectively, they're uninsured and they could buy an ACA Plan like anybody else. So how do you stop it?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Okay. I may just look at it on the table. I do not have an answer to that. Does anybody?",21,"Yes. Okay. I may just look at it on the table. I do not have an answer to that. Does anybody?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, Justin, if I understand you correctly, I think what we're having a little disconnect in the room is we have a population that does not qualify for Medicare or Medicaid because they haven't worked in a requisite number of quarters. Or even if you're",87,"Well, Justin, if I understand you correctly, I think what we're having a little disconnect in the room is we have a population that does not qualify for Medicare or Medicaid because they haven't worked in a requisite number of quarters. Or even if you're here and working through the visa process, you have to wait 5 years before you're eligible for Medicare. So I think there is a genuine population when we discuss it that cannot access the government coverage. Does that explain it for you?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Right. So you're saying there's not really much of this 3,000 population that just had to wait 3 months for Medicare before and is now getting ACA?",27,"Right. So you're saying there's not really much of this 3,000 population that just had to wait 3 months for Medicare before and is now getting ACA?"
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Right. He's specifically ask -- yes, I hear you, Justin. You're specifically asking about that 3-month waiting period and is anybody -- is anything going on there? Not -- does anyone -- I think, Justin, we'll have to get back to you and the rest of the sh",91,"Right. He's specifically ask -- yes, I hear you, Justin. You're specifically asking about that 3-month waiting period and is anybody -- is anything going on there? Not -- does anyone -- I think, Justin, we'll have to get back to you and the rest of the shareholders on that because it's not a question that I've heard asked and answered.
All right. Thank you very much. And thanks, everyone, for your sustained interest, and we look forward to talking to you on all these topics in 90 days. Thank you."
35644,404162533,1071305,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","And that ends today's conference. Thank you, all, for your participation. You may disconnect at this time.",18,"And that ends today's conference. Thank you, all, for your participation. You may disconnect at this time."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Welcome, and thank you for standing by. [Operator Instructions] And I would now like to turn the call over to Mr. Jim Gustafson. Sir, you may now begin.",28,"Welcome, and thank you for standing by. [Operator Instructions] And I would now like to turn the call over to Mr. Jim Gustafson. Sir, you may now begin."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Jess, and welcome, everyone, to our third quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO o",236,"Thank you, Jess, and welcome, everyone, to our third quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, Vice President of Investor Relations. And with me today are Kent Thiry, our CEO; Javier Rodriguez, CEO of the DaVita Kidney Care; Vijay Kotte, Chief Financial Officer of DaVita Medical Group; Jim Hilger, our Chief Accounting Officer and interim CFO; and LeAnne Zumwalt, Group Vice President.
I'd like to start with our forward-looking disclosure statements. During this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Our forward-looking statements are based upon information currently available to us, and we do not intend and undertake no duty to update these statements for any reason.
Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our Form 8-K submitted to the SEC and available on our website.
I'll now turn the call over to Kent Thiry, our Chief Executive Officer."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Okay. Thank you, Jim, and thank you, everyone, for joining on our call. We will start, as we always do, with our clinical performance, and then I will return before Q&A.Within the DaVita Medical Group, we mentioned during our Q2 call that we outperforme",142,"Okay. Thank you, Jim, and thank you, everyone, for joining on our call. We will start, as we always do, with our clinical performance, and then I will return before Q&A.
Within the DaVita Medical Group, we mentioned during our Q2 call that we outperformed in clinical quality compared to the same period in the prior year. Our strong performance has continued, and we remain on track to achieve 4 Stars or greater for our patients within each of our major health plan relationships.
Within Kidney Care, we continue to focus on vascular access where strong performance significantly improves survival and prevents unnecessary hospitalizations. The publicly reported government data released just this October shows that we have significantly outperformed the industry in this important clinical area.
Let's now move on to the nonclinical subjects, and I'll turn it over to Javier Rodriguez."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Kent, and good afternoon. Since we spoke last, a lot has happened. I will cover 3 topics: number one, Monday's announcement; number two, our Q3 Kidney Care performance; and number three, our outlook. So let's get started.We hope the release o",846,"Thank you, Kent, and good afternoon. Since we spoke last, a lot has happened. I will cover 3 topics: number one, Monday's announcement; number two, our Q3 Kidney Care performance; and number three, our outlook. So let's get started.
We hope the release on Monday was helpful. I won't be repetitive here, but we've had a lot of questions. So let me take some, and if I miss them, please bring them up in Q&A. As a full warning, I'll go into some technical detail because the subject matter requires it.
First, why did we announce the decision on Monday, only 2 days before our earning call? It's a simple answer. This is open enrollment that started yesterday, and we needed to provide clarity to our patients and our teammates.
Second, is this a permanent change in policy? No. We have only temporarily suspended support for applications to the American Kidney Fund for patients enrolled in minimum essential Medicaid coverage. When CMS provides guidance, which we expect will be within a couple of weeks, we will evaluate our future policy.
Third, does our announcement signify a concern over our historical practices? No. Our historical practices were legal and compliant. That said, the language in the RFI may confuse some, so I thought it would be useful to clarify further.
The RFI had primarily 3 concerns. One, whether patients enrolled in Medicare purchased an ACA Plan that was duplicative in coverage. None of our patients who were enrolled in Medicare enrolled in the ACA Plan. The regulations cited in the RFI, which referred to Medicare supplemental plans is not germane to the ACA Plans.
Number two, whether patients lost their Medicaid coverage as a result of purchasing an ACA Plan and therefore, were exposed to additional costs. Our patients did not lose their Medicaid coverage as a result of purchasing an ACA Plan and as a result, were not exposed to additional costs. Consistent with CMS' own education materials, we educated our patients on the ability to pick -- purchase an ACA Plan while retaining Medicaid coverage as a secondary. These patients did not apply for tax credits and subsidies.
And three, whether patients experienced a disruption in continuity of care as a result of purchasing an ACA Plan. Just a small portion of our Medicaid patients made the choice to purchase an ACA Plan, and they did so for their own personal reasons such as to have access to specialists who do not accept Medicaid or increased chance of qualifying for transplantation or other reasons. We are not aware of any patient experiencing a disruption in care likely because those patients who would have had such a disruption, made the choice not to enroll in an ACA Plan.
Lastly, there have been some questions around comparing our disclosure of 5,000 patients versus public information from other providers. I believe that the confusion is around some definitions. When we refer to individual market plans or ACA Plans, we refer to the full universe of individual plans, whether they're sold on or off the government-run exchanges. A distinction between these types of plans is not relevant because both affect the same risk pools and are generally subject to the same regulations. If you're trying to compare us to other providers, it is important to clarify definitions to ensure that the comparison is an apples-to-apples line.
Now let's discuss our Q3 performance. Overall, DaVita Kidney Care had a solid quarter. We delivered adjusted operating income of $439 million. For U.S. dialysis, our normalized non-acquired growth for the quarter was 4.4%, which falls within our long-term target range of 3.5% to 4.5%. While we're on the topic of volume, we want to share that we signed an amendment to the agreement of Renal Ventures to acquire 100% interest in their dialysis centers for $360 million, which is $55 million less than previously announced purchase price. We expect the transaction will close in the first quarter of 2017.
Our revenue per treatment was up sequentially by 1.7 -- $1.72 per treatment, primarily driven by an increase in seasonal administration of flu vaccine. Our patient care cost per treatment were up versus Q2 by $2.41 per treatment, driven by 2 primary factors: approximately 60% by an increase in labor and benefits costs and 40% by an increase in facility costs. We have seen a tightening in labor markets leading to some increase in our labor costs. In the near term, we may see these labor costs remain at higher levels. We expect that our facility costs to come down over the next couple of quarters.
Now onto our outlook. Since we have now visibility to the end of the year, we're updating our 2016 adjusted operating income guidance for Kidney Care to be in the range of $1.695 billion to $1.725 billion. We will provide you with 2017 guidance on our Q4 earnings call when we expect to have additional clarity on several variables, including open enrollment and policy changes from CMS.
Now I'll turn the call to Vijay Kotte for DMG."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thank you, Javier. First, financial performance. We noted on the Q2 call that we would see accelerated noncash amortization expense for the ACP brand during the transition to DMG, which would impact our reported operating income. This will run for 30 mont",341,"Thank you, Javier. First, financial performance. We noted on the Q2 call that we would see accelerated noncash amortization expense for the ACP brand during the transition to DMG, which would impact our reported operating income. This will run for 30 months at an incremental rate of slightly more than $2 million per month or $26 million on an annualized basis beginning September 2016. Including the impact of this accelerated amortization, operating income for the quarter was $33 million.
As we look at the full year, we are narrowing our 2016 adjusted operating income guidance to a range of $115 million to $145 million. This is effectively a slight increase as our guidance now includes the impact of the $9 million in accelerated brand amortization that was previously excluded.
A natural question is how to think about 2017. We're still in the midst of our budget process, and open enrollment plays a big part in our outlook. That being said, there are some things we know. First, $40 million in rate cuts, which includes $30 million related to the Medicare model change and $10 million for Medicaid. Second, we have the $26 million of accelerated brand amortization. And third, we are continuing to make incremental investments in the business. Despite these headwinds, the odds are they will be roughly flat year-over-year, but there are reasonable probabilities on the other side of that. We will go into further detail regarding our expectation for 2017 on the Q4 earnings call.
As we continue to look towards our long-term OI, our 2019 target remains $215 million.
Finally, I want to provide a few highlights on the operating progress we're making at DMG. With regard to claims process without the need for manual intervention, 2015 we're at 26%; and in 2016, 79%. With regards to services getting electronic authorizations, 2015 was 24%, 2016 is 47%. And finally, with regards to new tuck-in clinicians, in 2015, we had 18; and in 2016, we're at 44.
Now to Jim Hilger for some financial details on the quarter."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thanks, Vijay. I'll first address our international operations. Our international operating income was $368 million in the quarter, which includes the gain on the deconsolidation of the APAC JV of $374 million. We are on track to meet our guidance for app",600,"Thanks, Vijay. I'll first address our international operations. Our international operating income was $368 million in the quarter, which includes the gain on the deconsolidation of the APAC JV of $374 million. We are on track to meet our guidance for approximately $40 million in adjusted losses for 2016.
Our JV transaction with Khazanah and Mitsui closed on August 1. As you will recall, Khazanah and Mitsui have each subscribed to acquire 20% share of ownership of the joint venture. At closing, each partner made their first investment tranche of $50 million in return for a 6.7% ownership in the joint venture. This joint venture has been deconsolidated from our financials. Going forward, our pro rata share of its operating income will run through equity investment income in our income statement. As a result of this deconsolidation, we recorded a onetime noncash gain of $374 million. We are excluding this gain when reporting our adjusted non-GAAP financial results and excluding it from our adjusted operating guidance for 2016. We look forward to continuing our growth in Asia Pacific dialysis with the help of our new partners.
Next. I'd like to talk about a few tax items. In the third quarter, we recorded an adjustment related to tax assets created through the DMG acquisition escrow provisions. This adjustment resulted in a $27 million increase in corporate G&A expense that was offset by an equal reduction in income tax expense and thus, created no change in net earnings or earnings per share. We do not expect any ongoing impact from this adjustment.
Excluding this escrow provision tax adjustment and excluding the gain from the formation of the APAC dialysis joint venture, our tax rate attributable to DaVita was 40% in the quarter and 39% year-to-date. We expect our full year tax rate attributable to DaVita to be approximately 39%, when excluding all non-GAAP items.
Next, our interest expense increased slightly in the quarter to $105 million due to an increase in the interest rate cap amortization as well as the impact of the deconsolidation of the APAC joint venture. This higher level of interest expense reflects our go-forward run rate.
And finally, turning to our continued strong and consistent cash generation. Operating cash flow was $536 million in the third quarter and $1.92 billion for the last 12 months. We expect full year 2016 operating cash flow to be between $1.75 billion and $1.85 billion.
Since our last earnings release, we have repurchased 9.6 million shares for approximately $619 million. And through October, we have repurchased 13.3 million DaVita shares for approximately $868 million, which represents about 6.3% of the outstanding shares at the beginning of the year. Approximately 881 million remains outstanding under our board repurchase authorizations.
We continue to have a strong cash balance with nearly $1.6 billion in cash and short-term investments as of September 30. While $212 million was used in October to repurchase stock, and an additional $360 million will be used in the coming months for the completion of the Renal Venture acquisition, that still leaves us with over $1 billion of cash available before considering our continued strong cash-generating capabilities.
As discussed at our Capital Markets Day earlier this year, we expect to generate well over $5 billion in free cash flow to use for growth and share repurchases from 2016 to 2019. Even assuming a reasonable baseline of $1.5 billion in growth spending for development CapEx and acquisitions, this leaves over $3 billion for additional growth or share repurchase.
And now I'd like to turn it back to Kent for a few closing comments."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Thanks, Jim, and I'd actually like to make several additional comments. Some will be a little bit redundant to what JR said, but it's such an important topic, we think it's worthwhile in order to achieve good clarity. Allow me 8 different points, please.",1161,"Thanks, Jim, and I'd actually like to make several additional comments. Some will be a little bit redundant to what JR said, but it's such an important topic, we think it's worthwhile in order to achieve good clarity. Allow me 8 different points, please.
Number one. We fulfilled our regulatory responsibility to provide comprehensive education to our patients. This has been an industry requirement for the last 15 to 20 years, and then ACA was added onto that standard and long-standing process and practice.
Number two. A very small percentage of our Medicaid patients determined that an ACA Plan was better for them, and Javier mentioned some of the very significant reasons why some of those plans were way better for them and/or their families. I won't repeat the examples, but important and often beautiful improvements in care.
Number three. Nonetheless, if you look at the benchmark plan, an EGHP plan, you see that total ESRD costs, meaning dialysis and hospital-related costs, et cetera, was about 1.3% of the total medical costs. That again is total ESRD costs in the numerator and then total medical costs for the plan in the denominator. In the ACA Plans, we estimate right now that, that percentage is only up to about 1.6%. And so it is a low absolute number and it's a low increase number.
Number four. We were very sensitive to the fact that some of these patients choosing an ACA Plan meant that we would be paid higher rates, commercial rates versus Medicaid rates. And therefore, we created a very intense oversight process to make sure that we did everything possible to live up to the CMS standards around objective presentation of information and absolutely letting the patient choose.
Number five. We, nonetheless, got swept up in the current huge controversies around the sustainability of the exchanges, and you're all sensitive to the huge political forces in play on that subject.
Number six. Why did dialysis, and in part DaVita, become a visible part of that controversy? Well, a, letter a, we're national, and so our numbers get added up nationally unlike a lot of health systems which are regional or local; b, our patients stick out, they're very high cost, very easy to identify, very discreet; c, there have been abuses by providers in other segments and perhaps some abuses even in ESRD, and so upfront, we started to be painted with that brush by some without data to support; d, some payers did have very large year-over-year increases in dialysis expense, and it was originally assumed that this must be from the process that I described earlier. But in fact, in many, probably most instances, it was driven by other factors. For example, sometimes, a plan had a differentially attractive product and would gain significant market share literally moving from having 50% of the ESRD patients in a market to 80%, thereby guaranteeing at least a 60% increase in your cost, having nothing to do with anything else other than product design. As we all know, this has been a very dynamic period, probably the most dynamic period ever in terms of alternative product design for insurance plans. And also, people have been struck by how smart the consumers are and how much shopping and switching they do. A second explainer in several markets is when there was a bad actor in the payer world, meaning someone who did inappropriate steering of patients away from themselves, leaving one of their competitors with a disproportionate percentage. And again, we're talking about 30%, 40% shifts in market share in some instances. A third driver out of probably a potential list of 7 or 8, but I'll stop after 3, is areas with relatively poor Medicaid coverage because that would naturally mean that there's a higher probability that a Medicaid patient would find an ACA Plan more attractive. This is just to give you a sense of what kind of things actually drove a lot of those year-over-year increases for particular plans because as we mentioned earlier, the aggregate reality only moved from 1.3 to 1.6.
But letter e, those high examples were taken to CMS and positioned as being reasonably representative of a broader movement. And at that point, CMS did not have the data of the 1.3 and the 1.6.
On to number 7 of 8. CMS is now starting to realize, contrary to initial impressions that, a, some of the numbers were misleading. That's not to say they were inaccurate if they were from a particular plan. They were just misleading. And as you start to stare at a number like a 0.3 increase, and again this is our estimate, but as you compare that to 22% rate increases on average, you can see that we were not a material source of the problem, nor are we a material source of the solution. 
Letter b, our patients made sensible choices, and we provided lots of examples to CMS as have other providers.
C, the fact that enrollment of dialysis patients within the ACA plans looks to be flat or down even without any change in Medicaid access in 2017 and '18, and of course, would be down even more with any restriction on the Medicaid front.
Letter d, CMS now is starting to see some of the reasons for the dramatic disparities in year-over-year dialysis expense increases and seeing how they have to do with product design, competition, et cetera.
And lastly, e, they also have a better sense of how charitable premium assistance has been embedded in the ESRD economic and clinical ecosystem for 20 years with a lot of guardrails and with the OIG's blessing, including blessing the aspect of provider funding.
So number 8 and final comment is, of course, the big question on everyone's mind, including ours, is what exactly is CMS going to decide with respect to this portfolio of decisions. And we don't know. No one knows. I think to their credit, they don't know right now because they're continuing to absorb information, and we are incredibly grateful and respectful that they are doing that.
Moving on to DMG. Just one happy announcement, and that is that Chuck Berg is joining our leadership team as Executive Chair of DaVita Medical Group. He'll report to me in my role as CEO of the enterprise. Chuck's been on our board since 2007. He has a wealth of experience in the health plan world, including having been the very successful executive chair of WellCare Health Plans and prior to that, the CEO of Oxford Health Plans, where I was his nonexecutive chair. This experience, combined with his brain, makes him uniquely suited to help us evaluate our long-term strategic alternatives at DMG. And he will remain in our board in the meantime, and I and others look forward to working with him.
Operator, if you could please go ahead and open up the line for Q&A."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","[Operator Instructions] Our first question is coming from Justin Lake of Wolfe Research.",13,"[Operator Instructions] Our first question is coming from Justin Lake of Wolfe Research."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I guess my first question here is just the company bought back $600 million of stock in the last 4 months at prices that are 15% above the current price. With full knowledge of the issues out there in terms of the concerns around third-party payment for A",135,"I guess my first question here is just the company bought back $600 million of stock in the last 4 months at prices that are 15% above the current price. With full knowledge of the issues out there in terms of the concerns around third-party payment for ACA coverage, right, given the potentially significant impact on earnings here, the downstream impacts of just the government taking a harder look at third-party funding in general, managed care negotiations, et cetera potentially getting impacted, my question is should we take this as a sign of your comfort level with the potential of downstream impacts on third-party payment changes, et cetera, on the earnings power of the business? And if so, any color you could share on why your level of comfort is that high will be helpful."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Thanks, Justin. I would not say that the reason we chose to buy back was because any particularly distinctive level of confidence on what exactly the outcome was going to be. And certainly, if we could do it over again, we would have preferred to hav",113,"Yes. Thanks, Justin. I would not say that the reason we chose to buy back was because any particularly distinctive level of confidence on what exactly the outcome was going to be. And certainly, if we could do it over again, we would have preferred to have waited and be buying back more of it now. But awfully difficult to predict things. There's a lot of different variables, not only with respect to the issues you mentioned, but other issues, both threats and opportunities. And nonetheless, I would not say that we said, ""Gosh, there's some distinctive near-term downside, and we're going to go ahead and buy anyway."" I wouldn't make that claim."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Then maybe we could just talk about your commercial mix in general given this has been a big area of focus here. We look at the changes and the growth and -- in the commercial mix, and if we back out these 2,000 patients, it looks like it's been fla",165,"Okay. Then maybe we could just talk about your commercial mix in general given this has been a big area of focus here. We look at the changes and the growth and -- in the commercial mix, and if we back out these 2,000 patients, it looks like it's been flat over the last several years. But looking ahead and just thinking about the changes, looks like the -- from USRDS data, there hasn't really been much incidence growth in the pre-65 population over the last 10 years. And when we couple that with the aging of the baby boomers and the Medicare from kind of commercial years, there's the indication that it could put a fair amount of pressure on commercial mix over time. So I guess my question is can you tell me whether this is a reasonable view? And if so, how should we think about this factor in relation to your typical kind of mid-single-digit long-term growth algorithm for the dialysis?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. I think it's a very fair question, Justin. And I think if you wanted to identify other worrisome long-term trends, you would also look at improved treatment regimens for diabetics and hypertensives. And commercial patients are more likely to benefit",202,"Yes. I think it's a very fair question, Justin. And I think if you wanted to identify other worrisome long-term trends, you would also look at improved treatment regimens for diabetics and hypertensives. And commercial patients are more likely to benefit from improved treatment regimens. On the other hand, there's also things pushing in the other direction. We continue to be quite successful with our Non-Acquired Growth, and some of these hard times could lead a lot more small providers to sell or even shut down. In addition, we're very hopeful that Medicare Advantage continues to grow because we radically prefer a customer who cares about total value. And we tend to do much better in terms of both adding value to the system and getting reimbursed for it. In addition, as you know better than most, to the extent that the mix ever starts to put too much pressure on all the independent centers, the government has the easy option of doing that, which it's done 3 or 4 times before, and that's extending the MSP provision from originally 0 to 12 and 12 to 18 and 18 to 30. And so that's a safety valve that's never far away. Justin?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Yes. I -- Kent, if you could give me one more chance. I'll just ask you like does this mean that should we think about within the 6, let's just call it, mid-single-digit CAGR that you look for, for the dialysis business? This mix looks like just the likel",86,"Yes. I -- Kent, if you could give me one more chance. I'll just ask you like does this mean that should we think about within the 6, let's just call it, mid-single-digit CAGR that you look for, for the dialysis business? This mix looks like just the likely pressure that's going to be on commercial mix over the next 10 to 20 years. Is this in that number? Or could this have a negative impact on that number in the way you're looking at it?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, fair question. I would say that at the time we did the last Capital Markets, we incorporated all the variables, although that was a 3-year outlook. When we refresh our Capital Markets outlook at the next one, it will once again incorporate everything",162,"Yes, fair question. I would say that at the time we did the last Capital Markets, we incorporated all the variables, although that was a 3-year outlook. When we refresh our Capital Markets outlook at the next one, it will once again incorporate everything. And while some of the stuff that you're citing is most likely not going to be economically material within the near term, perhaps we should, for the first time in a long time, take a cut at sort of the 4 to 7 year time frame and stare at some of the upsides and downsides, the puts and takes, not only on mix but on cost structure, et cetera, also modality mix and some other things that can have a big impact on cash flow and return on capital. So we don't have anything distinctively thoughtful to say to you today from an analytical point of view, but that's probably a good assignment for the next Capital Markets."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Kevin Fischbeck of Bank of America Merrill Lynch.",14,"Our next question is coming from Kevin Fischbeck of Bank of America Merrill Lynch."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I have a lot of questions kind of similar to that, but I guess I appreciate all the color about the AKF change. I think that was very helpful. I think I understand those parameters. But I guess the question that I'm still struggling with is what the real",227,"I have a lot of questions kind of similar to that, but I guess I appreciate all the color about the AKF change. I think that was very helpful. I think I understand those parameters. But I guess the question that I'm still struggling with is what the real growth rate of the company has been over the past 3 years in the dialysis business because if I look at operating income growth over the last 3 years, it's been about 5% per year. But if I was to say that this 140 was either not sustainable or onetime in nature, then I'm getting like a 2% type growth in the dialysis business over the past 3 years. So how do we think about that? And that's the low end of what you guys think you're going to do over the next few years going forward. And when I think about the next few years versus the last few years, Medicare rates have been under pressure and likely will be in the same range. So why is the right way to think about growth over the next few years not the low end of that 3 to 7? Like what would cause you to do better than the low end of that range? Or is 4 at the low end the right way to think about it?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Right now, I would say if you wanted to weight the probabilities between the low end, middle and top, you would find the probability skewed to the low end, but it's not by a huge amount. And then in addition, of course, unit volume is, for us, in man",116,"Yes. Right now, I would say if you wanted to weight the probabilities between the low end, middle and top, you would find the probability skewed to the low end, but it's not by a huge amount. And then in addition, of course, unit volume is, for us, in many ways, of secondary importance with commercial mix and the nature of commercial mix of primary importance. And that number has got a lot of dynamism to it right now, as you well know. And so at this point, we're not revising that guidance, but we do look forward to a very intense analytical discussion at the next Capital Markets about the next generation of 3-year outlook."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Then I guess if we look at commercial mix and take out this maybe 1% that's related to the ACA, it looked like mix has basically been flat over the last 5 years, maybe down a little bit during a time when the economy is improving. So do you think th",117,"Okay. Then I guess if we look at commercial mix and take out this maybe 1% that's related to the ACA, it looked like mix has basically been flat over the last 5 years, maybe down a little bit during a time when the economy is improving. So do you think that, that's really reflective of what the industry has been seeing? Or I know from time to time you've raised flags about potentially competitors being aggressive on pricing. Has there been anything where you feel like you've purposely walked away from market share because people got competitive? Or is that kind of how you think mix overall for the industry has looked over that time period?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Our guess is that our trajectory of commercial mix is quite similar to others, and we have not experienced any example of someone in our mind foolishly seeking to gain shares through price reductions in an industry of almost pure variable cost, very stick",70,"Our guess is that our trajectory of commercial mix is quite similar to others, and we have not experienced any example of someone in our mind foolishly seeking to gain shares through price reductions in an industry of almost pure variable cost, very sticky volume and high likelihood of economic retaliation. So we haven't seen any of that go on, and so our guess is that competitor performance is comparable."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just one last question. On HCP, looks like the number of physicians and clinicians went up nicely sequentially, but we still saw a deceleration in revenue in that business for Q2 to Q3. Wanted to see what was going on there and whether the",65,"Okay. And then just one last question. On HCP, looks like the number of physicians and clinicians went up nicely sequentially, but we still saw a deceleration in revenue in that business for Q2 to Q3. Wanted to see what was going on there and whether the increase in clinicians is a good sign about a ramp-up in revenue over the next couple of quarters."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Over the long term, you should see a positive correlation. Right now in some cases, we were under staffed with physicians. And by adding them, we actually think we can reduce our MLR and the quantity that exceeds the incremental costs that we're addi",166,"Yes. Over the long term, you should see a positive correlation. Right now in some cases, we were under staffed with physicians. And by adding them, we actually think we can reduce our MLR and the quantity that exceeds the incremental costs that we're adding. In other cases, we're adding because we're doing some de novos and other work where we think by adding physician capacity, we're going to get more lives. It's just that there's some lag time. So we're very sensitive to the fact that at a time when the revenue trajectory is what it is, our physician recruiting is ramping up. But the good news is that shows what an attractive place we are for physicians and our hit rate in recruiting is very high. The concerning news for you is we're adding to costs at a time when revenues aren't going up at the same trajectory. And so we hear you, and over time, you should see the positive correlation you expect."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Is the right way to think about that as like a couple of quarter lag? Or a year lag? How long do we think about these doctors adding to the earnings?",32,"Okay. Is the right way to think about that as like a couple of quarter lag? Or a year lag? How long do we think about these doctors adding to the earnings?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, unfortunately, I don't think we're good enough yet to give you an empirical answer for that, and so I won't hazard a guess. Suffice it to say, we know you'll be watching each quarter.",35,"Yes, unfortunately, I don't think we're good enough yet to give you an empirical answer for that, and so I won't hazard a guess. Suffice it to say, we know you'll be watching each quarter."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Gary Lieberman of Wells Fargo.",11,"Our next question is coming from Gary Lieberman of Wells Fargo."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I guess just sticking with the topic of the day. I think there's a broader concern by some investors that potentially the AKF would be restricted more broadly from making premium support payments to historical patients that they would have been doing it f",66,"I guess just sticking with the topic of the day. I think there's a broader concern by some investors that potentially the AKF would be restricted more broadly from making premium support payments to historical patients that they would have been doing it for COBRA or for other factors. Can you talk about that? Do you think that is a risk? And why or why not?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. It is a risk, but the 2 big facts on that big issue are that for private plans to do a broad prohibition of charitable premium assistance is an exceptionally heavy lift because there are hundreds of such organizations all over the country, and thousa",108,"Yes. It is a risk, but the 2 big facts on that big issue are that for private plans to do a broad prohibition of charitable premium assistance is an exceptionally heavy lift because there are hundreds of such organizations all over the country, and thousands of hospitals that like those foundations and charities and the rest. And to try to deploy one that's focused on our patients would be discriminatory and subject to really intense lawsuits. And then separately, CMS does not have authority over the whole EGHP realm. They, of course, have authority over lots of other realms, but not that one. Is that responsive, Gary?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Yes, that's helpful. Any chance you could tell us what percentage of your commercial patients, if you know it, receive premium assistance from the AKF?",25,"Yes, that's helpful. Any chance you could tell us what percentage of your commercial patients, if you know it, receive premium assistance from the AKF?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I think at this point, we've decided that disclosing that is not in your best interest, although we'll continue to stare at that each quarter. But that's our current thinking. Of course, we incorporate all variables into our forecasts, but sometimes, some",50,"I think at this point, we've decided that disclosing that is not in your best interest, although we'll continue to stare at that each quarter. But that's our current thinking. Of course, we incorporate all variables into our forecasts, but sometimes, some of these swing factors are difficult to calibrate."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then on the same topic, I think there are some investors that believe that, in fact, it's illegal to -- for the Medicaid patients to have been given premium support. Can you just talk about that? And your understanding, I assume, from your persp",57,"Okay. And then on the same topic, I think there are some investors that believe that, in fact, it's illegal to -- for the Medicaid patients to have been given premium support. Can you just talk about that? And your understanding, I assume, from your perspective, it's not illegal? Can you just help us think through that?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Sure. I appreciate you bringing it up because we certainly heard the concern. And the very explicit references by CMS to how it is legal are multiple and really clear. And the RFI referred to a part of the statutes that didn't apply to the subject at hand",109,"Sure. I appreciate you bringing it up because we certainly heard the concern. And the very explicit references by CMS to how it is legal are multiple and really clear. And the RFI referred to a part of the statutes that didn't apply to the subject at hand. So it was literally not germane to the critical questions that you and others are worried about. And so we have continued to point to the very explicit language supporting our position. We have been in meetings with senior CMS officials and referred to the fact that it's very clearly legal and have never run into a single objection from anyone."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Gary, let me add one thing, Gary, that might help clear it up. It is the case that Medicaid patients cannot have federal subsidies, and so it's not that there aren't some rules that apply, but it is very clear that there was a conscious decision made to a",123,"Gary, let me add one thing, Gary, that might help clear it up. It is the case that Medicaid patients cannot have federal subsidies, and so it's not that there aren't some rules that apply, but it is very clear that there was a conscious decision made to allow Medicaid patients to make the choices that we made available to them. And I'll even add one other element. Back when the Affordable Care Act was being rolled out, we were encouraged by the administration to promote exchange products. We were even asked to put up signs in our centers promoting the ACA Plans. Now of course, it's 4 years later and a lot of things have changed, but that's the actual historical context."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Great. That's very helpful. And then, Jim, can you just remind us at what point you would have been restricted from purchasing your stock after the end of the quarter?",30,"Great. That's very helpful. And then, Jim, can you just remind us at what point you would have been restricted from purchasing your stock after the end of the quarter?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, we entered -- we typically enter restriction period at -- near the very end of the quarter, and we would be restricted throughout the period of time after the quarter ended until through this call.",36,"Well, we entered -- we typically enter restriction period at -- near the very end of the quarter, and we would be restricted throughout the period of time after the quarter ended until through this call."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Got it. But I thought you guys did, in fact, purchase some stock after the end of the quarter?",19,"Got it. But I thought you guys did, in fact, purchase some stock after the end of the quarter?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, we did, and that was subject to a plan that we put in place before we were blacked out.",20,"Yes, we did, and that was subject to a plan that we put in place before we were blacked out."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","So you did 10b-5 in place before it was blacked out?",12,"So you did 10b-5 in place before it was blacked out?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","That's correct.",3,"That's correct."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Chris Rigg of Susquehanna.",10,"Our next question is coming from Chris Rigg of Susquehanna."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I just wanted to again come back to the AKF issue. Obviously, you're pointing at $140 million of OI this year as that being the potential headwind for next year. But can you give us a sense for how that ramps during the first 2 years of the coverage expan",50,"I just wanted to again come back to the AKF issue. Obviously, you're pointing at $140 million of OI this year as that being the potential headwind for next year. But can you give us a sense for how that ramps during the first 2 years of the coverage expansions?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","How the $140 million ramped up?",6,"How the $140 million ramped up?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Like what was the exposure in 2014, net in '15? And now you're at $140 million for this year in roughly 2,000-ish patients.",23,"Like what was the exposure in 2014, net in '15? And now you're at $140 million for this year in roughly 2,000-ish patients."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Okay. I know we didn't calculate that number prior to the call. Why don't -- the people around the table here will see if we can and should generate that and share it before the call is over, but we don't have it at our fingertips.",46,"Okay. I know we didn't calculate that number prior to the call. Why don't -- the people around the table here will see if we can and should generate that and share it before the call is over, but we don't have it at our fingertips."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then sort of another qualitative-type question here on the AKF issue, but obviously, getting to some of the -- at least what's been sort of suggested from the managed care side is that by shifting some of these people from, call it, 100% Medicai",114,"Okay. And then sort of another qualitative-type question here on the AKF issue, but obviously, getting to some of the -- at least what's been sort of suggested from the managed care side is that by shifting some of these people from, call it, 100% Medicaid to sort of Medicaid as a supplemental, there may have been some out-of-pocket exposure here. I guess when you guys did your look back and reviewed the 2,000 or whatever that may have been in '15 and '14, what did you do? I guess I'm just trying to get some comfort here that you guys feel pretty comfortable that in no material way were the individuals harmed financially."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I'll take a first stab and then other people may want to add on. First of all, we dedicated a huge amount of time in developing materials and training our people and so that our historic discipline of presenting objectively was on steroids for this proces",181,"I'll take a first stab and then other people may want to add on. First of all, we dedicated a huge amount of time in developing materials and training our people and so that our historic discipline of presenting objectively was on steroids for this process. And we present very complete information that encompasses premiums, deductibles, co-pays, out-of-pocket stuff, potential federal tax credits, potential charitable premium assistance, individual versus family, high income versus low. And so we're thorough, and it's presented to the patients in ways that leaves most of them exceptionally grateful for the help and the clarity, and then they choose. So one can never say that theoretically, you couldn't have a patient choose something that was foolish. I'm sure out of 2,000 patients, there were some. But we have to respect the fact that it's their choice. In general, however, just as we've seen in the exchanges over the last 3 or 4 years, the average patient demonstrates a lot of economic common sense in how they move around between different products, particularly when they are helped."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","And Chris, this is Javier. I'll just add one important point, is that they never lose their Medicaid. Medicaid was in the secondary position, so the patients actually didn't incur additional costs.",32,"And Chris, this is Javier. I'll just add one important point, is that they never lose their Medicaid. Medicaid was in the secondary position, so the patients actually didn't incur additional costs."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay, okay. And then just one last one here on Kidney Care operating income for next year. You made reference in the Monday press release that there could be some theoretical offsets to the $140 million. If there are, can you give us a sense for what they",68,"Okay, okay. And then just one last one here on Kidney Care operating income for next year. You made reference in the Monday press release that there could be some theoretical offsets to the $140 million. If there are, can you give us a sense for what they are? And then just can you just give us some general sort of headwinds and tailwinds beyond the AKF issue?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, first of all, on mitigation, we'll be able to do a good job on that in the next quarterly call if we're in this scenario where that's the topic of the day. Separate from that, and then someone else may want to add, I mean, on the plus side, we have",129,"Well, first of all, on mitigation, we'll be able to do a good job on that in the next quarterly call if we're in this scenario where that's the topic of the day. Separate from that, and then someone else may want to add, I mean, on the plus side, we have a wonderful recurring unit growth. We have the potential accelerator of continued Medicare Advantage growth. On the cost structure side, we have the opportunities in the ESA area. And on the capital deployment side, we have the opportunity for more small operators filling a need to get out of this ever more complicated and challenging business. On the headwind side, I think we've laid them out with painful detail already, and so I won't list them again."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from John Ransom of Raymond James.",11,"Our next question is coming from John Ransom of Raymond James."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I did 1 day of law school and ran off in horror, so my peabrain isn't large to understand all these fine points. But to make it simple, one of your competitors said that the no-no in their opinion was to switch people off Medicaid, but that the ambiguity",124,"I did 1 day of law school and ran off in horror, so my peabrain isn't large to understand all these fine points. But to make it simple, one of your competitors said that the no-no in their opinion was to switch people off Medicaid, but that the ambiguity was when a new patient came in eligible for both Medicaid and an ACA Plan, that's where you could present both. Is what you're doing just sort of in line with that, that new patients come in are fair game. They don't have insurance, but existing patients with Medicaid, you're no longer going to try to switch them. I know I'm over simplifying, but is that a helpful way to think about it? Or no?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It's LeAnne. I think the -- you're confusing 2 things, so let's talk about patients who find us for ACA coverage made that choice and retained their Medicaid in the secondary. I think that answers the first question. There's no -- we're not substituting A",66,"It's LeAnne. I think the -- you're confusing 2 things, so let's talk about patients who find us for ACA coverage made that choice and retained their Medicaid in the secondary. I think that answers the first question. There's no -- we're not substituting ACA coverage for Medicaid. If they're keeping them, they're having both of them, and it's not subsidized by federal tax credits."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Does that answer just the first half of your question, John?",11,"Does that answer just the first half of your question, John?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Well, not really, but I'll follow up. I think there's so many cross-currents here, I don't want to drag this out on the call. And what about the second scenario where a patient comes in without any -- maybe they're eligible for Medicaid but they jus",100,"Okay. Well, not really, but I'll follow up. I think there's so many cross-currents here, I don't want to drag this out on the call. And what about the second scenario where a patient comes in without any -- maybe they're eligible for Medicaid but they just never signed up. How does that work? And is that something -- again, your competitor said we expect CMS to clarify the rules on that patient B that comes to them without any insurance at all. Is that a useful way or, again, was that a misleading comment by one of your competitors?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. I think we do have patients that come to us that are uninsured, and our education and process with those patients would be to find out all the avenues to which they could purchase coverage, whether they be Medicare or Medicaid or commercial plan, an A",82,"No. I think we do have patients that come to us that are uninsured, and our education and process with those patients would be to find out all the avenues to which they could purchase coverage, whether they be Medicare or Medicaid or commercial plan, an ACA Plan, et cetera. So our counselor's job is to make sure that each of the avenues is presented to that patient, and then the patient chooses what is best for them in their particular circumstance."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. LeAnne, hadn't heard from you in a while, so it's good to hear your voice. The second question I had was -- I mean, obviously in some of the comments, there were allegedly comments from either current or former DaVita employees who talked about bein",96,"Okay. LeAnne, hadn't heard from you in a while, so it's good to hear your voice. The second question I had was -- I mean, obviously in some of the comments, there were allegedly comments from either current or former DaVita employees who talked about being pressured to sign people up on commercial plans. So I'm sure you saw all that stuff. Just internally, what kind of controls do you have in place to investigate those kinds of comments? And what's your general view on that? True? Not true? Out of context? That would be helpful."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","John, thank you. This is Javier. First of all, would like to highlight that the numbers are small. But of course, regardless of the size of the numbers, we take each and every one very seriously. We did some huge, huge oversight here. We had to train a lo",173,"John, thank you. This is Javier. First of all, would like to highlight that the numbers are small. But of course, regardless of the size of the numbers, we take each and every one very seriously. We did some huge, huge oversight here. We had to train a lot of people in a very short amount of time, and so we had heavy oversight. And for a small number of people, they might have experienced that as negative. What we do is, of course, if we have any concerns, we give it to a third party. We give it to our compliance department. And they look into it and we rectify if there are any mistakes. But the bulk of what we've looked into has now materialized. And actually, when we've gone into some sessions, we've literally asked for evidence to be provided of our wrongdoing and alleged wrongdoing. And we've never been given any specifics because, of course, we would want to correct any mistakes if they were brought to our attention."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. That's great. And then let's switch gears and 2 more quick ones. Let's say we are in a scenario of a little more austerity on a number of fronts. I mean, there's obviously a big gap between your total CapEx and your maintenance CapEx. In a more aust",159,"Okay. That's great. And then let's switch gears and 2 more quick ones. Let's say we are in a scenario of a little more austerity on a number of fronts. I mean, there's obviously a big gap between your total CapEx and your maintenance CapEx. In a more austere scenario, and I'll just make up a number, let's say revenue per treatment is $340 to $345 for a bunch of reasons. How should we think about the likely reaction of the company? What levers would be likely to be pulled? And again, CapEx is one that would appear to be one where you have a lot of discretion over. And again, I ask this because there's a debate on the Street about should we look at DaVita on earnings per share? Or should we look at it on free cash flow? And free cash flow requires the assumption that CapEx is closer to maintenance than it is to actual."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, we hear you. The answer right now will be fairly generic. I mean, in a world where we would suffer some serious revenue compression, we would do what any responsible businessperson should do and very systematically go through every line item on the P",103,"Yes, we hear you. The answer right now will be fairly generic. I mean, in a world where we would suffer some serious revenue compression, we would do what any responsible businessperson should do and very systematically go through every line item on the P&L and every aspect of cash in and cash out. And we would enter into that process with the expectation that we would find some savings in the P&L side, and we would find some reductions on the CapEx side. And at the same time, we haven't quantified those, but we certainly do have some serious ranges of discretion."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. Was the reduction in price for Renal Ventures driven by the new thinking around ACA Plans? Or was it something else?",22,"Okay. Was the reduction in price for Renal Ventures driven by the new thinking around ACA Plans? Or was it something else?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No, it was something else. There was a part of the transaction that was contemplated at the beginning. And after further dialog, we are not going to acquire their infusion business. So that's why the price was changed.",38,"No, it was something else. There was a part of the transaction that was contemplated at the beginning. And after further dialog, we are not going to acquire their infusion business. So that's why the price was changed."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I see. And is that -- you still think you might get that done? I know it's been dragging on for over a year. Is that still to be done by the end of the year? Or maybe you never said, but that's our assumption. Is that a reasonable assumption?",50,"I see. And is that -- you still think you might get that done? I know it's been dragging on for over a year. Is that still to be done by the end of the year? Or maybe you never said, but that's our assumption. Is that a reasonable assumption?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","No. We think it will -- there are some chance of Q4. But if you were betting, I would probably go with Q1 because there's some regulatory stuff going on. So I think Q1 is [indiscernible]",36,"No. We think it will -- there are some chance of Q4. But if you were betting, I would probably go with Q1 because there's some regulatory stuff going on. So I think Q1 is [indiscernible]"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","[indiscernible] 18 months, is that a record? I would think 18 months might be a record.",16,"[indiscernible] 18 months, is that a record? I would think 18 months might be a record."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It is. It's a new record for us anyway.",9,"It is. It's a new record for us anyway."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And lastly, just thinking about potential good guys. ESA costs. Do you have a view of -- you've got your current contract with Amgen, obviously. But if you do a market check on what other folks are now paying for ESAs, what's your view on your kind of app",76,"And lastly, just thinking about potential good guys. ESA costs. Do you have a view of -- you've got your current contract with Amgen, obviously. But if you do a market check on what other folks are now paying for ESAs, what's your view on your kind of apples-to-apples cost versus what's currently -- if you were free of that contract, would that be a good guy that could be called out? And I'll stop there."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, it's LeAnne again. I think you have to put it into 2 buckets. Obviously, I think the public announcement by FMC as to their cost reductions associated with their using Mircera gives you one category. So clearly, I think they are enjoying a price that",139,"Yes, it's LeAnne again. I think you have to put it into 2 buckets. Obviously, I think the public announcement by FMC as to their cost reductions associated with their using Mircera gives you one category. So clearly, I think they are enjoying a price that is better than the rest of the marketplace. Then you take the rest of the marketplaces on Amgen products. And I think there was a lot of buzz about the move to Aranesp lowered the independents' and small providers' costs. Well, that's correct, it did. But that's a relative lowering, and our ESA cost has been historically off the best. And I think that holds true, and so you -- if you want to ask it again in a different way, but I think that should give you the answer you're looking for."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","So in short, probably unless somebody opens up that contract, probably not -- it's probably reasonable to assume not much movement on that -- on that line item through the terms of the contract?",34,"So in short, probably unless somebody opens up that contract, probably not -- it's probably reasonable to assume not much movement on that -- on that line item through the terms of the contract?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I don't know if that's necessarily the right conclusion. Of course, when you enter into a long-term contract, both parties will look into it as things change. Amgen, of course, is interested in seeing that we are a customer post contract renewal, and we w",123,"I don't know if that's necessarily the right conclusion. Of course, when you enter into a long-term contract, both parties will look into it as things change. Amgen, of course, is interested in seeing that we are a customer post contract renewal, and we want to be talking to all the parties that are out there. And so what we're trying to make sure is that we have the right term solution for the long haul, so we're looking at this. You seldom get a chance to look at an $800 million cost line, and so we are very eager in deploying the right level of rigor and resources to make sure that we get the right relationship going forward post '18."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, and I've got an answer for the question that Chris brought up, which is sort of this $140 million, how did it build over time? It won't be very precise, but it will give you directionally what you're seeking. And that is that the bulk of the growth c",117,"Yes, and I've got an answer for the question that Chris brought up, which is sort of this $140 million, how did it build over time? It won't be very precise, but it will give you directionally what you're seeking. And that is that the bulk of the growth came in '15 and '16. '14, it was a small number. If we had to estimate, in the $20 million or so range. In '15, the range is probably somewhere in the -- I don't know, double that, give or take. We don't have very precise numbers, but we just wanted to give you directionally that the bulk of it was in '16 with some growth in '15."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Gary Taylor of JPMorgan.",10,"Our next question is coming from Gary Taylor of JPMorgan."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Just a couple of things. Given some of the reports that some of the health plans have already attempted to identify patients with AKF subsidies and even potentially terminate some of those contracts, I just wanted to check in on commercial mix. I know you",81,"Just a couple of things. Given some of the reports that some of the health plans have already attempted to identify patients with AKF subsidies and even potentially terminate some of those contracts, I just wanted to check in on commercial mix. I know you disclosed it annually, not quarterly. But I do think last quarter, you did acknowledge that it was still trending higher year-over-year. So I wanted to see if that was still true for 3Q '16 versus '15."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","I'm sorry, Gary, your question is commercial mix? What period to what period?",14,"I'm sorry, Gary, your question is commercial mix? What period to what period?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Q3.",1,"Q3."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Just year-over-year in the third quarter. Is it still trending higher year-over-year in the third quarter?",17,"Just year-over-year in the third quarter. Is it still trending higher year-over-year in the third quarter?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It is. It is up year-on-year, Gary.",7,"It is. It is up year-on-year, Gary."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And sequentially, that probably hasn't done a lot. Is that fair?",11,"And sequentially, that probably hasn't done a lot. Is that fair?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","We've seen it go down slightly in the last quarter.",11,"We've seen it go down slightly in the last quarter."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then just back to Renal Ventures. Is that still ballpark 2,300 to 2,400 patients and then anticipating some divestitures? Is that still ballpark?",25,"Okay. And then just back to Renal Ventures. Is that still ballpark 2,300 to 2,400 patients and then anticipating some divestitures? Is that still ballpark?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And then I just want to go to the patient care costs, which you called out. And I think you talked about 60%, labor; 40%, facility costs. But that was in the context of a couple dollar sequential change given that ESRD OI was down year-over-year and the c",85,"And then I just want to go to the patient care costs, which you called out. And I think you talked about 60%, labor; 40%, facility costs. But that was in the context of a couple dollar sequential change given that ESRD OI was down year-over-year and the costs jumped about $6 year-over-year. Is that still the same -- would that still be the same ratio if I look at the year-over-year, that more than half of that's labor and the rest is facility cost?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes.",1,"Yes."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","And when you say facility cost, you said it's coming down, what exactly is driving that up temporarily?",18,"And when you say facility cost, you said it's coming down, what exactly is driving that up temporarily?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","It was a -- it's a bunch of miscellaneous line items. None of them particularly stick out. So it would just be giving you a very long list, and they just cumulatively added up to something this time, and so we're working on it.",44,"It was a -- it's a bunch of miscellaneous line items. None of them particularly stick out. So it would just be giving you a very long list, and they just cumulatively added up to something this time, and so we're working on it."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Last question. I believe you were talking about HCP's OI potentially being flat into '17. And you made no comments on consolidated or kidney, and I just wanted to confirm that, that, that was correct.",35,"Last question. I believe you were talking about HCP's OI potentially being flat into '17. And you made no comments on consolidated or kidney, and I just wanted to confirm that, that, that was correct."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, that's correct. We'll be providing guidance on '17 in the next quarterly call for Kidney Care, for U.S. Kidney Care.",21,"Yes, that's correct. We'll be providing guidance on '17 in the next quarterly call for Kidney Care, for U.S. Kidney Care."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Whit Mayo of Robert W. Baird.",12,"Our next question is coming from Whit Mayo of Robert W. Baird."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I'll try to keep it quick. But maybe one more on the AKF. It doesn't appear that you implemented this exchange initiative until 2015, at least according to the RFI submission. So one, just looking to confirm that. And the ACA obviously was implemented in",87,"I'll try to keep it quick. But maybe one more on the AKF. It doesn't appear that you implemented this exchange initiative until 2015, at least according to the RFI submission. So one, just looking to confirm that. And the ACA obviously was implemented in 2014, and you knew about it many years prior. So was there something that made you apprehensive about pursuing the strategy with patients and why perhaps it wasn't implemented in 2013 or '14 open enrollment? Just looking for any additional color."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","There was no conscious delay on our part.",8,"There was no conscious delay on our part."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. And then maybe just one last one. With the MA Star Ratings published, how would you characterize your -- how your health plan partners are positioned next year? And what do you think this means for DMG? And maybe the conclusion when you see -- when",53,"Okay. And then maybe just one last one. With the MA Star Ratings published, how would you characterize your -- how your health plan partners are positioned next year? And what do you think this means for DMG? And maybe the conclusion when you see -- when you look at scores like Humana's?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes, this is Vijay. Just to be clear, the '17 numbers are already fixed, right? So we don't see much of a change between '16 and '17. The Humana numbers were for payment year of 2018, and the only place where we saw a potential drop was in one market. And",108,"Yes, this is Vijay. Just to be clear, the '17 numbers are already fixed, right? So we don't see much of a change between '16 and '17. The Humana numbers were for payment year of 2018, and the only place where we saw a potential drop was in one market. And as you know, the Star scores are related to a number of factors. But our clinical quality was at a 4 Star and above, and we believe that in partnering with our health plans, there's some administrative opportunities to help neutralize some of the impact of the potential hit for 2018 for Humana in that one market."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our next question is coming from Patrick Wood of Citi.",10,"Our next question is coming from Patrick Wood of Citi."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I'll be very quick, and this should be fairly yes or no sort of small questions. I have 3, if I may. The first will be I was very interested to hear about the apples-to-apples comparison in terms of patient numbers in relation to the CMS RFI submission. I",170,"I'll be very quick, and this should be fairly yes or no sort of small questions. I have 3, if I may. The first will be I was very interested to hear about the apples-to-apples comparison in terms of patient numbers in relation to the CMS RFI submission. I'd be curious to hear what you guys think is an apples-to-apples number vis--vis what your competitors submitted. I'd be very curious to hear that. Equally, second question would be when I back off from your operating income sort of impact you guys kind of give us the $140 million, I get to about a 715-or-so dollar revenue implied per treatment for the exchange funds. Is that a fair kind of back out? Or is there other noise in that, that means our revenue per treatment number, that I got it wrong somehow? And then finally, I'll be very curious to hear of your commercial business. What percentage do you guys feel is out of network? It would be very helpful."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, let me tackle number one and number three, and then someone else can take a stab at number two. On out of network, we don't disclose exact percentages, but we've successfully dramatically reduced that number over the last 5 years. And strategically",191,"Well, let me tackle number one and number three, and then someone else can take a stab at number two. On out of network, we don't disclose exact percentages, but we've successfully dramatically reduced that number over the last 5 years. And strategically from a relationship point of view, we'd much prefer to be in network. And at the same time, of course, the payer's got to make a reasonable offer for that trade-off. And so that's the answer on out of network. On the patient count issue, the apples-to-apples issue, all we know is our number and our definition. And we've provided, we think, the right definition for you to be able to assess the economics associated with this issue. And then if other competitors slice and dice it in different ways, we can't really opine on that. You'll have to really talk to them about why they think it's the right way to do that. Hopefully, we're pretty clear about why we think batching on and off exchanges is the right way to look at it, for our shareholders at least. And then on the second one, can somebody..."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. On the implied revenue per treatment, you're doing -- you're about right. And of course, there's discrepancies geographically and by payer and product mix, et cetera. But yes, you're in the ZIP Code.",34,"Yes. On the implied revenue per treatment, you're doing -- you're about right. And of course, there's discrepancies geographically and by payer and product mix, et cetera. But yes, you're in the ZIP Code."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","Our last question is coming from Justin Lake of Wolfe Research.",11,"Our last question is coming from Justin Lake of Wolfe Research."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","I wanted to touch on the -- I think that people are trying to figure out the other $90 million of potential pressure here. And so I just wanted to walk through. Is there any way to think about where those patients came from? Specifically, you've got 3,000",151,"I wanted to touch on the -- I think that people are trying to figure out the other $90 million of potential pressure here. And so I just wanted to walk through. Is there any way to think about where those patients came from? Specifically, you've got 3,000 patients that are on ACA. About half of them are getting AKF assistance. I assume it's a lot less likely CMS does something to stop people who came to you with commercial to keep what they have or having AKF help them keep what they have versus maybe those that come to you uninsured and are just waiting for the 3-month Medicare period. Maybe CMS steps in on that. Is there some way to think about the -- that $90 million and how to think about the risk and maybe break it down to those 2 pools, keep what you have versus uninsured?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Let me take a little bit of a stab here, Justin. But I'm not sure we're going to be able to give you what you want. In total, there's kind of 3 buckets. There's the Medicaid bucket, which, of course, has gotten a huge amount of attention and discussion. T",222,"Let me take a little bit of a stab here, Justin. But I'm not sure we're going to be able to give you what you want. In total, there's kind of 3 buckets. There's the Medicaid bucket, which, of course, has gotten a huge amount of attention and discussion. Then there are the uninsured, but that label is kind of misleading because a very significant number of them came from state high-risk plans that shut down as part of the Affordable Care Act. So while they didn't have classic insurance, they were funded and they were typically funded at rates more like commercial than Medicare or Medicaid. And so for the system, there's no increase in cost from their emergence in the second bucket of ACA Plans. And then third, the third bucket, which is substantial, are people who are on private plans before. Before ACA existed, they had individual health insurance plans. And once ACA was there, they switched over. And so these are people who've been buying insurance for -- in the same way that everyone now on this call buys insurance where they're doing it individually as opposed to through their employer. So those are the 3 buckets. And then within that second bucket, there's some subsets. But at some point, continued parsing will get to pretty small numbers."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Okay. So maybe I'll just ask the question this way and jump off. There are people that are going to come to you that are uninsured that can qualify for Medicare for 3 months. If I were thinking about the potential risk bucket here, that would be the one w",106,"Okay. So maybe I'll just ask the question this way and jump off. There are people that are going to come to you that are uninsured that can qualify for Medicare for 3 months. If I were thinking about the potential risk bucket here, that would be the one where potentially now you're signing off for ACA plans where before, they would just have to wait 3 months uninsured and get Medicare. Is there any way to think about how CMS -- could CMS address that? Or effectively, they're uninsured and they could buy an ACA Plan like anybody else. So how do you stop it?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Yes. Okay. I may just look at it on the table. I do not have an answer to that. Does anybody?",21,"Yes. Okay. I may just look at it on the table. I do not have an answer to that. Does anybody?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Well, Justin, if I understand you correctly, I think what we're having a little disconnect in the room is we have a population that does not qualify for Medicare or Medicaid because they haven't worked in a requisite number of quarters. Or even if you're",87,"Well, Justin, if I understand you correctly, I think what we're having a little disconnect in the room is we have a population that does not qualify for Medicare or Medicaid because they haven't worked in a requisite number of quarters. Or even if you're here and working through the visa process, you have to wait 5 years before you're eligible for Medicare. So I think there is a genuine population when we discuss it that cannot access the government coverage. Does that explain it for you?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Analysts","Right. So you're saying there's not really much of this 3,000 population that just had to wait 3 months for Medicare before and is now getting ACA?",27,"Right. So you're saying there's not really much of this 3,000 population that just had to wait 3 months for Medicare before and is now getting ACA?"
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Executives","Right. He's specifically ask -- yes, I hear you, Justin. You're specifically asking about that 3-month waiting period and is anybody -- is anything going on there? Not -- does anyone -- I think, Justin, we'll have to get back to you and the rest of the sh",91,"Right. He's specifically ask -- yes, I hear you, Justin. You're specifically asking about that 3-month waiting period and is anybody -- is anything going on there? Not -- does anyone -- I think, Justin, we'll have to get back to you and the rest of the shareholders on that because it's not a question that I've heard asked and answered.
All right. Thank you very much. And thanks, everyone, for your sustained interest, and we look forward to talking to you on all these topics in 90 days. Thank you."
35644,404162533,1073218,"DaVita Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","DaVita Inc.","Operator","And that ends today's conference. Thank you, all, for your participation. You may disconnect at this time.",18,"And that ends today's conference. Thank you, all, for your participation. You may disconnect at this time."
